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Abstract 
The shikimate pathway is responsible for the biosynthesis of the aromatic amino acids and other 
aromatic metabolites in plants, micro-organisms and apicomplexan parasites. The shikimate 
pathway is essential in bacteria and plants, but absent from mammals, which has led to interest 
in the enzymes of the pathway as targets for the design of antimicrobial and herbicidal agents. 
3-Deoxy-D-arabino-heptulosonate 7-phosphate synthase (DAH7PS) catalyses the first commit-
ted step of the shikimate pathway, the condensation of phosphoenolpyruvate and erythrose 4-
phosphate to yield 3-deoxy-D-arabino-heptulosonate 7-phosphate. The subject of this thesis is 
the investigation of inhibition and allosteric regulation of the DAH7PS enzyme from Myco-
bacterium tuberculosis (MtuDAH7PS), the pathogen that causes tuberculosis. Tuberculosis 
remains a major health threat to the global community, and the emergence of multi-drug 
resistant strains highlights the need for new tuberculosis treatments. Inhibitors of MtuDAH7PS 
have the potential to be developed into new anti-tuberculosis drugs. 
Chapter 2 describes the design, synthesis and evaluation of active site inhibitors based on 
intermediate mimic scaffolds. The intermediate mimics synthesised represent the first reported 
example of inhibitors targeting the active site of MtuDAH7PS. The most active compounds 
tested displayed inhibition constants in the sub-micromolar range, making them the most potent 
inhibitors of any DAH7PS enzyme reported to date. 
MtuDAH7PS displays a complex and subtle mechanism of synergistic regulation: The enzyme 
is inhibited by binary combinations of the aromatic amino acids tryptophan (Trp), phenylalanine 
(Phe) and tyrosine (Tyr). Three allosteric binding sites were identified using X-ray crystallo-
graphic analysis of MtuDAH7PS in complex with Trp and Phe. While these crystal structures 
led to the identification of an allosteric binding site which preferentially binds Trp, the role and 
selectivity of the other two sites with respect to Phe and Tyr remained unclear. The results 
described in Chapter 3 provide structural and biochemical evidence for the hypothesis that each 
of the three allosteric binding sites has a preference for binding one of the aromatic amino acids 
Trp, Phe and Tyr, respectively. The results furthermore show that the ternary combination of 
Trp, Phe and Tyr synergistically regulates MtuDAH7PS, leading to almost complete loss of 
enzymatic activity in the presence of all three allosteric ligands. 
In Chapter 4, the interaction of MtuDAH7PS with the naturally less common D-enantiomers of 
the aromatic amino acids is described. It was found that the D-enantiomers of the aromatic 
amino acids have no effect on enzymatic activity of MtuDAH7PS, suggesting an efficient 
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mechanism by which the enzyme can discriminate between allosteric ligands of opposite 
configuration. Studies of the binding affinity of the D-amino acids to MtuDAH7PS as well as 
structural characterisation of MtuDAH7PS-D-amino acid complexes by X-ray crystallographic 
analysis suggest that D-Trp and D-Phe can still bind to their respective sites. The lack of 
inhibition is attributed to subtle differences in the binding mode of the D-enantiomers of the 
ligands compared to the L-enantiomers. 
Chapter 5 details the discovery of alternative ligands and inhibitors targeting the allosteric sites 
of MtuDAH7PS using virtual screening. Libraries of potential alternative ligands were docked 
into the allosteric sites of MtuDAH7PS and the predicted docking poses were used to guide the 
selection of compounds for physical screening. Using this approach, a number of ligands and 
inhibitors of MtuDAH7PS were discovered and their interaction with the enzyme structurally 
characterised. Comparison of the crystallographically observed binding modes of new ligands 
with the docking poses predicted by computational docking highlighted potential improvements 
to the virtual screening method. The analysis of the correlation between ligand binding modes 
and inhibition of enzymatic activity provided further insight into which interactions between the 
allosteric ligand and the binding site are crucial in order to achieve inhibition. The crystal 
structures of MtuDAH7PS in complex with the new alternative ligands can serve as a starting 
point for the design of ligands with increased affinity and potency. 
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Chapter 1 – Introduction 
 
2 
 
1.1 Tuberculosis 
1.1.1. The disease 
Tuberculosis (TB) is a disease caused by infection with Mycobacterium tuberculosis and was 
responsible for an estimated 1.4 million deaths globally in 2011.1 The estimated total number of 
incident cases of 8.7 million in the same year highlights the enormous global TB burden. 80% 
of the global tuberculosis cases are distributed among 22 countries, which are often located in 
poorer and less developed regions where diagnosis and treatment are hampered by lack of 
infrastructure and resources. Geographically, countries with the highest incident rate are mainly 
located in sub-saharan Africa and Southeast Asia. Co-infection of tuberculosis patients with 
Human Immunodeficiency Virus (HIV) presents a further challenge for treatment and disease 
control. An increasing number of drug-resistant cases of TB have been reported and the resistant 
strains of M. tuberculosis have been classed into categories according to the resistance they 
display: multi-drug resistant tuberculosis (MDR-TB) is caused by bacteria which are resistant 
against at least Isoniazid and Rifampicin, the current first-line drugs. Extensively drug-resistant 
tuberculosis (XDR-TB) strains are MDR-TB strains which are also resistant to any 
fluoroquinolone and one of the currently available injectable aminoglycosides capreomycin, 
kanamycin and amikacin. Recently, researchers in India reported TB strains which were 
insusceptible to any currently available drug, calling these strains “totally drug-resistant”, a 
classification not currently used by the WHO.2 The term “totally drug-resistant TB” has also 
very recently been used in connection with the examination of clinical isolates of TB from 
South African patients by researchers at the Centers for Disease Control and Prevention.3 The 
alarming rise of drug-resistance observed in TB strains and the fact that despite progress in 
worldwide tuberculosis control, tuberculosis incidence is only falling at a very modest rate of 
2% per year, requires a concerted research effort in order to improve diagnostics, treatment and 
vaccinations. The development of new drugs which are effective especially against emerging 
resistant strains is one important piece of the puzzle which will hopefully enable a significant 
improvement of the global health situation with regards to tuberculosis. 
1.1.2. The pathogen – Mycobacterium tuberculosis 
Mycobacterium tuberculosis is the pathogen that causes tuberculosis. M. tuberculosis is an 
aerobic, acid-fast, non-motile, non-encapsulated, non-spore forming bacillus whose discovery 
was first announced by Robert Koch in 1882.4 Due to its resistance to staining in the absence of 
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phenol, M. tuberculosis is classed as neither gram-positive nor gram-negative but instead as 
acid-fast – this definition is due to the fact that once stained, the bacterium resists decolouri-
sation with acidified organic solvents. This phenomenon might be connected to the nature of the 
cell wall of M. tuberculosis, which is lipid-rich and less permeable compared to the cell wall of 
other bacteria.5 While other parts of the body can be affected, the pathogen grows most 
successfully in oxygen-rich tissues, such as the lungs. M. tuberculosis divides only every 15–20 
hours, which is slow in comparison to other bacteria, such as Escherichia coli, which divide 
every 20 minutes.6 The slow growth rate in combination with M. tuberculosis being able to 
persist in a latent state are part of the reason why extended treatment periods, which are often 
hard to comply with by patients, are required in TB therapy.7 About one-third of the world 
population are estimated to have a latent TB infection.8 While only 10% of people infected with 
latent TB develop active symptoms, the presence of viable M. tuberculosis bacilli was shown by 
cultivation from tissues obtained from healthy individuals who died from traffic accidents but 
who had no macroscopic or histological evidence of tuberculosis.9  
Whereas the host pathogen-interaction and immunological response to TB infection is poorly 
understood, it appears that some aspects of the immune response associated with TB can favour 
persistence: the immune response in immunocompetent individuals leads to the formation of 
characteristic granulomas, which are defined as focal, compact collections of inflammatory 
cells.8 While these granulomas might be effective at containing the infection as part of the host 
immune response, there are indications that M. tuberculosis in granulomas have increased 
persistence and can more readily withstand treatment with anti-TB drugs which would kill them 
if they were not enclosed in granulomas. The latent TB infection can become active, often as a 
consequence of a compromised host immune response, which can be caused by co-infection 
with HIV, malnutrition or simply old age. The progression to active disease is characterised by 
release of viable M. tuberculosis from the granulomas into the patient’s airways, which can then 
be spread through pathogen containing droplets released into the environment through 
coughing.8  
1.1.3. Treatment 
First-Line Drugs 
The current first-line tuberculosis drugs as recommended by the WHO are Isoniazid, 
Rifampicin, Pyrazinamide, Ethambutol and Streptomycin (Figure 1.1). Isoniazid is a prodrug 
which requires activation by the catalase-peroxidase KatG, and mutations in the katG gene are a 
frequently observed cause of Isoniazid resistance.10-11 The products of the KatG catalysed 
activation of Isoniazid, the isonicotinic acyl radical and free radical species, especially nitric 
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Figure 1.1: First-line anti-tuberculosis drugs. 
oxide, are thought to cause disruption to multiple cellular processes in the bacteria: isonicotinic 
acyl-NADH adducts are proposed to cause inhibition of the enoyl-acyl carrier protein reductase 
(InhA), an enzyme involved in the mycolic acid cell wall synthesis. The products of the KatG-
catalysed activation of Isoniazid are also thought to interfere with nucleotide biosynthesis and 
respiration.10 This multi-pronged mechanism of action may explain why Isoniazid is still 
effective in the treatment of TB despite its extensive use. 
The mechanism of action of the antibiotic Rifampicin involves inhibition of bacterial RNA 
polymerase.12 While the active sites of mammalian and bacterial RNA polymerases are con-
served, Rifampicin’s selectivity for inhibiting the bacterial over the mammalian enzyme arises 
from it binding to a pocket adjacent to the active site. It has been proposed that binding of 
Rifampicin to the bacterial RNA polymerase makes it impossible to accommodate the nascent 
RNA strand and leads to termination of transcription after only a few nucleotides.13 
Pyrazinamide is a prodrug, which is converted to pyrazinoic acid by the enzyme pyrazin-
amidase.14 The exact mechanism of action of Pyrazinamide and its metabolites are still subject 
to debate: early hypotheses proposed the inhibition of fatty acid synthase I which is essential for 
the synthesis of fatty acids,15 but have since been discounted.16 The recently reported inhibition 
of trans-translation in M. tuberculosis by Pyrazinamide has resulted in a new hypothesis about 
Pyrazinamide’s mechanism of action and could also explain the effectiveness of the drug 
against dormant strains.17 
Ethambutol has bacteriostatic properties and interferes with mycobacterial cell wall synthesis 
through inhibition of different arabinofuranosyltransferases.18 These enzymes are involved in 
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the synthesis of the arabinogalactan and lipoarabinomannan components of the cell wall and 
inhibition of these pathways leads to truncated cell wall architectures.19 Ethambutol is used in 
combination with other anti-TB drugs and is thought to aid cell entry of these agents by making 
the mycobacterial cell wall more permeable. 
Streptomycin is a broad-spectrum antibiotic which was tested for its efficacy against pulmonary 
tuberculosis in 1946–1947 in what is regarded as the first randomised curative trial. Strepto-
mycin binds to the bacterial ribosome and leads to lower fidelity in codon recognition, resulting 
in mistranslation of mRNA and eventually bacterial cell death.20-21 
Second-Line Drugs 
Second-line or reserve drugs are used to treat MDR- and XDR-TB patients. In addition to 
requiring longer treatment regimes, the aminoglycosides Kanamycin and Amikacin are only 
available as injectables, making patient treatment compliance challenging. The WHO 
recommends drug susceptibility testing on the strains present in the individual patient prior to 
treatment in order to determine the most efficient combination of drugs. In the absence of drug 
susceptibility information the design of treatment regimens is recommended to follow known 
regional resistance profiles. A combination of at least four drugs is recommended by the WHO 
to be administered for MDR- and XDR-TB cases.22 The aminoglycosides Kanamycin and 
Amikacin interfere with bacterial protein biosynthesis by binding to the bacterial ribosome 
(Figure 1.2).23 The DNA gyrase from M. tuberculosis has been identified as a target of the 
fluoroquinolone drugs Levofloxacin and Moxifloxacin.24 At least one of the fluoroquinolones 
and one injectable aminoglycoside is to be included in the treatment regimen for MDR- and 
XDR-TB.25 para-aminosalicylic acid (PAS) inhibits folate metabolism, recent research by Rhee 
and co-workers revealed that PAS acts as a substrate of folate biosynthesis pathway enzymes 
and incorporation into various metabolites of the folate pathway suggests that PAS and its 
metabolites compete with the substrates of multiple enzymes.26 Ethionamide is structurally 
related to Isoniazid and cross-resistance with Isoniazid is common.27 Ethionamide inhibits 
mycolic acid synthesis and is commonly included in the treatment regimen for MDR or XDR-
TB due to its low cost and generally lower toxicity when compared to other second-line drugs.25 
Cycloserine inhibits both alanine racemase and D-alanine:D-alanine ligase, enzymes involved in 
the synthesis of the peptidoglycan cell wall. Although used for the treatment of TB in some 
cases where other regimens fail or are unavailable, Cycloserine is not endorsed by the WHO for 
general treatment due to toxic side effects.28 
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Figure 1.2: Second-line or reserve anti-tubercular drugs. 
Anti-TB drug development 
The proliferation of multi- and extensively drug resistant TB strains have caused an increase in 
research activity in the field of antitubercular drugs and a number of candidates are currently in 
clinical trials. Some of these are based on previously described scaffolds or repurposed drugs 
(Figure 1.3), whereas others are new active scaffolds (Figure 1.4).  
Gatifloxacin and Moxifloxacin belong to the fluoroquinolone class, and while they have been 
approved and in use for the treatment of MDR- and XDR-TB, they are also currently in phase 3 
clinical trials for potentially shortening current treatment duration.29-30 DC-159a, another 
fluoroquinolone, is currently in pre-clinical trials for MDR-TB with resistance against approved 
fluoroquinolones. DC-159a shows increased activity and different resistance patterns when 
compared to other fluoroquinolones.31-32 
Based on the scaffold of Ethambutol (Figure 1.1), SQ109 was identified from a focused screen 
of a library of 1,2-ethylenediamines.33-34 Ethambutol-resistant strains were susceptible to 
SQ109, suggesting an alternative mechanism of action: Boshoff and co-workers were able to 
demonstrate that SQ109 inhibits MmpL3, a membrane protein involved in the transport and 
attachment of mycolic acids to the mycobacterial cell wall.35 Clinical trials evaluating bacteri-
cidal activity of SQ109 in patients with pulmonary TB have been completed, but no results have 
been published.36 During the development of SQ109, screening of a focussed library of 
diamines yielded dipiperidine SQ609 as a further possible lead compound based on the 
ethambutol scaffold. SQ609 is currently in preclinical development.37-38 
Metronidazole, a nitroimidazole antibiotic with preferential activity against anaerobic orga-
nisms, was considered as a potentially attractive compound for treating non-replicating M. 
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tuberculosis.39 Despite the modest activity of Metronidazole in a TB mouse model,40 a phase 2 
clinical trial exploring the addition of Metronidazole to the standard regimen of second line 
drugs in the treatment of MDR-TB is currently underway in Korea.41 The nitroimidazofuran 
scaffold, originally developed as a radiotherapy agent in cancer treatment, shares the 
nitroimidazole moiety with Metronidazole. The original lead compound of this series, CGI-
17341, has activity against M. tuberculosis in vitro and in mouse models, was however not 
pursued further due to its mutagenicity.42 Synthesis of over 300 analogues of CGI-17341 
yielded PA-824, which shows activity against susceptible as well as poly- and multi-drug 
resistant strains. Furthermore, PA-824 shows comparable bactericidal activity to Metronidazole 
against dormant or latent TB cultures.43 Two Phase 2 clinical trials evaluating the efficacy of 
PA-824 alone and in combination with other TB drugs have recently been completed, but no 
results have been published.44-45 OPC-67683 is a structurally close analogue of PA-824, clinical 
trials for the treatment of MDR-TB with OPC-67683 are ongoing or completed.46-47  
TBA-354 is an improved second generation compound based on PA-824 and is the result of 
synthesis and testing of over 1000 analogues of PA-824.48-53 In late 2012, the Global TB 
Alliance announced TBA-354 as a candidate for clinical trials in 2013.54 
Linezolid is an antibiotic based on the (S)-2-oxazolidin-2-one scaffold which was introduced for 
the treatment of multidrug-resistant gram-positive pathogens.55 Linezolid and analogues also 
show activity against M. tuberculosis, although toxicity and adverse side effects are commonly 
observed.56 PNU-100480 and AZD-5847 are analogues which resulted from efforts to reduce 
toxicity and improve efficacy, both compounds are in clinical trials.57-62 
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Figure 1.3: Anti-TB drugs in development based on previously described scaffolds. Common structural 
elements of the fluoroquinolones, diamines, nitroimidazoles, and oxazolidinone classes of drugs are highlighted 
in red. 
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TMC207 or Sirturo™ is the first tuberculosis drug approved by the FDA in 40 years that works 
by a mechanism distinct from existing treatments (Figure 1.4).63 The drug was approved despite 
higher mortality in the treatment group compared to the placebo group based on its efficacy 
against MDR- and XDR-TB and its potential to fill an unmet medical need.64 TMC207 works 
by inhibiting subunit C of the mycobacterial ATP synthase.65 
As the most promising of a series of benzothiazinones, BTZ043 has recently been reported as a 
potential new lead structure. DprE1, a decaprenylphosphoryl-β-D-ribose 2′-epimerase involved 
in arabinan synthesis, has been identified as a target of BTZ043. DprE1 is a previously 
unrecognised target for TB drug development, and BTZ043 shows activity against multi- and 
extensively drug resistant strains.66 In an independent screen, Brodin and co-workers identified 
another potential new lead structure which targets DprE1: DNB1 is a representative of 
dinitrobenzamides identified from a phenotypic screen. DNB1 is active against TB in 
macrophages as well as XDR-TB.67  
A strategy to boost activity of anti-TB prodrugs which are enzymatically activated in the 
bacterial cell was reported by Baulard and co-workers: BDM31343 binds to EthR, a 
transcriptional repressor of the ethA gene which codes for the enzyme necessary for the 
activation of Ethionamide. BDM31343 in combination with Ethionamide was shown to increase 
in vitro efficacy of the prodrug against M. tuberculosis.68 
 
Figure 1.4: New scaffolds of compounds for anti-TB drug development. TMC207 is the most recent addition to 
the FDA-approved anti-TB drugs, the other compounds are in preclinical development.  
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1.2 Shikimate pathway 
The shikimate pathway is a metabolic pathway present in bacteria, plants and apicomplexan 
parasites.69-71 Erythrose 4-phosphate (E4P) and phosphoenolpyruvate (PEP) are converted to 
chorismate in seven enzyme catalysed steps. Chorismate is the precursor for a number of 
essential aromatic compounds such as the aromatic amino acids phenylalanine, tyrosine, and 
tryptophan. Chorismate is also used as a precursor for folate and Vitamin K biosynthesis. 
Whereas bacteria and plants can utilise the shikimate pathway to synthesise aromatic amino 
acids, the shikimate pathway is absent from mammals including humans, who rely on uptake of 
these essential amino acids in their diet. Due to their absence from humans and animals, 
enzymes of the shikimate pathway have attracted attention as targets for herbicide and antibiotic 
design.72 Glyphosate, the active ingredient in widely used herbicides, is an inhibitor of 5-enol 
pyruvate shikimate-3-phosphate (EPSP) synthase, the penultimate enzyme of the pathway.73-74 
11 
 
 
Figure 1.5: The shikimate pathway and the multiple pathways which use the endproduct chorismate. The 
reaction catalysed by DAH7PS is highlighted. 
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1.3 3-Deoxy-D-arabino-heptulosonate 7-phosphate synthase 
(DAH7PS) 
1.3.1 Mechanism 
The overall reaction catalysed by DAH7PS is the aldol-like condensation of phosphoenol-
pyruvate (PEP) and erythrose 4-phosphate (E4P) to yield 3-deoxy-D-arabino-heptulosonate 7-
phosphate (DAH7P (1.3), Figure 1.6a). Mechanistic studies have led to the elucidation of many 
of the key features of the reaction mechanism (Figure 1.6b).75-84 The first step is the nucleophilic 
attack of C3PEP on the carbonyl group C1E4P. Studies with isotopically labelled substrates have 
established that the (pseudo)-si face of the PEP double bond attacks the re-face of the E4P 
carbonyl group.83-84 All DAH7PS enzymes require a divalent metal ion for catalysis, a probable 
role for the metal ion in the active site is the positioning and activation of the E4P carbonyl 
group for nucleophilic attack. Protonation of the oxyanion by an active site general acid leads to 
the formation of intermediate 1.1. The oxocarbenium ion 1.1 is attacked by a water molecule 
yielding phosphohemiketal 1.2. Intermediate 1.2 has a transient chiral centre at C2 whose 
absolute configuration depends on which side of the oxocarbenium ion 1.1 is attacked by the 
incoming water molecule. The configuration of this center is unknown, this intermediate has not 
been isolated as it is unstable and eliminates phosphate to yield the reaction product DAH7P 
(1.3) in its open-chain form. The fact that the unusual cleavage of a C-OPO32- bond instead of 
the more commonly described cleavage of the CO-PO32- bond occurs in the reaction catalysed 
by DAH7PS has been shown by studies with 18O-isotopically labelled PEP.79 The product 
DAH7P exists in an equilibrium, with the cyclic pyranose form being favoured over the open-
chain form in solution. Cyclisation of DAH7P may either occur while still bound to the enzyme 
active site or after product release in solution. 
An alternative mechanism has been proposed in the literature where attack of water or hydroxyl 
at C2PEP precedes carbon-carbon bond formation between PEP and E4P.85 This proposal is 
problematic due to the following reasons: (1) it requires electrophilic reactivity at the C2PEP 
which is unprecedented. (2) The product of such a step would be a carbanion at C3PEP or in case 
of a concerted reaction, carbanionic character of C3PEP in the transition state. Such a species 
would be highly basic and would very likely be quenched by deprotonation of active site water 
molecules or acidic protein side chains such as lysine ammonium, glutamic or aspartic acid 
carboxylic acid moieties, both of which are found as conserved residues in proximity to the PEP 
binding site in the active sites of a number of DAH7PS enzymes. (3) In this mechanism, 
coordination of a water molecule to the metal ion has been proposed to activate the water
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Figure 1.6: (a) Reaction catalysed by DAH7PS and (b) reaction mechanism. 
molecule for deprotonation so that the postulated nucleophilic attack at C2PEP could be carried 
out by a, compared to water, more nucleophilic hydroxide ion. The presence of a water 
molecule coordinated to the metal ion however is likely to prevent E4P to bind in the correct 
orientation to form the observed product stereoisomer. In this mechanistic proposal, following 
attack of water or hydroxide at PEP, a rotation of the E4P carbonyl is required while a carbanion 
or transition state with carbanionic character at C3PEP is present or being formed. While the 
mechanism in which water attacks at PEP precedes carbon-carbon bond formation requires 
unprecedented reactivity of the PEP substrate and major reorganisation of the active site ligands 
during the catalytic cycle, the mechanism in which carbon-carbon bond formation occurs before 
water attack only requires minimal movement of non-proton atoms.  
1.3.2. Classification of DAH7PS enzymes 
DAH7PS enzymes characterised to date are divided into two families based on their molecular 
weight and sequence similarity. According to the nomenclature used by Jensen, these are 
referred to as type I and type II DAH7P synthases.86 Enzymes in the type I family can be further 
subdivided into type Iα and type Iβ subfamilies (Figure 1.7). Type I DAH7PS enzymes are 
generally smaller, with molecular weights below 40 kDa, as opposed to the Type II enzymes 
which usually have a monomeric molecular weight of around 54 kDa.  
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Figure 1.7: Structural comparison of DAH7PS subfamilies: the core catalytic units are shown in blue, N-
terminal extensions in red and internal insertions in yellow. Type Iα enzymes (exemplified by the structure of 
E. coli DAH7PS, PDB code 1GG1) display both an N-terminal extension and an insertion into the α5-β6 loop. 
Type Iβ enzymes are either undecorated or have a second globular domain fused to the catalytic subunit 
(examples clockwise from top left: Pyroccocus furiosus DAH7PS, PDB code 1ZCO; Thermotoga maritima 
DAH7PS, PDB code 1RZM; Listeria monocytogenes DAH7PS, PDB code 3NVT). Type II enzymes possess a 
large insertion into the α2-β3 loop and a long N-terminal extension, as exemplified by M. tuberculosis 
DAH7PS.  
The type Iα DAH7PS enzymes include the well-characterised enzymes from E. coli75, 77, 85, 87-88 
and Saccharomyces cerevisiae.78, 89 The type Iα enzymes share little sequence homology with 
the DAH7PS enzymes from the type Iβ subfamily, which include the enzymes from Pyroccocus 
furiosus,80, 82, 90 Thermotoga maritima,76, 91-92 Bacillus subtilis93-94 and Listeria monocytogenes.95 
The enzymes of the type Iβ subfamily are more similar to 3-deoxy-D-manno-octulosonate 8-
phosphate synthase (KDO8PS), an enzyme involved in the cell wall synthesis of gram-negative 
bacteria.96-97 KDO8PS and DAH7PS both utilise PEP, but KDO8PS uses A5P instead of E4P as 
its aldose phosphate substrate and thus forms an eight-carbon product.80 
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1.3.2 Structure of DAH7PSs 
While the overall sequence homology between individual DAH7PS enzymes from different 
families is often low, structural characterisation of DAH7PSs from different families by X-ray 
crystallography indicate that these enzymes share important common structural elements. All 
DAH7PS enzymes that have been structurally characterised possess a core (β/α)8 barrel or TIM 
barrel structure which houses the active site at the C-terminal end of the barrel.98 The structural 
and sequence information available indicates that the different subfamilies of DAH7PS enzymes 
have distinguishing extensions and insertions to this core catalytic unit (Figure 1.7). These 
decorations of the TIM barrel core have been shown to be associated with regulation: the N-
terminal extension of type Iα enzymes from E. coli and S. cerevisiae forms part of the binding 
site for aromatic amino acids which act as allosteric effectors.88, 99-101 The type Iβ enzymes 
include the structurally characterised enzymes from P. furiosus and Aeropyrum pernix, neither 
of which have significant extensions or insertions to the TIM barrel and no allosteric regulators 
for these enzymes have been found.82, 102 Another interesting group of enzymes in the type Iβ 
family possess a second globular domain which is attached to the core catalytic TIM barrel as 
either an N- or C-terminal extension. The DAH7PSs from L. monocytogenes and B. subtilis 
possess a chorismate-mutase like domain which has been hypothesised to be involved in 
binding chorismate or prephenate and thereby regulating the DAH7PS activity.93, 95 The type Iβ 
DAH7PS from T. maritima has an N-terminal extension which has structural and sequence 
homology to ACT-domains.76, 91, 103 Upon binding of the allosteric regulator tyrosine, the ACT-
domain undergoes a significant conformational shift which leads to a closed and inhibited state 
of the enzyme.92 It has been shown that the truncated DAH7PS from T. maritima missing the 
ACT domain is not inhibited by tyrosine, while fusion of the ACT domain to the unregulated 
DAH7PS from P. furiosus leads to a chimeric enzyme regulated by tyrosine. 92, 104 
M. tuberculosis DAH7PS (MtuDAH7PS) is the only type II enzyme which has been structurally 
characterised.105-106 Sequence comparison with type I enzymes show that the type II enzymes 
display significant insertions and type I and type II family enzymes share less than 10% amino 
acid sequence identity. The crystal structure of MtuDAH7PS however, showed that the overall 
fold of the enzyme is also a TIM barrel, albeit with extensive decorations of the core structure. 
These decorations have also been shown to be associated with the regulation of the enzyme by 
allosteric effectors (see a more detailed discussion in “1.4.2 Allosteric sites and regulation 
of MtuDAH7PS”, p. 20). 
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1.4 Mycobacterium tuberculosis DAH7PS 
1.4.1 Overall structure 
The monomeric structure of MtuDAH7PS displays a TIM barrel fold consistent with all other 
structurally characterised DAH7PS enzymes. The N-terminal extension and sequence insertions 
decorate the core catalytic barrel without causing any major alterations to the TIM barrel 
architecture (Figure 1.8): At the N-terminus, a β-strand (β0, residues 4–8) is followed the β0α0 
loop (residues 9–18) and then by three helices (α0a, α0b and α0c). The α2β3-loop is extended 
significantly by the insertion of two helices (α2a and α2b) which pack against the outside of the 
barrel. The barrel decorations play key roles in the quaternary structure assembly (Figure 1.9): 
the β0 strands from two monomers form an inter-monomer β-sheet at the dimer interface of the 
asymmetric unit. The α2a and α2b helices are located at the interface between two dimers and 
provide the contacts to form the tetramer which is the most likely biologically relevant 
assembly. Consistent with the type I DAH7PS enzymes, it was shown that the decorations to the 
core structure of MtuDAH7PS are also involved in allosteric regulation (see p. 20). 
Figure 1.8: Monomeric structure of M. tuberculosis DAH7PS (PDB code 3NV8), looking down the core barrel 
(left) and side-on view (right): the core catalytic unit is coloured blue, the N-terminal extension red and two 
helices inserted into the α2β3-loop are coloured in yellow. The manganese (II) ion is shown as a green sphere 
and indicates the location of the active site. 
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α2b 
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Figure 1.9: MtuDAH7PS tetramer (PDB code 3NV8), the N-terminal extension (coloured red) and α2β3-
insertion (coloured yellow) play key roles in the quaternary structure assembly. The core barrel residues are 
coloured blue, the active site metal ion is shown as a green sphere. 
Active Site 
While the overall sequence similarity between DAH7PS enzymes from different subfamilies is 
low, the active site contains a number of conserved residues which results in very similar active 
site architectures and substrate recognition patterns across all DAH7PSs. The active site of 
MtuDAH7PS can be divided into the PEP binding site, the metal binding site and the E4P 
binding site (Figure 1.10). 
 
Figure 1.10: Overview of the active site of MtuDAH7PS (PDB code 3NV8). PEP and PEP-binding residues are 
shown with yellow carbons, The manganese(II)-ion is shown as a purple sphere and the metal coordinating 
residues with purple carbons. The conserved KPRS motif for E4P binding is shown with green carbons. 
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The PEP binding site 
In the crystal structure of MtuDAH7PS, PEP mainly interacts with positively charged side 
chains (Figure 1.11). The PEP phosphate moiety forms a salt bridge with the guanidinium 
moiety of Arg337 and a hydrogen bond to the backbone amide N-H of Glu283. The carboxylate 
moiety of PEP forms a salt bridge with the guanidinium moiety of Arg126 and a hydrogen bond 
and salt bridge to the side-chain ammonium group of Lys306. The residues whose side chains 
are involved in interactions with PEP (Arg126, and Lys306, Arg337) are conserved across all 
DAH7PS subfamilies. 
 
Figure 1.11: The PEP binding site (PDB code 3NV8). Key interactions are shown with black dashes. 
E4P binding 
While there are no data on the binding mode of E4P in type II DAH7PS enzymes such as 
MtuDAH7PS, the highly conserved nature of the active site architecture across all DAH7PS 
enzymes suggests that the conclusions from studies on the type I DAH7PS enzymes are also a 
valid model for E4P binding in MtuDAH7PS and other type II DAH7PSs. In type I DAH7PSs, a 
conserved KPRS motif is implicated to play a key role in E4P binding, in type II DAH7PSs, a 
very similar KPRT motif is found at the equivalent position in the active site on the β2α2-loop 
of MtuDAH7PS. Since binding of both substrates normally leads to catalytic turnover, a number 
of methods have been used to deduce the binding mode of E4P. The only complex of DAH7PS 
with both substrates bound which has been structurally characterised stems from X-ray 
crystallographic analysis of the T. maritima DAH7PS in complex with PEP, Cd2+ and E4P 
(PDB code 1RZM).76 Due to the thermophilic nature of T. maritima DAH7Ps, catalytic turnover 
was negligible when the second substrate E4P was soaked into crystals at 4 °C. The E4P 
molecule in this structure was modelled in a non-productive orientation, the position of the 
phosphate and methylene hydroxyl groups however was consistent with earlier proposals. 
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Figure 1.12: Model for E4P binding proposed based on the crystal structure of P. furiosus DAH7PS.82 PEP and 
PEP-binding residues are shown with yellow carbons, The manganese(II)-ion is shown as a purple sphere and 
the metal coordinating residues with purple carbons. E4P and the conserved KPRT motif for E4P binding are 
shown with green carbons. Key interactions of E4P with the enzyme active site are shown with black dashes. 
The binding mode of the non-reactive E4P analogue glycerol 3-phosphate (G3P) was crystallo-
graphically observed in complex with S. cerevisiae DAH7PS and informed the modelling of the 
E4P binding mode.78 The model suggests that the E4P phosphate interacts with arginine and 
threonine of the KPR(S/T) motif. The hydroxyl groups of E4P interact with the proline 
backbone carbonyl of the KPR(S/T) motif and a metal-binding aspartate. A very similar binding 
mode was suggested for E4P in the P. furiosus DAH7PS (Figure 1.12).82 The conservation of 
the proposed E4P-binding residues across DAH7PS subfamilies further supports that they form 
the binding site for E4P. The important role of the KPR(S/T) motif in the models for E4P 
binding is evident in light of the majority of contacts between the enzyme and E4P being 
formed through these four residues.  
Metal binding site 
The metal binding residues and geometry are highly conserved among all subfamilies of 
DAH7PS enzymes. In MtuDAH7PS, a glutamate, aspartate, histidine and cysteine residue 
coordinate the metal ion in a trigonal bipyrimidal geometry with a vacant axial coordination site 
available for coordination and activation of the E4P aldehyde. 
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Figure 1.13: Metal binding site of MtuDAH7PS (purple, PDB code 3NV8). The manganese ion is shown as a 
purple sphere. 
1.4.2 Allosteric sites and regulation of MtuDAH7PS  
Kinetic analysis of the activity of MtuDAH7PS in the presence of potential allosteric inhibitors 
revealed that the presence of single aromatic amino acids had little or no effect on enzymatic 
activity. However, combinations of Trp and Phe and, to a lesser extent Trp and Tyr, resulted in 
synergistic inhibition of MtuDAH7PS.107 Soaking of Trp and Phe into crystals and analysis by 
X-ray diffraction resulted in ligands being observed in three binding sites, all of which are 
associated with the barrel extensions and insertions (Figure 1.14): site 1 is located near the 
dimer interface and has contributions from the N-terminal β0-strand. Site 2 is located near the 
tetramer interface and residues from the inserted α2a and α2b helices contribute to the binding 
site. Site 3 is nestled between the α0a and α0b-helices of the N-terminal extension and the α3-
helix of the core barrel. Site 1 and 2 are generally occupied in both subunits of the asymmetric 
unit (or four ligands per tetramer), while site 3 is found to be only occupied in one subunit of 
the asymmetric unit (or two ligands per tetramer).  
The occupancy of the three sites with Trp or Phe which was observed in different soaking 
conditions indicates that both binding sites and ligands can be promiscuous: soaking crystals in 
a solution containing a high concentration of Phe yields a structure in which Phe occupies all 
three binding sites. When only Trp was used as the ligand in soaking experiments, it was found 
to bind in site 2 at the concentrations used, while soaking of crystals in a solution containing 
both Trp and Phe resulted in site 2 being occupied by Trp and sites 1 and 3 being occupied by 
Phe. While these occupancies suggest that Trp is the preferred ligand for site 2, the role and 
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Figure 1.14: Allosteric binding sites of MtuDAH7PS (PDB code 3KGF): in this structure, Phe occupies site 1 
(purple spheres) and site 3 (yellow spheres). Trp occupies site 2 (cyan spheres). Residues in the core catalytic 
barrel are coloured blue, the N-terminal extension and the insertion into the α2β3-loop are shown in red and 
yellow cartoon representation, respectively. 
specificity of site 1 and 3 remain elusive. Site-directed mutagenesis of key residues for binding 
of the ligands in the sites was undertaken to elucidate the role of the binding sites. Mutation of 
arginine 171 (site 1) to alanine resulted in an enzyme whose activity was not affected by the Trp 
and Phe combination which was highly inhibitory for the wild-type enzyme. On the contrary, 
mutation of Arg256 to Ala (site 3) yielded a variant which still showed an allosteric response to 
the Trp/Phe-combination similar to the wild-type enzyme.107 
Comparison of the structure of MtuDAH7PS in complex with Trp and Phe with the unliganded 
structure shows that the overall conformation is virtually identical (RMSD 0.307 Å for 4669 
atoms). In particular, there is no significant conformational change observed in the active site 
which could explain the diminished binding of substrate or reduced catalytic competency of the 
enzyme. The results of molecular dynamics simulations suggest that the regulation occurs by an 
entropy-driven mechanism whereby binding of the allosteric regulators causes the E4P-binding 
loop to become more conformationally flexible, increasing the entropic cost of substrate 
binding. 108 While there is no large scale conformational change of the enzyme observed upon 
ligand binding, local changes in conformation near the respective binding site can be observed 
(Figure 1.15, Figure 1.17). 
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Site 1 is capped by a β-sheet which is composed of the β0-strands from the two different 
subunits, forming an arrangement resembling crossed arms. Upon Phe binding to site 1, the two 
β0-strands change their register relative to each other, so that the side chain of Trp3 of subunit B 
shifts from a solvent-exposed position at the N-terminal end of the β0-strand of subunit B to a 
position in between the two Phe ligands (Figure 1.15). In the unliganded structure, the 
equivalent position is occupied by Val5 of subunit B. Residues from two subunits contribute to 
the contacts of Phe in site 1 (Figure 1.16). The phenyl side chain of Phe is located in a 
hydrophobic pocket generated by the side chains of residues Trp3, Val55*, Tyr173* and 
Ala174* (an asterisk denotes residues contributed from the second monomer). The carboxylate 
group of the Phe ligand establishes a salt-bridge and hydrogen bond to the guanidinium moiety 
of Arg171 and a hydrogen bond to a water molecule. This water molecule in turn forms a 
hydrogen bond to the indole nitrogen of Trp3. The amino moiety of the Phe ligand forms 
hydrogen bonds to the backbone carbonyl of Phe91, the side-chain carbonyl of Asn175 and, 
mediated by a water molecule, to the main-chain carbonyl of Asn94. 
 
Figure 1.15: Overlay of the unliganded (blue, PDB code 3NV8) and Phe bound (yellow, PDB code 3NUD) 
MtuDAH7PS structures showing the local conformational change around site 1 upon Phe binding. Trp3 of 
subunit B shifts from a solvent exposed position in the unliganded structure (cyan sticks) to a position in 
between the two Phe ligands (yellow sticks) in the dimer interface (orange sticks). 
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Figure 1.16: Stereo view of Phe (green carbons) bound in site 1 of MtuDAH7PS. Residues contributed from 
subunit A and B are shown with yellow and blue carbons respectively. Key interactions are shown with red 
dashes, water molecules are shown as red spheres. 
In the structure which has Trp bound to site 2, residues 233–241 undergo a conformational 
change when compared to the unliganded structure (Figure 1.17). These residues are located in a 
loop region that connects the helices α2a and α2b with the β3-strand. Thr240 in the Trp bound 
structure adopts a conformation which allows the backbone carbonyl of this residue to establish 
a hydrogen bond to the Trp ligand amino moiety. The Cα of Thr240 undergoes a shift of 3.1 Å 
which propagates mainly to the preceding residues. Although site 2 is located close to the tetra-
 
Figure 1.17: Overlay of the unliganded (blue, PDB code 3NV8) and Trp bound (green, PDB code 3KGF) 
structure of MtuDAH7PS. The backbone carbonyl of Thr240 establishes a hydrogen bond to the amino group 
of the Trp ligand (green sticks). This results in conformational changes in the preceding residues on the α2bβ3-
loop. 
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Figure 1.18: Stereo view of Trp (green carbons) in site 2 of MtuDAH7PS (PDB code 3KGF). Key interactions 
are shown with red dashes, water molecules are shown as red spheres. 
mer interface the Trp binding site is made up of residues from exclusively one monomer (Figure 
1.18). The indole ring of Trp sits in a hydrophobic pocket lined by the side chains of Leu107, 
Ala110, Val111 and Leu194. The indole nitrogen establishes a buried hydrogen bond to the 
backbone carbonyl of Ala192. The amino moiety of the Trp-ligand forms hydrogen bonds to the 
main-chain carbonyl groups of Thr240 and Asn237. The carboxylate moiety of Trp forms a salt 
bridge and hydrogen bond to the side-chain ammonium group of Lys123 and two water 
molecules. One of these water molecules in turn establishes hydrogen bonds to the side-chain 
hydroxyl of Thr114 and the main-chain amide nitrogen of Val121. 
1.4.3 Interaction with chorismate mutase 
Chorismate mutase enzymes catalyse the conversion of chorismate to prephenate, the precursor 
of the amino acids Phe and Tyr (Figure 1.5). M. tuberculosis expresses two enzymes with 
chorismate mutase activity, one of which is secreted and whose exact function and potential role 
in the pathogenicity of M. tuberculosis remains elusive.109 The low activity of the putative 
intracellular M. tuberculosis chorismate mutase (MtuCM) was puzzling until Kast and co-
workers discovered that the intracellular chorismate mutase is activated by the formation of a 
non-covalent complex with MtuDAH7PS.110-111 The MtuDAH7PS-MtuCM complex could be 
characterised by X-ray crystallography and co-eluted from a size-exclusion column in the pre-
sence of chorismate/prephenate. The crystal structure of the complex shows the MtuDAH7PS 
tetramer interacts with two homodimers of MtuCM which are located on opposite sides of the 
MtuDAH7PS tetramer (Figure 1.19). The mainly α-helical structure of MtuCM spans across the 
tetramer interface of MtuDAH7PS. Interestingly, MtuCM appears unregulated in the absence of 
MtuDAHP7S. However, in the presence of MtuDAH7PS, MtuCM activity is regulated by Phe 
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and Tyr.111 This implies that the regulatory role of MtuDAH7PS in mycobacterial aromatic 
amino acid metabolism might be more profound than feedback-regulation by the pathway 
endproducts. 
 
Figure 1.19: Non-covalent complex between MtuDAH7PS (blue) and M. tuberculosis chorismate mutase (the 
two protein chains are shown in yellow and orange; PDB entry 2W19).111 
1.5 Aims of this thesis 
This thesis describes the exploration of the multiple interconnected binding sites of 
MtuDAH7PS with ligands that modulate activity. Both the active site and allosteric sites were 
targeted by structure-based and guided ligand design approaches. The results provide further 
insight into the design of potent active site inhibitors, the specificity of the allosteric binding 
sites with respect to their natural ligands as well as the discovery and characterisation of new 
non-natural allosteric ligands. 
Chapter 2 reports the design, synthesis and characterisation of mechanism-based inhibitors 
which were designed as intermediate analogues. The potential plasticity of the active site was 
further examined using compounds which display different spacing of key moieties for inhibitor 
binding. 
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Chapter 3 describes further X-ray crystallographic analysis of MtuDAH7PS in complex with 
allosteric ligands, clarifying the roles and selectivities of sites 1 and 3. 
Chapter 4 examines the interaction of the aromatic amino acids bearing the non-natural D-
configuration with MtuDAH7PS and the resulting implications for allosteric inhibitor design. 
Chapter 5 deals with the discovery of novel allosteric ligands for MtuDAH7PS, using 
compounds selected based on virtual screening. The structures of several new ligands in 
complex with MtuDAH7PS are used to inform the future design of non-natural allosteric 
inhibitors. 
  
Chapter 2 – Active site inhibitors of 
MtuDAH7PS 
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2.1 Introduction 
The design of enzyme inhibitors is frequently inspired by intermediates or the proposed tran-
sition state structures of the reaction catalysed by the target enzyme. The current mechanistic 
understanding of the reaction catalysed by DAH7PS includes two intermediates which could 
serve as the basis for inhibitor design: the planar oxocarbenium ion 1.1 or the tetrahedral 
phosphohemiketal 1.2 (Figure 2.1). PEP analogues which mimic either geometry have been 
reported as inhibitors of DAH7PS and other PEP-utilising enzymes (compounds 2.1 and 2.3).112-
113
 Extension of the planar vinylphosphonate 2.1, a mimic of PEP and the oxocarbenium ion 1.1 
to include a second phosphate moiety that was envisaged to interact with the E4P phosphate 
binding pocket resulted in a slight increase of inhibitory potency against E. coli DAH7PS.114 
The interpretation of the results was however further complicated by the lability of the inhibitor 
with regard to isomerisation. 
 
Figure 2.1: Proposed mechanism of the DAH7PS reaction and rationale for inhibitor design. 
The tetrahedral phosphohemiketal intermediate 1.2 presents another interesting starting point for 
inhibitor design. The configuration at the transient chiral centre at C2 depends upon which face 
of the oxocarbenium ion 1.1 is attacked by active site water, so that differences in inhibition 
observed with compounds mimicking the two configurations could provide insights into the 
mechanism of the enzyme-catalysed reaction. In addition, an extended intermediate mimic with 
a tetrahedral geometry at C2 would lack the vinylphosphonate moiety that caused the compli-
cations in assessing the extended oxocarbenium ion mimics. This chapter represents the first 
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example of synthesis and testing of inhibitors against a type II DAH7PS, the enzyme from the 
important pathogen M. tuberculosis. 
This chapter comprises two publications detailing the inhibition of M. tuberculosis DAH7PS by 
extended tetrahedral intermediate mimics:  
The initial studies were originally published in The Journal of Biological Chemistry: 
 
Reichau, S.; Jiao, W.; Walker, S. R.; Hutton, R. D.; Baker, E. N.; Parker, E. J. Potent inhibitors 
of a shikimate pathway enzyme from Mycobacterium tuberculosis. J. Biol. Chem. 2011; 286 
(18): 16197-16207. © the American Society for Biochemistry and Molecular Biology. 
 
Dr S.R. Walker designed and carried out preliminary work towards the racemic inhibitor 
synthesis. Dr W. Jiao conducted molecular modelling studies. Dr R.D. Hutton and Prof E.N. 
Baker assisted with X-ray crystallography. Prof E.J. Parker designed experiments and 
contributed to the writing of the manuscript. The author of this thesis wrote the publication 
manuscript and all co-authors contributed to the writing and/or revision of the manuscript. The 
author of this thesis carried out the synthesis, characterisation and testing of the racemic 
inhibitor and designed and carried out the synthesis, characterisation and testing of the 
enantiopure inhibitors. Refinement and deposition of the crystal structure reported in the 
manuscript was also carried out by the author of this thesis. 
The conformational change of active site residues involved in inhibitor binding in the initial 
study, specifically the movement of the conserved KPRS motif, prompted the investigation of 
the inhibitory potency of inhibitors of different chain-lengths. The adaptable synthesis 
developed during the initial enantiopure inhibitor synthesis was optimised to prepare and 
characterise an additional four inhibitors with micromolar inhibition constants against 
MtuDAH7PS, highlighting the ability of the binding site to accommodate ligands of different 
chain-lengths. This work has been published in RSC Advances:  
 
Reichau, S.; Parker, E. J., Active site plasticity of a critical enzyme from Mycobacterium 
tuberculosis. RSC Advances 2013, 3 (10), 3209-3212.  
Reproduced by permission of The Royal Society of Chemistry. 
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The author of this thesis carried out all the experimental and computational work included in 
this manuscript and wrote the manuscript. Prof E.J. Parker designed experiments and 
contributed to the writing of the manuscript. Further experimental details can be found in the 
supplemental material accompanying the publications which is reproduced in Chapter 7 or can 
be accessed online at: 
http://dx.doi.org/10.1074/jbc.M110.211649 
http://dx.doi.org/10.1039/C3RA00037K 
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Tuberculosis remains a serious global health threat, with
the emergence of multidrug-resistant strains highlighting the
urgent need for novel antituberculosis drugs. The enzyme 3-de-
oxy-D-arabino-heptulosonate 7-phosphate synthase (DAH7PS)
catalyzes the first step of the shikimate pathway for the biosyn-
thesis of aromatic compounds. This pathway has been shown to
be essential in Mycobacterium tuberculosis, the pathogen
responsible for tuberculosis. DAH7PS catalyzes a condensation
reaction between P-enolpyruvate and erythrose 4-phosphate to
give 3-deoxy-D-arabino-heptulosonate 7-phosphate. The
enzyme reaction mechanism is proposed to include a tetrahe-
dral intermediate, which is formed by attack of an active site
water on the central carbon of P-enolpyruvate during the course
of the reaction. Molecular modeling of this intermediate into
the active site reported in this study shows a configurational
preference consistent with water attack from the re face of
P-enolpyruvate. Based on this model, we designed and synthe-
sized an inhibitor of DAH7PS that mimics this reaction inter-
mediate. Both enantiomers of this intermediate mimic were
potent inhibitors of M. tuberculosis DAH7PS, with inhibitory
constants in the nanomolar range. The crystal structure of the
DAH7PS-inhibitor complexwas solved to 2.35 A˚. Both the posi-
tion of the inhibitor and the conformational changes of active
site residues observed in this structure correspond closely to the
predictions from the intermediatemodeling. This structure also
identifies a water molecule that is located in the appropriate
position to attack the re face of P-enolpyruvate during the
course of the reaction, allowing the catalyticmechanism for this
enzyme to be clearly defined.
Tuberculosis remains a serious global health threat with over
a million deaths per year. The recent emergence of multidrug-
resistant strains of Mycobacterium tuberculosis, the pathogen
that causes the lung disease, highlights the need for rapid devel-
opment of new antibacterial drugs to combat tuberculosis
(1–4).
3-Deoxy-D-arabino-heptulosonate 7-phosphate synthase
(DAH7PS)4 is an important enzyme in M. tuberculosis and
other pathogens. It catalyzes the first committed step in the
shikimate pathway, which is responsible for the biosynthesis of
aromatic amino acids and other essential aromatic metabolites
in microorganisms, plants, and apicomplexan parasites (5–7).
This pathway is absent in humans, and inhibitors of amino acid
biosynthesis have been shown to be effective antimicrobial and
herbicidal agents (8, 9). Gene disruption studies have demon-
strated thatM. tuberculosis is not viable if the shikimate path-
way is not operational (10). These findings make DAH7PS an
attractive target for drug development.
DAH7PS catalyzes the aldol-like condensation of P-enolpy-
ruvate and D-erythrose 4-phosphate (E4P) to yield 3-deoxy-D-
arabino-heptulusonate 7-phosphate (Fig. 1a). The reaction
mechanism has been subject to extensive study, and many of
the key details of themechanism have been elucidated (11–16).
The reaction occurs stereospecifically with respect to both sub-
strates, with the si face of P-enolpyruvate attacking the re face of
E4P. A divalent metal ion present in the active site is essential
for activity. The reaction takes place with cleavage of the C–O
bond of P-enolpyruvate rather than the O–P bond, requiring
water to attack C2 of P-enolpyruvate at some stage during the
reaction.
A mechanism consistent with the data published to date
starts with nucleophilic attack of P-enolpyruvate at the E4P
aldehyde moiety, resulting in the formation of oxocarbenium
species 1 (Fig. 1b). This oxocarbenium ion 1 can be attacked by
an active site water to form phosphohemiketal 2. It is notewor-
thy thatwater can potentially attack fromeither face of 1, giving
rise to two possible diastereoisomers of tetrahedral intermedi-
ate 2, differing in their absolute configuration at C2. Although
this stereogenic center is transient and the stereochemical
information is lost by elimination of phosphate in the final step
to generate the product DAH7P (3), the geometry of the
enzyme active site is likely to favor stereoselective attack of
* This research was funded in part by the Maurice Wilkins Centre for Molecu-
lar Biodiscovery.
Theatomic coordinates and structure factors (code3PFP) havebeendeposited in
the Protein Data Bank, Research Collaboratory for Structural Bioinformatics,
Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental text and Figs. S1–S4.
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Supplemental Material can be found at:
water to form one diastereoisomer of 2 preferentially. In this
way, DAH7P is formed in its acyclic form and cyclizes into its
cyclic pyranose form following release from the enzyme.
3-Deoxy-D-manno-octulosonate 8-phosphate synthase
(KDO8PS), an enzyme involved in the synthesis of the cell-wall
lipopolysaccharide of Gram-negative bacteria, is structurally
and evolutionary related to DAH7PS. KDO8PS catalyzes an
analogous reaction between P-enolpyruvate and the five-car-
bon sugar arabinose 5-phosphate (17). Studies of the reaction
mechanism of KDO8PS suggest that water is activated by the
active site metal prior to attack at the reaction intermediate
(18). Computational and structural studies of KDO8PS indicate
that after activation, water or hydroxide attacks from the si
face of P-enolpyruvate, resulting in the overall syn addition of
arabinose-5-phosphate and a hydroxyl group to the double
bond of P-enolpyruvate (19). Due to lack of comparable data for
the reaction catalyzed by DAH7PS, it is unclear whether these
findings also apply to the reaction catalyzed by DAH7PS.
Despite the similarities in their reaction chemistry, a number of
key structural and mechanistic differences of DAH7PS and
KDO8PS such as divalent metal ion requirement and substrate
specificity have also been identified (20).
M. tuberculosisDAH7PS (MtuDAH7PS) is the only member
of the DAH7PS type II family that has been structurally char-
acterized (21–23). Type II DAH7PS enzymes show very little
sequence similarity with their type I DAH7PS counterparts,
which are relatively well characterized and are found in organ-
isms such as Escherichia coli (14, 15) and Saccharomyces cerevi-
siae (16, 24). Both type I and type II DAH7PS enzymes share the
common triosephosphate isomerase (TIM barrel) fold, and
mechanistic studies have suggested that the key details of the
reaction chemistry are similar for enzymes of both DAH7PS
types (25). Despite the low sequence similarity, the active site
architecture of MtuDAH7PS shows remarkable correspond-
ence to that of type I enzymes (Fig. 2). P-enolpyruvate is held in
place by a tightly knit network of interactions. The P-enolpyru-
vate phosphate forms salt bridges to Lys306 (MtuDAH7PSnum-
bering) and Arg337 and forms a hydrogen bond to the backbone
N–H of Glu283, whereas the P-enolpyruvate carboxylate forms
a salt bridge to Arg126. The metal ion is coordinated by His369,
Glu411, Cys87, and Asp441 in a trigonal pyramidal fashion, leav-
ing one coordination site potentially free for the carbonyl moi-
ety of the E4P aldehyde moiety, thereby activating this func-
tionality to nucleophilic attack. The proposed E4P binding site
is constituted mostly by a 133KPRS136 motif that is highly con-
served in the type II subfamily, whereas members of the type I
DAH7P synthase subfamily display a very similar, also highly
conserved KPRT motif at the equivalent position. The best
indication of how E4P is bound to the enzyme can be found
in the crystal structure of S. cerevisiae type I DAH7PS
(SceDAH7PS) in complexwith the E4P analog, glycerol 3-phos-
phate (G3P) (16). Arginine and threonine from the KPRTmotif
interact with the G3P phosphate moiety, whereas the primary
hydroxyl group of G3P forms a hydrogen bond to the backbone
carbonyl of the proline residue of the KPRT motif, and the
secondary hydroxyl interacts with the metal-coordinating
aspartate.
Despite the many similarities in active site architecture and
reaction chemistry between DAH7P synthases from different
organisms and families, there are some significant distinctions
of type II DAH7P synthases. For example, Trp280 forms part of
the P-enolpyruvate binding site inMtuDAH7PS,whereas in the
E. coli and S. cerevisiae enzymes, this residue is replaced by Ala.
However, in the type I enzymes, the space occupied by Trp280 is
occupied by a Tyr residue from another part of the structure.
Another significant distinction between MtuDAH7PS and all
other DAH7P synthases characterized to date is its complex
mechanism of allosteric regulation, which we have recently
investigated in detail (22). Furthermore, the recent discovery
thatM. tuberculosis chorismate mutase is activated in complex
with DAH7PS suggests a key role of DAH7PS in the regulatory
network of aromatic metabolism ofM. tuberculosis (26).
In vitro studies with mechanism-based inhibitors have been
previously reported for E. coliDAH7PS (27, 28). Recent results
in our laboratory have shown that extension of inhibitors tar-
geting the P-enolpyruvate binding site to pick up interactions in
the E4Pbinding site leads to increased inhibitor potency (49). In
addition, carbohydrate-derived compounds, designed as
mechanism-based inhibitors of both KDO8PS and DAH7PS,
were shown to have mild antibacterial properties when tested
against E. coli, Yersinia enterocolitica, Pseudomonas aerugi-
nosa, Staphylococcus aureus, and Bacillus subtilis, although
FIGURE 1. Catalysis by DAH7PS. a, overall reaction catalyzed by DAH7PS. b, proposed mechanism of condensation of P-enolpyruvate (PEP) with E4P. H-Enz,
H-enzyme.
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further in vitro studies were suggested to confirm that these
compounds indeed target KDO8PS and/or DAH7PS (29).
However, to date, no inhibitors for the DAH7PS from the
pathogenM. tuberculosis have been reported. Herein we report
the design, synthesis, and testing of an intermediate mimic as
the first potent inhibitor of MtuDAH7PS in both its racemic
and its enantiomerically pure forms. The crystal structure of
the target enzyme in complex with the inhibitor shows that the
simplified intermediate analog binds in a fashion in accordance
with its design and thus provides valuable insight into both the
DAH7PS reaction mechanism and a lead structure for novel
potent antimycobacterial drugs targetingMtuDAH7PS.
EXPERIMENTAL PROCEDURES
Analytical Methods—Optical rotations []D20 were measured
at room temperature on a PerkinElmer Life SciencesModel 341
polarimeter; analyte concentrations are given in g/100 ml. Spe-
cific rotations are reported. NMR spectroscopy was carried out
on aVarianUNITY300MHzorVarian INOVA500MHzNMR
spectrometer. 1H and 13CNMR spectra are referenced to exter-
nal tetramethylsilane; 31PNMR spectra are referenced to exter-
nal 85% phosphoric acid.Mass spectrometry was performed on
BrukermaXis 3G orMicromass LCTby electrospray ionization
in positive or negative ionization modes.
UV-visible spectrophotometry was carried out on a Varian
CaryOne UV-visible spectrophotometer, in stoppered quartz
cells. The temperature was continuously controlled at 303 K
(30 °C) by the use of a jacketedmulticell holder, connected to an
external Varian Peltier temperature controller filled with either
water or ethylene glycol.
Expression, Purification, and Crystallization of MtuDAH7PS—
M. tuberculosis DAH7PS was overexpressed and purified as
described previously (21–23). A reservoir solution containing
400 M inhibitor was prepared by dissolving an appropriate
amount of solid rac-4 in crystallization buffer (0.1 M Tris-HCl
buffer at pH 8, 1.5 M ammonium sulfate, and 12% v/v glycerol).
500 l of enzyme stock solution was concentrated to 50 l
using centrifugation with a 10-kDa cutoff membrane, and the
resulting solution was diluted to 500 l using the inhibitor
solution. This process was repeated twice to buffer-exchange
the solution as completely as possible. 1 l of the buffer-ex-
changed enzyme solution (concentration 3–5 mg/ml) was
mixedwith 1l of crystallization buffer. Crystalswere grownby
sitting drop vapor diffusion over 300 l of reservoir solution
and appeared within 24 h at 25 °C. Crystals were flash-frozen in
liquid nitrogen in a cryoprotectant solution consisting of crys-
tallization buffer and 20% v/v glycerol.
Structure Determination—X-ray diffraction data were col-
lected at the MX2 beamline at the Australian Synchrotron (see
Table 1). The dataset was integrated using iMosflm (30). The
space group and cell parameters were identical to those of pre-
FIGURE 2.Active site architecture of DAH7PS. a, stereo view of the active site ofM. tuberculosisDAH7PS (PDB code 3NV8) (22) showing P-enolpyruvate (PEP,
yellow carbons) in its binding site. Themanganese iron is represented as a purple sphere. Major interactions between P-enolpyruvate and the enzyme and the
metal coordination sphere are shown as dashed lines. b, stereo view of the active site of S. cerevisiae DAH7PS in complex with P-enolpyruvate, G3P (yellow
carbons), and a Co2 ion (magenta sphere)(PDB code 1OF8) (16). A water molecule (WAT) on the re side of P-enolpyruvate (left in this orientation), which is
proposed to play the role of the substrate water, is shown as a red sphere.
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viously reported structures of MtuDAH7PS allowing phases
calculated from the original structure (Protein Data Bank
(PDB) code 2B7O) (21) to be used to solve the structure. The
structure was refined using the CCP4 software package (30) by
methods analogous to the ones described for the native struc-
ture (21). Both enantiomers of inhibitor 4 were built using the
Dundee PRODRG2 server (31). The two enantiomers of 4were
initially positionedmanually into the electron density observed
in the active site using COOT and then refined at half-occu-
pancy. The model was optimized using repetitive cycles of
model building with COOT and refinement with REFMAC5.
Water molecules were added automatically in COOT and ver-
ified using 2Fo Fc and Fo Fc maps and potential to hydro-
gen-bond to at least one protein atom or other water molecule.
A bias-removed Fo Fc omit map (see Fig. 5a) was generated
by deleting the ligand and active site waters from themodel and
subjecting the model to simulated annealing and refinement in
PHENIX. The 2Fo  Fc map obtained by this procedure (see
Fig. 5a) shows clear continuous electron density for ligand 4.
The structure was validated using SFCHECK, with 97.5% of
residues in the most favored region of the Ramachandran plot
(Table 1). The final model included two protein chains each
containing all 462 natural residues and two residues from His
tag cleavage, 554 water molecules, two manganese ions, one
sulfate ion, one chloride ion, and (R)- and (S)-4.
Inhibition Assays—Enzyme activity was monitored by fol-
lowing the loss of absorbance at 232 nm ( 2800 liters mol1
cm1) due to the consumption of P-enolpyruvate (32). Assays
were carried out in 50 mM 1,3-bis(tris(hydroxymethyl)methyl-
amino)propane buffer at pH 7.5 containing 1 mM tris(2-car-
boxyethyl)phosphine at 30 °C. The buffer solution was pre-
pared using ultrapure water, which was stirred over Chelex
resin (Bio-Rad) and filtered before use. Manganese(II) sulfate
stock solution (10 mM) was made up in ultrapure water pre-
treated with Chelex resin. P-enolpyruvate and E4P substrate
solutions were made up to10mM by dissolving the P-enolpy-
ruvate monopotassium salt and E4P monosodium salt
(Aldrich) in buffer solution. Accurate substrate concentrations
were determined by enzymatic reaction; the absorbance
changes of solutions containing one substrate in excess were
determined before and after conversion of the limiting sub-
strate by addedDAH7PShad occurred, and the extinction coef-
ficient of P-enolpyruvate was used to calculate the concentra-
tion of the limiting substrate. The absorbance change was
corrected by the absorbance change causedwhenDAH7PSwas
added to a control solution that did not contain E4P. For inhi-
bition studies, assay solutions containing manganese (II), vary-
ing concentrations of P-enolpyruvate and inhibitors, and buffer
were equilibrated at 30 °C. 2 l (1.3 mg/ml) of M. tuberculosis
DAH7PSwas added, and themixturewas equilibrated for 2min
before the reaction was initiated by the addition of E4P (11 l).
Final assay conditions were 10 MMn2, 5.2 nM DAH7PS, 100
M E4P, 57.6–115.2 M P-enolpyruvate, 0–940 nM inhibitor
with an appropriate amount of buffer tomake up a final volume
of 1 ml.
Lanzetta Phosphate Assay—Lanzetta reagent (33) was pre-
pared fresh as required from the following components: 3 parts
0.045% w/v malachite green in water, 1 part 4.2% w/v ammo-
niummolybdate in 4 M HCl, 0.1 parts 1.5% v/v Triton X-100 in
water. The components were mixed in the dark and stirred for
1 h before the solution was filtered through a 0.45-m syringe
filter. For the qualitative detection of phosphate-containing
fractions after anion exchange chromatography, a 20-l sample
of each fraction wasmixed with 250l of Lanzetta reagent, and
the color change was judged by optical inspection. For the
quantitative determination of inhibitor concentration, 300 l
of the inhibitor solutions was incubated with 10 l of calf alka-
line phosphatase solution (5 units/ml in 4 mM MgCl2) for at
least 2 h. To 100 l of the digested sample was added 700 l of
Lanzetta reagent, and the absorbance at 630 nm was deter-
mined after 20min.A calibration curve for the determination of
phosphate concentrationwas obtained from analogous analysis
of solutions of appropriate concentrations (6–150 M) of
KH2PO4, which had been dried in high vacuum for at least 3 h
before use. As a control, a glucose-6-phosphate solution of
known concentration was also digested with calf alkaline phos-
phatase and analyzed.
Modeling Procedure for Linear Intermediate and the
Designed Inhibitors—Modeling studies were carried out using
software packages from Schro¨dinger Suite 2006 software pack-
age (34–37); more detailed computational methods can be
obtained from the supplemental material. The previously
reported crystal structure of MtuDAH7PS (PDB code 2B7O)
(21) was used as the receptor. As a starting point for docking
studies, an ensemble of low-energy conformations of the
ligands (R)- and (S)-4 and both epimers of the tetrahedral inter-
mediate 2 were identified by conformational searches. The
modeling of the tetrahedral intermediate epimers into
the active site of MtuDAH7PS was carried out with the
Schro¨dinger Suite 2006 Induced Fit Docking protocol (36). The
induced fit docking procedure lead to an intermediate adapted
protein receptor in which several residues in the active site
adopted conformations different from the ones observed in the
native crystal structure (PDB code 2B7O). This intermediate
adapted structure of MtuDAH7PS was then used as a rigid
receptor for docking studies of compounds (R)- and (S)-4,
which were conducted using Glide (37).
Synthesis—All reactions were carried out under an inert
atmosphere of nitrogen in flame-dried glassware unless other-
wise stated. Organic solvents were dried before use by standard
methods (38). Dess-Martin periodinane (39, 40) was prepared
according to literature procedures. m-Chloroperbenzoic acid
was recrystallized from dichloromethane before use, and all
other reagents were purchased from Sigma-Aldrich and used
without further purification.
Preparative procedures and characterization of previously
unreported compounds can be found in the supplemental
material. A representative procedure for the final step of the
synthesis and characterization of inhibitor4 is outlined in detail
below.
HeptanoicAcid 2,7-Bisphosphate 4—Protected bisphosphate
11 (177 mg, 0.24 mmol) was dissolved in ethyl acetate (15 ml),
and palladium on charcoal (10% palladium/carbon, 57 mg,
0.053 mmol of palladium) was added. The reaction flask was
purged with hydrogen gas with three freeze-pump-thaw cycles.
The reaction mixture was stirred for 16 h, after which TLC
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indicated complete consumption of starting material 11. The
suspension was filtered through a Celite pad, the Celite was
washed with ethyl acetate and methanol, and the solvent was
evaporated under reduced pressure. The resulting residue
was dissolved in 1 M aqueous potassium hydroxide solution (7
ml) and stirred vigorously for 2.5 h. The reaction mixture was
passed down a column consisting of freshly regenerated
DOWEX50WX4-200 (H) resin (5 1 cm), and the column
was eluted with 50ml of water. The eluate was neutralized with
1 M potassium hydroxide solution and lyophilized. The crude
product was purified by anion exchange chromatography on
SOURCE-Q resin eluting with a gradient of water/aqueous
ammonium bicarbonate solution. Fractions containing the
desired product were identified using the qualitative Lanzetta
assay (see below), pooled, and lyophilized to give 42.5 mg of a
white powder consisting of the product and residual ammo-
nium bicarbonate. Lanzetta phosphate assay (see above) estab-
lished that the purity of the white powder yielded was 80% by
weight; the corrected yield for this step is thus 34%.
1HNMR (500MHz, D2O)  4.34 (td, J 5.6, 9.0Hz, 1H), 3.73
(q, J 6.4Hz, 2H), 1.63–1.76 (m, 2H), 1.49–1.59 (m, 2H), 1.22–
1.42 (m, 4H). 13C NMR (126 MHz, D2O)  24.0 (br), 25.2 (br),
30.1 (br), 33.7 (br), 65.4 (br), 76.1 (br), 180.5 (br). 31P NMR (121
MHz, D2O)  ppm 3.31 (t, J  6.0 Hz, 1P), 1.85 (d, J  8.8 Hz,
1P). HRMS[ESI,neg] calculated for C7H14O10P2 321.0140,
found 321.0131 [M-H]. []D20 (R)-4, -0.9 (c 1.8, H2O), (S)-4,
0.8 (c 1.9, H2O).
RESULTS
Modeling of the Reaction Intermediate into MtuDAH7PS
Active Site—To inform inhibitor design, the predicted tetrahe-
dral reaction intermediate (2, Fig. 3) was modeled into the
active site ofMtuDAH7PS. Because it is unknown from which
side the water attacks the P-enolpyruvate substrate during the
reaction, both possible epimers of the linear intermediate were
modeled.
Themodeling study produced a total of 30 possible poses for
the two possible C2 diastereoisomers of the tetrahedral inter-
mediate in the active site, out of which 17 retained the expected
P-enolpyruvate binding interactions. All 17 poses with correct
P-enolpyruvate orientation are from the S-isomer of the inter-
mediate, consistent with water attacking the C3 carbon of
P-enolpyruvate from its re face, which is the side opposite the
active site Mn2 ion.
The best pose from themodeling study (Fig. 3a) was selected
based on two criteria. The first is that the P-enolpyruvate part of
the tetrahedral intermediate retains the same interactions as
observed in the original crystal structure (PDBcode 2B7O). The
second is that the positioning of the E4P phosphate group
should be as close as possible to the phosphate group of G3P in
the crystal structure of SceDAH7PS (PDB code 1OF8), which is
considered to provide the best prediction for the E4Pphosphate
position. In the best pose (Fig. 3a), the P-enolpyruvate part of
the molecule interacts with Arg126, Lys306, Arg337, Arg284, and
Glu283. Arg284 bridges the phosphate groups of P-enolpyruvate
and E4P through salt bridges and hydrogen bonds. The E4P
phosphate group interacts with Arg284, Arg135, and Ser136,
which suggests that part of the KPRS motif (Arg135 and Ser136)
plays a key role in positioning of the E4P phosphate, as expected
from the G3P-bound SceDAH7PS structure. The E4P aldehyde
group, now converted to a hydroxyl group in the linear inter-
mediate, is at a distance of 2.2 Å from the metal ion. This indi-
cates that the aldehyde of E4P may be held in place by coordi-
nation to the metal ion before reaction occurs. The hydroxyl
group that corresponds to the incoming water molecule forms
FIGURE 3.Molecularmodeling studies and inhibitor design.a, themodeledbest pose of the tetrahedral open chain intermediate2 (S-isomer) from induced
fit docking to the active site ofMtuDAH7PS superimposed on the crystal structure of SceDAH7PS (PDB code 1OF8). The active site carbons from the modeled
structure are in green, and the active site residues of SceDAH7PS are shown with yellow carbons. The modeled linear intermediate molecule is shown with
magenta carbons, and the C2-hydroxyl group is pointing behind the plane. The residues are labeled according to the numbering inMtuDAH7PS. Themetal ion
is displayed as a purple sphere. Hydrogen bonds are represented by dashed lines. b, left, linear intermediate 2. Center, molecular model of linear intermediate 2
showing the preferred 2S-configuration. Right, simplified intermediate analog 4, synthetic target for this study.
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hydrogen bonds with Trp280, Glu248, and Lys133. Two of these
residues, Glu248 and Lys133, are conserved across the entire
DAH7PS family, whereas Trp280 is only conserved in the type II
enzymes.
Inhibitor Design—Combining results from the intermediate
modeling and previous work on mechanism-based inhibitors
(27, 28), we designed bisphosphate 4 (Fig. 3b) as a simplified
analog of the tetrahedral intermediate. The 2-phosphorylcar-
boxylic acid moiety targets the P-enolpyruvate binding site and
resembles phospholactate, which has been reported as an effi-
cient inhibitor of E. coli DAH7PS (27). Bisphosphate 4 repre-
sents a simplified analog of tetrahedral intermediate 2; the
phosphoryl and carboxyl moieties of compound 4 are pro-
posed to act as charged anchors arranged in a similar geom-
etry to those of intermediate 2 and held together by a non-
functionalized hydrocarbon linker. Given its low degree of
functionalization, bisphosphate 4 may be used as a lead
structure for specific introduction of functionality to
enhance enzyme-ligand affinity. In light of the results for
molecular modeling of the tetrahedral intermediate 2, which
suggest a preference for the S-configuration at C2, we
devised two syntheses leading to target compound 4 to assess
possible enantio-discrimination: one racemic synthesis,
which had already been proven useful in our laboratory, as
well as a chiral pool synthesis, which allowed control of the
absolute configuration at C2.
Synthesis of Racemic 4—The synthetic strategy toward rac-4
relies on the establishment of the key-hydroxyestermoiety by
aDarzens-type chain elongation of an aldehyde, amethodology
that has been used for the synthesis of related compounds (Fig.
4) (29, 41). The final deprotection was achieved by hydrog-
enolysis of the benzyl groups followed by hydrolysis of the iso-
propyl ester. The final product, rac-4, was purified by anion
exchange chromatography eluting with an ammonium bicar-
bonate gradient.
Crystal Structure—The racemic inhibitor 4 was co-crystal-
lized with DAH7PS from M. tuberculosis. Although generally
both purification of the enzyme and crystal growth are difficult
in the absence of P-enolpyruvate in the buffer solution, x-ray
diffraction quality crystals were obtained by buffer exchange of
the purified enzyme solution with a solution containing inhib-
itor 4 (Table 1). The crystal structure was solved by molecular
replacement using the previously determined MtuDAH7PS
structure (PDB code 2B7O) (21) as search model and was
refined using x-ray diffraction to 2.35 Å (Table 1) The asym-
metric unit contains two enzyme molecules as in other
MtuDAH7PS crystal structures; tertiary and quaternary struc-
tures are essentially unaffected by binding of inhibitor 4. Super-
imposition on the wild-type protein (PDB code 3NV8) (22)
showed that 5029 atoms could be matched with a root mean
square positional difference of 0.22 Å.
FIGURE 4. Synthesis of racemic inhibitor 4. (i) TBDMSCl, imidazole, dichloromethane, 61%. (ii) Dess-Martin periodinane, dichloromethane, 70% (crude). (iii)
isopropyl dichloroacetate, KOiPr, iPrOH, Et2O. iv, NaCNBH3,
iPrOH, 60% (two steps). (v) tetrabutylammonium fluoride, tetrahydrofuran, 56%. (vi) 1)
(BnO)2PN(
iPr)2, 1H-tetrazole, dichloromethane; 2) meta-chloroperbenzoic acid, 50%. (vii) 1) H2, palladium/carbon; 2) KOH, H2O; 3) DOWEX-H
; 4) SOURCE-Q
anion exchange chromatography, 42%.
TABLE 1
Data collectionand refinement statistics forM. tuberculosisDAH7PS in
complex with 4
Data collection
Crystal system Trigonal
Space group P3221
Unit cell parameters
a (Å) 203.58
b (Å) 203.58
c (Å) 66.49
Resolution range (Å) 55.641–2.35 Å (2.48–2.35)
Measurements 726,170
Unique reflections 65,888
Redundancy 11.0 (11.2)
Completeness (%) 100 (100)
I/(I) 5.0 (1.9)
Rmerge (%) 13.0 (39.2)
Wilson B-value (Å2) 26.5
Refinement
Resolution (Å) 51.16–2.35 (2.41–2.35)
Rcryst (%) 16.4
Rfree (%) 19.6
Amino acids (chain length
464 residues)
464 464 res.; 7136 atom sites
Water molecules 554
Other 2 Mn2a, 1 SO42, 1 Cl, (R)-4a, (S)-4a
Mean B (Å2)
Protein 25.13
Water 32.06
Other 12.12
r.m.s.d.b from target values
Bond lengths (Å) 0.010
Bond angles (°) 1.214
Dihedral angles (°) 5.634
Ramachandran
Most favored (%) 98.3
Allowed (%) 1.2
Disallowed (%) 0.5
PDB code 3PFP
a Refined at reduced occupancy.
b r.m.s.d., root mean square deviation.
Potent Active Site Inhibitors for M. tuberculosis DAH7PS
16202 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 18•MAY 6, 2011
 at Univ of Canterbury (CAUL), on March 29, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Clear continuous electron density for inhibitor 4 was found
in both active sites. The Fo Fc omitmap generated by remov-
ing the inhibitor and active site waters from the model and
subjecting the resulting model to simulated annealing and
refinement shows clear continuous density for inhibitor 4
and for awatermolecule in the active site (Fig. 5a). Based on the
electron density maps obtained, it could not be concluded
whether there is preferential binding of one of the enantiomers
from the racemic mixture. To represent this ambiguity, our
final model includes both (R)-4 and (S)-4 at half-occupancy.
Inhibitor 4 binds as predicted with its 2-phosphoryl and car-
boxylate moieties in the P-enolpyruvate binding site and in an
extended conformation so that the phosphate moiety on C7 is
located near the proposed E4P phosphate binding site (Fig. 5b).
Active site residues interacting with the P-enolpyruvate-mim-
icking portion of ligand 4 show little movement, consistent
with this portion of the inhibitor being a goodmimic of P-enol-
pyruvate. As expected, the conformations of the metal binding
residues were unaffected by binding of compound 4. The
2-phosphate moiety of inhibitor 4 forms salt bridges with
Arg284, Arg337, and Lys306 and a hydrogen bond to the back-
bone N–H of Glu283. The carboxyl group forms salt bridges
with Lys133 and Arg126 and coordinates to the manganese ion
present in the active site. The 7-phosphate moiety extends into
the tentative E4P phosphate binding site, forming salt bridges
with Lys380 and Arg135 and hydrogen bonds with the Ser136
hydroxyl group and backbone N–H. Conformational changes
relative to the P-enolpyruvate-liganded structure were
observed for the KPRS motif associated with inhibitor binding
(Fig. 5c). Arg135 and Ser136 interact with the 7-phosphate moi-
ety of inhibitor 4, moving closer into the active site pocket. The
side chain of Lys133 shows the biggest conformational change of
all active site residues, establishing a salt bridge to the carbox-
ylate group of ligand 4. This big movement may also be partly
due to increased electrostatic repulsion with the guanidinium
group of Arg135, which has moved closer into the active site.
Interestingly, the side chainmovement of Lys133 correlates well
with the movement that the induced fit molecular modeling
results predict for this residue to accommodate the proposed
reaction intermediate (Fig. 5d).
The superposition of structures of the DAH7PS-4-complex
and the induced fit-modeling results (Fig. 5d) show clearly that
the experimental binding mode of bisphosphate 4 closely
matches the in silico modeling of the proposed reaction inter-
mediate into the active site. The carboxylate and both phos-
phate groups of inhibitor 4 occupy positions that were pre-
dicted for the corresponding moieties of the intermediate
model, with minor deviations found in the carbon chain. A
crystallographically located water molecule occupies a position
very close to the predicted position of the intermediate 2-
hydroxyl group. This water is held in place by hydrogen bonds
to Trp280 and Glu248. The distance of this water to C2 of the
ligand is 3.4 Åwhen (R)-4 is modeled into the active site and 3.2
Å for the model containing (S)-4. Preliminary testing of rac-4
indicated that its Ki againstMtuDAH7PS was in the submicro-
molar range. Encouraged by these results, and to assesswhether
one enantiomer of 4 is preferentially bound by the enzyme, we
synthesized compounds (R)-4 and (S)-4 for inhibition assays.
Synthesis of (R)-4 and (S)-4—Because the previously de-
scribed synthesis of rac-4 offers little potential with respect to
stereoselective introduction of the -hydroxyester moiety,
another synthetic route was developed in which the chirality is
derived from a cheap and readily available chiral pool starting
material (Fig. 6). The chiral epoxyester 14 of appropriate con-
figuration was prepared from D- or L-serine, respectively, fol-
lowing a previously reported method (42). Ethyl glycidate 14
was ring-opened regioselectively to yield -hydroxyester 15.
Hydrogenolysis of ester 15 liberated the 7-hydroxyl group to
generate dihydroxyester 16, which could then be converted to
(R)-4 or (S)-4 using the same procedures as described above for
the racemic synthesis.
Inhibition Studies—(R)-4 and (S)-4were tested for inhibition
ofMtuDAH7PS. Although inhibitor 4was designed as a bisub-
strate inhibitor, it is known that DAH7PS operates by a sequen-
tial ordered reaction mechanism in which P-enolpyruvate has
to bind to the enzyme first (25). Thismeans that although com-
petition with P-enolpyruvate is most important to assess the
inhibitory potency, the fixed concentration of the second sub-
strate can influence the inhibition. The kinetic assays were car-
ried outwith P-enolpyruvate concentrations ranging from57 to
115 M at a fixed E4P concentration of 100 M, which corre-
sponds to four times the value determined for the Michaelis
constant for E4P (Km(E4P)). The concentrations of (R)-4 and
(S)-4 were varied from 0 to 940 nM. Even at these high levels of
E4P, (R)-4 and (S)-4 gave inhibitory constants of 360 50 and
620  110 nM respectively (see supplemental Figs. S1 and S2).
(R)-4 and (S)-4 represent the first potent inhibitors reported for
MtuDAH7PS and the first inhibitors with substantially greater
affinity than the substrate P-enolpyruvate (Km(PEP)  29 M
forMtuDAH7PS) for any DAH7P synthase.
Modeling of (R)-4 and (S)-4 into MtuDAH7PS Active Site—
Both (R)-4 and (S)-4weremodeled into theMtuDAH7PS active
site, and the results showed that there is little preference for
binding between the two isomers of inhibitor 4. Both isomers
adopt similar bindingmodes, which are also very similar to that
of the linear intermediate in the active site, with the R-isomer
having a slightly better docking score than the S-isomer. The
interactions found in the best poses from modeling of the two
isomers are the same as those observed in the crystal structure
of the MtuDAH7PS-4-complex (supplemental Fig. S3). These
modeling results in conjunction with the inhibition data
obtained for (R)- and (S)-4 and the tetrahedral intermediate
modeling results suggest that a fully functionalized C2-carbon
of the tetrahedral intermediate bearing carboxylate, phosphate,
and hydroxyl substituents is necessary to observe stereoselec-
tive recognition in the enzyme active site.
DISCUSSION
The study presented here demonstrates the successful com-
bination of synthetic, structural, and computationalmethods to
inform the design of novel lead structures of inhibitors for
MtuDAH7PS. Although both the substrate and the product of
the enzymatic transformation, P-enolpyruvate and DAH7P,
possess planar geometry atC2,mechanistic considerations sug-
gest that the enzyme active site is also set up to accommodate
preferentially a tetrahedral reaction intermediate. The high
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FIGURE 5. Stereo view of the active site of the enzyme in complex with 4 (only the (R)-enantiomer is shown for clarity). a, Fo  Fc simulated
annealing omit map contoured at 3 showing the electron density for inhibitor 4 (blue carbons) in the active site. WAT, water. b, interactions of 4 with
the active site residues (green carbons) andmetal ion (purple sphere). c, overlay of P-enolpyruvate (yellow carbons)-DAH7PS structure 3NV8 (cyan carbons)
with DAH7PS-4-complex (green carbons). d, overlay of the preferred pose of the linear intermediate (magenta carbons) and 4 (blue carbons; the oxygens
on the C2-phosphate were omitted for clarity). The enzyme structure experimentally obtained from the DAH7PS-4-complex (green carbons) superim-
poses well onto the enzyme structure obtained by induced fit modeling of the linear intermediate (yellow carbons, peptide; magenta carbons,
intermediate).
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inhibitory potencies of (R)- and (S)-4 confirm that intermediate
analogueswith tetrahedral C2 are a promising scaffold for high-
affinity inhibitors of DAH7PS.
The fact that the experimentally determined structure and
the induced-fit model are in good agreement firstly demon-
strates that inhibitor 4 is a good intermediate mimic, and sec-
ondly, verifies that our modeling approach is effective for pre-
dictions of enzyme-ligand interactions for MtuDAH7PS. The
structural information from the enzyme-inhibitor complex can
be used to inform future inhibitor design; based on the binding
mode of inhibitor 4 in the active site, modifications to the lead
structure allow the introduction of specific new interactions
with the enzyme. For example, additional hydroxyl groups at
C4 and C6 of inhibitor 4 with the appropriate absolute con-
figuration are expected to form hydrogen bonds to Asp441,
interactions that were observed in the modeling of the inter-
mediate (Fig. 3). Introduction of a C4-hydroxyl or other met-
al-coordinating group such as an amine or thiol group could
also lead to additional enzyme-inhibitor interactions
through metal coordination.
Inhibitor 4 is a highly charged molecule, featuring two phos-
phate groups and a carboxylate moiety. This characteristic of
this molecule is expected to significantly limit membrane per-
meability. Phosphates are abundant in naturally occurringmol-
ecules, making them highly interestingmoieties in the develop-
ment of drugs. Strategies to generate phosphate prodrugs
containing suitable masking groups that facilitate membrane
permeability and allow the release of the active drug inside the
cell have been developed, and examples of these prodrugs are in
clinical trials (43–45).
Although both enantiomers of inhibitor 4 displayed a high
affinity to the enzyme active site, the small difference in affinity
of the two enantiomers provides valuable insight into the
enzyme mechanism and its inhibition. The observation that
(S)-4 proved to be a slightly less potent inhibitor may be due to
the fact that the C2-hydrogen of (S)-4 points in the direction of
a water molecule also present in the active site, with interatom
distances that suggest a steric clash between these moieties
(supplemental Fig. S4). For the related enzyme KDO8PS, data
fromcomputational and crystallographic studies have led to the
proposition that the substrate water attacks P-enolpyruvate
from the si side during the course of the reaction (18, 19, 46). It,
however, so far remains unclear whether this mechanistic pro-
posal can be transferred toMtuDAH7PS or even DAH7P syn-
thases in general. In the crystal structure reported in this study,
a water molecule was located in close proximity to C2 of the
inhibitor on what would be the re side of P-enolpyruvate. The re-
semblance of this arrangement of inhibitor and water to the
location of the 2-hydroxyl group of the modeled tetrahedral
reaction intermediate, combined with the configurational pref-
erence observed for the docking of the intermediate, suggest
that inMtuDAH7PS, water attack proceeds from the re side of
P-enolpyruvate. This is further supported by studies of type I
DAH7P synthases from S. cerevisiae (16), E. coli (14), andTher-
motogamaritima (47), which located awatermolecule that was
suggested to attack P-enolpyruvate during the course of the
enzymatic reaction in a very similar environment. The glutamic
acid residue has been proposed as a general base catalyst to
facilitate nucleophilic attack of water. The highly conserved
nature of the arrangement of water in the P-enolpyruvate bind-
ing site suggests a common catalytic mechanism for all DAH7P
synthases that involves water attacking the re face of P-enolpy-
ruvate during the course of the reaction.
The combined results from intermediate modeling and the
structural and kinetic study of intermediate analog 4 allow sig-
nificant refinements of the proposed catalytic mechanism of
MtuDAH7PS (Fig. 7). P-enolpyruvate and E4P binding has
already been discussed in detail. We propose that the substrate
water is bound on the re face of P-enolpyruvate through hydro-
gen-bonding interactions with Trp280 and Glu248. Nucleophilic
attack of P-enolpyruvate at the E4P aldehyde moiety is facili-
tated by metal coordination, and the resulting oxyanion is pro-
tonated by Lys133. Both the intermediate modeling results and
the crystal structure of the intermediate analog show significant
movement of the Lys133 side chain upon ligand binding, posi-
tioning it in a suitable position to fulfill this role as a general
acid. The substrate water is activated for attack at C2 of P-enol-
pyruvate by deprotonation with Glu248.
A similar mechanism has been previously suggested in stud-
ies of S. cerevisiae andT. maritima type IDAH7PS (16, 47). The
FIGURE 6. Synthesis of enantiopure inhibitor 4. Yields are given for the synthesis of (R)-4; analogous procedures using L-serine as the startingmaterial were
used for the synthesis of (S)-4 in comparable yields. Please refer to the supplemental material for more detail. (i) HNO2, KBr, H2O then KOH/EtOH, 37% (two
steps). (ii) EtBr, Bn(Et)3NCl, CH2Cl2, 66%. (iii) BnO(CH2)4Br, magnesium, tetrahydrofuran, room temperature, then CuBrSMe2, 78 °C, then 14, 32%. (iv) H2,
palladium/carbon, EtOAc, 66%. (v) (BnO)2P-N(
iPr)2, 1H-tetrazole, dichloromethane, then meta-chloroperbenzoic acid 64%. (vi) H2, palladium/carbon, EtOAc,
then KOH/H2O, then DOWEX-H
, anion exchange chromatography, 27%.
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fact that a glutamate residue is found at the equivalent position
for M. tuberculosis type II DAH7PS and the crystallographic
localization of a suitable substrate water molecule in the
MtuDAH7PS-4-complex in this study as well as our modeling
results further support this mechanistic proposition. In the
next step, the now neutral Lys133 can abstract the proton from
Glu248, either by direct deprotonation or relayed via an active
site water molecule. This step regenerates both the Lys133
ammonium and the Glu248 carboxylate group necessary for the
next catalytic cycle. Lys306, which is positioned within hydro-
gen-bonding distance of the P-enolpyruvate phosphate, could
aid the elimination of phosphate from tetrahedral intermediate
2 by protonating the phosphate, thus making it a better leaving
group. Elimination of hydrogen phosphate yieldsDAH7PS pro-
tonated on the 2-keto moiety; this proton can then be removed
by Lys306. After dissociation of the product DAH7P, all active
site residues have returned to the protonation state that is
required for the next catalytic turnover. This mechanism is the
simplest that is in accordance with the data published to date,
and it accounts for all protonation and deprotonation steps
required on active site residues and intermediates. The only
major side chain movement of an active site residue is required
from the proton-shuttling Lys133, a residue that is not well
defined or possesses high B-factor values in some crystal struc-
tures of DAH7P synthases, indicating mobility of its side chain
(11, 21). Further support for the important role of both Lys133
and Lys306 comes from results in our laboratory that show that
both residues are essential for catalytic activity.5
CONCLUSION
By combining molecular modeling-guided and mechanism-
based design, we have synthesized the first potent inhibitor of
MtuDAH7PS. The crystal structure of the enzyme-inhibitor
complex shows that the structural features of the inhibitor
designed to mimic features of the natural substrates and pro-
posed reaction intermediate indeed lead to the predicted spe-
cific enzyme inhibitor interactions. Inhibitor 4 represents a
promising lead structure for antimycobacterial drugs and offers
ample opportunity for further modification to establish struc-
ture-activity relationships. The crystallographic location of an
active site water molecule has clarified the enzyme catalytic
mechanism.
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3-Deoxy-D-arabino-heptulosonate 7-phosphate synthase is an
important biosynthetic enzyme in Mycobacterium tuberculosis
and a potential drug target. We describe the synthesis, evaluation
and docking of inhibitors with various chain lengths, which
provide insight into the plasticity of the active site for inhibitor
binding.
Tuberculosis remains a serious global health threat, causing over a
million deaths annually. Co-infection with HIV and the emergence
of drug-resistant strains of Mycobacterium tuberculosis highlight
the need for new drugs.1 The shikimate pathway has been shown
to be essential for M. tuberculosis, as shown by gene knockout
studies,2 but it is absent frommammals. Thus, enzymes from this
pathway are promising targets for drug development. 3-Deoxy-D-
arabino-heptulosonate 7-phosphate synthase (DAH7PS) is the first
enzyme of the shikimate pathway. This enzyme catalyses the aldol-
like condensation of phosphoenolpyruvate (PEP) and erythrose
4-phosphate (E4P) (Fig. 1).3
DAH7PS from M. tuberculosis has been structurally and
functionally characterised, and has been shown to play a central
role in the regulation of the essential aromatic metabolism,
making it an attractive target for inhibitor design.4 We recently
reported the synthesis and evaluation of the first potent inhibitor
(2, Fig. 1) of DAH7PS fromM. tuberculosis.5 The design of inhibitor
2 was based on mimicking the proposed linear reaction
intermediate 1. The crystal structure of the enzyme-inhibitor
complex and inhibition results revealed that the phosphate and
carboxylate moieties provide sufficient specific interactions with
the enzyme active site for 2 to act as a potent inhibitor and a useful
intermediate mimic (Fig. 2). Our previously reported inhibitor 2
closely resembles the proposed intermediate with respect to the
position of the charged moieties that anchor it to the active site of
the enzyme, namely the carbon chain length of 2 is the same as in
the intermediate 1. The crystal structure of the enzyme-inhibitor
complex indicates that significant movement of a conserved active
site loop takes place after the binding of the inhibitor to the
enzyme. The loop bearing the conserved KPRS motif that interacts
with the C7-phosphate of 2 (Fig. 2). The conserved KPRS motif
undergoes a conformational change upon inhibitor binding.
Comparing the inhibitor-bound enzyme structure to the apo
enzyme, the guanidinium group of Arg135 is shifted by 1.6 Å,
resulting in a more closed-off active site. While this conforma-
tional change in the protein structure is likely to be associated
with an energetic cost, this in turn would be expected to be offset
by optimising the enzyme-inhibitor interactions in the new
conformation. This raises the question of whether close resem-
blance to the natural intermediates is in fact the best strategy for
the design of potent binders. An extension of the carbon chain of
inhibitor 2 may reduce the conformational rearrangement for the
binding of the inhibitor, whereas a shorter chain length would
require a more drastic conformational change. In order to explore
the extent of the plasticity of the active site of M. tuberculosis
DAH7PS, and to establish the optimum chain length for
inhibition, we have tested and evaluated a series of inhibitors
with shorter and longer chain lengths.
The synthesis of inhibitors with variable chain lengths and the
control of the absolute configuration at C2 was facilitated by the
adaptable design of the synthesis of inhibitor 2 (Scheme 1).
Epoxyester 6 was prepared by a previously reported method, which
allows the use of the two readily available enantiomers of serine as
starting materials and sources of chirality.6 In the key step,
epoxides 6 were opened with cuprate reagents, which in turn were
formed in situ by the transmetallation of the Grignard reagents
formed from bromides 3. Similar reactions have been reported
previously, but with little experimental detail.7
When the reaction was carried out with THF as a solvent,
titration of the organometallic solution revealed that the Grignard
reagent was formed in lower yields (5a: 38%, 5b: 45%). The main
side product was identified as the product of a Wurtz coupling
reaction, 4.8 This side reaction may have been promoted by the
presence of the benzyloxy group in the substrate, a functionality
seldom found in Grignard reagents, and evidence of the
Biomolecular Interaction Centre and Department of Chemistry, PO Box 4800,
University of Canterbury, Christchurch, New Zealand.
E-mail: emily.parker@canterbury.ac.nz; Fax: +64 3 364 2100; Tel: +64 3 364 2871
3 Electronic supplementary information (ESI) available: Detailed synthetic proce-
dures, characterisation of compounds, kinetic assay data and molecular modelling
procedure. See DOI: 10.1039/c3ra00037k
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competing Wurtz coupling has been reported for comparable
substrates.9 This side reaction could be suppressed by the use of
diethyl ether as the solvent and by the efficient activation of the
magnesium used. Hydrogenolysis of the benzyl protecting group
provided the diols 8 in good yields. Phosphorylation was carried
out using the phosphoramidite method with dicyanoimidazole as
the activator and it produced the fully protected inhibitor
precursors 9 (Scheme 1).10 Final deprotection was carried out by
the hydrogenolytic cleavage of the benzyl groups followed by the
hydrolysis of the ester. The final products were purified by anion
exchange chromatography using an ammonium bicarbonate
gradient for elution. Compounds C6R, C6S, C8R and C8S were
tested for their ability to inhibit DAH7PS from M. tuberculosis
(Fig. 3, Table 1). Kinetic analysis showed that all compounds were
competitive inhibitors with respect to PEP (see ESI3). The
compounds bearing the R-configuration at C2 proved to be
slightly better inhibitors, consistent with the inhibition profile of
the C7 inhibitors.5 The truncation of the chain of the parent
compound C7R/C7S results in an about 3-fold decrease in
inhibitor potency, while elongation leads to 8-fold lower inhibition
constants. Nevertheless, the inhibition constants are still in the
low micromolar range, representing some of the most potent
inhibitors reported for this enzyme. The series also shows that
there is no significant discrimination between the R and S
enantiomers with regards to inhibition. The slightly higher
potency of the R-enantiomers is likely due to the R-configuration
at C2 being able to more readily accommodate an active site water
molecule as observed in the co-crystal structure of C7 and the
enzyme.5 The inhibition results indicate that while a variation of
Scheme 1 Inhibitor synthesis: (a) Mg, BrCH2CH2Br, Et2O, r.t.; (b) CuBr?SMe2, THF,˜ 78 uC to r.t.; (c) H2, Pd/C, EtOAc, r.t.; (d) 4,5-dicyanoimidazole, (BnO)2PN(i-Pr)2, CH2Cl2, r.t.,
then m-CPBA; (e) H2, Pd/C, EtOAc, r.t., then KOH/H2O.
Fig. 2 Overlay of the enzyme-inhibitor 2 complex (enzyme-yellow carbons, inhibitor-
blue carbons), and the structure of the enzyme with its first substrate PEP bound
(enzyme-cyan carbons, PEP and water molecules have been omitted for clarity).
Fig. 1 Reaction catalysed by DAH7PS, proposed reaction intermediate 1 and active site inhibitor 2.
3210 | RSC Adv., 2013, 3, 3209–3212 This journal is  The Royal Society of Chemistry 2013
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chain length still yields potent inhibitors, the intermediate mimic
that most closely resembles the natural substrate, has the ideal
chain length. Interestingly, inhibitors C6R and C6S, which possess
a truncated chain, are more easily accommodated in the active site
than the inhibitors bearing the longer C8 chain length. The C8
inhibitors were designed in order to keep the conformational
change required of the active site upon ligand binding to a
minimum, they however show the comparably lowest inhibitory
potencies of the series. As noted for the parent compound, the
highly charged nature of these compounds means that the
masking of the phosphate groups is required to enhance the
membrane permeability of these molecules for biological activ-
ity.11
We explored the binding mode of the inhibitors reported in
this study by induced fit (or flexible) docking into the crystal
structure determined for the C7R-enzyme complex (Fig. 4 and S5,
ESI3). Docking poses for both the truncated C6 inhibitor and the
elongated C8 inhibitor retain the positioning and interactions of
the 2-phosphoryl-carboxylic acid head group observed in the C7-
enzyme complex crystal structure. However, our analysis of the
interactions of the enzyme with the primary phosphates at the end
of the carbon linker reveals that the most favourable hydrogen
bonding network between the ligand and the active site KPRS loop
can only be established by the C7 inhibitor. While the chain
length of the C6 compound is too short for the favourable
positioning of the C6-phosphate, the C8 inhibitor was docked in a
collapsed, probably energetically less favourable conformation.
Conclusions
In conclusion, our investigations into the active site plasticity ofM.
tuberculosis DAH7PS have shown that the KPRS motif interacting
with the primary phosphate of our inhibitors is located in a
mobile part of the protein for which multiple conformations are
energetically accessible. Our exploration of the ability of this
conformationally flexible binding site to accommodate inhibitors
of varying chain lengths resulted in several potent inhibitors of
Fig. 3 Kinetic data obtained for the inhibition of M. tuberculosis DAH7PS by
inhibitor C6R. Inhibitor concentrations: empty circles, no inhibitor; solid squares, 1.2
mM; empty triangles, 2.4 mM; solid triangles, 4.8 mM. The global fit to a competitive
inhibition model gave Vmax = 12¡ 0.4 mMmin
21, Km = 4.7¡ 1.0 mM, Ki = 1.1¡ 0.2
mM. (for complete assay conditions and data for C6S and C8R/C8S, refer to the ESI3).
Table 1 Inhibition constants
Compound Ki [mM]
1.10 ¡ 0.2a
1.40 ¡ 0.3a
0.36 ¡ 0.05b
0.60 ¡ 0.1b
3.00 ¡ 1a
5.00 ¡ 1a
a This study. b Ref. 5.
Fig. 4 Comparison of the docking poses for C6R (magenta carbons) and C8R (cyan
carbons). The induced fit docking model shows the side chain of Arg135 shifting in
accordance with the varying inhibitor chain length. The geometry of the hydrogen
bonding interactions of the primary phosphate of the inhibitor with the mobile
active site loop (red dashes) is less ideal when compared to the C7 inhibitors (see
ESI3 for details).
This journal is  The Royal Society of Chemistry 2013 RSC Adv., 2013, 3, 3209–3212 | 3211
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this potential drug target. It has also shown that inhibitors which
closely mimic the chain length of the intermediate are best suited
for the inhibition of this enzyme. We have demonstrated the
versatility of our synthetic route, which allows both the control of
the configuration on the inhibitor head group and the variation of
the tail. Now that we have established the optimum chain length,
we will continue to adapt this procedure in order to synthesise
inhibitors with alternative linkers in order to further increase
inhibitor potency.
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3.1 Introduction 
MtuDAH7PS displays an unusual mechanism of allosteric regulation whereby single aromatic 
amino acids do not significantly inhibit enzyme activity, combinations of aromatic amino acids 
however have a synergistic inhibitory effect. A combination of Trp and Phe displays the most 
potent inhibition, followed by Trp and Tyr.107 As outlined in Chapter 1, three ligand binding 
sites were identified on the enzyme by soaking of Trp and Phe into crystals of MtuDAH7PS and 
X-ray crystallographic analysis. These data show that Phe can bind to multiple sites, in the 
absence of Trp and at high soaking concentrations, Phe is found to be present in all three 
binding sites. Even in the presence of Trp, Phe can bind to two sites, site 1 and site 3 as outlined 
in Chapter 1. MtuDAH7PS is also inhibited by Trp in combination with Tyr, at the start of this 
work it was however not clear whether Tyr binds to the same binding site(s) as Phe. In addition, 
it was unclear whether the regulation by Trp/Tyr was due to the similarity of Phe and Tyr rather 
than a specific response of the enzyme in the presence of Tyr. 
The publication serving as this chapter describes work carried out in collaboration with multiple 
members of the Parker research group at the University of Canterbury, Prof Geoffrey B. 
Jameson at Massey University and Prof Edward N. Baker at the University of Auckland. The 
results presented clarify the selectivity and specificity of the three allosteric inhibitor binding 
sites of MtuDAH7PS, and show that the three binding sites combined enable an example of rare 
ternary synergistic regulation of the enzyme by the three pathway end products Trp, Phe and 
Tyr. 
This work has been accepted for publication in the Journal of Molecular Biology and is 
available online at the time of the submission of this thesis. It is reproduced with the permission 
of the copyright owner. The citation for the article is: 
Blackmore, N. J.; Reichau, S.; Jiao, W.; Hutton, R. D.; Baker, E. N.; Jameson, G. B.; Parker, E. 
J., Three Sites and You Are Out: Ternary Synergistic Allostery Controls Aromatic Amino Acid 
Biosynthesis in Mycobacterium tuberculosis. J. Mol. Biol. 2013, 425 (9), 1582-1592. © 2012, 
Elsevier. 
N.J. Blackmore carried out site-directed mutagenesis, expression, purification and characteri-
sation of variants, kinetic assays and ITC titrations. Dr W. Jiao analysed data and wrote parts of 
the manuscript. Dr R.D. Hutton expressed and purified enzyme and carried out ITC titrations. 
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Abstract
3-Deoxy-D-arabino-heptulosonate 7-phosphate synthase (DAH7PS) catalyzes the first step in the shikimate
pathway, the pathway responsible for the biosynthesis of the aromatic amino acids Trp, Phe, and Tyr. Unlike
many other organisms that produce up to three isozymes, each feedback-regulated by one of the aromatic
amino acid pathway end products,Mycobacterium tuberculosis expresses a single DAH7PS enzyme that can
be controlled by combinations of aromatic amino acids. This study shows that the synergistic inhibition of this
enzyme by a combination of Trp and Phe can be significantly augmented by the addition of Tyr. We used X-ray
crystallography, mutagenesis, and isothermal titration calorimetry studies to show that DAH7PS from M.
tuberculosis possesses a Tyr-selective site in addition to the Trp and Phe sites, revealing an unusual and
highly sophisticated network of three synergistic allosteric sites on one enzyme. This ternary inhibitory
response, by a combination of all three aromatic amino acids, allows a tunable response of the protein to
changing metabolic demands.
© 2013 Elsevier Ltd. All rights reserved.
Introduction
Allosteric regulation of protein functions is critical
for the control of metabolism. Allostery is the process
by which the binding of one or more effectors to a
protein causes a functional response at a distant
site. Allostery is widely observed in biological
systems and is crucial in signal transduction,
metabolism, catalysis, and gene regulation.1–5
Allostery arises from a ligand-induced perturbation
in the population distribution between different forms
of a protein. Protein molecules exist as ensembles of
different states and the population distribution of
these ensembles is defined by the free-energy
landscape of the particular protein system.3 Early
examples of allosteric regulation mostly featured
large changes in the average conformation of the
ensemble in oligomeric proteins (mainly enthalpy
driven). Such protein systems include hemoglobin
and aspartate transcarbamoylase.6,7 The well-
known Monod–Wyman–Changeux model of alloste-
ry (also known as the concerted model) has been
widely applied to explain the behavior of these
allosteric systems.6 More recently, allostery associ-
ated with more subtle changes in protein structure
has been investigated. Binding of an allosteric
effector may alter the free-energy landscape of the
protein so that allostery is mediated by changing the
dynamic fluctuations about the average conforma-
tion of the protein ensemble (mainly entropy
0022-2836/$ - see front matter © 2013 Elsevier Ltd. All rights reserved. J. Mol. Biol. (2013) 425, 1582–1592
driven).8–13 Both allosteric regulation in monomeric
proteins and purely entropy-driven allostery have
been described.14–16 The role of protein dynamics in
determining function is becoming more recognized,
contributing to the increase in our understanding of
protein function and regulation.8–13
The enzyme 3-deoxy-D-arabino-heptulosonate 7-
phosphate synthase (DAH7PS) catalyzes the first
reaction in the shikimate pathway, the pathway
responsible for the biosynthesis of the aromatic
amino acids Trp, Phe, and Tyr.17 This pathway is
present in microorganisms18,19 but absent in higher
organisms, making the enzymes in this pathway
good targets for antimicrobial drug development.
DAH7PS catalyzes the aldol reaction between
phosphoenolpyruvate (PEP) and erythrose 4-phos-
phate (E4P) to produce 3-deoxy-D-arabino-heptulo-
sonate 7-phosphate, which is converted to
chorismate via several enzyme-catalyzed steps. At
this point, the pathway branches: one branch
produces Phe and Tyr, and the other produces
Trp. As the first enzyme in a branched pathway,
DAH7PS is a major control point for the shikimate
pathway and the regulation of this enzyme is
essential for metabolic control.
Previous studies have shown that the DAH7PS
enzyme from Mycobacterium tuberculosis (Mtu-
DAH7PS) is feedback-regulated by the pathway
end products Trp, Phe, and Tyr by means of a
sophisticated mechanism of allosteric regulation.20
Dual combinations of Trp and Phe (or Trp and Tyr to
a lesser extent) show an inhibitory effect on
MtuDAH7PS, whereas Trp, Phe, or Tyr alone results
in limited inhibition. Crystal structures of ligand-free
MtuDAH7PS have been solved and showed that the
quaternary structure of this enzyme is a homote-
tramer of (β/α)8 TIM barrel subunits. The dimer and
tetramer interfaces are formed by accessory ele-
ments to the basic barrel. Crystal structures of
Phe+Trp-bound MtuDAH7PS (Fig. 1b) show that
Phe and Trp bind in distinct allosteric sites in the
dimer and tetramer interfaces, respectively, about
20 Å away from each other and over 20 Å away
from the active site. Furthermore, comparison with
the ligand-free MtuDAH7PS structure reveals that
there is no change in gross conformation of the
enzyme upon binding of allosteric effectors
(Trp+Phe).20 Studies using molecular dynamics
simulations have shown that the allostery observed
in MtuDAH7PS upon Trp+Phe binding is mainly
entropy driven and that inhibition is achieved by
the reduction in affinity of the enzyme for its
substrate E4P.21
The central role that MtuDAH7PS plays in the
regulation of aromatic amino acid biosynthesis has
been further highlighted by the observation that
MtuDAH7PS forms a complex with M. tuberculosis
chorismate mutase, the branch point enzyme for Tyr
and Phe biosynthesis.22 Formation of this complex
results in the activation of the chorismate mutase
and confers regulatory properties to this enzyme,
with no effect on the activity of MtuDAH7PS.
Here, we report the first-time observation of a
ternary response of MtuDAH7PS to all three
aromatic amino acids (Trp+Phe+Tyr). We dem-
onstrate that the binary inhibitory response in
MtuDAH7PS caused by Trp and Phe is augment-
ed by the binding of Tyr to an independent site on
the enzyme. As a result, the catalytic activity of
MtuDAH7PS is completely abolished when all
three aromatic amino acids are present. This
fine-tuning of enzyme activity by three different
allosteric effectors with three distinct binding sites
is, to our knowledge, unprecedented and provides
an important example of an extremely sophisticat-
ed and novel mechanism in protein allosteric
regulation. These findings may have implications
for the development of antimycobacterial drugs
targeting the allosteric sites of this essential
protein.
Fig. 1. (a) Monomer structure of MtuDAH7PS in complex with Phe and Trp (PDB 3KGF). Sites 1, 2, and 3 are labeled.
(b) Homotetramer of MtuDAH7PS in complex with Phe and Trp (PDB 3KGF). The N-terminal extra-barrel elements (the
N-termini and α0a–α0c helices) are shown in red, and the additional α2a, α2b helices are shown in yellow. Active-site
metal ions are shown as purple spheres. The Trp binding in site 1 is shown as cyan spheres, the Phe in site 2 is
shown as green spheres, and the Phe ligand in site 3 is shown as orange spheres.
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Results
Wild-type MtuDAH7PS is potently inhibited by
combination of all three aromatic amino acids
The catalytic activity of MtuDAH7PS was tested in
the presence of aromatic amino acids Trp, Phe, and
Tyr (Fig. 2a). In the presence of any single aromatic
amino acid, no significant loss of activity is observed
relative to the activity observed in the absence of
added aromatic amino acids. However, binary
combinations, particularly those involving Trp
(Trp+Phe, Trp+Tyr), show significant inhibition, as
previously reported.20 The most potent binary
combination, Trp+Phe, reduces the activity of the
wild-type MtuDAH7PS to 7% (Fig. 2a). Interestingly,
the inhibition observed from Trp+Phe is further
augmented by the addition of Tyr, and this ternary
combination of all three aromatic amino acids almost
Fig. 2. Influence of single aro-
matic amino acids and combina-
tions of aromatic amino acids on the
specific activity of wild-type Mtu-
DAH7PS and its mutants. (a) Mtu-
DAH7PS wild type. (b)MtuDAH7PS
R171A. (c) MtuDAH7PS R256A.
Each ligand is present at a concen-
tration of 200 μM and is denoted by
the single-letter amino acid code
(W, Trp; F, Phe; Y, Tyr). The
combinations FY, WY, WF, and
WFY refer to each amino acid
being present at a concentration of
200 μM, and WFF andWYY refer to
the presence of 200 μM Trp with
either 400 μM Phe or Tyr.
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completely eliminates MtuDAH7PS catalytic activity
(reduced to 1%). In order to investigate whether this
inhibition was attributable specifically to the pres-
ence of all three amino acids, rather than to
concentration effects of binary combinations, we
tested different binary combinations of aromatic
amino acids (WFF and WYY in Fig. 2a). The
inhibition observed in the ternary combination
(Trp+Phe+Tyr) exceeds the effects that arise from
the equivalent binary combinations of Trp+Phe or
Trp+Tyr (WFF or WYY), indicating that Tyr specif-
ically augments the inhibition of this enzyme by Trp
and Phe.
Crystal structures of DAH7PS reveal three
distinct aromatic amino acid binding sites
Intrigued by the discovery of inhibition of Mtu-
DAH7PS by a ternary combination of Trp+Phe+Tyr,
we sought structural information on the location of
the Tyr binding site. Previous structural studies have
identified three distinct sites for aromatic amino acid
binding on MtuDAH7PS (Fig. 1a).20 Site 1 is located
in the tetramer interface and made up mostly from
residues of the α2β3 loop extension and helix α1.
Site 1 is occupied by Trp. Site 2 is located in the
dimer interface, capped by the β0 sheet of the N-
terminal barrel extension. Site 2 is occupied by Phe
when Phe and Trp are included in the crystallization
conditions or soaked into the crystals. Site 3 is
located between the extra-barrel helices at the N-
terminus (helices α0a and α0b) and the α3 helix of
the main barrel (Fig. 1a). This site is filled in just two
of the four subunits of the biological unit. This site
was found to be occupied by Phe, in addition to site
2, when crystals were soaked in high concentrations
(2 mM) of Trp and Phe. When lower ligand concen-
trations for co-crystallization were employed
(100 μM Trp and Phe), site 3 is unoccupied.21 As
these concentrations for co-crystallization were
similar to those required for the inhibition by
Trp+Phe, site 1 and site 2 were identified as the
relevant sites for the inhibitory response to the binary
combinations of Trp and Phe. Moreover, mutation of
site 3 did not alter the inhibition of the enzyme by Trp
and Phe.20 These observations left the role of site 3
unclear. Therefore, extensive screening of crystal
soaking conditions was conducted in order to further
elucidate the ligand preferences of the respective
sites and to locate possible Tyr binding sites.
Tyr shows promiscuous binding to both site 2 and
site 3
The structure of MtuDAH7PS in complex with only
Tyr was determined at 2.3 Å resolution from a crystal
soaked in a solution containing Tyr at a concentra-
tion of 330 μM (Rfree=0.164, Table S2). The overall
conformation of the protein is virtually unchanged by
the presence of Tyr, with the rmsd between the
unliganded [Protein Data Bank (PDB) code 3NV8]
and Tyr-bound (PDB code 2YPP) structures being
0.240 Å (for 5033 atoms). After refinement of the
structure, clear continuous electron density corre-
sponding to Tyr was found in both site 2 and site 3
(Fig. S2 and Fig. S3). Tyr occupies site 2 in both sites
of the dimeric asymmetric unit (i.e., in all four sites of
the functional tetramer), whereas site 3 is only
occupied by Tyr in two of the four subunits, as had
been earlier observed for Phe.20 The soaking of
crystals in solutions containing lower concentrations
of Tyr resulted in structures that either had no Tyr
bound or partially defined electron density corre-
sponding to Tyr in both site 2 and site 3. Thus, Tyr
shows promiscuous binding to these two sites, but it
does not bind to site 1, in contrast to that observed at
high concentrations of just Phe (PDB code 3NUD).
In order to establish the binding sites involved in
the inhibition by the Trp+Tyr combination, we
obtained the crystal structure of MtuDAH7PS in
complex with both Trp and Tyr by soaking crystals in
a solution containing Trp and Tyr (2 mM concentra-
tion of each ligand). In the Trp+Tyr-soaked structure
(2.76 Å, Rfree=0.25, PDB code 2YPQ), Trp occupies
site 1 and, as observed in the Tyr-only structure,
sites 2 and 3 are occupied by Tyr. The binding mode
of Trp is consistent with the previously reported
structures (PDB codes 3NUE, 3RZI, and 3KGF) and
the Tyr binding mode is consistent with that found in
the Tyr-only soaked structure.
Tyr binding mode in site 2
Site 2 is located in the dimer interface and the Tyr
in this position interacts with residues from both
subunits (Fig. 3a). The Tyr side chain binds in a
pocket mostly formed by hydrophobic residues
(Trp3, Tyr173*, Ala174*, and Ala174, where *
indicates residues from the other subunit). The
carboxylate of Tyr forms hydrogen bonds to the
amide group of Asn175, a water molecule, which in
turn interacts with the indole N–H of Trp3, and a salt
bridge to the guanidinium moiety of Arg171. The
amino group of Tyr forms hydrogen bonds to the
backbone carbonyl of Phe91, the side-chain car-
bonyl of Asn175 and, mediated through a water
molecule, the main-chain carbonyl group of Asn94.
The two Tyr ligands in different subunits are
relatively close to each other, with the distance
between their hydroxyl groups being 4.8 Å. The
binding mode of Tyr in site 2 is very similar to the way
Phe was observed to bind to this site (see also Fig.
S5), the amino acid moieties of Tyr and Phe
establish the same contacts to the protein, and
there are no elements on the proteins that seem to
be predisposed for the recognition of the Tyr
hydroxyl group, albeit the addition of this moiety
can be accommodated in the binding site.
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Fig. 3. Stereo diagrams showing the binding of Tyr in site 2 and Tyr and Phe in site 3. (a) Tyr binding in site 2 of subunit
B is shown with yellow carbons; residues from subunit A are shown with blue carbons, and residues from subunit B, except
Arg171, are shown with red carbons (PDB code 2YPP). (b) Tyr binding in site 3 of subunit B is shown with blue carbons,
and residues from subunit B are shown with green carbons, except for Arg256, which is shown with red carbons. Two
water molecules mediating contacts between the Tyr ligand and the enzyme are shown as red spheres (PDB code 2YPP).
(c) Overlay showing the conformational change induced by binding of Tyr in site 3. In the unliganded (yellow carbons, PDB
code 3NV8) and Phe-liganded (purple carbons, PDB code 3NUD) structures, the loop containing Pro16 and Pro17 is in an
open conformation and, in the case of the Phe-bound structure, also poorly defined. In the Tyr-bound structure (blue
carbons, PDB code 2YPP), the carbonyl of Pro16 forms a hydrogen bond to the Tyr phenolic hydroxyl, causing a
conformational change in the loop containing Pro16. A very similar arrangement is observed in the Trp+Tyr-bound
structure (PDB code 2YPQ).
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Tyr binding mode in site 3
In contrast to Tyr binding in site 2, specific
interactions with the phenolic hydroxyl of Tyr are
established when Tyr binds in site 3: the main-chain
carbonyl of Pro16 and a water molecule, which in
turn interacts with the backbone amide N–H of
Leu261, are located 2.7 and 2.9 Å from the phenolic
oxygen, respectively. The carboxylate of Tyr in-
teracts with the guanidinium group of Arg256. The
amino group forms a salt bridge with the carboxylate
of Glu53 and a hydrogen bond to a water molecule,
which in turn makes contacts with the backbone
carbonyls of Leu259 and Ala257 (Fig. 3b). Compar-
ing the binding mode of Phe to that of Tyr in this site
reveals that the amino acid moieties of both ligands
interact in a very similar manner with the binding site
(Fig. 3c). The phenyl ring of both the Tyr and Phe
ligands also show similar orientations in both
structures. However, due to its phenolic hydroxyl
group, Tyr is able to establish an additional hydrogen
bond to Pro16.
While the overall conformation of the enzyme is
hardly affected by the presence of Tyr, several subtle
conformational changes occur in the β0α0 loop
comprising residues 10–18 near site 3 (Fig. 3c). The
amide nitrogen of Pro16 and its carbonyl group are
shifted by 2.2 Å and 1.4 Å, respectively, in the
presence of Tyr, enabling a hydrogen bond interac-
tion to be formed between the Pro16 carbonyl and
the Tyr hydroxyl group. In the absence of ligand or in
the presence of Phe in site 3, the β0α0 loop adopts a
more open conformation or is disordered.
Phe at low concentration preferentially binds to site 2
A new structure of MtuDAH7PS in complex with
Phe at 2.0 Å resolution was obtained by soaking
crystals for a limited time (1 h) in a solution contain-
ing a lower concentration (200 μM compared to the
previously used 2 mM) of Phe (Tables S1 and S2,
PDB code 2YPO,Rfree=0.159). The overall structure
obtained by this method is very similar to that
obtained using the higher soaking concentration of
Phe (PDB code 3NUD, rmsd=0.329 Å for 4533
atoms). However, in the crystals obtained at the
lower Phe concentration, the only ligand site that
showed clear continuous electron density corre-
sponding to Phe is site 2 (Fig. S1). This observation
confirms that site 2 is indeed the preferred binding
site for Phe. The binding mode of Phe in this new
structure is identical to the binding mode previously
observed.20
Amino acid substitutions at sites 2 and 3 reveal
allosteric site ligand selectivities
In order to further investigate the selectivity of sites
2 and 3 for Phe and Tyr, we made substitutions to
Ala for key Arg residues involved in ligand binding in
both site 2 at the dimer interface (R171, red carbons
in Fig. 3a) and site 3 (R256, red carbons in Fig. 3b).
These mutations did not affect protein folding (as
shown by circular dichroism spectrophotometry, Fig.
S4, Supplementary Material), and both mutant
enzymes were catalytically competent (full kinetic
characterization is provided in the Supplementary
Material, Table S3).
Mutation of Arg171 (at site 2) significantly impairs
Phe binding
Arg171 forms a salt bridge with the carboxylate
functionality of Phe or Tyr at site 2. In contrast to the
wild-type enzyme, the activity of R171AMtuDAH7PS
is only slightly inhibited by Trp+Phe (Fig. 2b). On the
other hand, R171AMtuDAH7PS retains significant
sensitivity to the combination of Trp and Tyr, with
specific activity reduced to ~40% of that observed
for this mutant in the absence of aromatic amino
acids (Fig. 2b). In the presence of all three ligands,
Trp, Phe, and Tyr, the R171AMtuDAH7PS activity is
similar to that observed in the presence of Trp and
Tyr. To further probe ligand binding, isothermal
titration calorimetry (ITC) was used to determine
the dissociation constants for Tyr and Phe (Table 1).
Phe and Tyr both bind to wild-typeMtuDAH7PS with
similar affinities (Kd~20 μM). However, Phe binding
to the R171AMtuDAH7PS mutant was severely
compromised (Kd≫1000 μM), demonstrating that
site 2, where R171 is located, is primarily responsi-
ble for binding Phe. On the other hand, Tyr was
found to bind to this enzyme variant with slightly
higher affinity, consistent with the presence of an
alternative site that shows a preference for the
binding of Tyr relative to Phe. Despite the relatively
tight binding of Tyr to the R171AMtuDAH7PS
mutant, the Trp+Tyr combination did not elicit the
same level of kinetic inhibition of this enzyme variant
as was observed for the wild-type MtuDAH7PS,
indicating that a competent site 2 is required for
maximal inhibitory response to Trp+Tyr (Fig. 2).
Mutation of Arg256 (at site 3) impairs Tyr binding
Arg256 is responsible for binding the carboxylate
functionality of Tyr or Phe in site 3. Site 3 was found
to be occupied by Phe when high concentrations of
this ligand were employed in crystal soaking
experiments, and by Tyr at low concentrations.
Arg256 was substituted by Ala in order to investigate
the relevance of Tyr and Phe binding to site 3. The
R256AMtuDAH7PS enzyme retains sensitivity to the
combination of Trp+Phe to a level comparable to
that observed for the wild-type MtuDAH7PS, con-
firming that site 3 plays a minor role in the inhibition
that arises from the binary combination of Trp and
Phe (Fig. 2c). In contrast, the inhibitory response of
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R256AMtuDAH7PS to the combination of Trp and
Tyr was essentially abolished. These observations
indicate that site 3 plays a key functional role in the
inhibition of MtuDAH7PS by the Trp+Tyr binary
combination. Notably, the ability of Tyr to augment
the inhibition of the Trp+Phe combination is lost for
the R256AMtuDAH7PS variant, indicating that a
competent site 3 is required for the response to all
three aromatic amino acids.
ITC experiments were conducted to further probe
ligand binding of the R256AMtuDAH7PS mutant.
Whereas Phe binding is unaltered by this mutation at
site 3, Tyr binding is slightly impaired. These
observations illustrate clearly the ability of Tyr to
bind to both sites 2 and 3 of MtuDAH7PS and the
preference of Phe for site 2 rather than site 3. The
observations that Tyr binds to R256AMtuDAH7PS
with a reduced affinity yet more tightly to the
R171AMtuDAH7PS indicate that while Tyr can bind
to both sites, it has a slight preference for site 3. Tyr
binds with lower affinity to both R256AMtuDAH7PS
and R171AMtuDAH7PS when the enzymes are
incubated with Phe prior to titration (Table 1). This
indicates that Tyr competes with Phe for binding to
both sites.
In summary, the influence of mutations of sites 2
and 3 on binding constants of Phe and Tyr to the
enzyme and on the inhibition by the combinations of
amino acids illustrates the functional importance of
these two sites. Consistent with the ligand-bound
crystal structures of the enzyme using varying
concentrations of ligands, site 2 is able to bind Phe
or Tyr, whereas site 3 is Tyr-selective and only binds
Phe at high concentrations. With respect to inhibi-
tion, maximum inhibition requires the binding of Phe
in site 2 whereas binding of Tyr in this site has,
remarkably, minor influence on inhibition. Site 3 is
required for the Tyr-mediated augmentation of the
inhibition caused by the Trp+Phe combination and
the functional response of the enzyme to all three
aromatic amino acids.
Discussion
Many key enzymes of biological pathways are
regulated by pathway end products, such as the α-
aminoadipate pathway that is responsible for lysine
biosynthesis in fungi and certain archaebacteria,23
the biosynthetic pathway of leucine,24 and that of
histidine.25 The shikimate pathway is a branched
pathway with multiple pathway end products and is
responsible for biosynthesis of aromatic amino acids
Trp, Phe, and Tyr. While the pathway flux can be
regulated in individual branches by feedback regu-
lation of specific enzymes down the pathway, and
MtuDAH7PS plays a role in this through complex
formation with the M. tuberculosis chorismate
mutase,22 there is also a need to govern the
entrance of valuable starting materials into the
system and limit the accumulation of reactive
intermediates, by regulating the enzymes in the
main trunk of the pathway. DAH7PS as the first
enzyme of the shikimate pathway represents a key
point for the regulation of the pathway output.
However, with multiple pathway end products, the
regulation of DAH7PS poses a big challenge,
because the three aromatic amino acids are required
in different concentrations in cellular environment.
Intracellular concentrations of aromatic amino acids
Phe, Trp, and Tyr in glucose-fed Escherichia coli
have been reported to be 18 μM, 12 μM, and 29 μM,
respectively.26 Therefore, the regulation of DAH7PS
needs to be tunable and responsive to different
concentrations of the three aromatic amino acids, so
that when only one type of aromatic amino acid is
overproduced, the entire pathway will not be shut
down and limit the supply of the other aromatic
amino acids. Different organisms adopt different
strategies for the regulation of this enzyme. For
example, in E. coli, multiple isozymes of DAH7PS
are expressed and each of the isozymes is inhibited
by one kind of aromatic amino acid. However, only
one DAH7PS enzyme is encoded by the M.
tuberculosis genome, which is a relatively uncom-
mon feature for organisms using the shikimate
pathway. In order to regulate overall pathway flux,
M. tuberculosis seems to have evolved a highly
sophisticated regulatory mechanism that is tunable
by multiple pathway end products using a single
DAH7PS enzyme.
MtuDAH7PS is relatively insensitive to Trp, Phe, or
Tyr alone at low concentrations; binary combinations
of aromatic amino acids that include Trp (Trp+Phe
Table 1. Dissociation constants measured from ITC inhibitor binding experiments
Titrated
ligand
Background
ligand
Kd (μM)
Wild-type MtuDAH7PS R171AMtuDAH7PS R256AMtuDAH7PS
Phe — 21±1a ≫1000 17±1
Tyr — 39±1a 19±2 54±4
Tyr Phe 12±1 40±3 120±20
Background Phe concentration is 50 μM.
ITC data are shown in the Supplementary Material (Tables S4 and Table S5; Figs. S6–S8).
a As reported by Jiao et al.21
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and Trp+Tyr) can inhibit the enzyme significantly,
with Trp+Phe being the most potent combination.
The binary response caused by Trp+Phe is found to
be augmented by the binding of Tyr and results in
almost complete loss of the enzyme activity. Crystal
structures of MtuDAH7PS in complex with different
ligands show that there are three distinctive allosteric
binding sites on the enzyme. Two of these allosteric
binding sites are located at the dimer and tetramer
interfaces of the enzyme, and the third site is located
on the exterior surface of the enzyme near the dimer
interface. Previously, it has been established that the
Trp binding site is located at the tetramer interface
(site 1) and that Phe can bind in both the dimer
interface site (site 2) and the third site (site 3).20 Site
2 together with the Trp binding site 1 have been
shown to be the sites that are responsible for the
binary inhibitory response caused by the Trp+Phe
combination.21 In this study, the role of site 3 and the
sites responsible for the binary response of Trp+Tyr
combination is clarified. The crystal structures of
MtuDAH7PS in complex with Tyr and Tyr+Trp
reveal that Tyr binding to site 3 may be more
favorable due to additional hydrogen-bonding in-
teractions formed between its hydroxyl moiety and
the enzyme; hence, this site is identified as the
selective binding site for Tyr. ITC measurements for
both the wild-type and mutants of MtuDAH7PS
confirm that site 3 is indeed a Tyr-selective site.
Inhibition studies demonstrate that this Tyr-selective
site contributes most of the inhibition response in the
Tyr+Trp combination and is required for the func-
tional response to the ternary combination of
aromatic amino acids.
Allosteric regulation of protein function by multiple
allosteric effectors has been reported for other
protein systems. Glutamine phosphoribosylpyropho-
sphate amidotransferase from Bacillus subtilis cata-
lyzes the initial reaction in de novo purine nucleotide
synthesis, and it was found to be synergistically
feedback-regulated by a combination of the adenine
di- and guanine mononucleotide ADP and GMP.27
The crystal structure of this enzyme in complex with
ADP and GMP established that ADP binds to the
allosteric site whereas GMP binds to the catalytic
site.28 Another example is aspartate transcarba-
moylase from E. coli, which catalyzes the first step in
the pyrimidine biosynthetic pathway and is syner-
gistically inhibited by pyrimidine cytidine and uracil
trinucleotides CTP and UTP, respectively. The
binding of allosteric effectors CTP and UTP causes
a change in overall conformation of the enzyme,
which shifts the enzyme from the active R-state to
the inactive T-state.29 Both enzymes catalyze the
first reaction in a biosynthesis pathway with multiple
end products and both are found to be synergistically
inhibited by the pathway end products. Synergistic
allostery appears to be a suitable general strategy
for metabolic control of pathways with multiple end
products, because the inhibitory response is en-
hanced only when more than one end product is
being overproduced.
However, the complexity of the allosteric regulation
observed forMtuDAH7PSappears to beunparalleled.
There are three distinctive allosteric binding sites
selective for each of the three aromatic amino acids
with respect to eliciting an inhibitory response. These
allosteric sites are located distant to the active site,
21 Å, 28 Å, and 24 Å away from the active-site metal
ion for Phe, Tyr, and Trp sites, respectively. However,
despite the long distances between the ligand sites,
occupancy of two or three allosteric sites operates
together to communicate an inhibitory signal to the
active site of the enzyme. The inhibition is fine-tuned
by the number of different allosteric effectors present,
providing a powerful and tunable regulatory response
to cellular aromatic amino acid demands.
Materials and Methods
Protein expression and purification of MtuDAH7PS
and MtuDAH7PS mutants
The allosteric binding site mutants of MtuDAH7PS were
produced using the QuikChange Lightning Site-Directed
Mutagenesis Kit (Stratagene) and conducted in accor-
dance with the manufacturer's instructions. A PCR primer
table is provided in the Supplementary Material, Table S6.
The resulting PCR products were transformed into
chemically competent One Shot TOP10 (Invitrogen) and
electrocompetent BL21 (DE3) pGroESL cell lines for
plasmid storage and protein expression, respectively.
Protein expression and purification of both wild-type and
mutant MtuDAH7PS were carried out as previously
described by Webby et al. except that Thesit [polyox-
yethylene(9)-lauryl-ether] was omitted from all buffers and
1 mM tris(2-carboxyethyl)phosphine (TCEP) (Sigma) was
added to all buffers.30
Enzyme assays and kinetic measurements
The kinetic parameters and measurements of the
mutants were determined using standard assay
conditions.30 MtuDAH7PS mutant activity was measured
by monitoring the loss of PEP at 232 nm (ε =
2.8103 M− 1 cm− 1 at 303 K) in the presence of E4P
using a Varian Cary 1 UV-visible spectrophotometer.30
The assay solution contained PEP (fixed at 300 μM or
varied to determine PEP Km) (Research Chemicals), E4P
(fixed at 300 μM or varied to determine E4P Km) (Sigma),
and MnSO4 (100 μM) (Sigma) in assay buffer {50 mM 1,3-
bis[tris(hydroxymethyl)methylamino]propane buffer
(Sigma), pH 7.5, and 1 mM TCEP}. PEP and E4P
solutions were made up in assay buffer and the MnSO4
solution was made up in ultrapure water. The reaction was
initiated by the addition of purified mutant MtuDAH7PS
(~2.5 mg/mL). Initial reaction rates were determined by a
least-squares fit of the initial-rate data. Km and kcat values
were determined by fitting the data to the Michaelis–
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Menten equation using the program GraFit (Erithacus
software).
Feedback inhibition studies
Solutions of L-Phe (Sigma), L-Tyr (Sigma), and L-Trp
(Sigma) in ultrapure water were added to standard assay
reaction mixtures to give a concentration of either 100,
200, or 400 μM in inhibitor studies. The assay solution
contained PEP (150 μM), E4P (150 μM), and MnSO4
(100 μM) in assay buffer. The reactions were initiated by
adding eitherMtuDAH7PS or mutant MtuDAH7PS. Stead-
y-state kinetic assays were conducted in the presence of
no, one, two, or all three aromatic amino acids.
Isothermal titration calorimetry
The binding of MtuDAH7PS and the allosteric binding
site mutants of MtuDAH7PS to the aromatic amino acid
ligands was assessed by ITC, using a VP-ITC unit
operating at 298 K (MicroCal, GE Healthcare). Protein
was purified in the binding buffer, and all solutions were
degassed in a vacuum before being used. The binding
buffer was 10 mM 1,3-bis[tris(hydroxymethyl)methyla-
mino]propane (pH 7.5), 150 mM NaCl, 200 μM MnSO4,
200 μM TCEP, and 200 μM PEP. All titrations are
composed of 29 injections of ligand (one 2-μL injection
followed by twenty-eight 10-μL injections), except titrations
of Tyr into wild-type MtuDAH7PS, which are composed of
57 injections (one 2-μL injection and fifty-six 5-μL in-
jections; Supplementary Material, Table S5).
To allow for diffusion of the ligand across the needle tip
during the equilibration period, the first data point was
routinely deleted. Heats of dilution experiments were
measured independently and subtracted from the integrat-
ed data before curve fitting in Origin 7.0 with the standard
one-site model supplied by MicroCal, except for the
analysis of R171AMtuDAH7PS with Trp, which used a
two-site sequential binding site model supplied by
MicroCal.
Structure determination
Crystals for soaking experiments were obtained as
previously described.30,31 Crystals were soaked in drop-
lets containing appropriate concentrations of amino acids
that had been pre-equilibrated against the same reservoir
as the crystallization drop. Diffraction data were collected
at the MX beamlines at the Australian Synchrotron.32
Structures were solved by molecular replacement using
the unliganded MtuDAH7PS dimer (PDB code 3NV8) as
the search model.33,34 The protein structure was devel-
oped in successive cycles of model building with Coot and
refinement with REFMAC5, using intensity-based twin
refinement.35,36 Structures were validated using the
MolProbity server37 and TLS groups were generated by
the TLSMD server.38 2Fo−Fc and Fo−Fc omit maps of the
ligand-binding sites were examined after complete refine-
ment of the protein backbone and side chains, and ligands
were modeled into appropriate density. Omit maps shown
in figures were generated before addition of ligands to the
model.
Accession numbers
Coordinates and structure factors have been deposited in
the PDB with accession numbers 2YPO, 2YPP, and 2YPQ.
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Chapter 4 – Interaction of D-amino acids 
with MtuDAH7PS 
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4.1 Introduction 
Biological systems display inherent chirality. The majority of naturally occurring proteins and 
peptides are synthesised from exclusively L-amino acids, and only very limited significance of 
D-amino acids in biological systems was assumed. Recent studies have revealed that the 
utilisation of D-amino acids in signalling and metabolism might be more widespread than 
previously thought.115-118 There are a number of examples where D-amino acids are utilised to 
fulfil specific tasks in biological systems, often due to their incompatibility with the majority of 
biomolecules of opposite handedness surrounding them: the peptidoglycan component of the 
bacterial cell wall contains D-Glu and D-Ala, where the less common D-configuration has been 
proposed to lead to higher stability of the resulting peptides against proteolysis.117 
The notion that animals do not synthesise and/or utilise D-amino acids had to be revised with the 
discovery of D-Ser and its signalling function in mammalian brains.119 In recent studies, Sharma 
and co-workers showed that the gene coding for alanine racemase is essential in M. 
tuberculosis.120 Alanine racemase converts L-Ala to D-Ala prior to incorporation into the 
peptidoglycan, and the authors of this study propose the enzyme as a potential target for anti-
tubercular drug design. Although their handedness differs from L-peptides, peptides made from 
D-amino acids can be designed to display binding motifs that are recognised by biomolecules. 
However, D-peptides display increased stability in biological systems due to their increased 
resistance to proteolysis, a feature which has received some attention in inhibitor design.121-123 
The discovery of the important roles D-amino acids play in these diverse systems prompts the 
question whether they may be more extensively used in biological systems than previously 
thought.117 This chapter explores whether the aromatic D-amino acids interact with the allosteric 
binding sites on MtuDAH7PS, and if they do, what effect if any they elicit on enzyme activity 
and structure. Arguably, using the enantiomers of the native ligands is the most subtle 
modification possible in the discovery of structure-activity relationships of the allosteric binding 
sites of MtuDAH7PS. Understanding the selectivity of the binding sites and how the allosteric 
signal is communicated between the multiple binding sites of this enzyme has implications for 
the design of alternative ligands as potential allosteric inhibitors. 
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4.2 Results 
4.2.1 Effect of aromatic D-amino acids on MtuDAH7PS activity 
The response of MtuDAH7PS to the presence of aromatic D-amino acids was examined using 
the standard assay conditions (see experimental section for details). Initial rates of the enzymatic 
reaction were determined at a concentration of PEP and E4P of 150 µM in the absence and 
presence of various combinations of aromatic D-amino acids and combinations of D- and L-
amino acids (Figure 4.1). 
 
Figure 4.1: Effect of aromatic D-amino acids and combinations of D- and L-amino acids on MtuDAH7PS 
activity. Error bars represent standard deviation of replicates, all activities are normalised to the activity 
obtained without addition of any aromatic amino acids. The concentration of both PEP and E4P was 150 µM. 
W=tryptophan, F=phenylalanine, Y=tyrosine. 
No combination of aromatic D-amino acids elicits a significant inhibitory response. Some 
reduction (76% residual activity) in activity is observed in the presence of D-Trp when L-Phe or 
L-Tyr are also present. However, the activities obtained in the presence of 1 mM D-Trp/1 mM  
L-Phe, 1 mM D-Trp/1 mM L-Tyr are very similar to the residual activities in the control 
experiments containing only 1 mM L-Phe or 1 mM L-Tyr respectively. This suggests that D-Trp 
has little effect even in the presence of L-Phe or L-Tyr, and certainly does not show synergistic 
inhibition as observed with L-Trp/L-Phe or L-Tyr combinations. The lack of inhibition of 
MtuDAH7PS by the non-natural enantiomers of the aromatic amino acids raises the question 
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whether this is due simply to a reduction of the binding affinity of the D-enantiomers or whether 
there are other mechanisms by which MtuDAH7PS distinguishes the two enantiomers of its 
allosteric effectors. 
4.2.2 Binding constants of D-Phe and D-Trp 
The binding constants of D-Phe and D-Trp to MtuDAH7PS were investigated by isothermal 
titration calorimetry (ITC, Figure 4.2). Solutions of D-Phe and D-Trp were titrated into the 
calorimeter cell containing MtuDAH7PS and a binding curve fitted to the measured heat 
changes. The affinity of D-Phe to the enzyme is only slightly lower when compared with the 
natural enantiomer: the dissociation constant (Kd) of D-Phe from MtuDAH7PS was determined 
as 93 ± 5 µM when a single-site model was fitted to the data (Figure 4.2a). This represents a 
4.5-fold reduction in affinity when compared to the dissociation constant (Kd) of L-Phe from the 
enzyme, which was determined as 21 ± 1 µM.108 This dissociation constant suggests that at the 
concentrations of D-Phe (1 mM) used in the enzymatic activity assay, virtually all binding sites 
for D-Phe on the protein are occupied. 
MtuDAH7PS interacts tightly with the natural L-enantiomer of Trp, the dissociation constant is 
4.7 ± 0.1 µM.108 In contrast, the affinity of MtuDAH7PS for the unnatural enantiomer D-Trp is 
significantly lower: a single-site model fitted to the ITC data of a titration of D-Trp into a cell 
containing MtuDAH7PS returns a Kd of 700 ± 150 µM for D-Trp (Figure 4.2b). As it has been 
observed that the presence of L-Phe can increase the affinity of the enzyme to L-Trp,108 it was 
therefore tested whether L-Phe has any influence on the binding constant of D-Trp. A solution of 
D-Trp was titrated into a cell containing enzyme in the presence of 200 µM L-Phe (Figure 4.2c). 
The change in the shape of the ITC curve suggests that the presence of L-Phe does influence the 
binding of D-Trp. Both an independent two-site model and a sequential two-site model provide 
a good fit to the data. The independent two-site model assumes the binding occurs at two 
distinct sites whose thermodynamic parameters are independent from each other, while the 
sequential two-site model is based on the assumption that the two sites are coupled. In light of 
the knowledge that presence of L-Phe modulates L-Trp binding and vice versa, it is reasonable 
to assume that the two binding sites are not independent. Fitting of a sequential two-site model 
to the ITC data gives the two dissociation constants as 550 ± 60 µM and 1500 ± 330 µM, 
respectively. 
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 (a)  
  
(b) (c) 
Figure 4.2: ITC data for titrations of D-Phe (a) and D-Trp ((b), (c)) into a cell containing 5 µM MtuDAH7PS 
tetramer, corrected for heats of dilution. (a) D-Phe (syringe concentration 3 mM) titration into a cell 
containing MtuDAH7PS: fit of a one-site model to the data gives a Kd of 93 ± 5 µM. (b) D-Trp (syringe 
concentration 12 mM) titration into a cell containing MtuDAH7PS: fit of a one-site model to the data gives a Kd 
of 700 ± 150 µM. (c) D-Trp (syringe concentration 12 mM) titration into a cell containing MtuDAH7PS in the 
presence of 200 µM L-Phe: fit of a a sequential two-site model to the data gives dissociation constants of 
550 ± 60 µM and 1500 ± 330 µM. 
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4.2.3 Crystal structures of MtuDAH7PS in complex with D-amino acids 
In order to elucidate the binding mode of the aromatic D-amino acids in more detail, crystal 
structures of MtuDAH7PS in complex with the aromatic D-amino acids were determined using 
single crystal X-ray diffraction. To this end, single crystals of MtuDAH7PS were grown in the 
absence of D-amino acids using the established conditions.105-106 The crystals were subsequently 
transferred to droplets containing all components of the crystallisation droplet with the addition 
of the respective aromatic D-amino acid or combinations of aromatic amino acids. Crystals were 
left to soak for 24 hours before they were cryo-protected and flash-frozen for analysis. Data 
collection and refinement statistics are given in Table 4.5 and Table 4.6. 
One noteworthy observation is that although the L-amino acids have been observed to bind to 
multiple sites even at low soaking concentrations (see Chapter 3), structures in which only a 
single site is occupied with a D-amino acid were found to be more readily obtainable. The 
increased selectivity of the allosteric sites of MtuDAH7PS with respect to the D-amino acids is 
reflected in a number of soak concentrations resulting in occupancy of only one of the binding 
sites (Table 4.1). For example, D-Phe was found to only occupy site 1 (the Phe site) when 
crystals were soaked for 24 hours at a D-Phe concentration of 2.5 mM. For comparison, in order 
to observe L-Phe only occupying the Phe site, a soaking concentration of 200 µM for only 1 
hour was sufficient (see Chapter 3), with higher concentrations or longer soaking times resulting 
in multiple sites occupied by L-Phe. Furthermore, D-Tyr was only present in site 1 at a soaking 
concentration of 1.6 mM, whereas a concentration of only 330 µM L-Tyr resulted in both site 1 
and site 3 being occupied. In order to observe promiscuous binding of D-Tyr to both site 1 and 
site 3, a soaking concentration of 5 mM was necessary. Interestingly, site 3, which was shown 
to be selective for L-Tyr over L-Phe and was established as the L-Tyr binding site in Chapter 3, 
is filled second in the soaking experiments conducted with D-Tyr. 
As was observed for the L-enantiomers, there is no major conformational change associated 
with binding of any of the D-amino acids to MtuDAH7PS, but occupancy of the respective sites
Table 4.1: Summary of soaking conditions and ligand occupancy for crystals soaked in D-amino acids. 
Ligand(s) Soaking conditions Site 1 ligand Site 2 ligand Site 3 ligand 
D-Phe 2.5 mM, 24h D-Phe Waters/ions Waters/ions 
D-Tyr  1.6 mM finala D-Tyr Waters/ions Waters/ions 
D-Tyr 5 mM, 24 h D-Tyr Waters/ions D-Tyr 
L-Phe/D-Trp 0.25 mM L-Phe, 2.5 mM 
D-Trp, 24 h 
L-Phe D-Trp Waters/ions 
a
 two additions of 0.2 µL of a 10 mM D-Tyr stock solution to a 2 µL drop, 24 hours between first and second addition 
and 24 hours between second addition and crystal freezing. 
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is accompanied by the same local conformational changes that are observed when the L-amino 
acids bind to the respective sites – namely:  
(1) the register change of Trp3 when site 1 is occupied (see Chapter 1, Figure 1.15, 
p. 22),  
(2) rearrangement of the α2aβ3-loop containing Thr240 when site 2 is occupied (see 
Chapter 1, Figure 1.17, p. 23)  
(3) shift of the loop containing Pro16 when Tyr is bound site 3 (see Chapter 3, Figure 
3c). 
Binding mode of D-Phe and D-Tyr in site 1 
D-Phe binds to site 1 in a very similar binding mode as the L-enantiomer (Figure 4.3). The 
conformation of the surrounding side chains is nearly identical, and the root mean square 
deviation (RMSD) between the position of D-Phe and L-Phe ligands is 1.463 Å. The phenyl side 
chain of D-Phe is slightly tilted in the hydrophobic pocket when compared to the binding mode 
of L-Phe, the carboxyl and amine groups of the amino acid moiety project into the same binding 
pockets for both Phe enantiomers. The only major difference of the D-Phe binding mode in 
site 1 when compared to the binding mode of L-Phe is the altered distance of the amino group of 
the ligand to the side-chain carbonyl group of Asn175 (Table 4.2). While the L-enantiomers 
form a hydrogen bond between their amino moiety and the side chain of Asn175, the geometry 
of the D-enantiomers does not allow this interaction to be established (Figure 4.3b). Comparing 
the binding mode of D-Tyr and L-Tyr in site 1 leads to the same conclusions: there is little 
difference between the overall binding mode of the enantiomers (RMSD of 0.067 Å when 
comparing all atoms of D-Tyr with all atoms of L-Tyr), and D-Tyr is unable to establish a 
hydrogen bond to Asn175 due its inverted configuration (Figure 4.3d). 
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(a) (b) 
(c) (d) 
Figure 4.3: D-Phe and D-Tyr in site 1. (a) Omit map showing the density into which D-Phe and two water 
molecules were modelled. 2Fo-Fc omit map contoured at 1.0 σ (blue mesh) and Fo-Fc omit map contoured at 
3.0 σ (green mesh). (b) Comparison of L-Phe (yellow sticks, waters shown as magenta spheres) and D-Phe 
(green sticks, waters shown as red spheres) binding mode in the Phe site. L-Phe establishes an additional 
hydrogen bond to Asn175 (red dashes) when compared to the D-Phe binding mode, the other interactions of D-
Phe (yellow dashes) are very similar to L-Phe. (c) Omit map showing the density into which D-Tyr and three 
water molecules were modelled. 2Fo-Fc omit map contoured at 1.0 σ (blue mesh) and Fo-Fc omit map 
contoured at 3.0 σ (green mesh). (d) Comparison of L-Tyr (yellow sticks, waters shown as magenta spheres) 
and D-Tyr (green sticks, waters shown as red spheres) binding mode in site 1. L-Tyr establishes an additional 
hydrogen bond to Asn175 (red dashes) when compared to the D-Tyr binding mode, the other interactions of D-
Tyr (yellow dashes) are very similar to L-Tyr. 
Table 4.2: Comparison of distances in Å for key protein-ligand interactions in the L- and D-amino acid bound 
structures (site 1). Lig=ligand. 
Structure Lig-NH3+-
Phe91 
main-chain 
(C=O) 
Lig-NH3+-
Asn175 
side-chain 
(C=O) 
Lig-NH3+-
HOH-Asn94 
backbone 
(C=O) 
Lig-COO--
Arg171 
guanidinium 
Lig-COO--
HOH-Trp3 
2YPO (L-Phe) 2.8 2.8 2.9, 2.9 2.8, 3.1 2.7, 2.8 
D-Phe 2.4 3.6 2.9, 2.8 2.9, 2.9 3.3, 3.1 
2YPP (L-Tyr) 2.8 2.7 2.9, 2.7 2.9, 3.0 2.7, 2.8 
D-Tyr 2.6 3.7 2.7, 2.9 3.0, 3.0 3.4, 2.9 
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Binding mode of D-Tyr in site 3 
Examination of the binding mode of D-Tyr in site 3 compared to its natural enantiomer L-Tyr 
reveals that again there is little difference in the overall binding mode of the two enantiomers 
(Figure 4.4). This is also reflected in the low RMSD of 0.128 Å when comparing all atoms of 
the D-Tyr ligand to all atoms of the L-Tyr ligand in site 3. One minor difference in the binding 
mode of D-Tyr is the distance between the phenolic oxygen of the D-Tyr side chain to the 
backbone carbonyl of Pro16, which is slightly longer than the analogous distance in the binding 
mode of L-Tyr. However, the loop containing Pro16 shows disorder and high atomic displace-
ment factors even in the presence of Tyr so that this discrepancy could also be due to this 
disorder and weak electron density for the residues concerned.  
 
 
Figure 4.4: D-Tyr in site 3. Left: Part of the electron density map in site 3 with D-Tyr bound. The model 
conformation for the Pro16 loop is in good agreement with the map, the omit map shows the density for D-Tyr, 
water molecules and a sulfate ion. 2Fo-Fc map contoured at 1.0 σ (blue mesh) and Fo-Fc omit map contoured at 
3.0 σ (green mesh). Right: Comparison of L-Tyr (yellow sticks, water molecules shown as magenta spheres) 
and D-Tyr (green sticks, water molecules shown as red spheres) binding mode in the Tyr site. The sulfate ion is 
shown in gold (sulfur) and red (oxygen). 
 
Table 4.3: Comparison of distances in Å for key protein-ligand interactions in the L-Tyr and D-Tyr bound 
structures (site 3). 
Structure Tyr-OH to 
Pro16 
C=O 
Tyr-NH3+ 
to Glu53 
COO- 
Tyr-NH3+ to 
HOH1 (near 
Leu259) 
Tyr-NH3+ to 
HOH2 (near 
Arg49) 
Tyr-COO- to 
Arg256 
2YPP (L-Tyr) 2.6 2.5 2.6 n.a. (no HOH) 2.6 
D-Tyr 3.1 2.4 2.6 3.5 2.5 
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Binding mode of D-Trp in site 2 
Information on the binding mode of D-Trp in site 2 was obtained from a crystal soaked in 
0.25 mM L-Phe and 2.5 mM D-Trp. Site 1 in this structure is occupied by L-Phe, whereas site 2 
is occupied by D-Trp. The binding mode of L-Phe in site 1 is virtually identical to the binding 
mode observed for L-Phe in site 1 in the L-Phe/L-Trp bound structure (PDB code 3KGF).107 The 
comparison of the residues that make up site 2 in the presence of the two enantiomers of Trp 
reveals that the protein backbone and side chains are in similar conformations (Figure 4.5). The 
omit map clearly shows electron density for the D-Trp indole ring, the fact that the density for 
the amino acid moiety is less well defined suggests some disorder in this part of the ligand. Two 
key interactions observed in the binding mode of L-Trp are also found in the binding mode of D-
Trp: the indole N-H of both enantiomers of Trp establishes a buried hydrogen bond to the 
Ala192 backbone carbonyl, and the carboxylate moieties of both enantiomers of Trp form salt 
bridges and hydrogen bonds to the side-chain ammonium group of Lys123. However, the 
inverted configuration of D-Trp results in the amino moiety of D-Trp adopting a position which 
does not allow the establishment of hydrogen bonds to the backbone carbonyl groups of Asn237 
and Thr240 on the α2bβ3-loop, interactions which are present in the binding mode of L-Trp (red 
dashes, Figure 4.5). In addition, contacts mediated by two water molecules between L-Trp and 
the binding site (magenta dashes, Figure 4.5) are not observed in the binding mode of D-Trp. 
 
 
Figure 4.5: D-Trp in site 1. Left: Part of the electron density map in site 2 with D-Trp bound. The model 
conformation for the α2bβ3-loop is in good agreement with the map, the omit map clearly shows the density 
for the indole group of D-Trp, while the density for the amino acid moiety is less well defined, suggesting 
disorder. 2Fo-Fc map contoured at 1.0 σ (blue mesh) and Fo-Fc omit map contoured at 3.0 σ (green mesh). 
Right: Comparison of binding mode of L-Trp (yellow sticks, water molecules shown as magenta spheres) and 
D-Trp (green sticks, water molecules shown as red spheres) in site 2. Key interactions of D-Trp are highlighted 
with yellow dashes. Red dashes indicate hydrogen bonds formed between the L-Trp amino group and Thr240 
and Asn237 which are not established by D-Trp due to the inversion of configuration. Magenta dashes show L-
Trp has additional water-mediated contacts to the protein which are absent in the D-Trp binding mode. 
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Table 4.4: Comparison of distances in Å for key protein-ligand interactions in the L-Trp and D-Trp bound 
structures (site 2). 
Structure Indole N-H 
to Ala192 
C=O 
Trp-
COO- to 
Lys123-
NH3+ 
Trp-NH3+ 
to Thr240 
C=O 
Trp-
NH3+ to 
Asn237 
C=O 
Trp-COO- 
to HOH1 
(near 
Thr114) 
Trp-COO- 
to HOH2 
3KGF 
(L-Trp) 
2.8 2.9, 3.2 2.8 2.6 2.8 2.5 
D-Trp 2.5 3.1, 3.5 3.7 3.6 3.7 n.a. (no 
HOH) 
 
Table 4.5: Data collection and refinement statistics for structures with D-Phe and D-Tyr bound in site 1. 
 D-Phe in site 1 D-Tyr in site 1 
A. Data collection   
Crystal system Trigonal Trigonal 
Space group P3221 P3221 
Unit cell parameters    
a (Å) 203.99 205.45 
b (Å) 203.99 205.45 
c (Å) 66.90 66.80 
Resolution range (Å)a 49.00–2.50  (2.57–2.50) 19.85–2.05 (2.09–2.05) 
Resolution where I/σ(I) = 2.0 3.00 2.48 
CC1/2 outer shell 0.770 0.608 
Measurements 620384 762663 
Unique reflections 55365 101083 
Redundancy 11.2 (11.5) 7.5 (7.5) 
Completeness (%) 100.0 (100.0) 99.9 (100.0) 
I/σ(I) 4.0 (0.9) 5.4 (0.8) 
Rmerge (%) 19.0 (85.0) 14.3 (102.6) 
Wilson B-value (Å2) 35.6 16.0 
B. Refinement   
Resolution (Å) 49.00–2.50 (2.57–2.50) 19.85–2.05 (2.10–2.05) 
Rcryst (%) 15.6b 20.0 
Rfree (%) 17.4b 22.7 
Amino acids (chain length 464 
residues) 
462 + 458 
7085 atom sites 
462 + 456 
7116 atom sites 
Water molecules 82 539 
Other 2 D-Phe ligands, 2 Mn2+, 5 Cl-, 6 
SO42-, 2 glycerol 
2 D-Tyr ligands, 2 Mn2+, 7 SO42-, 
4 glycerol 
Mean B (Å2)   
 Protein 36.3 15.3 
 Water 30.3 32.9 
 Other 36.4 33.4 
r.m.s.d. from target values   
 Bond lengths (Å) 0.007 0.023 
 Bond angles (°) 1.105 1.992 
 Dihedral angles (°) 5.684 6.333 
Ramachandran   
 Most favoured (%) 98.3 97.9 
 Allowed (%) 0.4 2.1 
 Disallowed (%) 0.3 0.0 
a
 according to CC1/2>0.5 cutoff; b intensity-based twin refinement was used.  
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Table 4.6: Data collection and refinement statistics for the structures with D-Tyr in site 1 and 3 and D-Trp in 
site 2 and L-Phe in site 1. 
 D-Tyr in site 1 and 3 D-Trp and L-Phe 
A. Data collection   
Crystal system Trigonal Trigonal 
Space group P3221 P3221 
Unit cell parameters    
a (Å) 205.74 207.97 
b (Å) 205.74 207.97 
c (Å) 66.64 67.03 
Resolution range (Å)a 47.37–2.05 (2.09–2.05) 45.03–2.33 (2.38–2.33) 
Resolution where I/σ(I) = 2.0 2.61 2.93 
CC1/2 outer shell 0.625 0.793 
Measurements 1152805 876944 
Unique reflections 101243 71044 
Redundancy 11.4 (11.3) 12.3 (12.7) 
Completeness (%) 100.0 (100.0) 100.0 (100.0) 
I/σ(I) 4.7 (0.7) 4.2 (0.6) 
Rmerge (%) 16.5 (123.3) 17.0 (133.4) 
Wilson B-value (Å2) 31.5 42.9 
B. Refinement   
Resolution (Å) 47.37–2.05 (2.10–2.05) 45.03–2.33 (2.39–2.33) 
Rcryst (%) 19.9 18.6b 
Rfree (%) 22.9 20.8b 
Amino acids (chain length 464 
residues) 
459 + 456 
7779 atom sites 
462 + 462 
7437 atom sites 
Water molecules 538 204 
Other 3 D-Tyr ligands, 2 Mn2+, 4 Cl-, 8 
SO42-, 1 glycerol 
2 D-Trp and 2 L-Phe ligands, 2 
Mn2+, 5 Cl-, 9 SO42-, 7 glycerol 
Mean B (Å2)   
 Protein 31.9 43.5 
 Water 35.2 41.9 
 Other 38.5 53.4 
r.m.s.d. from target values   
 Bond lengths (Å) 0.011 0.020 
 Bond angles (°) 1.452 2.000 
 Dihedral angles (°) 5.597 6.349 
Ramachandran   
 Most favoured (%) 96.9 98.0 
 Allowed (%) 3.0 1.9 
 Disallowed (%) 0.1 0.1 
a
 according to CC1/2>0.5 cutoff; b intensity-based twin refinement was used. 
  
73 
 
4.3 Discussion 
Handedness or homochirality is a property of all known biological systems. The majority of 
amino acids occurring in nature are the L-enantiomer, which corresponds to the (S)-confi-
guration for all proteinogenic amino acids apart from cysteine. In addition, the majority of 
naturally occurring carbohydrates are chiral and present as single enantiomers in the biological 
molecules for which they provide the building blocks, for example the sugars contained in the 
DNA backbone. The mismatch of the less common enantiomers of amino acids with the 
biological systems of opposite handedness has been exploited in biological chemistry, for 
example in protease-stable poly-D-peptides which disrupt the MDM2/p53 interaction important 
in some cancers.121-123 The study of the interaction of the D-enantiomers of the aromatic 
allosteric regulators of MtuDAH7PS can help understand the complex allosteric regulation and 
the influence of the ligands on the protein conformational ensemble as well as provide 
information for the design of potent allosteric inhibitors. 
The kinetic data show clearly that no combination of aromatic D-amino acids leads to a sig-
nificant reduction in enzymatic activity up to 1 mM concentration, indicating that MtuDAH7PS 
possesses an efficient mechanism of discriminating between aromatic amino acids of different 
handedness. The only combinations tested which lead to an appreciable reduction in enzymatic 
activity (D-Trp/L-Phe and D-Trp/L-Tyr) were only modest in their effect compared to the 
responses observed for the analogous L-Trp/L-Phe and L-Trp/L-Tyr combinations.107, 124 In 
addition, control experiments indicate that the response obtained with D-Trp/L-Phe and D-Trp/L-
Tyr respectively is comparable to the response from 1 mM L-Phe or L-Tyr alone. This response 
could be due to promiscuous binding of L-Phe/L-Tyr to multiple sites when they are present at 
high concentrations. In summary, data from activity assays suggest that the aromatic D-amino 
acids elicit no allosteric effect on the activity of MtuDAH7PS, which could be due either to lack 
of binding of the D-amino acids to MtuDAH7PS or due to the D-enantiomers not inducing the 
same allosteric signal as the L-enantiomer upon binding. 
Lack of binding can however be discounted on the basis of the results from isothermal 
calorimetry experiments, which show that the D-enantiomers of Trp and Phe bind to the 
enzyme. X-ray crystallographic studies on enzyme-ligand complexes furthermore established 
that the respective D-amino acid can still bind to the sites which had been established as the 
preferred sites for the corresponding L-amino acid in Chapter 3. According to the results from 
isothermal titration calorimetry, MtuDAH7PS binds D-Phe with only slightly reduced affinity 
when compared to L-Phe, while the affinity of the enzyme for D-Trp is significantly lower than 
for L-Trp. However, the lower affinity for D-Trp as compared to L-Trp is not sufficient to 
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explain the lack of inhibition in the presence of 200 µM L-Phe/1.8 mM D-Trp: from the binding 
constants it can be estimated that with this combination a significant portion of the enzyme will 
have both L-Phe and D-Trp bound (L-Phe is at approximately 10× Kd and D-Trp at 3× Kd), yet no 
significant reduction in enzyme activity is observed. The possibility that due to the significantly 
reduced affinity of site 2 to D-Trp, D-Trp and L-Phe both compete for site 1 and therefore do not 
elicit a response requiring occupancy of both sites, can be discounted on the basis of the crystal 
structure of MtuDAH7PS in complex with D-Trp and L-Phe. In this structure, D-Trp binds to site 
2 and L-Phe binds to site 1, providing evidence that these two amino acids can be bound to the 
appropriate sites at the same time. Furthermore, the modulation of D-Trp binding in the presence 
of L-Phe suggests that D-Trp still preferentially interacts with site 2, the preferred site for L-Trp. 
The combined insight from kinetic analyses, binding experiments and crystallographic studies 
indicates that binding of the aromatic D-amino acids does not result in the same signal being 
communicated between the allosteric sites and/or between the allosteric sites and active sites. 
The subtle differences in binding mode displayed by the D-amino acids could provide some 
insight into the pathways responsible for communication of allosteric site occupancy. The only 
significant difference between the binding mode of L-Phe and D-Phe in site 1 is the lack of a 
hydrogen bond between D-Phe and the Asn175 side-chain carbonyl. This may indicate that the 
ligand in site 1 needs to establish a contact to Asn175 in order for transmission of a signal from 
site 1 to either site 2 or the active site to occur. It is interesting to note that Asn175 has been 
implied to be important in the network responsible for allosteric regulation of MtuDAH7PS on 
the basis of statistical coupling analysis.125 Since this proposed crucial interaction occurs with 
the side chain of Asn175, mutation of this residue could provide some insight into the com-
munication of occupancy of site 1 to site 2 and/or the active site. The binding mode of D-Trp 
compared to L-Trp in site 2 also reveals the lack of two hydrogen bonding-interactions to the 
amino moiety of the D-Trp ligand as the most significant difference: the D-configuration leads to 
a geometry which does not allow interaction of D-Trp with the backbone carbonyl groups of 
Asn237 and Thr240 on the α2bβ3-loop. Interestingly, a partial conformational rearrangement of 
the α2bβ3-loop containing Thr240 typical of L-Trp binding is still observed in the presence of 
D-Trp, which indicates that establishment of a hydrogen bond between Thr240 and the ligand is 
not the major or only driving force for this conformational change to occur. Supporting 
evidence for this hypothesis is also provided by the study of the binding modes of alternative 
ligands in Chapter 5. The results discussed in Chapter 5 also suggest a crucial role of a contact 
between the ligand and Asn237 in order to achieve allosteric inhibition in site 2. 
Considering protein dynamics when discussing the allosteric regulation of MtuDAH7PS is of 
paramount importance: the absence of hydrogen bonding-interactions between D-Trp and both 
Asn237 and Thr240 is expected to have some impact on the dynamic behaviour of the α2bβ3-
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loop containing these two residues. This difference in dynamic behaviour might in turn lead to 
disruption of the occupancy signal from site 2 to site 1 and/or the active site, ultimately resulting 
in no allosteric regulation by D-Trp. The fact that the main-chain carbonyl groups of Asn237 
and Thr240 are involved makes this hypothesis challenging to probe by site-directed muta-
genesis, further insight could however be gained from molecular dynamics simulations with D-
Trp present in site 2 or mutations which affect the dynamic movement of the α2bβ3-loop. 
In conclusion, the lack of inhibition of MtuDAH7PS by D-amino acids yet again illustrates the 
sophistication of the network for allosteric regulation displayed by this enzyme. Despite binding 
to the appropriate sites, subtle differences in binding mode of the D-amino acids and their 
implications on protein dynamics appear to prevent a response to the less common enantiomers. 
From a ligand and inhibitor design point of view, the interactions necessary for inhibition and 
communication of site occupancy were clarified and will aid in future inhibitor design. 
  
  
Chapter 5 – New allosteric inhibitors of 
MtuDAH7PS by virtual screening 
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5.1 Introduction 
Traditional enzyme inhibitor design focusses on targeting enzyme active sites. Inhibitors are 
designed inspired by substrate, transition state or product structures and compete with the 
substrates for binding to the active site. Because of the conservation of the active site 
architecture of enzymes catalysing the same or similar reactions, achieving selectivity for a 
particular enzyme with active site inhibitors is often challenging.126-127 Moreover, increasing 
levels of drug resistance towards active-site targeting drugs highlights the need for the develop-
ment of novel strategies in drug discovery, which has led to allosteric sites as targets for 
inhibitor design and drug discovery receiving increased attention.128-129 The structural and 
mechanistic intricacies of allosteric regulation are often more complex than the active site 
architecture and reaction chemistry, are divergent between enzymes of identical function and 
have developed through evolutionary optimisation. Therefore, allosteric inhibitors offer the 
potential for the development of compounds with increased selectivity.126 In addition, allosteric 
drugs are attractive because they can be designed to both activate and inhibit the target of 
interest.127 
M. tuberculosis DAH7PS has three allosteric sites which endow the enzyme with an unusual 
mechanism of synergistic ternary allosteric regulation, and many of the details of the allosteric 
network and the interplay of allosteric sites and active site have been elucidated.107-108, 124-125 
However, it remains unclear which features of the binding mode of the native allosteric 
effectors Trp, Phe and Tyr are essential in the communication between the allosteric sites and 
between the allosteric sites and the active site. The discovery and study of new, non-natural 
ligands of the allosteric sites of MtuDAH7PS can help to provide further insight into the 
mechanism of allosteric regulation as well as generate starting points for inhibitor design. In 
addition to displaying a complex mechanism of allosteric regulation of its own function, 
MtuDAH7PS also forms a non-covalent complex with a chorismate mutase enzyme from M. 
tuberculosis (MtuCM). Formation of the non-covalent complex between MtuDAH7PS and 
MtuCM leads to an activation of the CM activity and its regulation by Phe and Tyr, two of the 
allosteric effectors of MtuDAH7PS.110-111 Alternative ligands for the allosteric sites of 
MtuDAH7PS are potential tool compounds in order to further investigate this interesting 
protein-protein interaction and the mechanism of transfer of allostery. As an ultimate goal, an 
inhibitor of both MtuDAH7PS and MtuCM activity will be an interesting candidate for anti-
tuberculosis drug development due to its ability to target both the first committed step 
(DAH7PS) and a downstream target (CM) in the biosynthesis of aromatic amino acids. 
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This chapter reports the use of a combination of virtual screening and fragment-based inhibitor 
design for the discovery of new allosteric ligands and inhibitors of MtuDAH7PS. Virtual 
screening uses computational algorithms to predict the binding mode of compounds to a 
predefined binding site, often referred to as docking.130-133 Scoring functions can be used to rank 
the binding poses of compounds according to their interactions with the binding site. In this 
chapter, virtual screening is used in order to reduce the number of compounds that are 
physically screened: the selection of compounds for physical screening is based on a favourable 
docking pose and score. Furthermore, the known allosteric inhibitors Trp, Phe and Tyr were 
used as starting points and inspiration for the discovery of new ligands. With molecular weights 
below 300 Da, Trp, Phe and Tyr can be regarded as fragment-like compounds, and the initial 
screen reported in this chapter used a fragment-based discovery approach. In contrast to 
traditional high-throughput screening methods which rely on the identification of medium to 
high affinity hits (affinity or IC50 in the low micromolar range) out of large libraries (>100,000 
compounds) with medium to high molecular weight (300–1200 Da), fragment-based ligand 
discovery approaches seek to find small (<300 Da molecular weight), low to medium affinity 
(high micromolar to millimolar) compounds from smaller libraries (up to a few thousand 
compounds) as starting points for elaboration.134-135 The fragment-like ligands generally 
establish a few good interactions with the binding site with comparatively few atoms, leading to 
high ligand efficiency. The small size of the fragments allows the exploration of different parts 
of the target site with different fragments, which can then be grown or merged into lead-like 
compounds. 
In this chapter, a ligand position predicted by computational modelling will be referred to as a 
“docking pose” throughout, in contrast to “binding mode”, which refers to a ligand position in a 
model derived from experimental X-ray diffraction data. In figures, docking poses of ligands 
will be shown with their hydrogen atoms as predicted by docking, and be distinguishable from 
crystallographically observed ligand binding modes by their different colours as specified in the 
respective figure legends. The hydrogen atoms of the protein receptor were included in the 
docking calculations, but will be omitted from figures for clarity. 
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5.2 Results 
5.2.1 Virtual screening 
Preparation of the receptor 
The virtual screening efforts and alternative ligand search focussed on site 1 and 2, because the 
role of site 3 as the Tyr binding site described in Chapter 3 was unclear at the start of the study 
detailed in this chapter. Before docking experiments were commenced, the available liganded 
structures of MtuDAH7PS were examined. Analysis of an overlay of the tetrameric assembly of 
the structures with PDB codes 3NV8 (no allosteric ligands), 3NUD (Phe bound), 3NUE (Trp 
bound) and 3KGF (Trp and Phe bound) shows that the only conformational changes occurring 
in the crystalline state upon ligand binding are localised at the allosteric binding sites (see 
Chapter 1).  
The conformation in presence of either Trp or Phe in site 2 is characterised by a rearrangement 
of the α2bβ3-loop, which connects the α2a and α2b helices with the β3 strand (Figure 5.1b). The 
peptide bond connecting Thr240 and Ala241 rotates by about 90 º, which places the backbone 
carbonyl of Thr240 within hydrogen bonding-distance to the ligand amino moiety. The residues 
Arg236–Gln239 form a structure which could be described as a one-turn helix. Upon binding of 
the native ligands Trp or Phe, this helix moves towards the bound ligand, enabling the backbone 
carbonyl of Asn237 to establish a hydrogen bond with the ligand amino moiety. The confor-
mation of the α2bβ3-loop is very similar independent of whether Trp or Phe are bound to the 
site. It was therefore concluded that treating the protein in the ligand-bound conformation as a 
rigid receptor apart from the rotation of side chains containing polar hydrogen atoms would be 
appropriate for this site. Two water molecules mediate interactions between the Trp ligand and 
the protein (Figure 5.1a) – one receptor used for docking therefore included these two water 
molecules, whereas another receptor excluding these waters was also prepared. The indole 
moiety of the Trp ligand binds in a hydrophobic pocket lined by the side chains of Leu107, 
Val111, Leu184 and Val197.  The indole N-H establishes a hydrogen bond to the carbonyl 
group of Ala192, which was considered a key interaction due to this polar interaction being 
buried in the solvent-excluded part of the binding site. The carboxylate moiety of Trp forms a 
salt bridge and hydrogen bond to the side-chain amino group of Lys123, as well as hydrogen 
bonds to the two water molecules mentioned above. One of these water molecules is in turn 
hydrogen bonded to the backbone amide nitrogen of Glu242, the other forms a bifurcated 
hydrogen bond to the side-chain hydroxyl group of Thr114 and the backbone amide nitrogen of 
81 
 
Val121. The Trp amino group forms hydrogen bonds to the backbone carbonyl groups of 
Thr240 and Asn237.  
Site 1 shows two more distinct conformations in the absence and presence of ligands: The side 
chain of Trp3 in subunit B is in a solvent exposed position at the end of the N-terminal β-strand 
in the absence of ligands, a conformation which will be referred to as “Trp3 out” (Figure 5.2b). 
In the presence of Phe (PDB code 3NUD, 2YPO) or Tyr (2YPP) however, Trp3 occupies a 
more buried position between the site 1 ligands from the two subunits, a conformation which  
 
(a) 
 
(b) 
Figure 5.1: (a) Binding mode of Trp (magenta carbons) in site 2, key interactions are shown with yellow 
dashes. (b) comparison of the conformation of the α2bβ3-loop in the absence (green carbons, PDB code 3NV8) 
and presence (blue carbons, 3NUE) of native ligands in site 2. 
 
(a) 
 
(b) 
Figure 5.2: (a) Binding mode of Phe (magenta carbons) in site 1, key interactions are shown with yellow 
dashes. (b) comparison of the conformation of the N-terminal β0-strand and the position of Trp3 in the 
absence (yellow, “Trp3 out”, PDB code 3NV8) and presence (blue, “Trp3 in”, PDB code 2YPO) of Phe. 
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will be referred to as “Trp3 in”. In the “Trp3 out” conformation, site 1 in subunit A and site 1 in 
subunit B are connected to each other and form an elongated continuous cavity that is lined with 
hydrophobic residues (Figure 5.2b). In the “Trp3 in”-conformation, the side chain of Trp3 
effectively separates the site 1 in subunit A from site 1 in subunit B so that the sites can be 
regarded as independent, albeit very similar binding sites. In order to explore potential ligands 
which can bind to either of these conformations, receptors reflecting these different confor-
mations were prepared and the compound libraries docked into both receptors. 
The key interactions of the native ligand Phe with site 1 are shown in Figure 5.2a: The phenyl 
moiety of the ligand points towards the hydrophobic centre of the binding site, whereas the 
amino acid moiety is involved in a number of polar interactions: the carboxylate group of Phe 
forms a salt bridge with the guanidinium moiety of Arg171, a hydrogen bond to the side-chain 
amide nitrogen of Asn175, and a water-mediated contact to the Trp3 indole nitrogen. The Phe 
amino group establishes a hydrogen bond to the side-chain amide carbonyl of Asn175, the 
backbone carbonyl of Phe91 and a water-mediated contact to Asn94. Trp has also been 
observed to bind in site 1 (undeposited fully refined data, Jiao et al.125), the key interactions are 
comparable to the binding mode of Phe, but although Trp was present in site 1 in both subunits, 
no shift from the “Trp3 out” to the “Trp3 in” conformation is observed in the presence of Trp. 
Test docking of the native ligands 
Generally, docking programs like Glide and GOLD used in this study, consist of three parts:130-
131, 133, 136-137
 
1. A mechanism for placing the ligand in the binding site: for this purpose, GOLD uses 
fitting points located at groups on the receptor protein capable of hydrogen bonding. 
Hydrogen bond donors on the ligand are mapped onto acceptors on the protein and vice 
versa. Hydrophobic fitting points are also determined and mapped onto the hydrophobic 
parts of the ligand.  
In contrast, Glide, the other docking program used in this study, employs a grid 
approach: the binding site is divided into sections of three-dimensional space, and for 
each point on the grid interaction potentials are pre-calculated. The grid only needs to 
be calculated once for each receptor, which speeds up subsequent evaluation of docking 
poses.  
2. A search algorithm to explore possible binding modes: GOLD uses a genetic algorithm, 
which aims to optimise the fitness of a population of docking solutions with respect to 
the scoring function. The genetic algorithm uses crossover and random mutation in 
order to evolve new solutions, with a bias towards higher scoring solutions propagating 
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to the next generation and the worst-scoring solutions being eliminated (“survival of the 
fittest”).  
Glide uses a docking “funnel” starting from the pre-defined receptor grid:136 ligand 
conformations are energy-minimised in the absence of the receptor and subsequently 
placed on grid points in the receptor. Ligands whose shape and size does not 
complement the binding site are rejected early on and more exhaustive conformational 
searches only conducted on ligands which display a good fit to the binding site. 
3. A scoring function to rank different binding modes: for each docking pose, the 
favourable interactions such as hydrogen bonds, attractive Coulomb interactions, and 
hydrophobic interactions are calculated. Unfavourable interactions, such as clashes of 
the ligand with the binding site, repulsive Coulomb interactions and internal 
conformational strain of the ligand are also taken into account. Different scoring 
functions differ in the individual functions they use to describe the different types of 
interactions, the relative weighting of the individual terms as well as whether and how 
they were parameterised against a set of crystallographically validated ligand binding 
modes and experimental affinities. One major difference between Goldscore and 
chemPLP, which were compared for docking in GOLD, is the implementation of a 
conformational search algorithm in chemPLP which increases the probability that a 
favourable docking geometry is further optimised in subsequent docking runs. On the 
other hand, Goldscore relies on an exhaustive or at least exhaustive enough search of 
the conformational space of the ligand to identify favourable docking poses. The 
scoring function implemented in Glide introduces modifications to the scoring functions 
used in GOLD: hydrogen bond-interactions are treated differentially depending on 
whether donor and acceptor are both neutral; one of them is charged and the other 
neutral; or both of them are charged.136 The scoring function used by Glide also takes 
into account solvation effects, which avoids charged ligand groups becoming 
completely desolvated in the docking pose. 
The known binding modes of the aromatic amino acids were used in order to choose the most 
appropriate scoring function and docking protocol for the screening of the fragment-like library. 
The native ligand was extracted from the crystal structure and docked back into the respective 
site using different scoring functions and docking protocols. For docking carried out in GOLD, 
for both site 1 and site 2 it was found that the Goldscore scoring function was most reliable in 
reproducing the crystallographically observed binding mode, followed by the chemPLP scoring 
function. Although some of the lower scoring poses obtained using the chemPLP scoring 
function did not match the observed ligand binding mode, the top ranked poses were 
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consistently in accordance with the native binding mode. Ligand docking using the chemPLP 
scoring function is faster when compared to Goldscore, possibly due to the improved 
conformational search implemented in chemPLP (see above). Only the top ranked solution for 
each compound was intended to be kept and examined. In order to take advantage of both the 
faster processing times which can be achieved with chemPLP and the higher reliability of the 
Goldscore scoring function, the initial docking during the virtual screening used the chemPLP 
scoring function followed by rescoring with Goldscore.133 
Trp was included in the library of compounds docked with Glide in order to assess the ability of 
the docking protocol to, firstly, correctly predict the binding mode of the native ligand Trp, and 
secondly, to score this docking pose accordingly so that the validated ligand would be included 
in the top-ranked poses. The docking pose predicted for Trp in site 2 – the ligand’s preferred 
site – is almost identical to the crystallographically observed binding mode (Figure 5.3). It 
should be noted that the crystallographically observed binding mode of Trp, when analysed 
according to the criteria used by the docking programs, displays some steric clashes with the 
binding site. In the evaluation of the predicted docking poses resulting from virtual screening, a 
small number of steric clashes with the binding site was therefore tolerated. The pose correctly 
predicted for the validated binder Trp ranked 22nd out of over 3000 compounds (among the top 
1% of compounds by docking score). The ability of the docking protocols to reproduce the 
experimentally observed binding modes as well as ranking them highly in the output hit lists 
gives some confidence that the top-ranked compounds will be enriched with true hits. 
Preparation of the libraries 
An in-house library composed by Dr Jack Flanagan at the Auckland Cancer Society Research 
Centre (ACSRC) containing approximately 16,000 fragment-like ligands with predicted high 
solubility was used in order to sample diverse chemical space for the discovery of new allosteric  
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Figure 5.3: Comparison of crystallographically observed binding mode of Trp (magenta carbons) with the 
docking pose predicted by Glide (yellow carbons, white hydrogens) in site 2. 
ligands. In parallel, focussed libraries which were biased to contain close analogues of the 
native ligands Trp, Phe and Tyr were designed: The ZINC database138 of commercially 
available compounds was searched for 3-substituted indoles which also had a proton in the 2- 
position. Substituents other than a proton at the 2-position were excluded because it was 
anticipated that this would lead to steric clashes with site 2 and disrupt the hydrogen bond 
between the indole N-H and Ala192. Due to the large number of compounds returned when the 
phenyl- and phenol-side chains of Phe and Tyr were used for substructure search in the ZINC 
database, a different approach was chosen to generate libraries biased towards compounds 
similar to Phe or Tyr: compounds that had a Tanimoto similarity of more than 50% to Phe or 
Tyr respectively were selected from the ZINC database. This resulted in libraries of about 3000 
compounds for Phe and Tyr each, a manageable number for docking with Glide on the available 
hardware. 
Docking results and compound selection 
The top 300 poses by docking score of each docking run were examined. A parameter of 
docking score divided by molecular weight was calculated and the poses of the top 300 
compounds according to this criterion also examined. Compounds were selected based on  
• complementary fit to the binding site  
ligands whose shape allowed a tight fit with the target site were chosen 
preferentially, furthermore the complementarity of electrostatic potentials of the 
ligand and the receptor in the docking pose was ensured. 
• ligand-receptor hydrogen bonds with good geometry 
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interactions between a hydrogen bond donor atom X-H and an acceptor atom :Y 
with a free pair of electrons were regarded as hydrogen bonds if the distance 
between X and Y was between 2.4 and 3.0 Å, and the X-H-Y angle was larger 
than 120º. Ligands with hydrogen bond angles closer to 180º were chosen 
preferentially. 
• absence of steric clashes 
a few small clashes in predicted binding poses were tolerated, especially if the 
binding pose showed a tight fit to the binding site (the crystallographic binding 
mode of Trp is considered to have a few small clashes, see page 82). A large 
number of small clashes or any bad clashes were a criterion for elimination of 
compounds.  
• potential for elaboration 
Compounds with predicted binding poses which project functionalisable bonds 
into vacant spaces of the binding cavity were picked with higher priority. This 
was envisaged to enable fragment-growing strategies should the hit and binding 
mode be validated. 
• Docked ligand efficiency 
Small, less functionalised ligands which gave good docking scores were also 
prioritised due to two reasons: firstly, achieving a good docking score with few 
atoms can be regarded as a higher ligand efficiency, a concept used in the 
fragment-based screening to identify promising structures for optimisation and 
to validate fragment-growing or -connection strategies.135 Secondly, less 
functionalised compounds are more likely to be readily available and less 
costly, and also more likely to be commercially available in building block 
quantities. This offers the potential of more rapid hit optimisation. 
5.2.2 Compounds selected from docking into site 2 (Trp site) 
Compounds VS1 to VS8 were chosen from the virtual screen of the diverse fragment library 
docked into site 2 (Trp site). Most of the compounds chosen were predicted to establish a 
contact to the backbone carbonyl of Ala192 (see docking poses in Figure 5.4) in their docking 
pose, a hydrogen bond which is also a key interaction in the binding mode of Trp. Indole 
analogues VS5 and VS6 showed interesting docking poses: VS5 is predicted to fit tightly into 
the binding site and to establish a hydrogen bond to Asn237 on the α2bβ3-loop. Furthermore, 
VS5 offers positions for potential derivatisation. VS6 contains a tetrazole moiety as a potential 
carboxylic acid isostere and the docked pose predicts close proximity of the potentially 
negatively charged tetrazole and the positively charged side chain of Lys123. A number of 
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arylamines or anilines were docked in a pose which predicted a hydrogen bond with good 
geometry between their amino moiety and Ala192. Of these, VS2, VS3 and VS8 were chosen to 
be evaluated as inhibitors. The predicted poses of VS2 and VS8 place oxygen atoms of the 
ligands in positions which are frequently found to be occupied by well-ordered water molecules 
in crystal structures of the enzyme. VS3 possesses a bisphenylether-like scaffold which lends 
itself to modular synthesis and functionalisation. In addition, this ligand was predicted to bind in 
a pose in which it interacts with parts of the extended binding site which do not interact with the 
native ligands Trp or Phe. VS4 was chosen on the basis of its versatile scaffold and the 
predicted binding pose showing two hydrogen bonds, one of which is to Ala192. The carboxylic 
acid moiety was also envisaged to provide a charge complementary to the side chain of Lys123. 
A number of sulfonamide derivatives were ranked highly in the virtual screen, from their 
predicted binding mode they show the potential to be a mimic of the amino acid moiety of the 
native ligands. VS1 was chosen as a representative of the sulfonamide class of compounds, the 
predicted binding pose shows hydrogen bonds of good geometry to Thr240 and Lys123, both 
key residues in the binding mode of the native ligands. In addition the triazole moiety of VS1 is 
predicted to establish another hydrogen bond to the side chain of Asn175. VS7 was chosen to 
explore whether the indole binding pocket could accommodate a hydrophobic naphthyl moiety 
which cannot establish the buried hydrogen bond to Ala192. VS7 also contains a glycolamide 
moiety as a potential mimic for the amino acid portion of the native ligands. 
Evaluation of the library of 3-substituted indoles docked into site 2 resulted in selection of 5 
main groups of compounds (Figure 5.7): 
1. Compounds exploring a potential cation-pi-interaction between the Lys123 ammonium 
moiety and the ligand: cation-pi-interactions have been utilised in supramolecular 
chemistry for some time, their importance in proteins and protein ligand complexes is 
now increasingly recognised.139-140 VS23 and VS24 were selected to according to this 
rationale, the aromatic groups that are predicted to bind in a geometry enabling a 
potential cation-pi-interaction with Lys123 were chosen to have electron-donating 
substituents. The increased electron density in the aromatic ring systems is proposed to 
result in a stronger cation-pi-interaction. 
2. 1,3,4-oxadiazole as a carboxylic acid replacement: two compounds which contained a 
1,3,4-oxadiazole were predicted to bind in a similar position to the native ligands’ 
carboxylic acid moieties were selected in order to explore their potential to mimic the 
acid group. Interestingly, the differing substituent in VS25 and VS26 leads to two 
different predicted orientations of the 1,3,4-oxadiazole in the docking pose: VS25 was 
88 
 
docked with the two nitrogens of the oxadiazole ring pointing towards Lys123, whereas 
the docking pose of VS26 shows the oxygen pointing in that direction. 
3. Derivatives of 2-(1H-indol-3-yl) acetamide: Due to the favourable binding mode 
predicted for (2-indolyl)-acetamides and a number of derivatives being readily 
available, it was decided to explore the potential of this class of compounds as 
alternative ligands for site 2. From the docking poses, the acetamide moiety shows 
potential to mimic the amino acid moiety of the native ligands: the carbonyl group of 
the acetamide ligand is predicted to interact with Lys123. Depending on its substituent, 
the amide nitrogen is predicted to establish a hydrogen bond to the backbone carbonyl 
group of Asn237. VS28–30 and VS32 can be regarded as condensation products 
between (2-indolyl)-acetamide and an amino acid. Their carboxylic acid moiety was 
docked in a position which enables formation of a hydrogen bond and salt bridge to 
Lys123. The introduction of the amino acid side chain in VS29, VS30 and VS32 creates 
the possibility of two stereoisomers: for VS29 and VS30, both enantiomers were ranked 
highly in the docking, whereas only one enantiomer of VS32 was found among the top 
ranked compounds. This may be due to the prediction that both carboxylates of VS32 
would interact with the amino group of Lys123, which would not be possible for the 
opposite enantiomer. The phenyl side chain of the (R)-enantiomer of VS29 is predicted 
to occupy a position in which a cation-pi-interaction with the Lys123 side-chain ammo-
nium group can be expected. The amide carbonyl and carboxyl moieties of the VS29 
ligand are predicted to also coordinate Lys123, resulting in a complete coordination 
sphere for this residue and its exclusion from water. It was deemed an interesting 
hypothesis to test whether ligands that display a docking pose that completely seques-
ters the ammonium group of Lys123 were going to be binders. In the crystallo-
graphically observed binding mode of the native ligands, the Lys123 ammonium moiety 
is solvent accessible as illustrated by the presence of one or more water molecules 
within hydrogen bonding distance. 
4. Methyl and fluoro-substituted tryptophan analogues: 4/5/6-methyl and -fluoro 
tryptophan were docked in close similarity to the binding mode of the native Trp ligand 
and were readily available from commercial suppliers. In light of the findings of 
Chapter 4 regarding the selectivity of site 2 for the L-enantiomer of Trp, it is interesting 
to note that although the library contained both enantiomers of the methyl- and fluoro-
analogues of Trp, only the L-enantiomers are found among the top 300 ranked docking 
poses. These derivatives were selected to explore the tolerance of the binding site for 
substituents in its most hydrophobic part: introduction of an additional methyl group in 
these positions might lead to increased hydrophobic interactions, however the increased 
steric bulk might cause clashes between the ligand and the binding site. The docking 
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pose for 5-methyl-tryptophan is one of the few docking poses which does not predict 
binding of the indole moiety in accordance with the binding mode of Trp – instead, the 
4-methyl-indole is predicted to bind in a flipped orientation. A reason for this could be 
steric clashes of the binding site with the 4-methyl substituent in the more commonly 
observed position of the indole ring. The fluorinated Trp-analogues were docked in 
virtually identical poses to the native Trp-ligand, for 5-fluoro-tryptophan (VS41), an 
additional hydrogen bond between the fluorine atom and the hydroxyl group of Thr114 
on the α1 helix is predicted in the docking pose.  
5. VS34 and VS35 are simple 3-substituted indole derivatives which achieve a good 
docking score with comparatively few atoms, resulting in high ligand efficiency. In 
addition they are readily and cost-effectively available compounds which were obtained 
in building block quantities for rapid elaboration should the fragments be found to bind. 
5.2.3 Compounds selected from docking into site 1 (Phe site) 
The majority of compounds selected from the virtual screening at site 1 were from the docking 
run into the receptor with the “Trp3 out” conformation (Figure 5.5). The more open 
conformation of the receptor results in the docked compounds exploring different sections of the 
linked binding sites from both subunits. The residues Arg171 and Asn175, which provide key 
contacts for the native Phe ligand, were frequently predicted to be involved in interactions with 
the compounds selected from the evaluation of docking poses. 
A number of compounds were selected which are only expected to fit into the binding site in the 
“Trp3 out” conformation, in order to examine whether the conformational change towards the 
“Trp3 in” conformation” is necessary for inhibition: 
• VS11 is docked in a position spanning the binding sites from both subunits and is 
predicted to establish an H-bond interaction at either end: the hydroxyl group of the 
ligand was predicted to interact with Pro8 of subunit A and the furan moiety was 
projected to bind to Arg171 and Asn175. 
• VS13 represents an interesting chemotype whose largely hydrophobic characteristic 
was chosen due to the hydrophobic nature of the binding site. The hydroxyl group of 
VS13 is predicted to provide hydrogen bonds to Pro8 and the side chain of Asp10, 
effectively bridging these two residues. 
• VS14 combines a hydrophobic ethyl-benzene moiety which spans the binding sites in 
both subunits. It displays a potentially negatively charged tetrazole group which is 
predicted to bind in close proximity to the positively charged Arg171 side chain. VS19 
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was chosen as another readily available tetrazole derivative with a predicted docking 
pose almost identical to VS14, but with a slightly different substitution pattern. 
• The predicted docking pose of VS16 also places a tetrazole moiety in a bridging 
position between Arg171 and Asn175, the methylene-hydroxyl group of VS16 provides 
an additional hydrogen bond to Pro8 in subunit B. 
• VS17 and VS18 were selected based on a docking pose predicted for a 1,2,4-
oxadiazole: switching the positions of the oxygen and adjacent nitrogen was envisaged 
to result in an improved pattern of hydrogen bonding interactions: an oxygen with its 
two lone pairs could interact with the side-chain hydrogen bond donors of Arg171 and 
Asn175, whereas the adjacent position only requires a nitrogen atom which can accept 
one hydrogen bond from the guanidinium moiety of Arg171. Both VS17 and VS18 
possess one methylene hydroxyl substituent and one hydrophobic substituent, their 
substitution pattern however is different: VS17 has a hydrophobic isopropyl group in 
the 3-position (if the oxygen atom is regarded as position 1) and a 2-methylene 
hydroxyl substituent, whereas VS18 displays a 2-phenyl group and the methylene 
hydroxyl moiety in the 3-position. 
• VS36 is an indole derivative which was selected from the results of the docking of the 
3-substituted indole library into site 1, it did not rank among the top solutions for site 2. 
The bulky benzyloxy-substituent is predicted to fit into site 1 in the “Trp3 out” confor-
mation, but clearly not into site 2. The potential selectivity arising from the increased 
steric bulk on the indole was deemed interesting for further examination. 
Three compounds which are also predicted to fit into the site in the “Trp3 in” conformation 
were selected from the virtual screen docked in site 1: 
• In the predicted docking pose, VS12 presents hydrogen bond acceptors complementary 
to the two donors in the guanidinium moiety of Arg171. In addition, this compound is 
predicted to bind with a tight fit to the α0-loop. 
• VS15 is predicted to bind in a more solvent exposed part of the binding site. The amino 
moiety of this ligand is predicted to establish two hydrogen bonds, one to the Phe91 
backbone carbonyl group and one to the Asn94 backbone carbonyl group. The 
chemotype of this compound also makes it a probable candidate for binding in site 2 
(Trp site). 
• VS20 was chosen as an available analogue of two phenylsulfonamides which showed 
interesting binding modes in site 1. In the predicted docking pose, the sulfonamide 
moiety establishes a number of good interactions with the residues crucial for binding 
the native Phe ligand, Arg171 and Asn175. The presence of a 2-hydroxyl group in this 
91 
 
class of ligands is envisaged to form a hydrogen bond to the main-chain carbonyl of 
Asn94. VS20 is also an interesting compound for binding to site 2.  
VS9, VS10, VS21 and VS22 were already available in the laboratory and complete the 
selection of 42 compounds selected for hit validation (Figure 5.6). Although these 
compounds were not scored among the top ranked poses in the docking, they are close 
analogues of the native ligands. 
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Figure 5.4: Structures and docking poses of compounds selected from the virtual screen of the fragment-based library against site 2. VS2 and VS3 were selected based on docking 
poses of analogues shown here. 
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Figure 5.4 (continued): Structures and docking poses of compounds selected from the virtual screen of the fragment-based library against site 2. 
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Figure 5.5: Structures and docking poses of compounds selected from the virtual screen of the fragment-based library against site 1.  
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Figure 5.5 (continued): Structures and docking poses of compounds selected from the virtual screen of the fragment-based library against site 1. VS17 and VS18 were not ranked in 
the top poses, the docking pose of the compound was the basis for their selection is shown. 
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Figure 5.5 (continued): Structures and docking poses of compounds selected from the virtual screen of the fragment-based library against site 1. VS20 was chosen based on the 
docking pose of a close analogue shown. 
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Figure 5.6: Compounds not docked in the virtual screen, chosen and tested due to their availability and similarity to the native ligands. 
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Figure 5.7: Structures and docking poses of compounds selected from the virtual screen of the native ligand-biased library against site 2. VS23 had two high-ranking docking poses, 
shown in yellow and blue respectively. 
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Figure 5.7 (continued): Structures and docking poses of compounds selected from the virtual screen of the native ligand-biased library against site 2.  
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Figure 5.7 (continued): Structures and docking poses of compounds selected from the virtual screen of the native ligand-biased library against site 2. 
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Figure 5.7 (continued): Structures and docking poses of compounds selected from the virtual screen of the native ligand-biased library against site 2.  
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Figure 5.7 (continued): Structures and docking poses of compounds selected from the virtual screen of the native ligand-biased library against site 2. VS36 represents an indole 
derivative that was picked due to its good fit into site 1 but not into site 2. 
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Figure 5.7 (continued): Structures and docking poses of compounds selected from the virtual screen of the native ligand-biased library against site 2. 
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5.2.4 Hit validation 
After compound selection from evaluation of docking poses resulting from the virtual screen, 
the selected compounds were purchased from commercial suppliers and the virtual screening 
hits examined and validated using two methods: inhibition of the activity of MtuDAH7PS was 
determined using kinetic assays, and binding modes of ligands were elucidated using X-ray 
diffraction on single crystals of MtuDAH7PS which had been soaked in solutions containing the 
putative ligands. 
5.2.4.1 Hit validation by kinetic assay 
The activity of MtuDAH7PS in the presence of the putative inhibitors VS1–42 was assayed 
using the standard UV-based assay system (see Chapter 7). Stock solutions of VS1–42 in 
dimethyl sulfoxide (DMSO) were added to the assay solution and initial rates obtained and 
compared to control reactions which only contained the vehicle DMSO (Figure 5.8). No 
inhibition of enzymatic activity was observed at DMSO-concentrations up to 10% v/v, which 
well exceeds the concentrations used for inhibition assays. Due to the unusual synergistic 
inhibition of MtuDAH7PS involving multiple sites and ligands, putative inhibitors were also 
assayed in the presence of Trp (red bars, Figure 5.8) or Phe (green bars, Figure 5.8) in order to 
assess whether they could act as a surrogate for either of these amino acids in the synergistic 
inhibition. Some compounds showed unexpected behaviour under the assay conditions, these 
are denoted with an asterisk in Figure 5.8: addition of VS7 and VS10 to the assay solution 
caused a high absolute absorbance reading outside the linear range of the spectrophotometer 
used and vastly different absorbance readings for repeats with identical concentrations. Initial 
rates in the presence of VS7 and VS10 were of poor reproducibility. In the presence of VS13, a 
decrease in absorbance in the absence of enzyme from the assay mixture was observed, 
suggesting that either degradation of VS13 or an unwanted side-reaction with PEP occurs. Due 
to their problematic behaviour in the assay system and the number of other compounds which 
could be identified as initial hits, VS7, VS10, and VS13 were disregarded for further screening 
and discussion in this thesis. 
The results show that a number of the compounds selected from virtual screening inhibit the 
activity of MtuDAH7PS. It is also evident that some compounds can act as surrogates for Trp or 
Phe: For example, VS18 causes no significant inhibition of enzymatic activity when present by 
itself (blue bars, Figure 5.8) or in combination with 200 µM Phe (green bars, Figure 5.8). 
However, VS18 in combination with Trp (red bars, Figure 5.8) causes enzymatic activity to 
decrease to 55% of the control reaction. Overall, the synergistic inhibition observed with either 
Trp or Phe is in line with the compounds causing an effect at the site they were selected to 
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target: VS1–10 were initial selections chosen from the virtual screen against site 2 (“Trp site”). 
VS3, the only compound from this group showing any significant inhibition, is active only in 
the presence of Phe. VS11–21 were selected from the virtual screen against site 1 (“Phe site”), 
and most active compounds from this group show their most potent inhibition when present in 
combination with Trp. VS22–42 are all indole-derivatives which are primed to target site 2 due 
to their similarity to Trp. However, some of these compounds were selected from a virtual 
screen of the indole-library docked into site 1 or showed high-scoring docking poses in both site 
1 and 2. In line with this selection approach to identify compounds which could target multiple 
sites and could act as a surrogate for either or both Trp or/and Phe, some compounds in the 
group VS22–42 show their highest inhibitory activity in combination with Trp (VS24, VS29, 
VS30) and some inhibit synergistically with Phe (VS23, VS36, VS40–42). 
 
  
 
Figure 5.8: Activity (% of control reaction) of MtuDAH7PS in the standard kinetic assay in the presence of 1 mM of compounds VS1–VS42 (blue bars) VS1–VS42 in the presence of 
200 µM Trp (red bars) and VS1–VS42 in the presence of 200 µM Phe (green bars). Activity is normalised to DMSO or DMSO/Trp or Phe controls. If inhibition was observed, rates 
are averages of at least duplicate experiments, error bars represent standard deviation of the repeats. The substrates PEP and E4P were at a concentration of 150 µM each. Asterisk 
(*) indicates compounds which showed unusual behaviour in the assay system used which are discussed in the text. 
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5.2.4.2 Hit validation using X-ray crystallography 
Compounds selected from virtual screening were further screened and examined using X-ray 
crystallographic analysis of MtuDAH7PS-ligand complexes. To this end, single crystals of 
MtuDAH7PS were grown using established conditions, soaked in solutions containing the 
putative ligands and the crystals then analysed by X-ray diffraction. The atomic resolution detail 
of this method enables the determination of the binding site(s) that the ligands are able to bind 
to and gives detailed information on the binding site conformation and the binding mode of the 
ligands. Insights gained from analysis of the crystal structures can be used to improve the 
ligands by structure-based design. Comparison of the crystallographically observed binding 
modes with the computationally predicted docking poses can lead to further insight on 
improving the docking protocol and compound selection process in order to more efficiently 
discover new ligands by virtual screening. It is of note that the soaking of crystals in solutions 
containing ligands did not affect crystal symmetry or unit cell dimensions significantly (Table 
5.5). The overall fold of the protein in the structure was also unaffected by crystal soaking, as 
evidenced by the low root-mean-square deviation (RMSD) obtained from superposition of the 
liganded structures with the structure in the absence of allosteric ligands (PDB code 3NV8, 
Table 5.1). Around the ligand binding sites, local conformational changes associated with ligand 
binding can still be observed and are discussed for each ligand. Some ligand solutions caused 
degradation of crystal quality: this ranged from loss of diffraction quality and intensity in 
crystals unchanged to visual inspection, to cracking of crystals in soak solutions, to complete 
dissolution of crystals in soaking experiments. Nevertheless, a number of MtuDAH7PS 
structures in complex with ligands selected from virtual screening could be obtained: the 
following section describes these crystal structures, the sites occupied by the ligands and the 
ligand binding modes in ascending order of ligand number. 
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Table 5.1: Root-mean-square deviations (RMSD) of MtuDAH7PS-VS complex crystal structures in 
comparison with the unliganded structure (PDB code 3NV8). The number of atoms used in the alignment is 
shown in brackets. 
Structure VS6 VS16 VS17 VS18 VS20 VS21 VS22 VS25 VS28 
RMSD [Å] 
(atoms) 
0.297 
(5423) 
0.229 
(5245) 
0.230 
(5250) 
0.219 
(5106) 
0.239 
(5086) 
0.324 
(5187) 
0.320 
(5155) 
0.267 
(5320) 
0250 
(5023) 
Structure VS32 VS35 VS37 VS38 VS39 VS40 VS41 VS42  
RMSD [Å] 
(atoms) 
0.350 
(5209) 
0.306 
(5015) 
0.320 
(5008) 
0.209 
(4897) 
0.228 
(5290) 
0.355 
(4928) 
0.342 
(4879) 
0.365 
(5041) 
 
 
VS6 
VS6 was observed to bind to both site 1 and site 2 in crystal soaking experiments (Figure 5.9). 
The observed electron density in the ligand binding sites is in accordance with partial occupancy 
with VS6, modelling of the ligand at 80% occupancy in both site 1 and site 2 gave good 
agreement between the model and electron density after refinement. 
VS6 in site 1 does not establish any direct contacts with the enzyme, the main interactions are of 
hydrophobic nature (Figure 5.9b). However, two water molecules were found within 3.0 and 
3.2 Å of the tetrazole and indole N-H moieties respectively. Only one VS6 molecule binds in 
the hydrophobic cavity generated by the two connected sites 1, and MtuDAH7PS retains the 
“Trp3 out” conformation. Overlay of the “Trp3 in” conformation of the enzyme with the 
binding mode of VS6 reveals that the “Trp3 in” conformation is not accessible to the enzyme: 
the position of the Trp3 side chain in the “Trp3 in” conformation would result in a clash with 
the VS6 tetrazole moiety.  
The indole moiety of VS6 slots deep into the hydrophobic pocket in site 2 (Figure 5.9d), which 
might be due to the negative charge of the tetrazole moiety as a carboxylate isostere being closer 
to the indole than the carboxylate in the native ligand Trp. The hydrogen bond between the 
indole N-H of VS6 and Ala192 has a less favourable angle than predicted from the docking 
pose and also when compared to the binding mode of the native Trp ligand. The tetrazole 
moiety of VS6 forms a Coulomb interaction with the positively charged side chain of Lys123. 
However, the closest distance between the VS6 tetrazole and the Lys123 ammonium moiety in 
the crystal structure is 3.8 Å, whereas the docking predicted this distance as 2.4 Å.  
VS6 binding does not induce a conformational change in the loop around Thr240 typical for Trp 
binding, and the closest distance between the ligand tetrazole moiety and the Thr240 backbone 
carbonyl is 4.3 Å. There are however other interactions of the VS6 ligand with this loop which 
are mediated by water molecules. 
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Figure 5.9: Binding mode of VS6 in site 1 and site 2: (a) Omit map showing electron density into which VS6 
and two water molecules were modelled. 2Fo-Fc map contoured at 0.8 σ shown as blue mesh, Fo-Fc map 
contoured at 2.5 σ shown as green mesh. (b) Apart from hydrophobic interactions, VS6 in site 1 establishes 
hydrogen bonds to two water molecules. (c) Omit map showing electron density into which VS6 and two water 
molecules were modelled. 2Fo-Fc map contoured at 0.8 σ shown as blue mesh, Fo-Fc map contoured at 2.5 σ 
shown as green mesh. (d) Interactions of VS6 with site 2 (yellow dashes). (e) Comparison of the predicted 
binding pose of VS6 (yellow carbons) and the binding mode of VS6 observed in the crystal structure (magenta 
carbons). 
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VS16 
Electron density which was modelled as a VS16 ligand was observed in site 1 (Figure 5.10a). 
VS16 spans binding site 1 of both subunits, the phenyl and tetrazole moieties bind in the 
hydrophobic centre of the connected binding sites. The “Trp3 out” conformation of 
MtuDAH7PS is retained upon binding of VS16, in line with the selection of this compound 
from the docking into the “Trp3 out” receptor. Similar to what was noted for VS6, the position 
of the VS16 ligand is incompatible with the “Trp3 in” conformation of the enzyme, as this 
would lead to major clashes. Apart from hydrophobic interactions, VS16 establishes a water-
mediated contact to the key residues Arg171 and Asn175 (Figure 5.10b). However, considering
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Figure 5.10: Binding mode of VS16 (magenta carbons) in site 1. (a) Omit map showing electron density into 
which VS16 and a water molecules were modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc 
map contoured at 3 σ shown as green mesh. (b) The water molecule mediates an interaction between the VS16 
ligand, Arg171 and Asn175 (yellow dashes). (c) Comparison between the docking pose predicted for VS16 
from the virtual screen (yellow carbons) and the observed binding mode of VS16 (magenta carbons). The 
ligand is observed to bind deeper in the hydrophobic environment of the binding site than predicted from 
modelling. 
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The mediating water molecule is located 3.1 Å from the ligand methylene hydroxyl moiety and 
2.8 and 3.1 Å from the side chains of Arg171 and Asn175 respectively, this interaction can be 
regarded as rather weak. The docking pose predicted stronger polar and hydrogen bonding 
interactions between the tetrazole moiety of the VS16 ligand and Arg171 and Asn175, whereas 
hydrophobic interactions dominate in the observed binding mode (Figure 5.10c). 
VS17 
VS17 binds in the centre of the hydrophobic tunnel generated by the two sites 1 that are 
connected in the “Trp3 out” conformation (Figure 5.11). Apart from the hydrophobic 
interaction, VS17 does not establish any direct interactions with the binding site (Figure 5.11b). 
However, two water molecules mediate contacts between the VS17 ligand and the protein: one 
water molecule is located 2.9 Å from the oxazole nitrogen and in turn establishes hydrogen 
bonds to the side chains of Arg171 and Asn175. The second water is within hydrogen bonding 
distance of the methylene hydroxyl group of VS17 and the backbone carbonyl of Pro8. 
The binding mode of VS17 does not reflect the rationale for the selection of this compound: the 
arrangement of the heteroatoms in the aromatic ring was designed to complement the geometry 
of hydrogen bond donors on the side chains of Arg171 and Asn175. However, the only overlap 
between the docking pose that led to the selection of VS17 and the actual binding mode of 
VS17 is the position of the hydrophobic isopropyl moiety (Figure 5.11c). 
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Figure 5.11: Binding mode of VS17 (magenta carbons) in site 1. (a) Omit map showing electron density into 
which VS17 and two water molecules were modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc 
map contoured at 3 σ shown as green mesh. (b) Two water molecules mediate key interactions between the 
VS17 ligand and the binding site (yellow dashes). (c) Comparison between the docking pose of the 1,2,4-
dioxazole (yellow carbons) which led to the selection of VS17 and VS18 for testing and the observed binding 
mode of VS17 (magenta carbons), revealing little overlap between the docking pose and the crystallo-
graphically observed pose. 
VS18 
Four molecules of VS18 were observed in the asymmetric unit of the crystals soaked with this 
ligand: two VS18 ligands were modelled into density in site 1 (Figure 5.12a), the other two 
VS18 ligands are located in positions between the protein molecules in the crystal lattice 
(Figure 5.13). The first VS18 molecule in site 1 is positioned in the centre of the hydrophobic 
cavity and establishes three hydrogen bonds to the protein (VS18a, Figure 5.12c): the methylene 
hydroxyl moiety of the VS18a ligand is located 2.5 Å from the carboxylate on the side chain of 
Asp10 in subunit A and 3.1 Å from the side chain amide moiety of Asn175 in subunit B. The 
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nitrogen in the isoxazole moiety of the ligand engages in a hydrogen bond with the backbone 
amide of Asp10 (subunit A), the N-N interatomic distance is 3.2 Å. 
The second molecule of VS18 in site 1 is located further towards the solvent-exposed β0α0-loop 
(VS18b, Figure 5.12d). In contrast to VS18a, VS18b does only form one direct hydrogen-
bonding contact with the enzyme: the methylene hydroxyl moiety of the ligand is located 3.2 Å 
from the backbone carbonyl of Ser53. An extensive network of water molecules that mediate 
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Figure 5.12: Binding mode of the two molecules of VS18 (magenta sticks) in site 1. (a) Omit map showing 
electron density into which VS18a, VS18b, a sulfate ion and water molecules were modelled. 2Fo-Fc map 
contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ shown as green mesh. (b) Binding of two 
ligands (magenta sticks) and a sulfate ion in the default view used for site 1. (c) Binding mode of the VS18a in 
site 1: the VS18a ligand has three hydrogen-bonding interactions, one to Asn175, and two to Asp10 (yellow 
dashes) (d) Binding mode of VS18b in site 1. Apart from hydrophobic interactions, an extensive network of 
water-mediated contacts between the ligand and the binding site is established (yellow dashes). 
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contacts between the ligand’s heteroatoms and the protein is however evident: The hydroxyl 
methylene group of the ligand is interacts with a water molecule (2.6 Å O-O distance) which in 
turn is hydrogen-bonded to the backbone carbonyl groups of both Pro13 and Met92. The 
isoxazole nitrogen establishes a hydrogen-bonding interaction with a water molecule (2.7 Å O-
O distance) which in turn is located at a distance of 3.1 Å from the backbone carbonyl group of 
Ser54. The same water molecule is also within hydrogen-bonding distance (2.7 Å) of another 
water molecule which in turn establishes an interaction with the main-chain carbonyl group of 
Asp10. 
One VS18 molecule (VS18c) is located in the inter-lattice space between three different 
tetramers of MtuDAH7PS (Figure 5.13a). The VS18 molecule (VS18c, Figure 5.13b) in this 
position interacts with residues from the β2α2-loop in the vicinity of the E4P-binding motif 
Lys133/Pro134/Arg135/Ser136 (KPRS motif). The ligand hydroxyl moiety is hydrogen-bonded 
to the Asp138 backbone amide group (O-N distance 2.9 Å).  The isoxazole nitrogen establishes 
an interaction to the backbone amide of Ile139: however, the rather long N-N distance of 3.2 Å 
and unfavourable angle indicates that this needs to be considered a weak interaction.  
The fourth molecule of VS18 (VS18d) was modelled into residual electron density which was 
observed in the vicinity of the β0-strand at the entrance of site 1 (Figure 5.13c). The only 
specific interaction between the VS18 ligand in this position and the protein is a hydrogen bond 
between the isoxazole nitrogen and the backbone amide group of Asp6 (VS18d, Figure 5.13d).  
Comparison of the binding mode and position of the two VS18 molecules in site 1 to the 
docking pose of the compound which inspired the selection of VS18 for testing reveals that 
while VS18 still binds to site 1, it binds in a different mode than anticipated from docking 
(Figure 5.14): the envisaged interaction with the key residues Arg171 and Asn175 is not 
observed in the crystallographically observed binding mode of either VS18 molecule in site 1. 
One of the VS18 molecules shows an interaction with Asn175 of the other subunit (Figure 
5.12c), but the corresponding Arg171 is in a different arrangement due to slight asymmetry of 
the site 1 from the different subunits. 
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Figure 5.13: Binding mode of VS18c and VS18d in the spaces between the protein molecule lattice. (a) Omit 
map showing electron density into which VS18c (yellow carbons) was modelled at a site located between three 
different MtuDAH7PS tetramers (coloured green, blue and orange respectively). 2Fo-Fc map contoured at 1 σ 
shown as blue mesh, Fo-Fc map contoured at 3 σ shown as green mesh. (b) Interactions (yellow dashes) of 
VS18c (yellow carbons) with the protein in the inter-lattice position close to the β2α2-active site-loop. The 
active site KPRS-motif is shown with red sticks. (c) Omit map showing electron density into which VS18d 
(yellow carbons) was modelled, at a position located near the entrance to site 1: 2Fo-Fc map contoured at 0.8 σ 
shown as blue mesh, Fo-Fc map contoured at 2.5 σ shown as green mesh. (d) Binding mode of VS18d shown in 
(c), key interactions are shown as yellow dashes. For better orientation, VS18a and VS18b in site 1 are shown 
with magenta carbons. 
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Figure 5.14: Comparison of the docking pose (yellow sticks) based on which VS18 was selected for testing and 
the actual location of the ligands (magenta carbons). 
VS20 
VS20 was selected based on docking poses of similar phenylsulfonamides predicted to bind to 
site 1, it was however also scored among the best 5% of compounds by docking score in the 
virtual screen against site 2. Crystals of MtuDAH7PS soaked in solutions containing VS20 
indeed showed electron density located in site 2 corresponding to VS20 (Figure 5.15a). In 
contrast to the native ligand Trp, presence of the VS20 ligand in site 2 does not induce a 
conformational change of the α2bβ3-loop. The α2bβ3-loop in the structure with VS20 bound 
was modelled in a conformation which is nearly identical to the conformation observed in the 
absence of allosteric inhibitors from site 2 (PDB code 3NV8, Figure 5.15c). Another interesting 
feature of the conformation of the site 2 in the presence of VS20 is the conformation around 
Ala192, the key hydrogen bond acceptor for the indole N-H of the native Trp ligand: the 
carbonyl group of Ala192 is rotated approximately 90º compared to the conformation of Ala192 
observed in the absence of ligand in site 2. A slight rotation of the Ala192 carbonyl is also 
observed when comparing the conformation of this residue in the absence of Trp from site 2 
(PDB code 3NV8) with the conformation in the presence of Trp (PDB code 3NUE), but the 
rotation is even more pronounced in the VS20-liganded structure. The phenyl moiety of VS20 is 
located deeper in the hydrophobic pocket lined by Leu107, Val111 and Leu194 than the indole 
moiety of the native Trp ligand. The oxygens on the sulfonamide moiety of the VS20 ligand are 
located at distances of 3.4 Å and 3.2 Å from the Lys side-chain ammonium group respectively. 
The side-chain hydroxyl of Thr114 is also located within 3.2 Å of one of the sulfonamide 
oxygens, whereas the other oxygen interacts with a water molecule (HOH1, Figure 5.15b) at a 
distance of 3.0 Å. While these distances are long compared to ideal hydrogen-bonding 
geometries, the interaction partners of the sulfonamide oxygens are arranged in a geometry 
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which corresponds well with the directions in which the oxygen lone pairs are expected to 
project. The hydroxyl moiety of the VS20 ligand forms a hydrogen bond with HOH1 (2.9 Å), 
HOH1 in turn is connected to the side-chain ammonium group of Lys123 and backbone amide 
of Glu242 mediated by another water molecule (HOH2, Figure 5.15b). Comparison of the 
binding pose predicted for VS20 from docking (Figure 5.15d) with the observed binding mode 
shows that in the observed binding mode, VS20 is rotated by about 60º compared to the docking  
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Figure 5.15: Binding mode of VS20 (magenta sticks) in site 2. (a) Part of the electron density map after 
refinement of the protein before addition of the VS20 ligand and water molecules into site 2, showing the 
conformation of the α2bβ3-loop, Lys123, Ala192 and difference electron density into which VS20 and two 
water molecules were modelled.  2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ 
shown as green mesh. (b) Interactions (yellow dashes) of VS20 (magenta sticks) with site 2. (c) Comparison of 
the conformation of Ala192 in the VS20-bound structure (blue), Trp-bound structure (yellow sticks, PDB code 
3NUE) and in the absence of ligand (green sticks, PDB code 3NV8). It is also evident that the comformation of 
the α2bβ3-loop in the VS20-bound structure is almost identical to the conformation observed in the absence of 
ligand from site 2. (d) Comparison of the docking pose predicted for VS20 (yellow sticks) and the observed 
binding mode (magenta sticks). 
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Pose and occupies a space located deeper in the hydrophobic cavity of site 2. In this orientation, 
VS20 is unable to establish the interaction between the ligand hydroxyl moiety and Ala192 as 
had been predicted by docking. The sulfonamide moiety of the ligand is located closer to the 
side chain of Lys123 than predicted in the docking pose. 
VS21 
Positive difference electron density for VS21 (phenethylamine) could be observed in crystals 
which had been soaked with the ligand (Figure 5.16a). The conformation of the α2aβ3-loop is
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Figure 5.16: Binding mode of VS21 (magenta carbons) in site 2. (a) Part of the electron density map after 
refinement of the protein before addition of the VS20 ligand and water molecules into site 2, showing the 
conformation of the α2bβ3-loop and difference electron density into which VS21 and a water molecule were 
modelled.  2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ shown as green mesh. 
(b) Interactions (yellow dashes) of VS21 (magenta carbons with site 2. (c) Comparison of the conformation of 
the α2bβ3-loop in the VS21-bound structure (blue) and the Trp-bound structure (green sticks, PDB code 
3NUE). 
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Very similar to the conformation when Trp (or Phe) is present is present in site (Figure 5.16c). 
However, the only polar interaction established between VS21 and the α2aβ3-loop is a water-
mediated contact between the VS21 amino moiety and the backbone amide nitrogen of Glu242 
(Figure 5.16b). The hydrophobic phenyl moiety of VS21 is positioned in the hydrophobic part 
of site 2, and in good agreement with the position the Trp side chain. 
VS22 
VS22 is found to bind to site 2 in both monomers in the asymmetric unit, whereas positive 
difference electron density corresponding to the ligand is only present in site 1 in subunit A. The 
binding mode of VS22 in site 2 closely resembles the binding mode of the native Trp ligand, 
which is unsurprising considering the close similarity of the two compounds. The conformation 
of the residues in site 2 observed in the VS22-bound structure, in particular the α2bβ3-loop, is 
virtually identical to the conformation observed in the Trp-bound structure (Figure 5.17a). The 
indole moiety of VS22 establishes a hydrogen bond to the backbone carbonyl of Ala192 (Figure 
5.17c). The carboxylic acid moiety of the ligand is located 3.1 Å from the side-chain 
ammonium group of Lys123 (Figure 5.17b). In addition, three water molecules that mediate 
contacts between VS22 and the binding site are located within hydrogen-bonding distance of the 
carboxylate of the ligand: one water molecule is hydrogen-bonded to the backbone carbonyl 
group of Thr240, another to the backbone amide group of Glu242 and the third establishes a 
bifurcated hydrogen bond to both the side-chain hydroxyl of Thr114 and backbone amide of 
Val121. In docking the 3-substituted indole library into site 2, VS22 was discarded after the 
high-throughput docking stage. The docking pose from the high-throughput, lower accuracy 
docking protocol used in the initial stage of the Glide virtual screening workflow correctly 
predicts the observed binding mode of VS22 (Figure 5.17a). However, this pose was not scored 
highly enough to advance to further stages of the virtual screening workflow. This may indicate 
that some smaller fragments may have been excluded as false negatives in the initial stages of 
the docking process. 
The only polar interactions of the VS22 ligand bound to site 1 is a salt bridge and two hydrogen 
bonds between the ligand carboxyl moiety and the side-chain guanidinium of Arg171 (Figure 
5.18). When compared to the binding mode of Trp in site 1, it is evident that VS22 binds in with 
its indole moiety in a flipped orientation (Figure 5.18c). It should be noted that while the shape 
of the positive difference electron density in site 1 allows modelling of a VS22 ligand into site 
1, the whole ligand is only visible in the electron density maps when looked at maps at lower 
sigma levels (0.8 σ for the 2Fo-Fc map and 2.5 σ for Fo-Fc map respectively). After refinement at 
full occupancy, the ligand atoms exhibited B-factors within the range of B-factors of the 
surrounding side chains, which was interpreted as confirmation of the presence of the ligand. 
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Figure 5.17: Binding mode of VS22 (magenta carbons) in site 2. (a) Trp (green) and VS20 (ligand magenta 
carbons, protein shown in blue) show very similar binding modes, the conformation of the binding site is also 
virtually identical for the two ligands. The docking pose predicted from initial high-throughput screening 
(yellow carbons) is in good agreement with the observed binding mode. (b) Part of the electron density map 
after refinement of the protein before addition of the VS22 ligand and water molecules into site 2, showing the 
conformation of the α2bβ3-loop, Lys123, Ala192 and difference electron density into which VS22 and three 
water molecules were modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ 
shown as green mesh. (c) Interactions (yellow dashes) of VS22 (magenta carbons) with site 2. 
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Figure 5.18: Binding mode of VS22 (magenta carbons) in site 1. (a) Omit map showing the positive difference 
electron density into which VS22 was modelled. 2Fo-Fc map contoured at 0.8 σ shown as blue mesh, Fo-Fc map 
contoured at 2.5 σ shown as green mesh. (b) Binding mode of VS22 in site 1 (key interactions shown as yellow 
dashes). (c) Comparison of the binding mode of VS22 (magenta carbons) and Trp (green carbons) in site 2. 
VS25 
VS25 was found to occupy site 1 conformation and the VS25 ligand extends across the sites 1 
of both subunits. MtuDAH7PS is found in the “Trp3 out” conformation and a conformational 
change to the “Trp3 in” conformation would cause unfavourable clashes with the VS25 ligand. 
VS25 was obtained as a racemic mixture of enantiomers from the supplier, but the electron 
density around the chiral centre suggests that the S-enantiomer is the main isomer present in the 
binding site (Figure 5.19a).The more hydrophobic fluorophenyl-moiety is found to bind at the 
centre of the binding site. The indole N-H of the VS25 ligand forms a hydrogen bond to the 
backbone carbonyl of Asn94 (N-O distance 2.8 Å). The amino and 1,3,4-oxadiazole moieties of 
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the ligand are located slightly too far away from protein atoms to be considered hydrogen-
bonded: the VS25 amino group is located at a distance of 3.3 Å from the Phe91 backbone 
carbonyl group (Figure 5.19b). The nitrogens in the oxadiazole ring are are found at distances of 
3.3 to 3.6 Å from the potential hydrogen-bonding partners on the side chains of Arg171 and 
Asn175. The computational docking of VS25 predicted the ligand to bind in a flipped binding 
mode which saw the indole moiety placed in the other subunit (Figure 5.19c). The position of 
the oxadiazole and fluorophenyl moieties spanning the hydrophobic centre of the binding site 
was however predicted with reasonable accuracy. 
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Figure 5.19: Binding mode of VS25 (magenta carbons) in site 1. (a) Omit map showing electron density into 
which VS25 was modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ 
shown as green mesh. (b) Interactions (yellow dashes) of VS25 with site 1. (c) Comparison of binding mode 
predicted for VS25 from docking (yellow carbons) and observed binding mode (magenta carbons). 
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VS28 
VS28 binds to site 2, the residues Leu238–Ala241of the α2bβ3-loop adopt a conformation 
which is very similar to the conformation of these residues in the presence of the native ligand 
Trp (Figure 5.20). However, the conformation of the preceding residues Ala234–Asn237 differs 
between the VS28 and Trp-bound structure: Asn237 is located further from the binding site so 
that this conformation can be regarded as a partial rearrangement of the unliganded to the 
liganded conformation of site 2. The indole moieties of Trp and VS28 bind in a virtually 
identical manner (Figure 5.20b). The N-H bond of the amide group contained in VS28 projects
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Figure 5.20: Binding mode of VS28 (magenta carbons) in site 2. (a) Part of the electron density maps showing 
the conformation of the α2bβ3-loop and difference electron density into which VS28 and a water molecule 
were modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ shown as green 
mesh. (b) Interactions (yellow dashes) of VS28 (magenta carbons) with site 2. (c) Comparison of binding mode 
predicted for VS28 from docking (yellow carbons) and observed binding mode (magenta carbons). 
123 
 
Towards the carbonyl group of Thr240, however, the N-O distance is 3.3 Å, too far for a strong 
interaction. The carboxyl moiety of the VS28 ligand is in a favourable position for Coulomb 
interaction and hydrogen bonding to the side-chain ammonium of Lys123, with 2.8 Å being the 
shortest distance between the charged groups. The carboxyl group of VS28 also establishes a 
hydrogen bond to a water molecule, which in turn interacts with the side-chain carboxyl of 
Glu242. The position of the indole and carboxylate moieties of VS28 were predicted accurately 
in the computational docking pose, however, the amide moiety was predicted to occupy a 
position closer to Lys123 (Figure 5.20c). 
VS32 
VS32 was observed to bind to site 2 (Figure 5.21), the rearrangement of the α2bβ3-loop 
observed upon Trp binding is also observed in the presence of VS32 (Figure 5.21c). However, 
in the presence of VS32, an additional rearrangement of the residues in site 2 which has not 
been previously observed, takes place: Ala192, whose carbonyl group accepts a key hydrogen 
bond from the indole N-H in the binding mode of Trp, is located on a short loop-structured 
motif (Gly190–Leu191–Ala192) connecting the α2 (residues 165–189) and α2a-helices 
(residues 193–208). The conformation of this region is very similar when the structures in the 
absence of ligands from site 2 and the Trp-bound structure are compared. However, the indole-
ring of VS32 binds in the position that the side chain of Leu194 occupies in both the ligand-free 
and Trp-bound structures. Residues Ser193, Leu194 and His195 at the start of helix α2a are 
significantly shifted compared to the ligand-free structure, and a change in Cα-positions is 
observed to propagate through the α2a-helix as far as Arg202 (Table 5.2). 
Despite the unprecedented rearrangement of site 2 upon VS32 binding, the indole N-H of the 
VS32 is still hydrogen-bonded to the backbone carbonyl of Ala192. One carboxylic acid moiety 
of the ligand is placed favourably close to the side-chain ammonium group of Lys123. This 
carboxylic acid group is also hydrogen-bonded to a water molecule which mediates an 
interaction with the backbone amide of Glu242. The other carboxylic acid group of the VS32
Table 5.2: Displacement of α-carbons (Cα) between their positions in the ligand-free structure (PDB code 
3NV8) and in the presence of VS32. 
Residue Leu191 Ala192 Ser193 Leu194 His195 Leu196 Val197 His198 
Cα-displace-
ment (Å) 
0.9 0.7 1.4 3.7 4.1 1.5 2.2 4.3 
Residue Asp199 Trp200 Asn201 Arg202 Glu203 Phe204 Val205 Arg206 
Cα-displace-
ment (Å) 
2.6 1.1 2.8 1.8 0.7 0.9 0.7 0.8 
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ligand points away from the α2bβ3-loop and is located in the position which, in the structure 
with the native ligand Trp, is occupied by the phenyl ring of Trp. The presence of two 
carboxylic acid moieties on VS32 makes it likely that only one of these will be ionised. The 
most favourable ionisation state in the observed binding mode would suggest that the carboxylic 
acid group interacting with Lys123 is ionised, whereas the other carboxylic acid group pointing 
into the hydrophobic cavity lined by the side chains of Leu107 and Val111 is uncharged. 
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Figure 5.21: Binding mode of VS32 (magenta carbons) in site 2. (a) Part of the electron density maps showing 
the conformation of the α2bβ3-loop and difference electron density into which VS32 and two water molecules 
were modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ shown as green 
mesh. (b) Interactions (yellow dashes) of VS32 with site 2. (c)  VS32 (magenta) binding in site 2 (protein shown 
in blue) compared to Trp binding (yellow sticks). The shift of the α2-α2a-loop containing Ala192 and Leu194 
observed in the VS32-bound structure is highlighted with the arrow. (d) comparison of the binding pose of 
VS32 predicted from computational docking and the receptor used for modelling (yellow) with the 
crystallographically observed binding mode of VS32 (magenta carbons) and the rearranged conformation of 
binding site 2 (protein shown in blue). 
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The computational docking used a rigid binding site with the exception of rotation of groups 
containing polar hydrogen atoms. The unexpected rearrangement of site 2 of MtuDAH7PS upon 
binding of VS32 unsurprisingly results in the docking pose predicted for VS32 being far from 
the observed binding mode (Figure 5.21d). 
VS35 
VS35 was found in both site 1 and site 2 (Figure 5.22 and Figure 5.23). VS35 is a close 
analogue of Trp and the binding mode of VS35 in site 2 is virtually identical apart from VS35 
missing the carboxyl group present in Trp. The conformation of the residues surrounding site 2 
is in close agreement between the VS35- and Trp-bound structures. One interesting feature 
observed in the VS35-bound structure is a large sphere of electron density between Glu242 and 
Lys123 which was modelled as a chloride ion (Figure 5.22a and b).∗ This is the first observation 
of an ordered anion located in site 2, and can be rationalised when considering the charge 
balance around this area of the protein: in the Trp bound structure, the negatively charged 
carboxylate group of the Trp ligand interacts with the positive charge of the Lys123 side-chain 
ammonium, and the positively charged ammonium group of Trp is located in the vicinity of the 
negatively charged side chain of Glu242. In contrast to this overall near charge-neutral 
arrangement in the Trp binding mode, VS35 does not possess a carboxylate group and hence an 
additional negative charge in form of the chloride ion located in the VS35-bound structure is 
sensible. 
VS35 binds to site 1 in both of the subunits (Figure 5.23): the protein retains the “Trp3 out” 
conformation also observed in the absence of native ligands from site 1. Electron density 
between the ligands in the two subunits was modelled as a glycerol molecule, a similar 
arrangement has been observed previously in a co-crystal structure with Trp at high 
concentration, in which Trp ligands are present in site 1.125 Apart from hydrophobic interactions 
of the indole moiety of VS35, one hydrogen bond between the VS35 amine and the side-chain 
carbonyl of Asn175 is established (N-O distance 2.9 Å).  Comparison of the binding mode of 
Trp and VS35 in site 1 shows that the indole moiety of VS35 binds in a flipped orientation in 
both subunits (Figure 5.23c). In contrast, the amine groups of Trp and VS35 occupy the same 
position. 
                                                     
∗
 the purification buffer of MtuDAH7PS contains sodium chloride. 
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Figure 5.22: Binding mode of VS35 (magenta carbons) in site 2. (a) Part of the electron density maps showing 
the conformation of the α2bβ3-loop and difference electron density into which VS35 and a chloride ion were 
modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ shown as green mesh. 
(b) Interactions (yellow dashes) of VS35 with site 2. (c) VS35 binding in site 2 (ligand carbons shown in 
magenta, protein shown in blue) compared to Trp binding (yellow) shows that both binding modes and 
binding site conformations are virtually identical. (d) Comparison of the binding pose of VS35 predicted from 
computational docking (yellow) with the crystallographically observed binding mode of VS35 (ligand carbons 
shown in magenta, protein shown in blue) shows very close agreement. 
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Figure 5.23: Binding mode of VS35 (magenta carbons) in site 1. (a) Omit map showing the difference electron 
density into which VS35, a glycerol and two water molecules were modelled. 2Fo-Fc map contoured at 1 σ 
shown as blue mesh, Fo-Fc map contoured at 3 σ shown as green mesh. (b) Interactions (yellow dashes) of 
VS35 (magenta carbons) with site 1. (c) VS35 binding in site 1 (magenta carbons) compared to Trp binding 
(yellow carbons) shows that VS35 binds with a flipped indole moiety. 
Tryptophan analogues VS37–42 
Due to their structural and chemical similarity with each other and with the native ligand Trp, 
the 4/5/6-methyl (VS37–39) and 4/5/6-fluoro-substituted tryptophan-analogues (VS40–42) will 
each be discussed as a group. At high concentrations, Trp has been observed to bind to all three 
allosteric sites on MtuDAH7PS.125 This promiscuous binding is also observed for some of the 
methyl-substituted analogues of Trp and all of the fluoro-substituted analogues of Trp in this 
study. VS37–42 were obtained as racemic mixtures before the lack of inhibition of 
MtuDAH7PS by the non-natural enantiomers of the aromatic amino acids detailed in Chapter 4 
had been discovered. However, during final refinement of the structures reported below, the 
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knowledge of the relative affinity of the non-natural enantiomers to and selectivity of the 
MtuDAH7PS binding sites gained in the experiments discussed in Chapter 4 was incorporated 
as follows: if the electron density around the amino acid moiety of the ligand was diffuse and 
could be interpreted as either enantiomer or a mixture of enantiomers being present, both 
enantiomers of the ligand were modelled into the binding site at half occupancy. This was more 
frequently encountered for ligands in site 1, in line with the finding that for Phe, the preferred 
native ligand of site 1, both enantiomers show similar affinity to MtuDAH7PS (see Chapter 4). 
If however the electron density clearly indicated the presence of only one ligand enantiomer, 
only that enantiomer was added to the model, despite the fact that the soaking condition 
contained a racemic mixture of the ligand. Again, in line with the findings in Chapter 4, this 
situation was encountered for some ligands in site 2: site 2 shows a strong discrimination 
between L-Trp, the preferred native ligand enantiomer, and the unnatural enantiomer D-Trp (see 
Chapter 4). 
Site 2 
Methyl-substituted analogues of Trp 
Only the R-enantiomer of VS37 was modelled into site 2 (Figure 5.24). Perhaps unsurprisingly, 
the addition of the 4-methyl group did not affect the binding mode of VS37 when compared to 
the binding mode of Trp: The α2bβ3-loop displays a conformation very similar to the 
conformation observed in the presence of Trp, and the key interactions established by Trp are 
also present in the binding mode of VS37 (Figure 5.24c). While the addition of the 4-methyl 
group can be tolerated, this moiety is also solvent-exposed in the binding mode observed, and is 
expected to result in little potential to increase ligand affinity through additional hydrophobic 
interactions. The binding mode of VS37 was accurately predicted by docking (Figure 5.24e). 
In the crystal structure obtained from crystals soaked in solutions containing VS38, the ligand in 
site 2 and the α2bβ3-loop are less well defined (Figure 5.24b). After inspection of the electron 
density maps, the VS38 ligand was modelled as a 1:1 mixture of both enantiomers at a 
combined occupancy of 0.9. The model of the α2bβ3-loop in closest agreement with the poorly 
defined electron density indicates that Asn237 does not move as far into the binding site as 
observed in the presence of Trp. In contrast to the Trp binding mode, there is no hydrogen bond 
interaction between the VS38 amino moiety and Asn237. The increased steric bulk of the 5-
methyl group in VS38 leads to a slight shift of the VS38 ligand when compared to the binding 
mode of Trp (Figure 5.24f). The docking pose for VS38 predicted an even more substantial 
rotation of the indole moiety as a consequence of the 5-methyl substitution, this however was 
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Figure 5.24: Binding mode of VS37 (left, magenta carbons) and VS38 (right, magenta carbons) in site 2. Both 
enantiomers of VS38 were part of the final model, only R-VS38 is shown for clarity. (a) and (b): Omit map 
showing the conformation of the α2bβ3-loop and the difference electron density into which ligands were 
modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ shown as green mesh. 
(c) and (d): Key interactions of the ligands with the binding site (yellow dashes). (e) and (f): Comparison of the 
observed binding mode of the VS37 and VS38 ligands (magenta carbons) with the binding mode of Trp (green 
carbons, from PDB code 3NUE) and the binding pose predicted from docking (yellow carbons).  
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not confirmed in the observed binding mode (Figure 5.24f). Whereas the increased steric bulk 
of 5-methyl tryptophan (VS38) can still be accommodated in site 2, 6-methyl tryptophan 
(VS39) was not observed to bind to site 2 at the soaking concentrations used. 
Fluoro-substituted analogues of Trp 
Ligands VS40–42, which are tryptophan analogues with a fluoride substituent at the 4-, 5- or 6-
position of the indole ring respectively, were observed to bind to site 2 as evidenced by positive 
difference electron density after refinement of the protein (Figure 5.25 and Figure 5.26). The 
binding mode of the fluoro-substituted Trp-analogues and the binding site conformation is 
virtually identical to the Trp-bound structure, and the observed binding modes of VS40–42 were 
correctly predicted by the computational docking pose (Figure 5.25c and Figure 5.26e, f). The 
fluoro-substituents in the 5- and 6- position offer the potential for additional interaction of the 
ligand with the protein as they point towards the peptide backbone of the α1-helix:141 the 5-
fluoro substituent in VS41 points towards the peptide bond between Ala110 and Val111. The 6-
fluoro-substituent in VS42 points towards the backbone carbonyl group of Leu107 (Figure 
5.26d). While the geometry of this interaction is not ideal, the binding mode of VS42 indicates 
that a small substituent can be accommodated at this position. 
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Figure 5.25: Binding mode of VS40 (magenta carbons) in site 2. (a) Part of the electron density map showing 
the conformation of the α2bβ3-loop and the difference electron density into which VS40 and three water 
molecules were modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ shown 
as green mesh. (b) Interactions (yellow dashes) of VS40 (magenta carbons) with site 2. (c) Binding mode of 
VS40 in site 2 (magenta carbons) compared to the Trp binding mode (green carbons) and the predicted pose 
from computational docking (yellow carbons). 
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Figure 5.26: Binding mode of VS41 (left, magenta carbons) and VS42 (right, magenta carbons) in site 2. (a) 
and (b): Omit map showing the conformation of the α2bβ3-loop and the difference electron density into which 
ligands were modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ shown as 
green mesh. (c) and (d): Key interactions of the ligands with the binding site (yellow dashes). For VS42, a 
section of the α1-helix is shown as sticks to illustrate the interaction of VS42 with Leu107. (e) and (f): 
Comparison of the observed binding mode of the VS41 and VS42 ligands (magenta carbons) with the binding 
mode of Trp (green carbons, from PDB code 3NUE) and the binding pose predicted from docking (yellow 
carbons). 
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Site 1 
Methyl-substituted analogues of Trp 
VS37 (4-methyl tryptophan) and VS39 (6-methyl tryptophan) were observed to bind to site 1. A 
VS37 molecule was modelled into positive difference electron density in site 1 of subunit A 
(Figure 5.27a), both enantiomers of the ligand were included in the final model. The protein 
remained in the “Trp3 out” conformation, with exception of a dimethyl sulfoxide molecule 
(used in ligand stock solutions) and water molecules, no other interpretable electron density was 
observed in site 1 of subunit B. The binding mode of the VS37 ligand retains many features of 
the binding mode of Trp in site 1 (Figure 5.27c), VS37 however binds slightly tilted. Resulting 
from this tilted binding mode, a small displacement of the VS37 amino moiety leads to the loss 
of a hydrogen bond between this moiety and Asn175, an interaction observed when Trp is 
bound at this site. The docking pose predicts the overall position of the VS37 ligand well, the 
extent of the tilt in the experimentally obtained binding mode is however not accurately 
predicted by the pose resulting from modelling. 
Both enantiomers of VS39 were modelled at half occupancy into positive difference electron 
density present in site 1 in subunit A, residual electron density in site 1 of subunit B was 
modelled as two glycerol molecules from the mother liquor (Figure 5.27b, d). The binding site 
is observed in the “Trp3 out” conformation, the methyl substituent on VS39 is in a position 
which would likely cause clashes with the protein in the “Trp3 in” conformation. The amino 
acid moiety of VS39 binds in an almost identical position to the amino acid moiety of Trp in the 
Trp-liganded structure, the indole moiety of VS39 is however flipped by 180º (Figure 5.27f). 
VS39 was not among the top-ranked poses in the computational docking runs, therefore no 
comparison of the predicted binding pose from docking and crystallographically observed 
binding mode will be discussed. 
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Figure 5.27: Binding mode of VS37 (left, magenta carbons) and VS39 (right, magenta carbons) in site 1. The 
final model included both enantiomers of the ligands at half occupancy, only the R-enantiomer is shown in the 
figure for clarity. (a) and (b): Omit map showing the difference electron density into which ligands were 
modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ shown as green mesh. 
(c) and (d): Key interactions of the ligands with the binding site (yellow dashes). (e) and (f): Comparison of the 
observed binding mode of the VS37 and VS39 ligands (magenta carbons) with the binding mode of Trp (green 
carbons, from PDB code 3NUE) and the binding pose predicted from docking (yellow carbons). VS39 was not 
in the top-ranked docking results for site 1, therefore, no docking pose is displayed in (f).  
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Fluoro-substituted analogues of Trp 
In crystal structures obtained from crystals soaked in solutions containing fluoro-substituted 
tryptophans VS40–42, clear positive difference electron density corresponding to the respective 
ligands was observed in site 1 of both subunits (Figure 5.28a, Figure 5.29a, Figure 5.30a). Both 
enantiomers of the ligands were included in the final model at half occupancy each. The 
position and established interactions of the amino acid moiety of all ligands VS40–42 are 
almost identical to what is observed in the Trp-bound structure, suggesting the fluoro-
substitution has little impact on the binding mode of this part of the molecule. However, the 
different positions of the fluoride-substituent in VS40 to VS42 lead to different binding modes 
and protein conformations being observed in the crystal structures: 
VS40 (4-fluoro tryptophan) binds in good agreement with the binding mode observed for Trp, 
the fluoro substituent forms an additional hydrogen bond to a water molecule which is in turn 
hydrogen-bonded to the backbone carbonyl group of Asn94 (Figure 5.28b). This water molecule 
is observed in a number of structures with the native amino acid ligands Phe, Tyr and Trp bound 
in site 1, it mediates a contact between the amino moiety of native ligand and Asn94. The 
predicted docking pose correlates well with the observed binding mode (Figure 5.28c). 
The indole moiety of VS41 (5-fluoro-tryptophan) binds in a flipped orientation when compared 
to the binding mode of Trp (Figure 5.29b, c). The computational docking predicts a pose for 
VS41 with a completely different orientation of the indole moiety than observed in the crystal 
structure, and falsely predicts a hydrogen bond between the indole N-H and Asn94 (Figure 
5.29d). 
VS42 (6-fluoro-tryptophan) also displays a flipped orientation of its indole moiety compared to 
the Trp binding mode (Figure 5.30b, c), placing the two fluoride substituents from the VS42 
ligands in the two different subunits at a distance of only 3.3 Å from each other. The docking 
pose predicts the indole moiety ofVS42 to bind in a similar position, but different orientation to 
the crystallographically observed binding mode (Figure 5.30d). 
Interestingly, the structures of MtuDAH7PS in complex with the three fluoro-substituted Trp-
analogues are different with respect to the conformation of the N-terminus: The electron density 
in the structure containing VS41 supports a “Trp3 in” conformation of the protein as evidenced 
by the well-defined density for the Trp3 side chain (Figure 5.29a). In the VS42 liganded 
structure, the electron density does not support a conformational change, and the starting “Trp3 
out”-conformation was retained throughout refinement. Further evidence against a “Trp3 in”-
conformation in the VS42-liganded structure are clashes which are expected to arise with the 
fluoride-substituents of the VS42 ligands in a “Trp3 in”-conformation of the protein. The poor 
electron density of the N-terminal region of the protein in the VS40-liganded structure was 
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interpreted as a sign of increased flexibility and disorder of these residues. However, some 
electron density for the side chain of Trp3 in a “Trp3 in” conformation was observed and the 
electron density of the surrounding residues is in agreement with the “Trp3 in” conformation. 
The “Trp3 in” conformation was therefore chosen as the most appropriate model of the electron 
density present, it must however be noted that there are likely contributions of other 
conformations of the N-terminal region to the observed scattering which have not been included 
in the model.  
 
(a) 
 
(b) 
 
(c) 
Figure 5.28: Binding mode of VS40 in site 1. Both enantiomers were present in the final model, only the R-
enantiomer is shown for clarity. (a) Omit map showing the difference electron density into which VS40 and 
two water molecules were modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 
3 σ shown as green mesh. (b) Interactions (yellow dashes) of VS40 with site 1. (c) VS40 binding in site 1 (green) 
compared to Trp binding (cyan) and docking both from modelling (yellow). 
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Figure 5.29: Binding mode of VS41 (magenta carbons) in site 1. Both enantiomers were present in the final 
model, only the R-enantiomer is shown for clarity. (a) Omit map showing the refined density for Trp3 
supporting the “Trp3 in” conformation of the protein, and the difference electron density into which two 
molecules VS41 and a water molecule were modelled. 2Fo-Fc map contoured at 1 σ shown as blue mesh, Fo-Fc 
map contoured at 3 σ shown as green mesh. (b) Interactions (yellow dashes) of VS41 with site 1. (c) VS41 
binding in site 1 (magenta carbons) compared to Trp binding (green carbons) reveals a flipped indole moiety 
in VS41. (d) Comparison of the observed binding mode of VS41 (magenta carbons) with the predicted pose 
from computational docking (yellow carbons). The falsely predicted interaction of the VS41 indole with Asn94 
is shown as red dashes. 
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Figure 5.30: Binding mode of VS42 (magenta carbons) in site 1. Both enantiomers were present in the final 
model, only the R-enantiomer is shown for clarity. (a) Omit map showing the difference electron density into 
which two molecules VS42 and a water molecule were modelled. 2Fo-Fc map contoured at 1 σ shown as blue 
mesh, Fo-Fc map contoured at 3 σ shown as green mesh. (b) Interactions (yellow dashes) of VS42 (magenta 
carbons) with site 1. (c) VS42 binding in site 1 (magenta carbons) compared to Trp binding (green carbons) 
reveals a flipped indole moiety in VS42. (d) Comparison of the observed binding mode of VS42 (magenta 
carbons) with the predicted pose from computational docking (yellow carbons). 
Site 3 
The fluoro-substituted Trp-analogues were found to bind to site 3 supported by positive 
difference electron density in site 3 in subunit B (Figure 5.31a, c, e). The observation that only 
site 3 in subunit B of the two subunits in the asymmetric unit is occupied by ligand holds true 
for the structures with the ligands VS40–42 present. The final models contained both enantio-
mers of the VS40–42 ligands at half occupancy. The binding modes of the fluoro-Trp-analogues 
are almost indistinguishable from the binding mode of Trp in site 3 in the Trp-liganded 
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Figure 5.31: Binding modes of VS40–42 (magenta carbons) in site 3. The left column shows electron density 
maps for the β0α0-loop (containing Leu15 and Pro16) and the difference electron density maps into which 
ligands VS40 (a), VS41 (c),VS42 and a sulfate ion (e), and water molecules were modelled. 2Fo-Fc map 
contoured at 1 σ shown as blue mesh, Fo-Fc map contoured at 3 σ shown as green mesh. The right column 
shows the interactions of the ligands (magenta carbons) VS40 (b), VS41 (d) and VS42 (f) with binding site 3 
(yellow dashes) and a comparison with the Trp binding mode in this site (green carbons), which is almost 
indistinguishable from the binding mode of ligands VS40–42. 
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structure obtained at high concentrations (undeposited),125 and can generally be described as 
follows (Figure 5.31b, d, f): the carboxylate group of the ligand forms salt bridges and hydro-
gen-bonding interactions with the side chains of Arg23 and Arg256. The ligand amino moiety 
forms a salt bridge and hydrogen bond with the side-chain carboxylate of Glu53, a hydrogen 
bond with the backbone carbonyl group of Arg256 and a water-mediated contact to the 
backbone carbonyl of Leu259. The indole N-H moiety forms a hydrogen bond with the carbonyl 
group of Pro16 on the β0α0-loop, which moves in towards the binding site upon ligand binding 
(see also the binding mode of Tyr detailed in Chapter 3). The substitution with fluorine in the  
4-, 5- or 6-position of the Trp-indole moiety results in subtle differences among the binding 
modes of VS40 to VS42: the 6-fluoro-substituent allows VS42 to establish a water-mediated 
contact to the backbone amide of Leu261, which is unique to the VS42 binding mode (Figure 
5.31f). The 5-fluoro-substituent on VS41 points directly towards the backbone of the short β-
strand formed by residues 259–261, potentially introducing fluorine-backbone interactions 
(Figure 5.31d).141 The distance between the VS41 indole N-H moiety and the Pro16 carbonyl is 
3.6 Å, slightly longer than the equivalent distance observed for VS40 (3.1 Å), VS42 (3.2 Å) and 
Trp (3.3 Å) binding to site 3. 
5.3 Discussion 
Traditional methods for ligand and inhibitor discovery rely on high-throughput screening of 
large physical compound libraries with associated high cost and time investment. In this 
chapter, a different approach to ligand/inhibitor-discovery was explored: a fragment-based 
ligand design approach allows for screening of a large chemical space with fewer compounds 
smaller in molecular weight. In the approach described in this chapter, the initial compound 
selection was further reduced using the combination of a fragment-based approach with a virtual 
screening step. Virtual screening can be a fast and cost-effective tool in order to identify 
potential starting points and interesting classes of compounds for further elaboration into a lead 
compound. The studies detailed in this chapter provide some valuable insights into the 
discovery of new ligands and allosteric inhibitors of MtuDAH7PS by virtual screening. 
Furthermore, the correlation of inhibitory activity of the alternative ligands with the structural 
insight into their binding mode MtuDAH7PS provides further insight into which interactions 
with the binding sites cause an inhibitory response.127 
The knowledge about the structure and binding mode of the native ligands Trp, Phe and Tyr was 
used to construct a small, focussed library of compounds for initial screening. The combination 
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of structural and biochemical information about the target enzyme MtuDAH7PS with the virtual 
screening method to preselect the most promising candidates resulted in a high hit rate among 
the compounds tested. Out of the 42 compounds evaluated by kinetic assays and X-ray crystal-
lographic screening, crystal structures of 17 ligands (40% of tested compounds) in complex 
with the target enzyme could be obtained. Even excluding the closest analogues to Trp, VS37–
42, a quarter of the ligands selected could be observed by screening using X-ray 
crystallography. 14 out of the 42 compounds (33 %) were observed to inhibit enzymatic activity 
by 20% or more when present either by themselves or in combination with Trp or Phe. The 
observation that a number of ligands show synergistic activity with the native ligands suggests 
that the ligands target the allosteric sites specifically and can act as surrogates for the native 
ligands. 
5.3.1 Accuracy of docking for predicting binding poses 
The docking programs used in this study, GOLD and GLIDE, were both generally successful in 
predicting the binding mode of the indole-derived compounds, perhaps unsurprisingly given the 
similarity of the compounds selected to the native Trp ligand. It should be noted that although 
two different docking programs were used, a comparison of their relative efficiency in 
predicting binding poses or enrichment of hits was not the purpose of this study. More 
importantly, the docking protocol and parameters used in either docking program were 
optimised in order to correctly predict the binding modes of Trp and Phe, the experimentally 
validated ligands at the start of this study. Correlation of the predicted docking poses with the 
experimental binding mode was higher in more constricted and well-defined sites such as site 2 
and site 1 in the “Trp3 in” conformation. Binding modes predicted for docking into the large 
binding site generated by site 1 in the “Trp3 out” conformation yielded a number of false 
predictions of the position of the ligands in the docking. It should be noted that the compound 
selection for site 1 based on virtual screening was focussed on compounds which were predicted 
to interact with Arg171 and Asn175, due to the importance of these residues in the binding 
mode of the native Phe ligand. However, a number of the compounds, namely VS16, VS17 and 
VS18, were predicted to make interactions with Arg171 and Asn175 in their docking poses or 
docking poses which inspired their selection. Experimentally, these compounds were instead 
found to bind in the centre of the extended hydrophobic tunnel generated by the sites 1 from 
both subunits. Further support for the importance of hydrophobic interactions in the 
determination of ligand binding modes comes from the comparison of the experimental binding 
mode with the predicted pose of VS20 in site 2 (Figure 5.15d): The pose from docking predicted 
VS20 to bind in an orientation which optimises hydrogen bonding interactions and charge-
complementarity with the binding site. In contrast to this, the experimentally observed binding 
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mode sees VS20 located deeper in the hydrophobic part of the binding site, to the detriment of 
hydrogen-bonding potential. These findings suggests that the docking protocol and algorithm – 
and probably compound selection by the modeller – placed too much emphasis on polar and 
hydrogen-bonding interactions as opposed to hydrophobic interactions and shape 
complementarity. This applies especially but not exclusively to the correct prediction of the 
binding mode of ligands in site 1 in the “Trp3 out” conformation. The increased number of 
crystal structures of MtuDAH7PS in complex with allosteric ligands resulting from this study 
provides an extended test set which can be used to improve docking methodology and tailor the 
virtual screening towards specific sites and/or types of ligands. Once the adjusted docking 
parameters facilitate the reproduction of the experimental binding modes in docking predictions, 
the results of future virtual screening campaigns can be interpreted with increased confidence. 
The compounds which were identified as initial hits can serve as the blueprint for focussed 
libraries of derivatives of these compounds which further explore chemical space in order to 
enhance binding and inhibition. For example, the phenyl-cyclopentadienyl skeleton of ligands 
VS16 and VS18 could be used for fragment elaboration in site 1. 
5.3.2 Structural characterisation of new allosteric ligands 
The approach of virtual screening-guided fragment selection led to the discovery of 17 new 
ligands for MtuDAH7PS whose binding mode was crystallographically characterised. It is 
noteworthy that a number of ligands identified to bind to MtuDAH7PS in crystal soaking 
experiments were not found to be inhibitory under the conditions of the kinetic assay – namely 
VS6, VS16, VS20, VS21, VS22 and VS25. This may be due to  
(a) Low affinity of the ligand: the concentrations used for crystal soaking usually greatly 
exceeded the concentrations used in the kinetic assay. The high soaking concentrations 
could force occupation of the binding sites in the soaking experiments, whereas only a 
small fraction of the binding sites would be occupied at the 1 mM concentration used in 
the inhibition assay. Higher concentrations of ligands are not straightforward to assay 
due to their high absorbance at the wavelength used for the UV-based assay. Given the 
number of hits which gave both inhibition of enzyme activity and whose binding mode 
was structurally characterised, ligands which have little or no effect at 1 mM 
concentration can safely be disregarded at this stage. The binding modes of these 
compounds may however still be helpful in inspiring the design of improved ligands, or 
in elucidating the binding mode features required to achieve inhibition (for a detailed 
discussion see section 5.3.3, p. 144).  
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(b) The ligand binding mode is not adequate to cause inhibition: as was already discussed 
in Chapter 4, subtle differences in binding mode and interactions of the allosteric 
ligands with their binding sites can result in ligands binding with appreciable affinity, 
but not causing inhibition. Some insight into which interactions might be important to 
cause inhibition will be discussed in section 5.3.3, p. 144. 
Conversely, VS3, VS14, VS15, VS23, VS24, VS29, VS30 and VS36 were observed to cause 
inhibition in the kinetic assay, but no binding could be observed in crystal soaking experiments. 
The binding mode of these ligands might be incompatible with the crystal form used for 
soaking: the binding site might not be accessible to the ligand due to crystal packing interactions 
with adjacent protein molecules in the crystal lattice. Co-crystallisation of the protein in the 
presence of the ligand could help determine further structures of MtuDAH7PS-ligand 
complexes with ligands whose binding mode is incompatible with the crystal form for soaking. 
However, co-crystallisation in the presence of ligands often requires individual optimisation of 
crystallisation conditions for each ligand, it was therefore not pursued further in this study. 
Alternatively, the inhibition of MtuDAH7PS activity might be due to a non-specific interaction, 
such as ligand aggregates causing inhibition of MtuDAH7PS, the ligand causing partial or 
complete denaturation of the enzyme, or inhibition caused by chelation of the active site metal 
by the ligand. Because a number of hits showed reproducible inhibition and did not display 
problematic behaviour in the assay used, further investigations into the nature of inhibition by 
the problematic compounds were not pursued further. 
Out of the series of indole acetamides VS27–32, VS28 and VS32 are observed to bind to site 2. 
VS29, VS30 and VS32 can be regarded as derivatives of VS28 bearing substituents on the 
carbon located in the α-position relative to the carboxylic acid moiety. The docking pose for 
VS28 and its derivatives predicted a slightly different orientation of this α-carbon, which 
resulted in the α-substituents being docked in positions which would enable interaction with the 
binding site. However, the experimentally observed binding mode of VS28 projects the two α-
methylene protons much more out of the site towards the surrounding solvent. Substituents in 
this position are therefore anticipated to protrude out of the binding site and not engage in the 
interactions predicted by docking which led to their selection. Interestingly, VS29 and VS30 do 
show significant inhibition, in particular in combination with Trp (Figure 5.8). This suggests 
that these compounds might act as a surrogate for Phe and possibly bind to site 1. However, 
soaking of crystals in solutions of VS29 and VS30 did not result in structures which showed 
electron density for these ligands. This might be due to their binding site not being accessible in 
the crystal packing of the crystal form used or a more substantial reorganisation of the protein 
conformation might be necessary to accommodate these ligands. The binding mode of VS32, 
which shows an unprecedented reorganisation of site 2, could be regarded as supporting 
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evidence for this hypothesis. Co-crystallisation experiments with VS29 and VS30 could help 
elucidate their binding site and probable mechanism by which they achieve inhibition. 
5.3.3 Correlation between binding modes and inhibition 
The binding modes of ligands in site 2 were analysed according to interactions established 
between the ligands with the binding site and whether the α2bβ3-loop underwent a 
conformational change from the unliganded structure (Table 5.3). The residues Thr240 and 
Asn237 are located on the α2bβ3-loop and are involved in hydrogen bonding contacts with the 
amino moiety of the native ligand Trp. It is however evident that neither an interaction with 
Thr240 nor Asn237 is an absolute requirement for the rearrangement of the α2bβ3-loop upon 
ligand binding. For example, VS21 (phenethylamine) and VS22 (indole acetic acid) do not 
establish a direct interaction with either Thr240 or Asn237, yet the α2bβ3-loop in these 
structures is found in a conformation resembling the conformation of the loop in the presence of 
Trp. VS21 and VS22 were however not inhibitory under the conditions assayed, indicating that 
the mere rearrangement of the α2bβ3-loop to the Trp-bound conformation is not sufficient to 
cause inhibition. Site 2 was also observed in a partially rearranged conformation: in the pre- 
Table 5.3: Summary of interactions of ligands found to bind in site 2. The α2bβ3-loop was considered “in” if its 
conformation was comparable to the Trp-bound structure (PDB code 3NUE), “out” if comparable to the 
unliganded structure (PDB code 3NV8). “partial” denotes partial rearrangement of the loop between the two 
conformations. “water-med.” denotes a water mediated contact. Inhibitory ligands are shaded green, non-
inhibitory ligands are shaded orange. 
Ligand α2bβ3-loop Ala192 
H-bond 
Thr240 
H-bond 
Asn237 H-
bond 
Lys123 
interaction 
VS35 in yes yes yes none 
VS37 in yes yes yes good 
VS40 in yes yes yes good 
VS41 in yes yes yes good 
VS42 in yes yes yes good 
VS6 out yes no no very weak 
VS20 out no no no ok 
VS21 in no no no unfavourable 
VS22 in yes water-med. no weak 
VS28 partial yes long no good 
VS32 partial yes no no good 
VS38 partial yes yes no good 
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sence of ligands VS28, VS32, and VS38, residues Leu238, Ala239 and Thr240 are in a 
conformation resembling the Trp-bound structure, but the residues Arg236 and Asn237 are 
positioned further away from the binding site, more in line with the conformation in the absence 
of ligand. It has to be noted that in a number of structures, the electron density for the residues 
236–237 is poorly defined but interpretable taking into account the well-defined position of the 
flanking residues and geometric restraints. The poorly defined electron density could be 
interpreted as this region of the protein being more flexible than the surrounding residues, a 
notion which is supported by the different conformations adopted by the α2bβ3-loop in liganded 
and unliganded structures, and by molecular dynamics simulations.107-108 However, in the 
structures containing inhibitory ligands, the electron density corresponding especially to Asn237 
is commonly more defined than in the absence of ligand or in the presence of non-inhibitory 
ligands. The observation that all inhibitory ligands in site 2 establish a hydrogen bond to both 
Thr240 and especially Asn237 and lead to a more defined conformation of the α2bβ3-loop 
points towards a critical role of restricting the dynamic fluctuations of this loop in order to 
achieve inhibition. Future ligand design should therefore pay particular attention to compounds 
which are envisaged to establish a contact to Asn237 or anchor the α2bβ3-loop in a 
conformation resembling the Trp-bound structure by other means. 
Only VS17 and VS18 showed significant inhibition of enzymatic activity and were located in 
site 1, making the analysis of ligand contacts and protein conformations necessary for inhibition 
more challenging for site 1 (Table 5.4). In addition, VS18 was found in four positions in the 
asymmetric unit: Considering that VS18 was only inhibitory in combination with Trp, one or 
both of the two molecules in site 1 (VS18a and VS18b in Table 5.4) are more likely to be 
responsible for the inhibitory activity. Between the two VS18 molecules and VS17, VS18a is 
the ligand that displays the most direct contacts to the binding site, and it is hydrogen-bonded to 
Asn175, a key residue in the binding of the native amino acid ligands. Asn175 has also been 
implicated to be involved in communication of the occupancy of site 1 in the study of the 
interaction with the aromatic D-amino acids in Chapter 4. On the other hand, VS18b interacts 
with the protein mainly through hydrophobic interactions and a network of water-mediated 
contacts (Figure 5.12d). The majority of residues involved in the binding mode of VS18b are 
not involved in binding the native ligands in site 1, which could be taken as a further indication 
that this molecule plays a secondary or no role in the inhibition. However, the position and 
contacts established by VS18b can be used to inform a fragment-growing strategy, starting from 
VS18a or other fragments observed to bind to other parts of site 1. The correlation between the 
binding mode in site 1 and inhibitory profile of VS35 (2-indole ethylamine) is informative and 
further supports a crucial role of Asn175: VS35 is slightly inhibitory (80% residual activity) 
when present alone, but shows no inhibition in combination with Trp or Phe. The only specific 
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Table 5.4: Summary of interactions of ligands bound in site 1. “partial” denotes partial rearrangement 
towards the “Trp3 in”-conformation. “water-med.” denotes a water mediated contact. Inhibitory ligands are 
shaded green, non-inhibitory ligands are shaded orange, ligands only inhibitory in combination with Phe 
shaded in grey. 
Ligand “Trp3 in” 
shift 
Arg171 
interaction 
Asn175 
interaction 
Phe91 Asn94 
VS18a no no yes no no 
VS18b no no no no no 
VS17 no water-med. water-med. no no 
VS35 no no yes no no 
VS37 no yes no yes water-med. 
VS39 no yes yes yes water-med. 
VS40 partial yes yes yes water-med. 
VS41 yes yes yes yes water-med. 
VS42 no yes yes yes water-med. 
VS25 no yes yes yes yes 
VS6 no very weak  no no no 
VS16 no water-med. water-med. no no 
 
interaction of VS35 with the binding site is a hydrogen bond to Asn175. Consequently, taking 
into account that VS35 binding to site 2 also displayed what could be termed “minimal motif for 
inhibition”, it could be argued that VS35 is able to establish the interactions that are key to 
achieving inhibition in both site 1 and site 2. The small inhibitory potency observed for VS35 
and absence of synergy with Trp or Phe could be due to a weaker affinity of VS35 compared to 
the native ligands, potentially due to the missing carboxylate group. In the presence of Trp or 
Phe, the native ligand might be able to out-compete VS35 in binding to site 1 or 2 or both, thus 
resulting in no inhibition. 
VS25 is the only ligand that contradicts the notion that a contact to Asn175 is essential in order 
to achieve inhibition: VS25 does establish a hydrogen bond to Asn175, yet it is not inhibitory in 
combination with neither Trp nor Phe, and most surprisingly, weakly activates activity when 
present alone (Figure 5.8). Further investigation is needed to validate this observation and to 
elucidate the mechanism of this activation. 
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5.3.4 Structure-activity relationships of tryptophan-analogues 
Methyl- and fluoro-substituted analogues of tryptophan were tested for their binding to and 
inhibition of MtuDAH7PS and some structure-activity relationships will be proposed in the 
following discussion. It should be noted that the methyl- and fluoro-tryptophan derivatives were 
purchased and used as a racemic mixture of enantiomers before the lack of inhibition by the D-
enantiomers of the aromatic amino reported in Chapter 4 was discovered. The S-enantiomers 
(corresponding to D-Trp) of the methyl- and fluoro-substituted Trp-analogues are also quite 
unlikely to elicit an inhibitory response, the inhibitory potency of the R-enantiomers 
(corresponding to the natural L-Trp) can therefore be expected to be greater than the data in 
Figure 5.8 obtained from the racemic compounds indicate. For future investigations, the 
requirement for the amino acid moiety to be of R-configuration in order to achieve inhibition 
should be taken into account and only highly enantio-enriched amino acid analogues should be 
used. Nevertheless, some valuable insight can be gained from the binding mode and structure-
activity relationships observed for the racemic Trp-analogues. 
The methyl-substituted tryptophan analogues VS37–39 could be observed to bind to at least one 
site. However, the increased steric bulk around the indole rings results in only VS37 displaying 
promiscuous binding to both site 1 and site 2, whereas VS38 only binds to site 2 and VS39 only 
binds to site 1. The binding mode of the methyl-tryptophans is altered in accordance with steric 
repulsion of the introduced substituent: introduction of the 4-methyl group in VS37 is 
accommodated in site 2, but no favourable hydrophobic interaction is introduced. In site 1, 
steric repulsion between the methyl group of VS37 and the binding site leads to a rotated 
orientation of the ligand when compared to the Trp binding mode. In the binding mode of VS37 
in site 1, this results in the loss of a hydrogen bond between the ligand amino group and 
Asn175, which was observed in the binding mode of Trp. The 5-methyl substitution of VS38 
can be accommodated in site 2, but leads to a slight shift of the indole moiety of the ligand. This 
results in VS38 not establishing a hydrogen bond to the backbone carbonyl of Asn175, which is 
proposed to be crucial to achieve inhibition (see section 5.3.3, page 144). 6-Methyl tryptophan 
(VS39) is not accommodated in site 2; this could be due to steric repulsion of the additional 
methyl-group with the residues Leu107, Val111 and Val197. VS39 in site 1 binds in an 
orientation with a flipped indole, which also points towards steric repulsion with the binding site 
introduced with the 6-methyl substituent. In summary, 4/5/6-methyl substitution can be 
accommodated in some cases, but no benefit of this substitution is evident from the binding 
modes of VS37–39. Conversely, the 5- and 6-methyl substitution introduces steric bulk which 
impedes binding of VS38 to site 1 and VS39 to site 2. In accordance with this, only modest if 
any inhibitory activity could be observed for VS37–39 (Figure 5.8).  
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Substitution of hydrogen for fluorine in drug molecules is common, as strategically placed 
fluorine atoms can have profound influence on drug metabolism, increase bioavailability and 
provide additional interactions with the target protein.141-142 The results from kinetic analysis 
indicate that 4/5/6-fluoro tryptophan (VS40–42) can act as a surrogate for Trp: VS40–42 show 
very small inhibitory effect when present alone, but 40-50% inhibition of activity is observed 
for VS40–42 when present in combination with Phe. The results obtained from crystal soaking 
studies allow the conclusion that 4/5/6-fluoro-substitution on the Trp core is readily 
accommodated in all three binding sites of MtuDAH7PS. The binding modes which were 
observed for VS41 (5-fluoro tryptophan) and VS42 (6-fluoro tryptophan) in site 2 indicate that a 
small substituent – such as fluorine and potentially a hydroxyl-group – can be accommodated 
and that these positions have potential to introduce additional contacts through fluorine-
backbone interactions.141 Judging by the binding modes of VS41 and VS42, introduction of a 
hydroxyl group at the 5- and 6-position or both positions could be accommodated and provide 
additional contacts with site 2. 
Although the fluorine substituents on VS40–42 can be accommodated in site 1, the potential to 
introduce new interactions with the binding site is not as evident as discussed for site 2 above. 
The increased lipophilicity of fluorinated compounds compared to hydrocarbons could however 
improve the affinity to the largely hydrophobic cavity of site 1. 
An interesting finding is that all fluoro-tryptophan derivatives examined bind to all three 
allosteric sites of MtuDAH7PS, a feature which makes this class of compounds unique among 
the ligands studied. VS40–42 also were the only ligands in this study that were found to bind to 
site 3, which was not explicitly targeted. Site 3 was however envisaged to be able to bind some 
of the ligands, taking into account the promiscuous binding of the native aromatic amino acid 
ligands. Considering that the indole N-H moieties of Trp and Trp-analogues act as hydrogen 
bond donors in both site 2 and 3, introduction of electron-withdrawing fluoro-substituents on 
the indole might strengthen this hydrogen bond through electronic effects. This, together with 
the ability of all three binding sites to accommodate a fluoro-indole moiety, could potentially 
allow the development of a promiscuous ligand that binds to all three allosteric sites based on a 
fluoro-indole. 
5.3.5 Potential fragment elaboration strategies 
The binding modes of some of the ligands screened by crystal soaking can be used as 
inspiration for fragment modification, fragment growing or fragment merging strategies.  
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The docking pose for VS20 in site 2 predicts a hydrogen bond between the ligand hydroxyl 
moiety and Ala192. Although this was not observed in the crystal structure of VS20 in complex 
with MtuDAH7PS (Figure 5.15c and d), the observed binding mode suggests that introduction 
of a hydroxyl group meta to the sulfonamide moiety of the ligand would be in a suitable 
position to hydrogen bond to Ala192. The orientation of the ortho-hydroxyl group present in 
VS20 is predisposed to be used to attach a group which is capable of interacting with the α2aβ3-
loop. Interaction with the α2aβ3-loop and in particular Asn237 has been found to be essential to 
achieve inhibition with ligands targeting site 2. Modification of the fragment VS20 with known 
binding mode according to the knowledge gained about the ligand features required for 
inhibition could thus be used to generate an inhibitor from the non-inhibitory fragment VS20. 
VS18 is one of the most interesting ligands to consider for elaboration. Chemically, compound 
VS18 is only distantly if at all related to the native amino acid ligands, yet is inhibitory to 
enzymatic activity when present in combination with Trp. One or more of the multiple positions 
which VS18 was observed to occupy in the soaked MtuDAH7PS crystals could result in the 
ligand being able to act as a surrogate for Phe. The fact that two VS18 ligands were observed to 
bind to site 1 offers the opportunity to merge the two fragment-like ligands into a larger 
compound based on the orientation of the two VS18 ligands observed in site 1. The first starting 
point for elaboration should be VS18a which binds in an orientation which most resembles the 
native Phe ligand. The methylene-hydroxyl carbon could be used to install a linker to which a 
moiety resembling the second ligand molecule in site 1, VS18b, could be connected (Figure 
5.32). Another potential point of elaboration could be inspired by the location of an adventitious 
sulfate ion from the crystallisation condition which was found to bind in site 1 in addition to the 
two VS18 molecules. A linker of suitable length could be installed in the 3- or 4-position of the 
phenyl moiety of VS18, connecting the fragment to a group capable of mimicking the sulfate 
ion. 
 
 
Figure 5.32: Binding mode of the two molecules of VS18 and a sulfate ion in site 1 and potential connections 
(dashed lines) for elaboration of fragment VS18. 
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Elaboration of VS18 and examination of analogues of this ligand could also provide some 
further insight into the role and potential significance of the two additional positions in which 
VS18 was observed in the crystal structure. The location of these VS18 molecules in the inter-
lattice space and the limited interactions established between the ligands and the protein at 
previously uncharacterised binding sites could suggest they are an artefact of the high soaking 
condition used. On the other hand, one VS18 molecule is found to bind to a loop region close to 
the catalytic centre and might be able to be elaborated further in order to establish contacts with 
the active site. This elaboration could include insight gained from the design of active site 
inhibitors detailed in Chapter 2 or a fragment-based virtual screen targeting the active site. 
An overlay of a selection of compounds found to bind in site 1 shows that the fragments overlap 
but bind in slightly different positions (Figure 5.33). This information can be used in a fragment 
merging strategy: for example, the position of the phenyl moieties of VS16 and VS18 overlap, 
but the isoxazole and tetrazole moiety of the two ligands project into opposite regions of the 
binding site, making inhibitors of 1-tetrazolyl-(3 or 4)-isoxazolyl-phenyl structure interesting 
candidates for further study. Similarly, VS35 binds in a part of the binding site not addressed by 
the other, more hydrophobic ligands VS16–18 and could inform fragment growing strategies. 
The orientation of the VS16–18 fragments relative to VS35 suggests that a flexible methylene 
linker could be used to connect an imidazole moiety to VS16 or VS17 which would occupy the 
same position as the imidazole ring in VS35. Further elaboration could see the incorporation of 
the amino group of VS35 in order to establish a contact to Asn175, which is hypothesised to be 
vital in order to achieve inhibition in site 1. 
 
 
Figure 5.33: Left: Overlay of selected fragments found to bind to site 1. VS16 (cyan sticks), VS17 (yellow 
sticks), VS18 (green sticks) and VS35 (magenta sticks). Right: Potential fragment elaboration based on 
observed binding modes of fragments. 
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5.4 Conclusion 
Using a virtual screening-guided fragment selection process, a number of new ligands of the 
allosteric sites of MtuDAH7PS were discovered and their binding modes elucidated by X-ray 
crystallography. Some of the ligands show activity as allosteric inhibitors and/or can act as 
surrogates for the natural ligands Trp and Phe in the synergistic inhibition of MtuDAH7PS. The 
structural insight into the ligand binding modes revealed some potential strategies to increase 
ligand affinity and potency. The comparison of binding modes of ligands without inhibitory 
activity with the ligands that were inhibitors highlighted correlations between the ligand-binding 
site-interactions and inhibitory activity. These findings helped further elucidate the mechanism 
of the unusual synergistic inhibition of MtuDAH7PS, as well as provided the basis for future 
inhibitor design targeting the allosteric sites.  
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Table 5.5: Data collection and refinement statistics for structures in Chapter 5. 
 VS6 VS16 VS17 
A. Data collection    
Crystal system Trigonal Trigonal Trigonal 
Space group P3221 P3221 P3221 
Unit cell parameters     
a (Å) 204.63 204.44 204.74 
b (Å) 204.63 204.44 204.74 
c (Å) 66.55 66.84 66.55 
Resolution range (Å) 55.79–2.20 
(2.32–2.20) 
49.15–2.06 
(2.11–2.06) 
47.22–2.38 
(2.44–2.38) 
Resolution where I/σ(I) = 2.0 2.30 2.35 2.61 
CC1/2 outer shell 0.731 0.872 0.905 
Measurements 324687 1534976 1003313 
Unique reflections 77956 98857 64049 
Redundancy 4.2 (4.2) 15.5 (14.6) 15.7 (14.7) 
Completeness (%) 91.2 (91.9) 99.8 (95.5) 99.6 (94.4) 
I/σ(I) 5.8 (1.8) 6.4 (0.9) 6.5 (1.3) 
Rmerge (%) 11.4 (42.4) 11.0 (85.8) 11.7 (59.3) 
Wilson B-value (Å2) 27.2 34.9 32.3 
B. Refinement    
Resolution (Å) 53.21–2.20 
(2.25–2.20) 
49.15–2.06 
(2.11–2.06) 
47.22–2.38 
(2.44–2.38) 
Rcryst (%) 16.3a 15.4 14.1a 
Rfree (%) 17.6a 18.0 16.4a 
Amino acids (chain length 
464 residues) 
462 + 464  
(7497 atom sites) 
460 + 464 
(7823 atom sites) 
462 + 464 
(7657 atom sites) 
Water molecules 274 490 352 
Other 2 VS6 ligands, 2 
Mn2+, 1 Cl-, 6 SO42-, 1 
glycerol 
1 VS16 ligand, 2 
Mn2+, 2 Cl-, 14 SO42-, 
5 glycerol, 3 DMSO 
1 VS17 ligand, 2 
Mn2+, 4 Cl-, 16 SO42-, 
5 glycerol  
Mean B (Å2)    
 Protein 27.7 34.9 34.1 
 Water 30.7 40.5 31.9 
 Other 25.4 54.5 50.6 
r.m.s.d. from target values    
 Bond lengths (Å) 0.006 0.018 0.007 
 Bond angles (°) 0.949 1.873 1.177 
 Dihedral angles (°) 4.825 6.134 5.390 
Ramachandranb    
 Most favoured (%) 98.5 98.4 98.4 
 Allowed (%) 1.2 1.4 1.4 
 Disallowed (%) 0.3 0.2 0.2 
a
 intensity-based twin refinement was used. b as determined by the MolProbity server.143 DMSO: dimethyl sulfoxide. 
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Table 5.5 (continued): Data collection and refinement statistics for structures in Chapter 5. 
 VS18 VS20 VS21 
A. Data collection    
Crystal system Trigonal Trigonal Trigonal 
Space group P3221 P3221 P3221 
Unit cell parameters     
a (Å) 203.73 203.14 204.70 
b (Å) 203.73 203.14 204.70 
c (Å) 66.48 66.80 66.70 
Resolution range (Å) 48.94–2.22 
(2.26–2.22) 
47.17–2.29 
(2.34–2.29) 
47.27–2.63 
(2.72–2.63) 
Resolution where I/σ(I) = 2.0 2.65 2.79 3.00 
CC1/2 outer shell 0.677 0.786 0.586 
Measurements 446282 794700 211394 
Unique reflections 77567 70791 47498 
Redundancy 5.8 (5.6) 11.2 (10.9) 4.4 (4.4) 
Completeness (%) 99.0 (98.5) 99.6 (96.5) 99.9 (98.8) 
I/σ(I) 5.1 (0.8) 4.3 (0.9) 4.1 (1.1) 
Rmerge (%) 14.5 (88.3) 17.8 (82.3) 18.0 (69.9) 
Wilson B-value (Å2) 29.3 29.2 27.1 
B. Refinement    
Resolution (Å) 48.94–2.20 
(2.27–2.22) 
47.17–2.29 
(2.35–2.29) 
47.27–2.63 
(2.70–2.63) 
Rcryst (%) 17.7a 18.2 15.3a 
Rfree (%) 19.1a 21.8 18.6a 
Amino acids (chain length 
464 residues) 
464 + 464  
(7619 atom sites) 
459 + 464 
(7537 atom sites) 
461 + 464 
(7504 atom sites) 
Water molecules 267 298 231 
Other 4 VS18 ligands, 2 
Mn2+, 5 Cl-, 11 SO42-, 
13 glycerol 
2 VS20 ligands, 2 
Mn2+, 1 Cl-, 10 SO42-, 
4 glycerol, 8 DMSO 
2 VS21 ligands, 2 
Mn2+, 3 Cl-, 7 SO42-, 6 
glycerol  
Mean B (Å2)    
 Protein 29.7 29.5 27.6 
 Water 27.7 31.3 23.8 
 Other 39.0 52.8 39.6 
r.m.s.d. from target values    
 Bond lengths (Å) 0.007 0.014 0.012 
 Bond angles (°) 1.230 1.736 1.499 
 Dihedral angles (°) 5.379 6.306 6.016 
Ramachandranb    
 Most favoured (%) 98.5 97.7 96.5 
 Allowed (%) 1.4 1.9 3.3 
 Disallowed (%) 0.1 0.4 0.2 
a
 intensity-based twin refinement was used. b as determined by the MolProbity server.143 DMSO: dimethyl sulfoxide. 
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Table 5.5 (continued): Data collection and refinement statistics for structures in Chapter 5. 
 VS22 VS25 VS28 
A. Data collection    
Crystal system Trigonal Trigonal Trigonal 
Space group P3221 P3221 P3221 
Unit cell parameters     
a (Å) 204.93 203.89 205.47 
b (Å) 204.93 203.89 205.47 
c (Å) 66.34 66.11 66.42 
Resolution range (Å) 47.17–1.97 
(2.00–1.97) 
46.97–2.03 
(2.06–2.03) 
47.26–2.30 
(2.35–2.30) 
Resolution where I/σ(I) = 2.0 2.38 2.20 2.64 
CC1/2 outer shell 0.621 0.900 0.799 
Measurements 1243857 738018 452235 
Unique reflections 112715 101477 71161 
Redundancy 11.0 (10.7) 7.3 (7.2) 6.4 (6.2) 
Completeness (%) 99.9 (98.0) 99.9 (99.5) 99.7 (96.2) 
I/σ(I) 5.1 (0.8) 5.6 (1.5) 4.6 (1.1) 
Rmerge (%) 20.1 (91.4) 13.3 (52.6) 15.1 (68.9) 
Wilson B-value (Å2) 20.1 8.6 29.6 
B. Refinement    
Resolution (Å) 47.17–1.97 
(2.02–1.97) 
46.97–2.03 
(2.08–2.03) 
47.26–2.30 
(2.36–2.30) 
Rcryst (%) 12.9a 19.9a 18.2a 
Rfree (%) 15.4a 21.6a 19.7a 
Amino acids (chain length 
464 residues) 
462 + 464  
(7603 atom sites) 
462 + 464 
(7589 atom sites) 
462 + 462 
(7507 atom sites) 
Water molecules 313 357 261 
Other 3 VS22 ligands, 2 
Mn2+, 2 Cl-, 6 SO42-, 8 
glycerol 
1 VS25 ligand, 2 
Mn2+, 2 Cl-, 10 SO42-, 
4 glycerol 
2 VS28 ligands, 2 
Mn2+, 3 Cl-, 11 SO42-, 
1 glycerol  
Mean B (Å2)    
 Protein 20.2 8.3 29.9 
 Water 24.9 21.4 30.3 
 Other 31.7 28.3 48.1 
r.m.s.d. from target values    
 Bond lengths (Å) 0.015 0.009 0.007 
 Bond angles (°) 1.718 1.337 1.107 
 Dihedral angles (°) 6.052 5.733 5.358 
Ramachandranb    
 Most favoured (%) 98.3 97.7 98.2 
 Allowed (%) 1.5 1.9 1.6 
 Disallowed (%) 0.2 0.4 0.2 
a
 intensity-based twin refinement was used. b as determined by the MolProbity server.143 
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Table 5.5 (continued): Data collection and refinement statistics for structures in Chapter 5. 
 VS32 VS35 VS37 
A. Data collection    
Crystal system Trigonal Trigonal Trigonal 
Space group P3221 P3221 P3221 
Unit cell parameters     
a (Å) 202.63 204.55 204.30 
b (Å) 202.63 204.55 204.30 
c (Å) 66.32 66.41 66.27 
Resolution range (Å) 48.67–2.00 
(2.03–2.00) 
44.29–1.95 
(1.98–2.95) 
47.07–1.80 
(1.83–1.80) 
Resolution where I/σ(I) = 2.0 2.48 2.30 2.13 
CC1/2 outer shell 0.485 0.500 0.564 
Measurements 1128649 877117 1656377 
Unique reflections 103920 115706 146258 
Redundancy 10.9 (10.3) 7.6 (7.6) 11.3 (11.3) 
Completeness (%) 99.0 (99.0) 100.0 (100.0) 100.0 (99.9) 
I/σ(I) 3.1 (0.8) 5.2 (0.7) 4.5 (0.5) 
Rmerge (%) 23.2 (104.7) 14.4 (108.0) 13.3 (175.4) 
Wilson B-value (Å2) 26.8 25.3 29.6 
B. Refinement    
Resolution (Å) 48.67–2.00 
(2.05–2.00) 
44.29–1.95 
(2.00–1.95) 
47.12–1.80 
(1.85–1.80) 
Rcryst (%) 16.5a 14.2a 15.2 
Rfree (%) 18.5a 16.1a 17.4 
Amino acids (chain length 
464 residues) 
458 + 464  
(7526 atom sites) 
462 + 464 
(7915 atom sites) 
458 + 462 
(8159 atom sites) 
Water molecules 256 491 611 
Other 2 VS32 ligands, 2 
Mn2+, 12 SO42-, 4 
glycerol, 2 DMSO 
4 VS35 ligands, 2 
Mn2+, 3 Cl-, 13 SO42-, 
8 glycerol 
3 VS37 ligandsb, 2 
Mn2+, 1 Cl-, 16 SO42-, 
28 glycerol, 5 DMSO  
Mean B (Å2)    
 Protein 29.9 25.4 29.0 
 Water 25.5 31.1 37.8 
 Other 40.6 34.1 47.1 
r.m.s.d. from target values    
 Bond lengths (Å) 0.007 0.013 0.020 
 Bond angles (°) 1.136 1.580 1.969 
 Dihedral angles (°) 5.415 6.037 6.052 
Ramachandranc    
 Most favoured (%) 96.9 97.9 98.1 
 Allowed (%) 2.9 2.0 1.6 
 Disallowed (%) 0.2 0.1 0.3 
a
 intensity-based twin refinement was used. b enantiomeric ligands modelled in one position at half occupancy were 
counted as one ligand. c as determined by the MolProbity server.143 DMSO: dimethyl sulfoxide. 
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Table 5.5 (continued): Data collection and refinement statistics for structures in Chapter 5. 
 VS38 VS39 VS40 
A. Data collection    
Crystal system Trigonal Trigonal Trigonal 
Space group P3221 P3221 P3221 
Unit cell parameters     
a (Å) 203.78 204.12 205.43 
b (Å) 203.78 204.12 205.43 
c (Å) 66.43 66.36 66.57 
Resolution range (Å) 33.35–2.10 
(2.14–2.10) 
44.19–1.95 
(1.98–1.95) 
47.31–2.02 
(2.05–2.02) 
Resolution where I/σ(I) = 2.0 2.37 2.42 2.39 
CC1/2 outer shell 0.527 0.524 0.544 
Measurements 640717 1640957 798225 
Unique reflections 90935 115132 105247 
Redundancy 7.0 (3.6) 14.3 (14.3) 7.6 (7.6) 
Completeness (%) 98.7 (94.0) 100.0 (100.0) 100.0 (100.0) 
I/σ(I) 5.9 (1.1) 4.7 (0.5) 6.5 (0.7) 
Rmerge (%) 12.1 (70.8) 16.3 (151.1) 11.7 (113.1) 
Wilson B-value (Å2) 30.5 29.7 32.2 
B. Refinement    
Resolution (Å) 33.37–2.10 
(2.15–2.10) 
44.19–1.95 
(2.00–1.95) 
47.31–2.02 
(2.07–2.02) 
Rcryst (%) 18.2 14.7a 15.6a 
Rfree (%) 21.1 16.3a 17.9a 
Amino acids (chain length 
464 residues) 
462 + 462  
(7763 atom sites) 
462 + 464 
(7788 atom sites) 
462 + 458 
(7800 atom sites) 
Water molecules 380 436 611 
Other 2 VS38 ligandsb, 2 
Mn2+, 15 SO42-, 6 
glycerol, 
1 VS39 ligandb, 2 
Mn2+, 1 Cl-, 13 SO42-, 
14 glycerol 
5 VS40 ligandsb, 2 
Mn2+, 4 SO42-, 8 
glycerol,  
Mean B (Å2)    
 Protein 30.8 29.9 32.5 
 Water 32.8 33.1 36.0 
 Other 47.5 41.3 31.8 
r.m.s.d. from target values    
 Bond lengths (Å) 0.008 0.014 0.016 
 Bond angles (°) 1.283 1.665 1.686 
 Dihedral angles (°) 5.808 6.078 6.368 
Ramachandranc    
 Most favoured (%) 97.6 97.9 97.6 
 Allowed (%) 2.3 1.7 2.2 
 Disallowed (%) 0.1 0.4 0.2 
a
 intensity-based twin refinement was used. b enantiomeric ligands modelled in one position at half occupancy were 
counted as one ligand. c as determined by the MolProbity server.143 
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Table 5.5 (continued): Data collection and refinement statistics for structures in Chapter 5. 
 VS41 VS42 
A. Data collection   
Crystal system Trigonal Trigonal 
Space group P3221 P3221 
Unit cell parameters    
a (Å) 206.08 205.59 
b (Å) 206.08 205.50 
c (Å) 66.65 66.43 
Resolution range (Å) 44.62–1.98 
(2.01–1.98) 
36.98–1.96 
(1.99–1.96) 
Resolution where I/σ(I) = 2.0 2.46 2.21 
CC1/2 outer shell 0.546 0.610 
Measurements 1279206 1105427 
Unique reflections 112641 115231 
Redundancy 11.4 (11.4) 9.6 (6.0) 
Completeness (%) 100.0 (100.0) 99.5 (94.5) 
I/σ(I) 5.2 (0.6) 4.9 (1.0) 
Rmerge (%) 14.7 (130.4) 13.7 (80.9) 
Wilson B-value (Å2) 30.5 21.5 
B. Refinement   
Resolution (Å) 44.62–1.98 
(2.03–1.98) 
36.98–1.96 
(2.01–1.96) 
Rcryst (%) 15.3a 15.5 
Rfree (%) 17.4a 18.3 
Amino acids (chain length 
464 residues) 
462 + 456  
(7858 atom sites) 
460 + 464 
(8084 atom sites) 
Water molecules 483 652 
Other 5 VS41 ligandsb, 2 
Mn2+, 1 Cl-, 5 SO42-, 6 
glycerol, 
5 VS42 ligandsb, 2 
Mn2+, 1 Cl-, 6 SO42-, 7 
glycerol 
Mean B (Å2)   
 Protein 30.6 20.9 
 Water 34.5 37.7 
 Other 32.8 35.1 
r.m.s.d. from target values   
 Bond lengths (Å) 0.016 0.018 
 Bond angles (°) 1.729 1.816 
 Dihedral angles (°) 6.366 6.294 
Ramachandranc   
 Most favoured (%) 97.7 97.5 
 Allowed (%) 2.1 2.4 
 Disallowed (%) 0.2 0.1 
a
 intensity-based twin refinement was used. b enantiomeric ligands modelled in one position at half occupancy were 
counted as one ligand. c as determined by the MolProbity server.143 
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This thesis describes the mechanism- and structure-based discovery of new ligands and 
inhibitors of MtuDAH7PS. The investigations combine synthetic organic chemistry, protein X-
ray crystallography and computational modelling techniques in order to explore the inhibition 
and regulation of this crucial enzyme from M. tuberculosis, one of the most wide-spread deadly 
pathogens threatening humankind. The findings in this thesis include the design, synthesis and 
testing of the most potent active site inhibitors of MtuDAH7PS known to date, further insight 
into the enzyme’s complex and unusual allosteric regulation, as well as studies which initiate 
the targeting of its allosteric sites for inhibitor design. 
6.1 Potent inhibition and mechanistic insight from study of 
intermediate mimics 
Bisphosphate inhibitors were designed and synthesised as intermediate mimics and active site 
inhibitors of MtuDAH7PS. Extension of mimics of PEP (the first substrate to bind to the 
enzyme) in order to establish additional contacts in the binding site of E4P (the second 
substrate) in the sense of a multivalent inhibitor came to fruition in this project after promising 
initial studies on E. coli DAH7PS.114, 144 The inhibitors described are the first example of active 
site inhibitors of MtuDAH7PS and are the most potent inhibitors reported for DAH7PS enzymes 
from any organism. An adaptable inhibitor synthesis was developed which allows the control of 
the absolute configuration of the tetrahedral intermediate mimic as well as the combination of 
various PEP-mimicking head groups with tails that can interact with the E4P binding site. 
Future research will expand upon the synthetic approach developed in order to generate more 
potent inhibitors of DAH7PS enzymes from M. tuberculosis and other organisms (Figure 6.1). 
The bisphosphate intermediate mimic binds to the enzyme active site in an extended 
conformation, due to the number of rotatable bonds however, the molecule has many degrees of 
freedom. The loss of conformational flexibility upon binding of the inhibitor to the active site is 
likely associated with a significant entropic cost. Introduction of a double bond into the linker 
region could help pre-organise the bisphosphate in an extended conformation, which is 
anticipated to result in a lower entropic cost of binding of the inhibitor to the active site and 
hence more potent inhibition (Figure 6.1). Other potential improvements which could be made 
to the active site inhibitors described in Chapter 2 relate to their phosphate groups: firstly, the 
phosphate groups will likely be labile under physiological conditions and phosphatase enzymes 
are expected to be able to cleave the phosphate-ester bond. Replacement of the phosphate 
groups with more stable phosphate isosteres such as phosphonates could help alleviate this 
problem. Secondly, the highly charged nature of the inhibitors is anticipated to negatively affect 
oral availability and cellular uptake. Studies using prodrugs of phosphates and phosphonates in
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Figure 6.1: Future directions for active site inhibitors. Introduction of a rigid linker could lead to an inhibitor 
conformation pre-organised for binding. Stable phosphate isosteres are required in order to increase inhibitor 
stability. Cellular uptake can be improved by development of a prodrug which has its charges masked with 
groups R and R1 which are labile after cellular uptake. 
order to improve cell uptake and efficacy of have been reported.145-148 The charge of the 
phosphate or phosphonate moiety is masked by addition of groups which will be removed from 
the phosphate/phosphonate-moiety by host or pathogen enzymes once the prodrug has entered 
circulation or the pathogen respectively. The properties of the masking group, such as 
lipophilicity, stability under different cellular conditions and towards prodrug-processing 
enzymes, can be used to fine-tune the activity profile of the prodrug. 
The interaction of the most potent inhibitor with the enzyme active site was structurally 
characterised. These studies showed that the charged moieties of the intermediate mimic are 
sufficient to orient the inhibitor in a binding mode that closely resembles the modelled 
intermediate of the enzymatic reaction in the active site. The crystallographic observation of a 
water molecule supported by the stronger inhibition by one enantiomer of the intermediate 
mimic helped clarify some aspects of enzymatic catalysis: the results support a mechanism in 
which the active site water molecule that attacks C2 of PEP during the reaction approaches from 
the re-face of PEP. The structural insight into the inhibitor binding mode can be used for future 
elaboration of the intermediate mimics in order to generate more potent inhibitors. 
Bisphosphate inhibitors of varying chain lengths were synthesised in order to explore the 
plasticity of the active site and its ability to accommodate inhibitors whose chain length differs 
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from the intermediate they are designed to mimic. This study led to the optimisation of the 
synthetic route and highlighted its versatility. The results also confirmed that mimics of the 
exact chain length of the reaction intermediate are the most potent inhibitors, informing future 
active site inhibitor design. 
6.2 The third allosteric binding site of MtuDAH7PS prefers 
to bind tyrosine 
As the first enzyme of the shikimate pathway, DAH7PS is a control point for metabolic flux 
into the pathway. MtuDAH7PS displays a complex mechanism of synergistic regulation by the 
aromatic amino acids and pathway end products Trp, Phe and Tyr. Previous studies focussed on 
the response to binary combinations of amino acids, especially the Trp/Phe-combination, and 
uncovered the mainly entropy-driven mechanism of allosteric regulation by analysing the 
motions of the protein in molecular dynamics simulations.107-108 However, whereas the interplay 
between sites 1 and 2 was considered increasingly well understood, whether or not site 3 played 
a role in the allosteric regulation of MtuDAH7PS remained elusive. Results from kinetic 
analysis, site-directed mutagenesis and isothermal titration calorimetry obtained by Nicola 
Blackmore, another member of the Parker research group, showed that site 3 is involved in a 
very unusual example of ternary synergistic allostery by which the combination of all three 
aromatic amino acids Trp, Phe and Tyr completely abolished MtuDAH7PS activity. Research 
undertaken as part of this thesis contributed X-ray crystallographic evidence in support of site 3 
being a Tyr-selective site, as well as showing that Phe at low concentrations preferentially binds 
to site 1. These studies have contributed to our understanding of the diverse mechanisms by 
which allosteric regulation of proteins can occur as well as provided information of use for 
inhibitor design targeting the allosteric sites of MtuDAH7PS. 
6.3 MtuDAH7PS effectively discriminates L- from D-amino 
acids 
The inversion of a chiral centre is arguably one of the most subtle variations of a molecule from 
a physical and chemical perspective. In the largely homochiral environment of proteins 
however, molecules of opposite handedness can often have markedly different effects. The 
study of the interaction of aromatic D-amino acids with MtuDAH7PS described in this thesis 
shows that the enzyme has an efficient mechanism of discriminating allosteric ligands of 
different handedness. Aromatic D-amino acids lack an effect on MtuDAH7PS activity at 
concentrations well exceeding the concentrations of the corresponding natural L-enantiomers 
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required for inhibition. Isothermal titration calorimetry measurements showed that the enzyme 
has a significantly lower affinity for D-Trp as compared to L-Trp. This lower affinity could be 
partly responsible for the reduced response to D-Trp. However, the affinity of the enzyme for D- 
and L-Phe does not show the same marked difference. X-ray crystallographic characterisation of 
MtuDAH7PS in complex with the aromatic D-amino acids revealed that at sufficiently high 
concentrations, the respective binding sites are filled with their preferred ligands. Subtle 
differences in the binding modes of the D-amino acids compared to the binding modes of their 
enantiomers suggest crucial roles of two asparagine residues in the communication between the 
allosteric sites and the allosteric sites and the active sites. Due to the inversion of chirality, D-
amino acids in site 1 are unable to establish a hydrogen bond to the side chain of Asn175 whilst 
retaining all other interactions observed for the L-enantiomers. In site 2, the geometry at the 
chiral centre of D-Trp prevents the formation of a hydrogen bond with Asn237, a key interaction 
in the binding mode of L-Trp. Contacts to both Asn175 and Asn237 were also correlated with 
inhibitory activity of ligands discovered through virtual screening (see below), making these 
two residues interesting targets for site-directed mutagenesis. 
The side chain of Asn175 is involved in the putative crucial interaction with the allosteric 
regulator in site 1 (Figure 6.2), a mutation of Asn175 to Ala should provide some insight into 
the role of this residue in ligand recognition and transmission of the allosteric signal. If the 
interaction of the allosteric ligand with the side chain of Asn175 is the main driving force of an 
allosteric signal being transmitted from site 1, like the results of this study suggest, removal of 
the side chain in an Asn175 to Ala mutation would lead to an enzyme variant whose mechanism 
of regulation is affected in one or more of the following ways: a reduced affinity of the aromatic 
 
Figure 6.2: Comparison of the binding mode of L-Phe (yellow) and D-Phe (green) in site 1. The study of 
alternative ligands and D-amino acid ligands suggest that the hydrogen bond between the L-Phe ligand and the 
side chain of Asn175 (red dashes) is crucial for the transmission of the allosteric signal. 
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amino acids to site 1 is almost certainly going to be a side-effect of the mutation, and if ligand 
affinity is too severely compromised, only very limited conclusions would be possible from the 
study of the Asn175Ala variant. However, the fact that D-Phe still binds in site 1 despite the 
absence of a hydrogen bond interaction with Asn175 makes it likely that ligand affinity to site 1 
will not be severely affected. The communication pathway by which occupancy of site 1 results 
in increased affinity for the ligand at site 2 could also be disrupted by this mutation, leading to 
loss of synergistic allosteric inhibitor binding and possibly synergistic inhibition in the Asn175 
to Ala variant. The communication pathway of site 1 to the active site could be affected, leading 
to a variant in which binding of the allosteric effector in site 1 does not elicit an inhibitory 
response. 
The main chain of Asn237 and the conformation of the surrounding α2bβ3-loop are involved in 
ligand-recognition in site 2 (Figure 6.3). Molecular dynamics simulations and the disorder 
observed in the α2bβ3-loop in many crystal structures of MtuDAH7PS suggest that this region 
of the protein is flexible, and binding of the allosteric inhibitor Trp results in a more ordered, 
less flexible conformation of the α2bβ3-loop.108 The results of the study of alternative ligands 
binding to site 2 suggest that in order to cause an allosteric signal, establishment of a hydrogen 
bond to the backbone carbonyl of Asn237 is a key interaction. This interaction between the 
ligand and Asn237 might serve to stabilise the α2bβ3-loop in a conformation which results in 
transmission of the allosteric signal. Because the main-chain carbonyl moiety of Asn237 is 
involved in the putative crucial interaction with the ligand, site-directed mutagenesis which 
would only influence the side chain of Asn237 cannot be used to remove this interaction. 
However, mutations influencing the flexibility and mobility of the α2bβ3-loop in the vicinity of  
 
Figure 6.3: Interactions of L-Trp (magenta carbons) with the α2bβ3-loop: Thr240 and Asn237 (shown with 
yellow carbons) establish key hydrogen bonds to the L-Trp ligand (red dashes). Gly232 (green carbons) is an 
interesting target for mutagenesis in order to probe the role of the conformational flexibility of the α2bβ3-loop.  
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Asn237 may provide further insight into the role of Asn237 and the surrounding residues: Dr 
Wanting Jiao, another researcher in the Parker research group, has identified Gly232 as a 
potential target for mutagenesis through molecular dynamics simulations.125 Gly232 is located 
at the end of helix α2b leading into the α2bβ3-loop. The conformational flexibility of Gly232 is 
expected to be a major contributor to the flexibility observed in the α2bβ3-loop. A Gly232 to 
Pro mutation was carried out by Nicola Blackmore and the resulting enzyme variant is currently 
being studied. Preliminary results indicate that the Gly232Pro mutation leads to a variant 
MtuDAH7PS enzyme which behaves as if Trp was bound in site 2 even in the absence of the 
ligand.149 The influence of the dynamics of the α2bβ3-loop could be probed further by other 
mutations which influence the loop’s flexibility: mutation of one of the residues in the single-
turn helix motif formed by Asp235–Gln239 or residues Thr240–Glu242 which lead up the the 
β3-strand to glycine could result in an increased flexibility of the α2bβ3-loop. If the hypothesis 
of a rigid α2bβ3-loop being required for transmission of the allosteric signal is true, the 
increased flexibility due to the introduction of glycine should lead to a variant less sensitive to 
Trp or other site 2 allosteric ligands. 
6.4 Discovery of new allosteric ligands 
A virtual screening campaign against the allosteric sites of MtuDAH7PS was carried out. Both a 
diverse library of drug-like commercially available fragments and libraries which were designed 
to resemble the native ligands Trp, Phe and Tyr were docked and compounds for physical 
screening selected according to docking score and favourable predicted binding mode. The 
comparison of predicted docking poses with observed binding modes revealed strengths and 
weaknesses of the docking protocols used: in short, hydrophobic interactions were generally 
underestimated both in the predicted docking poses as well as during visual inspection of the 
poses during compound selection. Furthermore, the docking poses indicated that the 
optimisation of predicted hydrogen bonding interactions was overemphasised by the docking 
protocol to the detriment of optimisation of hydrophobic interactions. The observed binding 
modes of a number of ligands showed that increased emphasis on hydrophobic interactions in 
both the docking protocol and evaluation of docking poses may help to increase the agreement 
between computationally predicted docking poses and experimentally observed ligand binding 
modes. The larger set of crystallographically determined ligand binding modes available 
through the studies carried out in this thesis can be used to improve the docking protocol to 
more accurately predict binding modes in future virtual screens as well as yield higher 
enrichments of true ligands in top-ranked ligand poses. Future virtual and physical screening 
approaches can use focussed libraries of analogues of the ligands with crystallographically 
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validated binding modes in order to reveal structure-activity relationships and improve binding 
and inhibition. 
Using the combined approach of fragment-based ligand design and virtual screening, the crystal 
structures of 17 new ligands in complex with MtuDAH7PS were determined. Analysis of these 
structures allowed deductions about which ligand and binding mode features are required for 
conformational rearrangements of the binding sites as well as some insight into key interactions 
required to achieve allosteric inhibition. Ligands with chemotypes closely related to the native 
ligands Trp, Phe and Tyr as well as ligands with distinctly different chemotypes were 
discovered. A small structure-activity relationship study was carried out using fluoro- and 
methyl-substituted tryptophan analogues, revealing some of the functionality which can be 
accommodated in the various binding sites. The fluoro-tryptophans were the only group of 
ligands which were found to bind to all three allosteric binding sites, indicating their potential 
for elaboration into a consensus ligand which can bind and cause inhibition at multiple sites on 
the enzyme. A number of ligands which showed inhibition in the enzyme activity assay were 
unable to be structurally characterised in complex with MtuDAH7PS. Future research can be 
directed towards elucidating the target sites of these ligands and the mechanism by which they 
cause inhibition. For example, optimisation of co-crystallisation conditions for ligands which 
were not amenable to soaking could be carried out and yield structural information about the 
target site and binding mode of the ligands. Experiments which can assess protein-ligand 
binding in solution, such as waterLOGSY and STD-NMR could be used to further characterise 
the protein-ligand interaction. If the ligands with unknown target sites do bind to the binding 
sites of the aromatic amino acids, displacement of the alternative ligands by the native aromatic 
amino acid ligands can be detected by these NMR techniques.150-153 
Targeting a network of promiscuous distant allosteric sites with subtle communication pathways 
as it is observed in MtuDAH7PS with small-molecule inhibitors may appear challenging from a 
drug discovery point of view; however, the discovery and study of alternative ligands and their 
effect on this complex system can offer a complementary approach to the biochemical study of 
the protein using mutagenesis and biophysical techniques. The natural allosteric ligands Trp, 
Phe and Tyr bind to MtuDAH7PS promiscuously at multiple sites, and occupancy of one site 
influences the ligand affinity at another site. The prediction of the occupancy of a given site at a 
given ligand concentration is therefore non-trivial, as well as the isolated analysis of effects 
contributed by a single ligand or a single site. The development of alternative ligands of known 
effect and/or high selectivity for one site can therefore deliver tool compounds which will help 
further elucidate the mechanism of allosteric regulation. Furthermore, study of alternative 
ligands results in a more in-depth understanding of the ligand features essential for inhibition at 
each respective site. This may lead to the development of a consensus ligand that is able to 
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achieve significant inhibition of MtuDAH7PS activity by binding to multiple allosteric sites at 
the same time. 
Alternative ligands for MtuDAH7PS also have potential use for the further investigation of the 
complex formation between MtuDAH7PS-MtuCM as reported by Sasso et al.,110-111 as tool 
compounds as well as inhibitors. In contrast to the synergistic inhibition of MtuDAH7PS which 
requires the presence of two aromatic amino acids for inhibition, chorismate mutase activity in 
the MtuDAH7PS-MtuCM complex has been reported to be significantly inhibited in the 
presence of single amino acids, Phe or Tyr, as well as synergistically by Phe and Tyr. This 
suggests the possibility of a single ligand targeting the allosteric sites of MtuDAH7PS being 
able to significantly inhibit MtuCM activity. If both MtuDAH7PS and MtuCM activity can be 
inhibited by a single ligand, that ligand would be an interesting candidate for an anti-TB drug 
based on inhibition of the shikimate pathway at both the very first step (DAH7PS) and at a 
crucial branch point further downstream (CM). The DAH7PS-CM non-covalent interaction and 
transfer of allostery described for the enzymes from M. tuberculosis represents the only example 
of such an interaction in the shikimate pathway reported to date, indicating it may be limited to 
certain organisms. Targeting of this complex therefore offers the possibility of narrow-spectrum 
antimicrobials selective for M. tuberculosis. Future research in this area is going to be enabled 
by the results described in this thesis. 
6.5 Concluding remarks 
The sophistication and subtlety of the interplay of the multiple binding sites of M. tuberculosis 
DAH7PS is a testament to the power of evolution which led to the development of such a 
complex system. There is still much more to be learnt about the intricacies which link enzyme 
structure and dynamics with function and how this can be exploited for the design of bioactive 
compounds. However, the findings described in this thesis have contributed to the 
understanding of inhibition and allostery of M. tuberculosis DAH7PS and have highlighted 
multiple avenues for inhibitor design. 
 
   
  
Chapter 7 – Experimental details 
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7.1 General Experimental 
7.1.1 Reaction conditions and work-up 
All reactions were carried out in flame-dried glassware under an inert atmosphere of nitrogen or 
argon gas and stirred with magnetic stirrers unless otherwise stated. Removal of solvents in 
vacuo was carried out using a rotary evaporator under reduced pressure with the water bath 
temperature not exceeding 40 ºC unless otherwise stated. Solid products were dried in an oil 
pump vacuum at room temperature. Reactions at −78 ºC, −40 ºC, and −20 ºC were cooled using 
baths of solid carbon dioxide/acetone, solid carbon dioxide/acetonitrile, and ice/salt mixtures 
respectively. 
7.1.2 Solvents and reagents 
Reagents were obtained from commercial suppliers and used without further purification unless 
stated otherwise. Before use, solvents were dried by passage through alumina columns in a 
solvent purification system custom-built by the Chemistry Department workshop according to 
published plans.154 
Copper(I) bromide dimethyl sulfide complex was prepared from cuprous bromide as previously 
reported.155 CuBr was washed with methanol until no more coloured impurities were washed 
out, and the resulting green-tinged powder dried in a high vacuum. The solid was dissolved in 
dimethyl sulfide and insoluble impurities removed by filtration if necessary. The CuBr • SMe2 
complex was precipitated by the addition of PET ether, the precipitate separated by filtration, 
washed with PET ether and dried in a stream of nitrogen. The off-white crystals were stored 
under a blanket of nitrogen in a stoppered flask, avoiding exposure to light as much as possible. 
Silver(I) oxide was freshly prepared following a previously published procedure:156 NaOH (7.99 
g, 0.20 mol) was dissolved in water (200 mL) and heated to 80–90 °C. This solution was added 
to a solution of AgNO3 (34 g, 0.20 mol) in water (200 mL) at 80–90 °C. The hot suspension was 
filtered to collect a dark brown precipitate that formed. The precipitate  was washed with hot 
water (200 mL) and ethanol (200 mL) before it was dried for 4 h under high vacuum while 
heated with an oil bath at 100 °C, yielding 18.74 g (0.08 mol) silver(I) oxide. Iodoxybenzoic 
(IBX) and Dess-Martins periodinane were prepared as previously described.157-158 Butane-1,4-
diol was distilled and stored over activated 4 Å molecular sieves. Isopropylalcohol was dried 
over 4 Å molecular sieves. Lead tetraacetate was dissolved in hot glacial acetic acid and any 
undissolved black solid lead oxide removed by filtration. The white crystals formed upon 
cooling were separated by filtration and stored in a desiccator with phosphorous pentoxide and 
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powdered KOH overnight before use. Molecular sieves were activated by repeated heating with 
a heat gun under oil pump vacuum. 
DOWEX 50WX8-100 was used packed in a column of approximately 1×10 cm. Before each 
use, at least 100 mL of 4 M aqueous hydrochloric acid was passed through the column, the 
column washed with water until the eluate was only slightly acidic (pH 6–7) to pH paper. For 
more thorough regeneration, the column was washed with hydrochloric acid and water as 
described above, followed by 50–100 mL 1 M aqueous sodium hydroxide solution. The sodium 
hydroxide solution was washed off the column with multiple column volumes of water until the 
eluate was of near neutral pH. This treatment was followed by another acid wash before use. 
Salicylaldehyde phenylhydrazone for the titration of Grignard reagent solutions was synthesised 
and used according to previous literature reports.159 An accurately weighed sample of 
salicylaldehyde phenylhydrazone (60–80 mg) was placed under an atmosphere of nitrogen or 
argon and dissolved in dry THF. The solution containing the Grignard reagent was added via 
cannula, the endpoint was determined by a colour change of the solution from yellow to orange, 
judgement of the endpoint was improved by placing a white paper underneath the flask. 
7.1.3 Chromatography 
Merck Kieselgel 60F254 pre-coated aluminium-backed plates were used for thin layer 
chromatography (TLC). Visualisation of the spots was achieved using a UV lamp (254 nm), and 
by staining with basic potassium permanganate solution or ethanolic phosphomolybdic acid 
(PMA), followed by gentle heating with a hot air gun. Flash column chromatography was 
carried out using Silica 60 230-400 mesh and analytical reagent grade solvents. 
7.1.4 NMR spectroscopy 
NMR spectroscopy was carried out on Varian INOVA 300, Agilent 400MR and Varian VNMR 
500 spectrometers. 1H-NMR spectra were calibrated to the signal of the residual protons of the 
deuterated solvent stated and chemical shifts δH are reported relative to tetramethylsilane. 13C-
NMR spectra were calibrated to the signal of the deuterated solvent indicated and chemical 
shifts δC are reported relative to tetramethylsilane. 31P-NMR spectra were calibrated and 
chemical shifts δP reported relative to an external standard of 85% phosphoric acid. In cases 
where line broadening due to the pH of a sample being too close to the pKa of the phosphate 
groups was suspected, a small amount of deuterochloric acid (DCl) in D2O was added to the 
sample. All chemical shifts are reported in parts per million (ppm) and coupling constants (J) in 
Hertz (Hz).  
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7.1.5 Mass spectrometry 
High resolution mass spectrometry was carried out on a Bruker maXis 3G or Micromass LCT 
Classic spectrometers, using positive or negative electrospray ionisation. 
7.1.6 Melting points 
Melting points (mp) were recorded on an Electrothermal IA6304 melting point block and are 
uncorrected. 
7.1.7 UV-visible spectrophotometry 
UV spectrophotometry was carried out on a Varian Cary® UV 100 spectrophotometer in 
stoppered quartz cuvettes of 1 mm, 2 mm, or 10 mm path length. The standard assay 
temperature of 30 ºC was maintained using a Varian Peltier thermostat connected to the jacketed 
multi-cell holder.  
7.1.8 IR-Spectroscopy 
Infrared spectra were recorded on a Perkin Elmer Spectrum One IR spectrometer. Liquids and 
oils were analysed as a neat film between two potassium bromide plates, solids were analysed 
as a nujol mull between potassium bromide plates or by diffuse reflectance as a finely ground 
powder of analyte mixed with potassium bromide. 
7.1.9 pH measurements 
The pH of buffers and other aqueous solutions was determined using a UB10 Ultrabasic 
Benchtop pH meter from Denver Instrument Company or a SevenCompact S220 pH meter from 
Mettler Toledo. For samples of small volume, a micro glass body combination pH electrode was 
used. The sample pH was adjusted using aqueous hydrochloric acid (1 M or 10 M) and sodium 
hydroxide (1 M or 10 M) solutions unless indicated otherwise. 
7.1.10 Preparation of buffers and kinetic assay solutions 
All buffers and assay solutions were prepared using water from a Millipore Milli-Q system. 
This water is referred to as Milli-Q water throughout this thesis. All buffers and assay solutions 
were filtered prior to use after the last solid component had been added and dissolved. 
The buffers used contained: 
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• Immobilised metal-affinity chromatography (IMAC) binding buffer: 
20 mM 1,3-bis(tris(hydroxymethyl)methylamino)propane (BTP) pH 7.5, 150 mM 
sodium chloride, 200 µM tris(2-carboxyethyl)phosphine (TCEP), 200 µM phosphoenol-
pyruvate (PEP), 100 µM manganese(II) sulfate, 20 mM imidazole. 
• IMAC elution buffer: 
20 mM BTP pH 7.5, 150 mM sodium chloride, 200 µM TCEP, 200 µM PEP, 100 µM 
manganese(II) sulfate, 500 mM imidazole. 
• Size-exclusion chromatography (SEC) buffer: 
10 mM BTP pH 7.5, 150 mM sodium chloride, 200 µM TCEP, 200 µM PEP, 100 µM 
manganese(II) sulfate. 
• Assay Buffer: 
50 mM BTP pH 7.5, 1 mM TCEP. 
 
For the preparation of solutions used in kinetic assays, solid PEP monopotassium salt (Alfa 
Aesar) was dissolved in the appropriate volume of assay buffer to yield a 10 mM stock solution. 
Manganese(II) sulfate solutions and active-site inhibitor solutions for kinetic assays were 
prepared by dissolution of the solid in Milli-Q water. All kinetic assay solutions were filtered 
through a 0.45 µm syringe filter before use. 
Preparation of E4P 
Solutions of erythrose 4-phosphate E4P for kinetic assays were prepared using a variation of 
previously described methods.160-161 Glucose 6-phosphate (G6P, 547 mg, 1.94 mmol, mono-
sodium salt) was dissolved in 3 mL water and 350 mL glacial acetic acid added. This solution 
was placed in a three-necked round-bottom flask under a nitrogen stream and equipped with a 
stirrer bar and dropping funnel. Lead tetraacetate (1.50 g, 3.40 mmol, 1.75 eq) was dissolved in 
glacial acetic acid (75 mL) and concentrated sulfuric acid (0.9 mL) added to this solution. The 
lead tetraacetate solution was added to the G6P solution dropwise over 4 h at room temperature. 
The presence of excess oxidant should be avoided and can be checked by moistened starch-
iodide paper. The addition is accompanied by the formation of a white lead sulfate precipitate. 
The resulting reaction mixture was stirred for another hour at room temperature, filtered through 
celite and the filter cake washed with water (200 mL). The combined acetic acid and aqueous 
filtrates were concentrated to about 50 mL using a rotary evaporator under oil-pump vacuum 
and equipped with a dry-ice/acetone condenser. The solution was then diluted with water (100–
200 mL) and concentrated again, and repeated 3–5 times to remove acetic acid. Alternatively, 
removal of acetic acid was achieved using overnight continuous liquid-liquid extraction of the 
aqueous phase with ether. The resulting crude solution of E4P was purified using anion-
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exchange chromatography on Source 15Q resin, eluting with a gradient of ammonium formate 
(0–2 M) in 0.2 M aqueous formic acid. E4P-containing fractions were identified by enzyme 
assay with MtuDAH7PS (see page 176) and pooled. The combined E4P-containing fractions 
were passed down a column packed with DOWEX 50WX8-100 resin (H+-form) and the eluate 
concentrated by rotary evaporation (see above) to yield the desired E4P-concentration (20–30 
mM as determined by enzyme assay, see page 176). Solutions were aliquoted (500 µL), snap-
frozen in liquid nitrogen and stored at −80 ºC. In order to allow for equilibration of monomeric, 
dimeric and oligomeric species of E4P, solutions were thawed the day before use, stored at 4 ºC 
overnight and equilibrated at room temperature for at least 1 h before kinetic assays were 
carried out. 
7.1.11 Expression and purification of MtuDAH7PS 
Expression and purification of MtuDAH7PS was carried out following published procedures.105-
107
 BL21(DE3)-pGroESL-MtuDAH7PS cell cultures were grown in autoclaved LB (Lennox LB) 
at 20 g L-1 containing the appropriate antibiotics. Pre-cultures in LB (Lennox LB) media 
containing the appropriate antibiotics were inoculated using a glycerol stock scraping and 
grown overnight with shaking (180 rpm) at 37 ºC. Typically, 50 mL of pre-culture per litre of 
cell culture were used to inoculate growths. Cells were grown at 37 ºC until mid-logarithmic 
phase (OD600 of 0.4–0.8 AU). The temperature was lowered to 23 ºC before induction of protein 
expression by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG, 0.5 mM final 
concentration), and growth was continued overnight. Cells were harvested by centrifugation 
(14,000 g for 30 min at 4 ºC) and the cell pellets either immediately subjected to lysis and 
protein purification or flash-frozen in liquid nitrogen and stored at −80 ºC for purification at a 
later date. 
Cell pellets were resuspended in lysis buffer [SEC buffer with Benzonase® Nuclease (Novagen) 
and complete EDTA-free protease inhibitor cocktail tablets (Roche) added according to the 
manufacturer’s guidelines] and were lysed by 3–5 passages through a Microfluidics M-110P 
Microfluidiser. Cell debris was removed by centrifugation at 48,000 g for 30 min at 4 ºC. The 
supernatant was syringe-filtered before the first chromatographic purification step. The presence 
of a cleavable N-terminal His-tag in the MtuDAH7PS construct enables the purification of the 
protein using immobilised metal-ion affinity chromatography (IMAC), detailed as follows: 
The cell lysate was loaded onto an IMAC column (GE Healthcare) and the column washed with 
5–10 column volumes of IMAC binding buffer to remove non-interacting components of the 
lysate. The bound protein was then eluted from the column using a gradient from IMAC binding 
buffer to IMAC elution buffer (0–100% gradient over 20 column volumes, 100% elution buffer 
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for 3 column volumes). Fractions containing His-tagged MtuDAH7PS were identified using the 
absorbance at 280 nm, pooled and diluted by half by addition of the appropriate volume of SEC 
buffer. Tobacco etch virus (TEV) protease was added to cleave the His-tag. After 1 h at room 
temperature the solution was loaded onto an IMAC column, this time collecting the flow-
through containing MtuDAH7PS with the His-tag removed. The solution was concentrated and 
final purification carried out using size-exclusion chromatography on a HiLoad 26/60 
Superdex™ 200 prep grade column (GE Healthcare) eluting with SEC buffer. A SDS-PAGE gel 
illustrating the progress of a typical purification is shown in Figure 7.1. 
 
Figure 7.1: SDS-PAGE gel showing the purification of MtuDAH7PS. PL: cell debris pellet after lysis, insoluble 
fraction of proteins. SN: supernatant, soluble fraction of proteins. His1: pooled fractions after first IMAC run 
(His-tagged MtuDAH7PS). MWM: molecular weight marker, labels indicate molecular weight in kDa. Post-
TEV: sample after exposure to TEV protease. His2FT: flow through of the second IMAC run (MtuDAH7PS 
with cleaved His-tag). SEC: pooled fractions after the final SEC purification step. 
7.1.12 Enzyme storage 
Immediately after completion of the purification, MtuDAH7PS solutions were concentrated to 
around 2 mg/mL protein concentration, dispensed into aliquots ranging from 50 µL to 1 mL in 
volume depending on intended use and flash-frozen by submersion in liquid nitrogen. Enzyme 
aliquots were stored at −80 ºC until required. While in use, enzyme solutions were kept on ice at 
all times. 
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7.1.13. Buffer exchange and protein concentration 
Protein concentration was carried out by centrifugation in 20 mL or 1 mL concentrators with a 
10,000 Da molecular weight cut off (MWCO) membrane. Buffer exchange for crystallisation or 
prior to ITC experiments was performed by repeatedly concentrating the protein solution and 
diluting with the appropriate buffer. 
7.1.14 Enzyme activity assay 
Enzymatic activity of MtuDAH7PS was assayed based on the method reported by Schoner and 
Hermann:162 the consumption of PEP was followed by monitoring the absorbance at a 
wavelength of 232 nm (the extinction coefficient for PEP is ε(PEP, 280 nm, 25 ºC) is 2800 M-1 
cm-1) using a Varian Cary 100 UV spectrophotometer (see above). Kinetic assays were 
performed in 1 cm, 2 mm or 1 mm path-length quartz cuvettes, depending on the absorbance of 
the assay mixture used. Reaction mixtures were prepared by pipetting appropriate volumes of 
stock solutions into the cuvette to give the desired assay concentrations: typical assays 
contained PEP (0–200 µM), E4P (0–200 µM), manganese sulfate (100 µM), MtuDAH7PS and a 
volume of assay buffer to make up the appropriate volume (1 mL for 1 cm path-length cuvettes, 
300 µL for 1 mm and 2 mm path-length cuvettes). Reactions were initiated either by addition of 
enzyme or addition of E4P. In both cases, the reaction mixture with all components but the 
initiating component was incubated at 30 ºC and the absorbance followed in the 
spectrophotometer. Reactions were initiated once the absorbance was constant. Initial rates were 
determined using the slope of a linear least square fit to the UV trace from 0.5 min after 
initiation to 1 min after initiation (1 mL path-length cuvettes) or 15 s after initiation to 45 s after 
initiation (shorter path-length cuvettes), respectively. Rate measurements were repeated at least 
twice or until at least two measurements which agreed within 10% standard deviation of each 
other were recorded. The errors for kinetic measurements were estimated as the standard 
deviation of replicates. Models were fitted to the rate data using the program Grafit.163 
7.1.15 Substrate concentrations 
The concentrations of PEP and E4P were determined using the standard assay system. To 
determine for example the concentration of E4P, an unknown but limiting amount of E4P was 
reacted with excess PEP and the absorbance before and after reaction recorded. The absorbance 
difference corrected by the enzyme absorbance can be converted into consumed PEP and 
therefore E4P as limiting reagent using the Beer-Lambert Law (A = ε c l with path-length l and 
the extinction coefficient of PEP (ε(PEP, 280 nm, 25 ºC) = 2800 M-1 cm-1). 
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7.1.16 Lanzetta assay for detection and quantification of phosphates 
Lanzetta reagent was prepared fresh as required from the following components:164 3 parts 
0.045% w/v malachite green in water, 1 part 4.2% w/v ammonium molybdate in 4 M HCl, 0.1 
parts 1.5% v/v Triton X-100 in water. The components were mixed in the dark and stirred for 
1 h before the solution was filtered through a 0.45 µM syringe filter. For the qualitative 
detection of phosphate-containing fractions after anion-exchange chromatography, a 20 µL 
sample of each fraction was mixed with 250 µL of Lanzetta reagent and the colour change 
judged by optical inspection. For the quantitative determination of inhibitor concentration, 
300 µL of the inhibitor solutions were incubated with 10 µL calf alkaline phosphatase solution 
(5 units/mL in 4 mM MgCl2) for at least 2 h. To 100 µL of the digested sample was added 
700 µL Lanzetta reagent and the absorbance at 630 nm determined after 20 min. A calibration 
curve for the determination of phosphate concentration was obtained from analogous analysis of 
solutions of appropriate concentrations (6–150 µM) of KH2PO4 which had been dried in high 
vacuum for at least 3 h before use. As a control, a glucose-6-phosphate solution of known 
concentration was also digested with calf alkaline phosphatase and analysed. 
7.1.17 Crystallography 
Crystallisation of MtuDAH7PS 
M. tuberculosis DAH7PS was crystallised using the hanging drop vapour diffusion method in 
24-well VDX plates with applied sealant (Hampton Research).  0.5 mL of the reservoir solution 
(0.1 M Tris-HCl (pH 7.0–8.0), 1.5 M NH4(SO4)2, 12% v/v glycerol in Milli-Q aqueous solution) 
was placed in the bottom of the wells. Hanging drops were set up by mixing 1 µL of purified 
MtuDAH7PS solution (3–5 mg/ml) with 1 µL of the reservoir solution on a siliconised glass 
cover slide, which were inverted to seal the crystallisation wells. Crystals usually formed 
overnight or within 1–2 days at 20 ºC and were of needle or wedge shape (Figure 7.2). 
Crystal soaking 
For crystals which were intended to be soaked in solutions containing ligands, multiple hanging 
droplets were prepared on the cover slide and equilibrated against reservoir solution in the same 
well. Droplets for crystallisation of MtuDAH7PS were setup using the method described above. 
The droplets for soaking were generated by mixing 1 µL of SEC buffer with 1 µL reservoir 
solution to which the desired concentration of the ligand/combination of ligands had been 
added. After crystals had formed and all droplets were deemed equilibrated against the reservoir 
solution (1–3 days), MtuDAH7PS crystals were transferred from the crystallisation drop to the 
soaking drop and left to soak for the time indicated. Soaking with tyrosine was carried out by 
178 
 
 
Figure 7.2: Typical MtuDAH7PS crystals obtained from established crystallisation conditions. 
one or multiple successive addition(s) of a concentrated stock solution of (1 mM or 10 mM) Tyr 
directly to the droplet containing well-formed crystals of MtuDAH7PS. 
Cryoprotectant solutions contained reservoir solution (with the respective ligand concentration 
in case of soaking experiments) and an additional 10–20% v/v glycerol. Crystals were mounted 
on magnetic crystal caps with cryo loops (Hampton Research, Mitegen) and immersed in a 
droplet of the cryoprotectant solution for 1–2 seconds before they were flash-frozen in liquid 
nitrogen, placed in either a sample storage cassette (Crystal Positioning Systems) or the 
Australian Synchrotron puck system and transported to the Australian Synchrotron using a dry-
shipper (Taylor-Wharton CX100). 
Data collection and processing 
Single crystal X-ray diffraction data were collected at the MX1 and MX2 beamlines at the 
Australian Synchrotron using the Blu-Ice software.165 Data processing was carried out using 
XDS166, iMosflm167 and Scala or Aimless.168-169 It should be noted that the proposition of the 
CC1/2 as resolution cutoff criterium for protein X-ray diffraction data was published while 
research contained in this thesis was carried out.170 Consequently, some datasets contained in 
this thesis were processed using the resolution where I/σ(I) = 2 and Rmerge < 0.5 as resolution 
cut-off, and some using CC1/2 > 0.5 as the resolution cut-off criterion. 
Structure solution 
The search model for structure solution was generated by removal of all non-protein atoms from 
PDB entry 3NV8. The whole dimer thus obtained was used as the search model in structure 
solution. Rapid preliminary assessment of the large number of datasets obtained from soaking 
was carried out using the molecular replacement option of Autorickshaw,171-172 with subsequent 
manual processing if ligand density was observable. Structures were solved either by molecular 
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replacement with MOLREP173 or by two cycles of rigid body refinement of the search model 
using REFMAC5.174 
Model building and refinement 
The final model was obtained by multiple iterations of model rebuilding in COOT175 and 
refinement using REFMAC5.174 Twinned data were refined using intensity-based twin 
refinement. All datasets used the same set of reflections for the calculation of Rfree (from PDB 
entry 3KGF, as this was the highest resolution dataset available at the start of this research), 
which was extended to include reflections at higher resolution where necessary. Model 
validation tools in COOT and MolProbity143 were used to detect and correct unlikely geometries 
in the model. In the refinement of ligand-bound structures, the model of the protein in the 
absence of any ligands was refined and rebuilt until the model was in close agreement with the 
electron density map. At this stage, waters and ligands other than the ligands of interest were 
added to the model apart for the regions of the structure where the electron density suggested 
the presence of the ligands of interest. Waters were added into appropriate electron density if the 
water would have at least one hydrogen bond to the protein. Waters in secondary and higher 
shells were only added if the position of the water molecule allowed the establishment of an 
uninterrupted chain of interactions to a protein atom. Ions and non-specifically bound ligands 
(for example, glycerol from the crystallisation buffer or DMSO from virtual screening 
compound stocks) were modelled into appropriate density and their occupancy refined by 
inspection of electron density maps after refinement. After the model and electron density was 
judged in good agreement in all regions apart from the ligand binding site(s) of interest, the 
electron density in the ligand binding site(s) was examined. If appropriate electron density was 
present, the ligand of interest, waters and potential other adventitiously bound molecules were 
added to the model and the final rounds of refinement carried out. 2Fo−Fc and Fo−Fc omit maps 
shown in figures were generated using the program FFT (CCP4 program suite) before addition 
of the ligands to the model. 
7.1.18 Protein structure figures 
Figures of protein structures were created using PyMOL (Version 1.3, Schrödinger LLC).176 
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7.2 Experimental for Chapter 2 
The research described in Chapter 2 was subject of two publications before submission of this 
thesis. The supplementary material to these publications reporting experimental details is 
appended with permission of the copyright owners and can also be accessed at 
http://dx.doi.org/10.1074/jbc.M110.211649 
This research was originally published in The Journal of Biological 
Chemistry. Reichau, S.; Jiao, W.; Walker, S. R.; Hutton, R. D.; Baker, E. N.; 
Parker, E. J. Potent Inhibitors of a Shikimate Pathway Enzyme from 
Mycobacterium tuberculosis. J. Biol. Chem. 2011; 286 (18): 16197–16207. 
© The American Society for Biochemistry and Molecular Biology. 
and 
http://dx.doi.org/10.1039/C3RA00037K 
Reichau, S.; Parker, E. J., Active site plasticity of a critical enzyme from 
Mycobacterium tuberculosis. RSC Advances 2013, 3 (10), 3209–3212. 
Reproduced by permission of The Royal Society of Chemistry. 
For the first publication (J. Biol. Chem.), all experimental work apart from molecular modelling 
and protein purification was carried out by the author of this thesis. Molecular Modelling was 
carried out by Dr Wanting Jiao. Dr Richard D. Hutton carried out protein purification and 
assisted with protein crystallisation. 
All experimental and computational work reported in the second publication (RSC Advances) 
was carried out by the author of this thesis. 
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SYNTHESIS AND CHARACTERIZATION OF COMPOUNDS 
Compound 6 (1) and compounds 12-14 (2) were synthesized according to literature procedures and 
had analytical data consistent with those reported. 
 
Preparation of 4-benzyloxy-1-butanol 
 
Silver(I) oxide was prepared freshly as follows: NaOH (7.99 g, 0.20 mol) was dissolved in water 
(200 mL) and heated to 80-90°C. This solution was added to a solution of AgNO3 (34 g, 0.20 mol) in 
water (200 mL) at 80-90°C. The hot suspension was filtered to collect the dark brown precipitate that 
formed. The precipitate was washed with hot water (200 mL) and ethanol (200 mL) before it was 
dried for 4 h under high vacuum while heated with an oil bath at 100°C. The silver oxide obtained 
from this procedure (18.74 g, 0.08 mol) was added to a solution of 1,4-butanediol (4.47 g, 0.05 mol) 
and benzyl bromide (10.2 g, 7.1 mL, 0.06 mol) in dichloromethane. The mixture was stirred at room 
temperature for 10 h, then filtered through a plug of celite. The celite was washed with 
dichloromethane and the solvent evaporated under reduced pressure. The crude product was purified 
by flash column chromatography on silica gel eluted with a gradient of ethylacetate/PET ether (20 % 
v/v to 50 % v/v) solvent to yield 5.35 g (59 %) of the desired product. 1H NMR (500 MHz, 
CHLOROFORM-d) δ 7.28 - 7.39 (m, 5H), 4.52 (s, 2H), 3.60 (t, J = 6.2 Hz, 2H), 3.51 (t, J = 6.1 Hz, 
2H), 3.13 (br. s., 1H), 1.61 - 1.74 (m, 4H). 13C NMR (126 MHz, CHLOROFORM-d) δ 138.0, 128.2, 
127.5, 127.4, 72.8, 70.1, 62.2, 29.6, 26.3. HRMS[ESI,pos] Calcd for C11H16O2Na 203.1043 found 
203.1047 [M+Na]+. 
 
Preparation of 4-benzyloxy-1-bromobutane 
 
Triphenylphosphine (5.58 g, 0.02 mol) and 4-benzyloxy1-butanol (2.513 g, 0.014 mol) were dissolved 
in dichloromethane (25 mL) and cooled to 0°C. N-bromosuccinimide (3.730 g, 0.021 mol) was added 
in batches with stirring. The reaction mixture was stirred at 0°C for 1.5 h, was the allowed to room 
temperature and stirred for an additional 3 h. The solvent was evaporated under reduced pressure and 
the resulting brown viscous oil was triturated with PET ether (3x50 mL). The combined PET ether 
extracts were evaporated under reduced pressure to yield a colorless oil. The crude product was 
purified by flash column chromatography on silica gel (10% ethyl acetate/PET ether) to yield 2.6 g 
(78%) of the desired bromide. 1H NMR (500 MHz, CHLOROFORM-d) δ 7.28 - 7.40 (m, 5H), 4.53 
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(s, 2H), 3.53 (t, J = 6.2 Hz, 2H), 3.46 (t, J = 6.8 Hz, 2H), 1.97 - 2.04 (m, 2H), 1.75 - 1.82 (m, 2H). 13C 
NMR (126 MHz, CHLOROFORM-d) δ 138.3, 128.3, 127.5, 127.5, 72.8, 69.2, 33.7, 29.6, 28.3. 
HRMS[ESI,pos] Calcd for C11H15OBrNa 265.0198 found 265.0204 [M+Na]+. 
 
Preparation of propan-2-yl 7-[(tert-butyldimethylsilyl)oxy]-2-hydroxyheptanoate (9) 
 
Alcohol 6 (2.65 g, 12.1 mmol) in dichloromethane solution (5 mL) was added to a suspension of 
Dess-Martin Periodinane (5.65 g, 13.3 mmol) in dichloromethane (20 mL). The solution was stirred 
for 1 h, after which complete consumption of starting material 6 was indicated by TLC analysis. The 
reaction mixture was poured into ether (100 mL) and aqueous 1 M sodium hydroxide solution was 
added (200 mL) until all the white precipitate had dissolved. The organic phase was separated, the 
aqueous phase was extracted with ether (2x120 mL) and the combined organic extracts washed with 
1 M aqueous NaOH (50 mL) and brine (100 mL). The organic phase was dried over sodium sulphate, 
filtered and the solvent evaporated under reduced pressure to give 1.945 g of a pale yellow oil. This 
crude aldehyde 7 was used in the next step without further purification. 
18 mL of a freshly prepared potassium isopropoxide solution (potassium (810 mg, 20.7 mmol) 
dissolved in 20 mL isopropyl alcohol) was added to a solution of isopropyl-2,2-dichloroacetate (3.1 g, 
18 mmol) in a mixture of isopropanol (5 mL) and ether (10 mL) at 0°C. The crude aldehyde 7 (1.95 g, 
6.30 mmol) was added and the mixture stirred at 0°C for 3 h, during which the solution turned dark 
orange. Ether (50 mL) and water (25 mL) were added and the solution was stirred until the precipitate 
dissolved. The organic phase was separated, the aqueous phase was extracted with ether (100 mL) and 
the combined organic extracts dried over sodium sulphate. After filtration, the solvent was evaporated 
under reduced pressure to yield 3.4 g of crude chloroepoxide 8 which was used immediately in the 
next step without further purification. 
Chloroepoxide 8 was dissolved in isopropanol (20 mL) and sodium cyanoborohydride (587 mg, 
9.3 mmol) was added as a solid. The reaction mixture was heated to reflux for 19 h and then quenched 
by the addition of saturated aqueous ammonium chloride solution (10 mL). Volatile components were 
removed by evaporation under reduced pressure, the residue was taken up in dichloromethane and 
water added until all the precipitate dissolved. The organic phase was separated and the aqueous 
phase was extracted with dichloromethane (200 and 150 mL). The combined organic extracts were 
dried with brine and sodium sulphate and the solvent evaporated under reduced pressure. Flash 
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column chromatography on silica gel (eluent 20% ethyl acetate/PET ether) afforded 1.6 g (42% yield 
from alcohol 6) of the desired α-hydroxyester 9 as a colorless oil. 1H NMR (300 MHz, 
CHLOROFORM-d) δ 5.10 (spt, J = 6.3 Hz, 1H), 4.13 (ddd, J = 4.4, 5.8, 7.1 Hz, 1H), 3.60 (t, J = 6.5 
Hz, 2H), 2.78 (d, J = 5.9 Hz, 1H), 1.70 - 1.85 (m, 1H), 1.33 - 1.62 (m, 7H), 1.29 (d, J = 2.6 Hz, 3H), 
1.27 (d, J = 2.9 Hz, 3H), 0.89 (s, 9H), 0.05 (s, 6H). 13C NMR (75 MHz, CHLOROFORM-d) δ 174.9, 
70.4, 69.4, 63.1, 34.4, 32.7, 26.0, 25.6, 24.5, 21.8, 18.3, -5.3. HRMS[ESI,pos] Calcd for 
C16H34NaO4Si 341.2119, found 341.2122 [M+Na]+. 
 
Synthesis of propan-2-yl 2,7-dihydroxyheptanoate (10) 
 
α-Hydroxyester 9 (342 mg, 1.07 mmol) was dissolved in THF (10 mL) and a 1 M solution of 
tetrabutylammoniumfluoride in THF (3.6 mL, 3.6 mmol) added. The reaction mixture was stirred at 
room temperature for 3 h after which volatile compounds were removed under reduced pressure. The 
crude product was purified by flash column chromatography on silica gel (eluent 50% ethyl 
acetate/PET ether) to afford 123 mg (56%) of the desired dihydroxyester 10 as a colorless oil. 1H 
NMR (300 MHz, CHLOROFORM-d) δ 5.03 (spt, J = 6.3 Hz, 1H), 4.07 (dd, J = 4.1, 7.3 Hz, 1H), 
3.56 (t, J = 6.5 Hz, 2H), 2.96 (br. s., 2H), 1.31 - 1.78 (m, 8H), 1.23 (d, J = 2.6 Hz, 3H), 1.20 (d, J = 
2.6 Hz, 3H). 13C NMR (75 MHz, CHLOROFORM-d) δ 174.7, 70.2, 69.1, 62.3, 34.1, 32.3, 25.3, 24.3, 
21.6, 21.6. HRMS [ESI, pos] Calcd for C10H21O4 205.1440, found 205.1433 [M+H]+. 
 
Preparation of propan-2-yl 2,7-di{[bis(benzyloxy)phosphoryl]oxy}heptanoate (11) 
 
1H-Tetrazole (300 mg, 4.28 mmol) was added to a solution of dihydroxyester 10 (123 mg, 
0.60 mmol) and dibenzyl N,N-diisopropylphosphoramidite (810 µL, 787 mg, 2.30 mmol) in 
dichloromethane (7 mL). After stirring the reaction mixture for 3 h at room temperature, it was cooled 
to 0°C and m-chloroperbenzoic acid (633 mg, 3.70 mmol) was added. After 2 h, the reaction mixture 
was allowed to warm to room temperature and after an additional hour the reaction was quenched by 
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addition of 10% w/v aqueous sodium thiosulfate solution (15 mL). The organic phase was separated, 
washed with 10% w/v aqueous sodium thiosulfate solution (2x15 mL), saturated aqueous sodium 
bicarbonate solution (2x15 mL) and dried with brine (15 mL) and sodium sulfate. Filtration and 
removal of the solvent under reduced pressure afforded the crude product as an oil. Flash column 
chromatography on silica gel (eluent 1% methanol/dichloromethane) yielded 218 mg (50%) of the 
desired product 11 as a pale yellow oil. 1H NMR (500 MHz, CHLOROFORM-d) δ 7.28 - 7.40 (m, 
20H), 4.98 - 5.19 (m, 8H), 4.74 (td, J = 6.1, 7.9 Hz, 1H), 3.94 (apparent q, J = 6.6 Hz, 2H), 1.73 - 1.80 
(m, 2H), 1.50 - 1.58 (m, 2H), 1.24 - 1.39 (m, 4H), 1.23 (d, J = 6.2 Hz, 5H). 13C NMR (126 MHz, 
CHLOROFORM-d) δ 169.4 (d, JPC=3.3 Hz), 135.9, 135.8, 135.7, 135.6, 128.5, 128.5, 128.5, 128.4, 
128.4, 127.9, 127.9, 127.8, 75.5 (d, JPC=6.1 Hz), 69.4, 69.3, 69.3, 69.2, 69.1, 67.6 (d, JPC= 6.1 Hz), 
32.7 (d, JPC=6.2 Hz), 29.9 (d, JPC=7.2 Hz), 24.9, 24.0, 21.6. 31P NMR (121 MHz, CHLOROFORM-d) 
δ ppm -2.8 (app spt, J=7.9 Hz, 1 P), -3.6 (app sxt, J=7.8 Hz, 1 P). HRMS[ESI,pos] Calcd for 
C38H46O10P2Na 747.2464, found 747.2448 [M+Na]+. 
 
Synthesis of ethyl (2R)-7-(benzyloxy)-2-hydroxyheptanoate (R)-15 
 
Cuprous bromide dimethylsulfide complex was prepared following the procedure the described by 
Nakamura et al.(3) Cuprous bromide dimethylsulfide complex was recrystallized fresh before each 
use from a solution in dimethylsulfide by addition of PET ether. The resulting white solid was dried in 
a stream of nitrogen for 3-5 h. 
Magnesium turnings (185 mg, 7.60 mmol) were ground under a stream of nitrogen and then 
suspended in THF (4 mL). After addition of 1,2-dibromoethane (15.0 µL, 32.7 mg, 0.17 mmol) the 
solution was heated to reflux for 10 minutes. The solvent was discarded, the activated magnesium 
turnings were washed with fresh THF (4 mL) which was also discarded. The turnings were suspended 
in fresh THF (4 mL) and 4-benzyloxy-1-bromobutane (738 mg, 3.00 mmol) in THF solution (2 mL) 
was added. The reaction mixture was heated to reflux for 1 h, during which a green solution formed. 
The excess magnesium was left to settle and the Grignard solution transferred dropwise via cannula to 
a flask containing a suspension of cuprous bromide dimethyl sulfide complex (626 mg, 3.00 mmol) in 
THF cooled to -78°C. The solution was stirred at -78°C for 20 minutes before (R)-ethylglycidate ((R)-
14, 174 mg, 1.50 mmol) was added in THF solution (2 mL). The mixture was stirred at -78°C for 2 h, 
quenched at that temperature by the addition of saturated aqueous ammonium chloride solution 
(15 mL) and allowed to warm to room temperature. The mixture was transferred to a separating 
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funnel and water was added until all precipitate had dissolved. The organic phase was separated and 
the aqueous phase extracted three times with ether (2x50 mL and 100 mL). The combined organic 
phases were washed with brine (2x40 mL), dried over sodium sulphate, filtered and evaporated. The 
crude product was purified by flash column chromatography on silica gel (20% ethyl acetate/PET 
ether) to yield 133 mg (32%) of α-hydroxyester (R)-15 as a colorless oil. The preparation of (S)-15 on 
a 6.6 mmol scale (referring to (S)-ethylglycidate) following a similar procedure yielded 483 mg (26%) 
of the desired product. Spectral data are identical to those reported for (R)-15 with the exception of 
optical rotation (see below). 1H NMR (500 MHz, CHLOROFORM-d) δ 7.28 - 7.39 (m, 5H), 4.48 - 
4.53 (m, 2H), 4.24 (q, J = 7.3 Hz, 2H), 4.17 (dd, J = 4.2, 7.5 Hz, 1H), 3.48 (t, J = 6.4 Hz, 2H), 1.76 - 
1.84 (m, 1H), 1.59 - 1.70 (m, 3H), 1.37 - 1.52 (m, 4H), 1.30 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, 
CHLOROFORM-d) δ 175.3, 138.6, 128.3, 127.6, 127.5, 72.9, 70.3, 70.2, 61.6, 34.3, 29.6, 25.9, 24.6, 
14.2. HRMS[ESI,pos] Calcd for C16H24O4Na 303.1566, found 303.1567 [M+Na]+. [α]D20 (R)-15 -1.4 
(c 2.3, CHCl3), (S)-15 +0.9 (c 2.1, CHCl3). 
 
Preparation of ethyl-(2R)-2,7-dihydroxyheptanoate (R)-16 
 
α-hydroxyester (R)-15 (600 mg, 2.10 mmol) was dissolved in ethyl acetate and 10% Palladium on 
charcoal (257 mg, 0.24 mmol Pd) was added. The reaction flask was purged with hydrogen gas with 
three freeze-pump-thaw cycles, then stirred at room temperature for 3 days.1 The reaction mixture was 
filtered through a celite pad and the celite washed with ethyl acetate (50 mL). The solvent was 
evaporated under reduced pressure to give a yellow oil. The crude product was purified by flash 
column chromatography on silica gel (60% ethyl acetate/PET ether) to yield the desired 
dihydroxyester (R)-16 as a pale yellow oil (265 mg, 66%).1H NMR (300 MHz, CHLOROFORM-d) δ  
4.17 (q, J = 7.0 Hz, 2H), 4.11 (dd, J = 4.3, 7.5 Hz, 1H), 3.55 (t, J = 6.5 Hz, 2H, ), 3.31 (br. s, 1H), 
2.64 (br. s, 1H), , 1.29 - 1.79 (m, 8H), 1.23 (t, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CHLOROFORM-
d) δ 175.1, 70.2, 62.3, 61.4, 34.1, 32.2, 25.2, 24.4, 14.0. HRMS[ESI,pos] Calcd for C9H18O4Na 
213.1097, found 231.1096 [M+Na]+. [α]D20 (R)-16 +0.8 (c 1.8, CHCl3), (S)-16 -0.8 (c  2.3, CHCl3). 
                                                      
1 This long reaction time is exceptional, typical reaction times are 12-15 h. Reactions were monitored 
by TLC, in this particular example full conversion had not occurred overnight so that hydrogenolysis 
was continued. 
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Preparation of ethyl-(2R)-2,7-di{[bis(benzyloxy)phosphoryl]oxy}heptanoate (R)/(S)-17 
 
(R)/(S)-17 were synthesized from (R)/(S)-17 in an analogous  procedure to the synthesis of 11. (R)- 
and (S)-17 could be obtained in 64% and 74% yield respectively. Spectral data for the two 
enantiomers were identical except for optical rotation, the data for (R)-17 is listed below. 1H NMR 
(500 MHz, CHLOROFORM-d) δ 7.29 - 7.39 (m, 20H), 4.99 - 5.18 (m, 8H), 4.77 (td, J= 5.9, 8.0 Hz, 
1H), 4.18 (m, 2H), 3.94 (q, J= 6.6 Hz, 2H), 1.77 (q, J = 6.7 Hz, 2H), 1.54 (m, 2H), 1.27 - 1.37 (m, 
4H), 1.25 (t, J= 7.2 Hz, 3H). 13C NMR (126 MHz, CHLOROFORM-d) δ 169.9 (d, JPC=3.3 Hz), 
135.9, 135.82, 135.80, 135.73, 135.70, 135.6, 128.51, 128.49, 128.47, 128.46, 128.42, 127.90, 127.86, 
127.8, 75.4 (d, JPC=5.4 Hz), 69.4 (m), 69.1 (m), 67.6 (d, JPC=6.0 Hz), 61.5, 32.7 (d, JPC=6.4 Hz), 29.9 
(d, JPC=6.9 Hz), 24.9, 24.1, 14.1.  31P NMR (121 MHz, CHLOROFORM-d) δ -0.4 (sept, J=7.9 Hz, 
1P, P-2), -1.24 (sext, J=7.8 Hz, 1P, P-7). [α]D20 (R)-17 +2.9° (c 2.2, CHCl3), (S)-17 -2.9° (c 2.2, 
CHCl3). HRMS[ESI,pos] Calcd for C37H45O10P2 711.2488, found 711.2478 [M+H]+.  
 
INHIBITION STUDIES 
Assay conditions are described in the main manuscript. Initial rates were obtained by a linear least 
square fit of the initial rate data. Each rate measurement is the average of at least duplicate 
measurement with less than 10% standard deviation. Rate measurements were repeated until at least 
two rates were found to agree within 10% standard deviation. The negative rates obtained from 
consumption of PEP were converted into progress rates using Beer’s Law and the extinction 
coefficient of PEP ε=2800 L mol-1 cm-1(30°C, 232 nm) (4).  Error bars in the graphs (Figure S1 and 
Figure S2) show the standard deviation of rates used to obtain average rates. The kinetic data obtained 
was globally fitted to the equation 
! = !!"#× !!!× 1 + !!! + !  
using the computer program GraFit®.(5) Vmax represents the maximum progress rate, [S] represents 
the concentration of the substrate PEP, Km represents the Michaelis-constant for PEP, [I] represents 
the concentration of inhibitor present and Ki represents the inhibition constant with respect to PEP. 
Grafit® data and fits were replotted using ORIGIN®(6) to allow inclusion of error bars. 
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Figure S1: Results of Inhibition assays with R-4, represented as Michaelis-Menten-Plot. Inhibitor 
concentrations: squares – no inhibitor; circles [R-4]= 470 nM; triangles – [R-4]=940 nM. Error bars 
are standard deviations of averaged rates, [PEP] has an error of ±10%. Solid lines represent the global 
fit obtained using all assay measurements (21 data points in total) in Grafit® to a model of 
competitive inhibition, giving Vmax=15 ± 2 µM min-1, Km=120 ± 30 µM , Ki= 360 ± 50 nM. 
 
Figure S2: Results of Inhibition assays with S-4, represented as Michaelis-Menten-Plot. Inhibitor 
concentrations: squares – no inhibitor; circles [S-4]=390 nM; triangles – [S-4]=780 nM. Error bars are 
standard deviations of averaged rates. [PEP] has an error of ±10%. Solid lines represent the global fit 
obtained using all assay measurements (21 data points in total) in Grafit® to a model of competitive 
inhibition,  in Grafit®, giving Vmax=13 ± 2 µM min-1, Km=100 ± 30 µM , Ki= 620 ± 110 nM. 
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DETAILED INHIBITOR MODELING PROCEDURE AND RESULTS 
The structures of both possible diastereoisomers of the linear intermediate and the designed inhibitor 
4 were built using the protein builder in Maestro (7) of the Schrödinger Suite 2006 and then 
minimized with MacroModel (8). The Polak-Ribiere Conjugate Gradient (PRCG) minimization 
method was used with up to 5000 iterations and a gradient convergence threshold of δ=0.05 
kJ/(mol*Å). A conformational search was then carried out for each isomer in order to generate an 
ensemble of low-energy conformers to find a suitable starting conformation for the later docking 
calculation. Conformational searches were conducted with the MCMM Serial Torsional Sampling 
method and were run with a GB/SA water model, using the OPLS2005 force field, with 3000 steps for 
the conformational search and an energy window of 12.0 kJ/mol for collecting appropriate 
conformers. All the conformers from the conformational search were clustered by consideration of 
torsional RMS deviation of the backbones, and the representatives were selected based on the 
clustering statistics, which were then used in the docking calculations as the starting conformation for 
each epimer of the linear intermediate.  
The modeling of the linear intermediate epimers into the active site of MtuDAH7PS was carried out 
with the Schrödinger Suite 2006 Induced Fit Docking protocol (9). The active site in chain A of the 
unliganded crystal structure of MtuDAH7PS was used as the receptor. The center of the receptor grid 
was defined as the centroid of residues 87, 126, 133, 134, 135, 136, 137, 248, 250, 280, 282, 283, 284, 
306, 337, 366, 369, 380, 382, 409, 411, 440, and 441 as defined in the wild type MtuDAH7PS crystal 
structure (PDB-code 2B7O) (10). For the initial docking, the van der Waals radii of the linear 
intermediate atoms were scaled to 0.8. The 20 best solutions from the initial docking were kept. All 
residues of the protein within a 5 Å distance of the respective linear molecule solution were refined. 
The ligands were re-docked, with a van der Waals radius scale of 0.8, to the top 20 newly generated 
protein structures if the energy was within 30 kcal/mol of the best protein structure. 
The (R)- and (S)-isomers of inhibitor 4 were modeled into MtuDAH7PS by docking flexible inhibitors 
into the rigid receptor with the “intermediate adapted” conformation of the active site. This grid is 
generated based on the best pose from induced fit modeling of the linear intermediate molecule, from 
which the active site conformation, especially the residues in close proximity to the modeled linear 
intermediate molecule (within 5 Å), have adopted different conformations from the original crystal 
structure (2B7O), to optimize interactions with the modeled linear intermediate. Therefore, this active 
site conformation can be considered as “intermediate-adapted” and can be used in modeling of 
inhibitors that are designed to mimic the binding mode of the linear intermediate molecule. The 
inhibitor docking was conducted in Glide (11) with OPLS2005 force field and extra precision (XP) 
mode. 90000 poses per ligand were kept for initial docking, and scoring window for keeping initial 
poses was 5000. The best 1000 poses per ligand were kept for energy minimisation with a distance 
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dependent dielectric constant of 2 and a maximum of 5000 conjugate gradient steps. Ten poses per 
ligand were saved for evaluation. 
 
 
Figure S3: Best pose of inhibitors (magenta carbons) (R)-4 (top) and (S)-4 (bottom) when modeled 
into the intermediate adapted conformation of MtuDAH7PS (carbon: green, nitrogen: blue, oxygen: 
red, sulfur: yellow, manganese: gray sphere). All hydrogen atoms except for the C2 hydrogen of 4 
highlighting the inhibitor configuration were omitted for clarity, the C2 hydrogen of (S)-4 points away 
from the viewer into the plane. Enzyme conformation and inhibitor binding closely resemble the 
experimentally determined structure. 
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Figure S4: Side-on view (Figure S3 rotated approximately 90° around vertical axis) of the best poses 
of inhibitors (R)-4 and (S)-4 (magenta carbons) when modeled into the intermediate adapted 
conformation of MtuDAH7PS. This view illustrates the hydrogen pointing towards ((S)-4) and away 
from ((R)-4) Glu248 and Trp280 in the foreground on the left. This potential steric clash of (S)-4 with 
a water molecule (red sphere) coordinated to these residues can be used to rationalize the slightly 
lower inhibitory potency of (S)-4. The distance between H2 of (S)-4 and the water molecule (black 
dashed line) is only 1.7 Å. 
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General 
Reactions were carried out under an inert atmosphere of nitrogen unless stated otherwise. 
Solvents were dried and purified using standard procedures.1 CuBr●SMe2 was prepared 
freshly from CuBr following a published procedure,2 all other reagents were used as 
purchased. NMR spectra were recorded on either a Varian UNITY 300 MHz or Varian 
INOVA 500 MHz NMR spectrometer. 1H and 13C-NMR spectra were referenced to residual 
protonated solvent or internal tetramethylsilane. 31P-NMR spectra were externally referenced 
to 85% phosphoric acid. Mass spectrometry was performed on a Bruker maXis 3G mass 
spectrometer. Optical rotations were measured on a Perkin Elmer 341 Polarimeter.  Due to 
most compounds characterised for this study possessing low rotations at the standard 589 nm 
wavelength, different wavelengths were chosen to determine the optical rotation, details are 
given with the analytical data for the respective compounds. Infrared spectra were recorded 
on a Perkin Elmer Spectrum One IR spectrometer. UV-Visible spectroscopy was carried out 
on a Varian Cary® 100 Bio UV-Visible spectrometer. 
Synthesis 
General procedure for the preparation of bromides (3) 
The appropriate neat 1,x-diol (1 eq) was placed in a flask under a stream of nitrogen. Finely 
powdered KOH (1.2 eq) was added and the suspension heated to about 100°C with stirring, 
which resulted in some of the KOH being dissolved. Benzyl bromide (1 eq, neat) was added 
dropwise at a rate which resulted in a controlled reflux. After complete addition, the reaction 
mixture was heated to reflux for 4 h, cooled to room temperature and diluted with 
dichloromethane. The organic phase was washed with 1 M HCl and dried over magnesium 
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sulfate before the solvent was removed under reduced pressure. The crude product was 
purified by flash chromatography eluting with 30-50% ethyl acetate/PET ether giving the 
monobenzylated diols S1a-b. Yields and analytical data are summarized below. 
 
 
S1a 
40% yield, Rf 0.32 (50% EA/PET ether). 1H-NMR (500 MHz, CHLOROFORM-d)  ppm 7.3 
- 7.4 (m, 5 H, Ph-H), 4.5 (s, 2 H, Ph-CH2-O), 3.8 (t, J=5.7 Hz, 2 H, CH2OH), 3.7 (t, J=5.8 
Hz, 2 H, CH2OBn), 2.4 (br. s., 1 H, -OH), 1.9 (quin, J=5.8 Hz, 2 H, CH2CH2OH). 13C-NMR 
(126 MHz, CHLOROFORM-d)  138.1 (C-CH2-O), 127.7 (Ar-C), 127.6 (Ar-C), 73.2 (Ph-
CH2-O), 69.2 (CH2OH), 61.7 (CH2OBn), 32.1 (CH2CH2OH). HRMS [ESI,pos] Calcd for 
C10H14O2Na 189.0891, found 189.0889  [M+Na]+. NMR data is in accordance with the 
literature.3 
 
 
S1b 
27% yield, Rf 0.28 (40% EA/PET ether). 1H NMR (500 MHz, CHLOROFORM-d)  ppm 7.3 
- 7.4 (m, 5 H, Ar-H), 4.5 (s, 2 H, Ph-CH2), 3.6 (br. t, J=6.0, 6.0 Hz, 2 H, CH2OH), 3.5 (t, 
J=6.5 Hz, 2 H, BnO-CH2), 1.6 - 1.7 (m, 2 H, H2/H4), 1.5 - 1.6 (m, 2 H, H2/H4), 1.4 - 1.5 (m, 
2 H, H3). 13C-NMR (126 MHz, CHLOROFORM-d)  138.5 (Ar-C), 128.3 (Ar-C), 127.6 
(Ar-C), 127.4 (Ar-C), 72.8 (Ph-CH2, 70.2 (CH2OH), 62.6 (BnO-CH2), 32.4 (CH2CH2OH), 
29.4 (BnO CH2CH2), 22.4 (BnOCH2CH2CH2). NMR data is in accordance with the 
literature.3 
 
Monobenzylated diols S1 (1 eq) were dissolved in THF at 0°C and stirred while solid PPh3 
(1.5 eq) and NBS (1.5 eq) were added alternatingly in portions. After complete addition, the 
mixture was stirred at room temperature for 2 h or until TLC indicated complete conversion 
of starting material. The solvent was removed under reduced pressure to yield a brown oil, 
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which was added to rapidly stirring PET ether. The precipitated solids were removed by 
filtration, the filtrate dried over MgSO4 and concentrated in vacuo to yield the crude product. 
Purification was carried out by flash chromatography eluting with a gradient of 20% to 50% 
dichloromethane/PET ether giving the bromides 3 with yields and analytical data summarized 
below. 
 
 
3a 
73% yield, Rf 0.28 (20% DCM/PET ether). 1H-NMR (500 MHz, CHLOROFORM-d)  ppm 
7.3 - 7.4 (m, 5 H, Ar-H), 4.5 (s, 2 H, Ph-CH2), 3.6 (t, J=6.0 Hz, 2 H, BnOCH2), 3.6 (t, J=6.5 
Hz, 2 H, Br-CH2), 2.1 - 2.2 (m, 2 H, BnOCH2CH2). 13C-NMR (126 MHz, CHLOROFORM-
d)  138.1 (Ar-C1), 128.4 (Ar-C), 127.7 (Ar-C), 127.6 (Ar-C), 73.2 (Ph-CH2), 69.2 
(BnOCH2), 61.7 (Br-CH2), 32.1 (BnOCH2CH2). HRMS [ESI,pos] Calcd for C10H13OBrNa 
251.0047, found 251.0053  [M+Na]+. NMR data is in agreement with literature values.4 
 
 
3b 
91% yield, Rf 0.49 (10% EA/PET ether). 1H NMR (500 MHz, CHLOROFORM-d)  7.28 - 
7.43 (m, 5H, Ph-H), 4.49 (s, 2H, Ph-CH2), 3.47 (t, J = 6.31 Hz, 2H, BnOCH2), 3.39 (t, J = 
6.78 Hz, 2H, Br-CH2), 1.80 - 1.95 (m, 2H, BnOCH2CH2), 1.57 - 1.73 (m, 2H, BrCH2CH2), 
1.48 - 1.57 (m, 2H, BnOCH2CH2CH2). 13C-NMR (126 MHz, CHLOROFORM-d)  138.5 
(Ar-C), 128.3 (Ar-C), 127.5 (Ar-C), 127.4 (Ar-C), 72.9 (Ph-CH2), 69.9 (Br-CH2), 33.6, 32.5, 
28.8, 24.9 (4 CH2). NMR data is in agreement with literature values.5 
 
Epoxide ring opening. Carried out under argon atmosphere. Magnesium turnings (3.4 eq 
with respect to bromide) were freshly ground under a stream of argon and suspended in a 
known volume of dry diethylether under argon. A mixture of the respective bromide 3 (1 eq) 
and dibromoethane (0.08 eq with respect to bromide) was dissolved in a known volume of 
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dry diethylether. The total volume of this solution was recorded before dropwise addition to 
the Mg suspension was started. The speed of addition was chosen so that a gentle reflux of 
the reaction mixture was maintained. After complete addition, the Grignard reagent solution 
was stirred for 1 h at room temperature before the solution was titrated against a THF or 
diethylether solution of salicylaldehyde phenylhydrazone (typically 70-80 mg in 10 mL 
solvent).6 
The Grignard solution was added dropwise via cannula to a stirred suspension of 
CuBr●SMe2 (1 eq with respect to Grignard reagent) which had been pre-cooled to -78°C. 
After complete addition, the suspension was stirred for one hour, during which most of the 
solid dissolved and formed an orange/red solution. Ethyl glycidate (0.5 eq with respect to 
Grignard reagent) dissolved in a small volume of THF was added and the resulting reaction 
mixture allowed to gradually warm to room temperature over 3-5 hours. The reaction was 
quenched by the addition of saturated aqueous ammonium chloride solution. The aqueous 
phase was extracted twice with ether and the combined organic extracts washed with water 
and dried over MgSO4. The solvent was removed under reduced pressure and the crude 
product purified by flash column chromatography eluting with 30% ethyl acetate/PET ether, 
providing -hydroxy esters 7 in yields and with analytical data summarized below. 
 
 
R-7a 
67% yield from ethyl glycidate, Rf 0.35 (30% EA/PET ether). 1H-NMR (500 MHz, 
CHLOROFORM-d)  7.2 - 7.4 (m, 5H, Ar-H), 4.5 (s, 2H, Ph-CH2), 4.2 (q, J = 7.2 Hz, 2H, 
OCH2CH3), 4.16 (ddd, J = 4.2, 5.6, 7.4 Hz, 1H, H2), 3.47 (t, J = 6.4 Hz, 2H, H6), 2.85 (d, J = 
5.9 Hz, 1H, -OH), 1.77 - 1.85 (m, 1H, H3a), 1.44 - 1.72 (m, 5H, H3b/H4/H5), 1.25 - 1.31 (m, 
3H, OCH2CH3). 13C-NMR (126 MHz, CHLOROFORM-d)  175.2 (COOEt), 138.5 (Ar-C), 
128.3 (Ar-C), 127.5 (Ar-C), 127.4 (Ar-C), 72.8 (Ph-CH2), 70.3 (C2), 70.1 (C6), 61.6 
(OCH2CH3), 34.1 (C3), 29.4 (C5), 21.5 (C4), 14.1 (OCH2CH3). HRMS [ESI, pos] Calcd for 
C15H22O4Na 289.1410, found 289.1404 [M+Na]+. IR (neat, [cm-1]) 3449 (-OH), 2936, 2863 
(CH2), 1735 (C=O). ሾߙሿଶ଴ -5.0° (436 nm, c 3.2, CHCl3). 
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S-7a 
59% yield from ethyl glycidate. Analytical data are identical to R-7a above, apart from ሾߙሿଶ଴ 
+5.4° (436 nm, c 3.44 , CHCl3). 
 
 
R-7b 
55% yield from ethyl glycidate, Rf 0.25 (20% EA/PET ether). 1H-NMR (500 MHz, 
CHLOROFORM-d)  ppm 7.2 - 7.4 (m, 5 H, Ph-H), 4.5 (s, 2 H, PhCH2O), 4.3 (qd, J=7.1, 
1.3 Hz, 2 H, COOCH2CH3), 4.1 - 4.2 (m, 1 H, H2), 3.5 (t, J=6.6 Hz, 2 H, H8), 2.7 (br. s., 1 
H, -OH), 1.7 - 1.8 (m, 1 H, H3a), 1.6 - 1.7 (m, 4 H, H4/H7), 1.3 - 1.5 (m, 5 H, H3b/H5/H6), 
1.3 (t, J=7.0 Hz, 3 H, COOCH2CH3). 13C-NMR (126 MHz, CHLOROFORM-d)  175.4 
(C1), 138.7, 128.3, 127.6, 72.9 (PhCH2O), 70.4 (C2/C8), 70.4 (C2/C8), 61.6 (COOCH2CH3), 
34.3 (C3), 29.6 , 29.1, 26.0, 24.7 (4 CH2), 14.2 (COOCH2CH3). HRMS [ESI, pos] Calcd for 
C17H26O4Na 317.1723, found 317.1724 [M+Na]+. IR (neat, [cm-1]) 3449 (-OH), 3030 (CAr-
H), 2932, 2858 (CH2), 1735 (C=O). ሾߙሿଶ଴ -5.2° (436 nm, c 2.5, CHCl3). 
 
 
S-7b 
65% from ethyl glycidate. Analytical data are identical to R-7b above, apart from ሾߙሿଶ଴ +5.3° 
(436 nm, c 2.4, CHCl3). 
Hydrogenation. To a solution of -hydroxy esters 7 (1eq) in ethyl acetate was added Pd on 
charcoal (0.1 eq Pd). The reaction vessel was charged with an atmosphere of hydrogen by 
means of three freeze-pump-thaw cycles. The reaction mixture was stirred overnight or until 
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TLC indicated complete conversion of starting material. The catalyst was removed by 
filtration through a celite pad, the celite pad was washed with ethyl acetate and the combined 
filtrates concentrated under reduced pressure. The crude product was purified by flash 
column chromatography on silica gel eluting with 80% ethyl acetate/PET ether. Yields and 
analytical data for the diols 8 obtained are summarized below. 
 
 
R-8a 
74% yield, Rf 0.25 (80% EA/PET ether). 1H-NMR (500 MHz, CHLOROFORM-d)  ppm 4.2 
(q, J=7.2 Hz, 2 H, COOCH2CH3), 4.2 (ddd, J=7.3, 5.7, 4.2 Hz, 1 H, H2), 3.6 (t, J=6.2 Hz, 2 
H, H6), 3.2 (d, J=5.9 Hz, 1 H, -OH), 2.2 (br. s., 1 H, -OH), 1.7 - 1.9 (m, 1 H, H3a), 1.4 - 1.7 
(m, 5 H, H3b/H4/H5), 1.3 (t, J=7.2 Hz, 3 H, COOCH2CH3). 13C-NMR (126 MHz, 
CHLOROFORM-d)  175.1 (C1), 70.3 (C2), 62.3 (C6), 61.6 (OCH2CH3), 33.9 (C3), 32.1 
(C5), 21.0 (C4), 14.1 (OCH2CH3).HRMS [ESI, pos] Calcd for C8H16O4Na 199.0941, found 
199.0941 [M+Na]+. IR (neat, [cm-1]) 3390 (-OH), 2940, 2869 (CH2), 1733 (C=O). ሾߙሿଶ଴ -
14° (365 nm, c 2.55, CHCl3). 
 
COOEt
OH
HO  
S-8a 
88% yield. Analytical data are identical to R-8a above, apart from ሾߙሿଶ଴ +13.7° (365 nm, c 
2.91, CHCl3). 
 
 
 
R-8b 
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66% yield, Rf 0.42 (80% EA/PET ether). 1H-NMR (500 MHz, CHLOROFORM-d)  4.22 (q, 
J = 7.20 Hz, 2H, OCH2CH3), 4.11 - 4.18 (m, 1H, H2), 3.61 (t, J = 6.60 Hz, 2H, H8), 2.96 (br. 
s, 1H, -OH), 1.71 - 1.85 (m, 1H, H3a), 1.31 - 1.66 (m, 9H, H3b/H4/H5/H6/H7), 1.28 (t, J = 
7.20 Hz, 3H, COOCH2CH3). 13C-NMR (126 MHz, CHLOROFORM-d)  175.3 (C1), 70.3 
(C2), 62.7(C8), 61.5 (OCH2CH3), 34.2 (C3), 32.5 (C4/C5/C6/C7), 29.0 (C4/C5/C6/C7), 25.5 
(C4/C5/C6/C7), 24.6 (C4/C5/C6/C7), 14.1(OCH2CH3). HRMS [ESI, pos] Calcd for 
C10H20O4Na 227.1254, found 227.1252  [M+Na]+. IR (neat, [cm-1]) 3391 (-OH), 2932, 2860 
(CH2), 1732 (C=O). ሾߙሿଶ଴ -5.4° (436 nm, c 2.33, CHCl3) 
 
 
S-8b 
86% yield. Analytical data are identical to R-8b above, apart from ሾߙሿଶ଴ +5.0° (436 nm, c 
2.4, CHCl3). 
 
Phosphorylation. Diols 8 (1 eq) and dibenzyl N,N-diisopropylphosphoramidite (4 eq) were 
dissolved in dichloromethane and cooled to 0°C. Solid dicyanoimidazole (4.8 eq) was added 
in one portion, the reaction mixture allowed to warm to room temperature and stirred for 4 h 
or until TLC indicated complete conversion of starting material. A solution of m-CPBA (6.3 
eq) in dichloromethane was dried over MgSO4 before addition to the reaction mixture. The 
reaction mixture was stirred for 2 h and then quenched by addition of a 10% aqueous sodium 
thiosulfate solution. The organic phase was separated, washed with 10% aqueous sodium 
thiosulfate solution, saturated aqueous sodium bicarbonate solution and the combined 
aqueous phases backextracted with dichloromethane. The combined organic phases were 
washed with brine, dried over MgSO4 and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography on silica gel using 50% ethyl 
acetate/PET ether as eluent. Yields and analytical data for the phosphorylated diols 9 are 
summarized below. 
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 R-9a 
80% yield, Rf 0.36 (60% EA/PET ether). 1H-NMR (500 MHz, CHLOROFORM-d)  ppm 7.3 
- 7.4 (m, 15 H, Ph-H), 4.9 - 5.2 (m, 8 H, BnO-CH2), 4.8 (dt, J=7.9, 6.1 Hz, 1 H, H2), 4.1 - 4.2 
(m, 2 H, H6), 3.9 (q, J=6.6 Hz, 2 H, COOCH2CH3), 1.7 - 1.8 (m, 2 H, CH2), 1.6 (dt, J=12.7, 
6.5 Hz, 2 H, CH2), 1.4 (quin, J=7.8 Hz, 2 H, CH2), 1.2 - 1.3 (t, J=7.2 Hz 3 H, COOCH2CH3). 
13C-NMR (126 MHz, CHLOROFORM-d)  ppm 169.8 (d, J=3.3 Hz), 135.7 (d, J=6.5 Hz), 
135.7 (d, J=7.4 Hz), 135.6 (d, J=7.0 Hz), 128.5 (s), 128.4 (s), 127.9 (s), 127.8 (s), 127.8 (s), 
75.2 (d, J=5.6 Hz), 69.4 (d, J=4.7 Hz), 69.4 (d, J=4.7 Hz), 69.1 (d, J=5.6 Hz), 67.2 (d, J=6.0 
Hz), 61.5 (s), 32.3 (d, J=6.5 Hz), 29.4 (d, J=7.4 Hz), 20.5 (s), 14.0 (s). 31P{1H}-NMR (202 
MHz, CHLOROFORM-d)  ppm 0.3 (s, 1P), -0.6 (s, 1P). 31P-NMR (202 MHz, 
CHLOROFORM-d)  ppm 0.3 (sept, J=8 Hz, 1P), -0.6 (sext, J=8 Hz, 1P). HRMS [ESI, pos] 
Calcd for C36H43O10P2 697.2326, found 697.2340 [M+H]+. IR (neat, [cm-1]) 3065, 3035, 
2960, 1754 (C=O), 1276 (P=O), 1015 (P-O-C), 735, 697 (monosubstituted aryl). ሾߙሿଶ଴ +4.5 
(436 nm, c 2.5, CHCl3). 
 
 
S-9a 
87% yield. Analytical data are identical to R-9a above, apart from ሾߙሿଶ଴ -4.7° (436 nm, c 2.4, 
CHCl3). 
 
 
 
R-9b 
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80% yield, Rf 0.18 (50% EA/PET ether). 1H-NMR (500 MHz, CHLOROFORM-d)  ppm 7.3 
- 7.4 (m, 15 H, Ph-H), 5.1 (qd, J=11.4, 7.5 Hz, 2 H, POCH2Ph), 5.0 - 5.1 (m, 6 H, 
POCH2Ph), 4.7 - 4.8 (m, 1 H, H2), 4.2 (qd, J=7.2, 3.5 Hz, 2 H, H8), 4.0 (q, J=6.6 Hz, 2 H, 
COOCH2CH3), 1.8 (q, J=7.0 Hz, 2 H, H3), 1.5 - 1.6 (m, 2 H, H7), 1.3 (dd, J=13.2, 6.6 Hz, 2 
H, H4), 1.2 (t, J=7.0 Hz and overlapping m, 7 H, COOCH2CH3/H5/H6). 13C NMR (126 
MHz, CHLOROFORM-d)  ppm 170.0 (d, JPC=3.3 Hz, C1), 135.8 (d, JPC=6.5 Hz, 
POCH2CPh), 135.7 (d, JPC=7.4 Hz, POCH2CPh), 135.6 (d, JPC=7.0 Hz, POCH2CPh), 128.5 (s, 
Ar-C), 128.5 (s, Ar-C), 128.4 (s, Ar-C), 128.4 (s, Ar-C), 128.4 (s, Ar-C), 127.9 (s, Ar-C), 
127.8 (s, Ar-C), 127.7 (s, Ar-C), 75.5 (d, JPC=5.6 Hz, C2), 69.4 (d, JPC=5.6 Hz PhCH2OP), 
69.3 (d, JPC=5.6 Hz, PhCH2OP), 69.1 (d, JPC=5.6 Hz, PhCH2OP), 67.7 (d, JPC=6.0 Hz,C8), 
61.4 (s, COOCH2CH3), 32.8 (d, JPC=6.0 Hz, C3), 29.9 (d, JPC=7.0 Hz, C7), 28.4 (s, 
C4/C5/C6), 25.0 (s, C4/C5/C6), 24.3 (s, C4/C5/C6), 14.0 (s, COOCH2CH3). 31P{1H}-NMR 
(202 MHz, CHLOROFORM-d)  ppm 0.3 (br. s., 1 P), -0.6 (s, 1 P). 31P NMR (202 MHz, 
CHLOROFORM-d)  ppm 0.3 (spt, J=6.5 Hz, 1 P), -0.6 (sxt, J=6.7 Hz, 1 P). HRMS 
[ESI,pos] Calcd for C38H46O10P2Na 747.2458, found 747.2463 [M+Na]+. IR (neat, [cm-1]) 
3034, 2933, 2860 (CH2), 1753 (C=O), 1271 (P=O), 1015 (P-O-C), 737, 697 (monosubstituted 
aryl). ሾߙሿଶ଴ +4.4° (436 nm, c 2.3, CHCl3). 
 
 
S-9b 
79% yield. Analytical data are identical to R-9b above, apart from ሾߙሿଶ଴ -4.7° (436 nm, c 2.5, 
CHCl3). 
 
Final deprotection. Fully protected diphosphates 9 (1 eq) were dissolved in ethyl acetate, 
palladium on charcoal (0.l eq) added and the flask charged with an atmosphere of hydrogen 
using three freeze-pump-thaw cycles. The mixture was stirred overnight or until TLC 
indicated complete conversion of starting material. The catalyst was removed by filtration 
through a pad of celite, the celite pad was washed with ethyl acetate and methanol. The 
solvent was evaporated, 1 M KOH added and the reaction mixture stirred vigorously for 2 h. 
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The reaction mixture was passed down a column of DOWEX 50WX8-100 (H+-form, 
approximately 1 cm x 10 cm) and the column washed with water. The combined eluate was 
neutralized with 1 M KOH and lyophilized. The crude product was purified by anion 
exchange chromatography on column containing Source Q resin eluting with a gradient of 0-
0.6 M ammonium bicarbonate. Fractions containing phosphate were determined using the 
qualitative Lanzetta assay (see below), pooled and lyophilized. Yields and analytical data of 
final products are summarized below. 
 
 
C6R 
61% yield. 1H-NMR (500 MHz, DEUTERIUM OXIDE)  ppm 4.35 (br., 1H, H2), 3.74 (br, 
2H, H6), 1.72 (br, 2H, H5), 1.56 (br, 2H, H4), 1.40 (br, 1H, H3a), 1.31 (br, 1H, H3b). 13C-
NMR (126 MHz, DEUTERIUM OXIDE)  ppm 180.2 (d, J=4.2 Hz, C1), 76.0 (d, J=5.1 Hz, 
C2), 65.2 (d, J=5.6 Hz, C6), 33.4 (d, J=4.2 Hz, C4), 30.1 (d, J=7.4 Hz, C5), 20.7 (s, C4). 
31P{1H}-NMR (202 MHz, DEUTERIUM OXIDE)  ppm 3.0 (br s, 1P), 1.7 (br s, 1P). 31P-
NMR (202 MHz, DEUTERIUM OXIDE)  ppm 3.0 (br. t, J=6.5 Hz, 1P), 1.7 (d, J=8.8 Hz, 
1P). HRMS [ESI,pos] Calcd for C6H15O10P2 309.0135, found 309.0127 [M+H]+. ሾߙሿଶ଴ +4.2° 
(546 nm, c 1.2, H2O). 
 
 
C6S 
14% yield. Analytical data are identical to C6R above, apart from ሾߙሿଶ଴ -1.9° (546 nm, c 1.3, 
H2O). 
 
C8R 
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5% yield. 1H-NMR (500 MHz, DEUTERIUM OXIDE)  4.29 - 4.40 (m, 1H, H2), 3.77 (q, J 
= 6.60 Hz, 2H, H8), 1.69 (br m, 2H, CH2), 1.55 (br m, 2H, CH2), 1.21 - 1.41 (m, 6H, 3 CH2). 
13C-NMR (126 MHz, DEUTERIUM OXIDE)  ppm 179.9 (d, JCP=4.2 Hz, C1), 76.2 (d, JCP 
=5.6 Hz,C2), 65.6 (d, JCP =5.6 Hz, C8), 33.4 (d, JCP =5.1 Hz, C3), 29.8 (d, JCP =7.0 Hz, C7), 
28.3 (s, C4/C5/C6), 24.7 (s, C4/C5/C6), 24.0 (s, C4/C5/C6). 31P{1H} NMR (202 MHz, 
DEUTERIUM OXIDE)  ppm 2.2 (s, 1 P), 1.2 (s, 1 P). 31P NMR (202 MHz, DEUTERIUM 
OXIDE)  ppm 2.2 (t, J=6.5 Hz, 1 P), 1.2 (d, J=8.5 Hz, 1 P). HRMS [ESI,neg] Calcd for 
C8H17O10P2 335.0302, found 335.0313 [M-H]-. ሾߙሿଶ଴ +7.9° (436 nm, c 1.0, H2O). These data 
are consistent with the data reported for the racemic compound.7 
 
 
C8S 
25% yield. Analytical data are identical to C8R above, apart from ሾߙሿଶ଴ -4.0° (436 nm, c 1.0, 
H2O). 
Lanzetta phosphate assay. Lanzetta reagent8 was prepared fresh as required from the 
following components: 3 parts 0.045% w/v malachite green in water, 1 part 4.2% w/v 
ammonium molybdate in 4 M HCl, 0.1 parts 1.5% v/v Triton X-100 in water. The 
components were mixed in the dark and stirred for 1 h before the solution was filtered 
through a 0.45 M syringe filter. For the qualitative detection of phosphate-containing 
fractions after anion exchange chromatography, a 20 L sample of each fraction was mixed 
with 250 L of Lanzetta reagent and the color change judged by optical inspection. For the 
quantitative determination of inhibitor concentration, 300 L of the inhibitor solutions were 
incubated with 10 L calf alkaline phosphatase solution (5 units/mL in 4 mM MgCl2) for at 
least 2 h. To 100 L of the digested sample was added 700 L Lanzetta reagent and the 
absorbance at 630 nm determined after 20 minutes. A calibration curve for the determination 
of phosphate concentration was obtained from analogous analysis of solutions of appropriate 
concentrations (6-150 M) of KH2PO4 which had been dried in high vacuum for at least 3 h 
before use. As a control, a glucose-6-phosphate solution of known concentration was also 
digested with calf alkaline phosphatase and analyzed. 
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Enzyme Purification and Assays 
DAH7PS from Mycobacterium tuberculosis (MtuDAH7PS) was overexpressed and purified 
as previously described.9 Cell lysate containing His6-tagged protein was loaded onto an 
IMAC column (GE Healthcare). Non-binding contents of the lysate were eluted with a buffer 
containing a low imidazole concentration (20 mM), then a gradient to high imidazole 
concentration was applied to elute His6-tagged MtuDAH7PS. The fractions containing 
MtuDAH7PS were diluted by half with SEC buffer and tobacco etch virus protease (1 mg) 
was added to cleave the His-tag. After 1 h at room temperature the solution was loaded onto 
an IMAC column, this time collecting the flow through containing His-tag cleaved 
MtuDAH7PS. The solution was concentrated and final purification carried out using a 
HiLoad 26/60 Superdex™ 200 prep grade column (GE Healthcare) eluting with a buffer 
containing 10 mM bis-tris propane (BTP) at pH 7.5, 150 mM NaCl, 200 M tris(2-
carboxyethyl)phosphine) (TCEP), 200 M PEP, 200 M MnSO4. 
Enzymatic activity assays were carried out as previously described.10 The loss of PEP was 
monitored at a wavelength of 232 nm. For rate measurements, the enzyme (2 L, 2.1 mg/mL) 
was incubated with varying concentrations of PEP (0-35 M) and inhibitor (0-4.8 M), 
MnSO4 (100 M), with buffer (50 mM BTP pH 7.5, 1 mM TCEP) added to a final volume of 
1 mL. The reaction was initiated by the addition of the second substrate E4P (5 L, giving a 
cuvette concentration of 135 M). Initial rates were determined using the slope of a linear 
least square fit to the UV trace from 0.5 minute after initiation to 1 minute after initiation. 
Rate measurements were repeated at least twice or until at least two measurements which 
agreed within 10% standard deviation of each other were recorded.  
The rate data obtained was globally fitted to the equation 
ݒ ൌ ௠ܸ௔௫ ൈ ሾܵሿ
ܭ௠ ൈ ൬1 ൅ ሾܫሿܭ௜ ൰ ൅ ሾܵሿ
 
using the program Grafit.11   
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Figure S 1: Enzyme assay results for inhibitor C6R, inhibitor concentrations: empty circles: no inhibitor; solid 
squares: 1.2 M; empty triangles: 2.4 M; solid triangles: 4.8 M. The global fit gave Vmax 12 ± 0.4 M min-1, 
Km 4.7 ± 1.0 M, Ki 1.1 ± 0.2 M. 
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Figure S 2: Enzyme assay results for inhibitor C6S, inhibitor concentrations: empty circles: no inhibitor; solid 
squares: 1.2 M; empty triangles: 2.3 M; solid triangles: 4.6 M. The global fit gave Vmax 12 ± 0.4 M min-1, 
Km 4.5 ± 0.8 M, Ki 1.4 ± 0.3 M.  
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Figure S 3: Enzyme assay results for inhibitor C8R, inhibitor concentrations: empty circles: no inhibitor; solid 
squares: 54 M; empty triangles: 108 M; solid triangles: 216 M. The global fit gave Vmax 13.7 ± 0.8 M min-
1, Km 7 ± 3 M, Ki 3 ± 1 M.  
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Figure S 4: Enzyme assay results for inhibitor C8S, inhibitor concentrations: empty circles: no inhibitor; solid 
squares: 70 M; empty triangles: 140 M; solid triangles: 280 M. The global fit gave Vmax 13.2 ± 0.9 M min-
1, Km 6 ± 2 M, Ki 5 ± 1 M.  
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Modeling procedure 
This procedure was modified from a previous report.10 The structures of the ligands for 
docking were built using the protein builder in Maestro 12 of the Schrödinger Suite 2011 and 
then minimized with MacroModel.13 Ligands were generated as fully deprotonated penta-
anions, only the more inhibitory R-enantiomers were used for docking studies. The Polak-
Ribiere Conjugate Gradient (PRCG) minimization method was used with up to 5000 
iterations and a gradient convergence threshold of δ=0.05 kJ/(mol*Å). An ensemble of low-
energy conformers for docking was generated using MCMM Serial Torsional Sampling with 
a GB/SA water model and the OPLS2005 force field, with 3000 steps for the conformational 
search with an energy window of 12 kJ/mol for appropriate conformers. The conformational 
search returned conformers which were largely similar to each other, with similar relative 
placement of phosphate and carboxylate moieties but varying with respect to the torsional 
angles along the carbon chain. Three conformers which sampled representative carbon chain 
torsions were picked from the conformational ensemble and used in the induced fit docking.  
The conformation of the active site of M. tuberculosis DAH7PS in complex with the C7 
inhibitor (pdb code 3PFP) was used as the starting point for the induced fit docking of C6R 
and C8R with the Schrödinger Suite 2011 Induced Fit Docking workflow.14 The active site of 
chain A of the asymmetric unit was used as the receptor, chain B was removed from the 
model before docking. The native C7 ligand from the crystal structure (pdb code 3PFP) was 
defined as the centre of the receptor grid and the box size automatically determined by the 
Schrödinger software. For the initial docking, the van der Waals radii of the linear 
intermediate atoms were scaled to 0.8, the receptor atoms were scaled to 1.0. The 20 best 
solutions from the initial docking were kept. All residues of the protein within a 5 Å distance 
of the docking pose of the respective ligand molecule were refined. The ligands were re-
docked, with a van der Waals radius scale of 0.8, to the top 20 newly generated protein 
structures if the energy was within 30 kcal/mol of the best protein structure. Docking 
solutions which retained the interactions of the 2-phosphoryl carboxylic acid moiety 
headgroup as observed in the native crystal structure (pdb code 3PFP) were picked. The 
selection was further refined by elimination of solutions which had unfavourable carbon 
chain backbone torsions or clashes with protein atoms. 
As a benchmark of docking performance, the native C7 ligand was redocked into the 
receptor. The docking results overlayed with the native binding mode observed in the 3PFP 
crystal structure with an rmsd of 0.305 Å.  
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Induced fit docking of the newly synthesised inhibitors C6R and C8R showed largely 
unaltered interactions with and identical placement of the 2-phosphoryl carboxylate moiety 
when compared with the C7R enzyme complex crystal structure (Figure S 5, panels A and 
B). The docking solutions highlight the importance of the appropriate length carbon chain 
linker: the docking pose of the C6R inhibitor with truncated carbon chain does not allow 
placement of the 6-phosporyl moiety in the site that was occupied by the 7-phosporyl group 
in the enzyme-C7R complex (Figure S 5, panel A). The induced fit docking algorithm did 
rearrange the mobile KPRS motif in order to optimize enzyme ligand interactions: the 
positively charged sidechain of Arg135 shifted by 1.7Å (distance between the carbons in the 
guanidinium groups) when compared to the crystal structure used as the starting point for the 
induced fit docking (3PLP), which results in a similar distance between this moiety and the 
terminal phosphate of the ligand in both the modeled and the native crystal structure. Ser136 
was also shifted by the induced fit docking protocol, but to a lesser extend, which results in 
the hydrogen bonding interactions between the backbone N-H and hydroxyl group of Ser136 
and the respective ligand being less favourable in the pose for the C6R ligand when 
compared to the values from the C7-enzyme complex crystal structure.(Figure S 5, panel C, 
refer to Table S1 for hydrogen bond distances and angles). 
Table S1: Hydrogen bond distances and angles from induced fit docking results (C6R and C8R) and crystal 
structure (C7R).a 
 d(H-bond1 Ser136-
OH-ligand) [Å] 
angle (H-bond1) 
[°] 
d(H-bond2 Ser136-
NH-ligand [Å] 
Angle (H-bond2) 
[°] 
C6R docking 2.9 123.0 3.0 153.0 
C7R crystal structure 2.7 130.6 2.8 166.4 
C8R docking 3.0 112.7 3.1 122.9 
aH-bond1: the distance corresponds to the distance between the Ser136-hydroxyl oxygen and the closest phosphate oxygen on the ligand. 
The angle corresponds to the angle defined by the phosphorous atom, the phosphate oxygen and the Ser136-hydroxyl oxygen making the 
hydrogen bond. H-bond2: the distance corresponds to the distance between the Ser136-backbone amide nitrogen and the closest phosphate 
oxygen on the ligand. The angle corresponds to the angle defined by phosphorous atom, the phosphate oxygen and the Ser136-backbone 
amide nitrogen making the hydrogen bond. 
The docking poses obtained from induced fit docking of C8R show a preference for the C8-
phosphate being placed in the same location in which the corresponding 7-phosphate was 
found in the C7-enzyme complex crystal structure, despite the longer carbon chain of the 
C8R inhibitor (Figure S 5, panel B). This results in C8R being docked in a collapsed and 
twisted rather than linear conformation, which might represent a higher energy conformer of 
the ligand. The twisted conformation of the ligand in turn causes the hydrogen bonding 
geometry between Ser136 and the C8-phosphate to be less favourable when compared to the 
C7 ligand (Table S1). This docking solution is the only pose in which H-bond2 is formed 
between the Ser136 backbone N-H and the alkyl-substituted oxygen on the 8-phosphoryl 
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group, all other structures show the Ser136 backbone N-H bonded to a charged phosphate 
oxygen (Figure S 5, panels D and E). 
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 F th y y S in  Fi
gu
re
 S
 5
: C
om
pa
ri
he
 m
ob
ile
 K
PR
S 
m
ye
llo
w
 c
ar
bo
ns
, C
7R
ye
llo
w
 c
ar
bo
ns
, C
7R
Se
r1
36
 sh
ow
n 
as
 re
d
nh
ib
ito
r C
8R
, h
yd
ro
A
C
 
is
on
 o
f i
nd
uc
ed
 fi
t d
m
ot
if 
hi
gh
lig
ht
ed
 b
y 
R
: b
lu
e 
ca
rb
on
s)
 a
n
R
: b
lu
e 
ca
rb
on
s)
 a
n
d 
da
sh
es
. D
: C
7R
-e
n
og
en
 b
on
ds
 b
et
w
eeA
 
 
do
ck
in
g 
re
su
lts
 fo
r 
co
lo
re
d 
st
ic
ks
, a
ll 
o
nd
 th
e 
do
ck
in
g 
re
su
l
nd
 th
e 
do
ck
in
g 
re
su
l
nz
ym
e 
co
m
pl
ex
 c
ry
n 
th
e 
lig
an
d 
an
d 
Se
 
D
C
6R
 a
nd
 C
8R
 w
ith
ot
he
r e
nz
ym
e 
re
si
du
lt 
fo
r i
nh
ib
ito
r C
6R
lt 
fo
r i
nh
ib
ito
r C
8R
ys
ta
l s
tru
ct
ur
e,
 th
e 
h
er
13
6 
sh
ow
n 
as
 re
d D
 
h 
th
e 
cr
ys
ta
l s
tru
ct
u
ue
s s
ho
w
n 
in
 g
ra
y.
 A
R
 (m
ag
en
ta
 c
ar
bo
ns
)
R
 (c
ya
n 
ca
rb
on
s)
. C
:
hy
dr
og
en
 b
on
ds
 b
et
da
sh
es
. 
 
re
 o
f t
he
 C
7R
-e
nz
y
A
: s
up
er
po
si
tio
n 
of
). 
B:
 su
pe
rp
os
iti
on
 o
: d
oc
ki
ng
 p
os
e 
of
 in
tw
ee
n 
th
e 
lig
an
d 
an
dB
 
E 
ym
e 
co
m
pl
ex
, L
ys
13
f t
he
 C
7R
-e
nz
ym
e 
c
of
 th
e 
C
7R
-e
nz
ym
e
nh
ib
ito
r C
6R
, h
yd
ro
d 
Se
r 1
36
 sh
ow
n 
as
 
33
-P
ro
13
4-
A
r1
35
-S
co
m
pl
ex
 c
ry
st
al
 st
ru
e 
co
m
pl
ex
 c
ry
st
al
 st
og
en
 b
on
ds
 b
et
w
ee
n
s r
ed
 d
as
he
s. 
E:
 d
oc
 
Se
r1
36
 b
el
on
gi
ng
 to
uc
tu
re
 (p
ro
te
in
: 
tru
ct
ur
e 
(p
ro
te
in
: 
n 
th
e 
lig
an
d 
an
d 
ck
in
g 
po
se
 o
f 
o 
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 References 
 
1. Armarego, W. L. F.; Chai, C., Purification of Laboratory Chemicals. 5th 
ed.; Butterworth-Heinemann: Oxford, 2003. 
2. Matsuo, Y.; Muramatsu, A.; Tahara, K.; Koide, M.; Nakamura, E., Org. 
Synth. 2006, 83, 80-87. 
3. (a) Parmar, D.; Duffy, L. A.; Sadasivam, D. V.; Matsubara, H.; Bradley, P. 
A.; Flowers, R. A.; Procter, D. J., J. Am. Chem. Soc. 2009, 131 (42), 15467-15473; 
(b) Thompson, A. M.; Delaney, A. M.; Hamby, J. M.; Schroeder, M. C.; Spoon, 
T. A.; Crean, S. M.; Showalter, H. D. H.; Denny, W. A., J. Med. Chem. 2005, 48 
(14), 4628-4653. 
4. (a) Frankowski, K. J.; Golden, J. E.; Zeng, Y.; Lei, Y.; Aubé, J., J. Am. 
Chem. Soc. 2008, 130 (18), 6018-6024; (b) Ziegler, F. E.; Klein, S. I.; Pati, U. K.; 
Wang, T. F., J. Am. Chem. Soc. 1985, 107 (9), 2730-7. 
5. Dai, C.; Narayanam, J. M. R.; Stephenson, C. R. J., Nature Chem. 2011, 3 
(2), 140-145. 
6. Love, B. E.; Jones, E. G., J. Org. Chem. 1999, 64 (10), 3755-3756. 
7. Harrison, A. N.; Reichau, S.; Parker, E. J., Bioorg. Med. Chem. Lett. 2012, 
22 (2), 907-911. 
8. Lanzetta, P. A.; Alvarez, L. J.; Reinach, P. S.; Candia, O. A., Anal. 
Biochem. 1979, 100 (1), 95-97. 
9. Webby, C. J.; Baker, H. M.; Lott, J. S.; Baker, E. N.; Parker, E. J., J. Mol. 
Biol. 2005, 354 (4), 927-939. 
10. Reichau, S.; Jiao, W.; Walker, S. R.; Hutton, R. D.; Baker, E. N.; Parker, 
E. J., J. Biol. Chem. 2011, 286 (18), 16197-16207. 
11. GraFit, Version 5.0.13; Erithacus Software Limited: 2006. 
12. Maestro, Version 9.2; Schrodinger, LLC: New York, NY, 2011. 
13. MacroModel, Version 9.9; Schrodinger, LLC: New York, NY, 2011. 
14. Schrodinger Suite 2011 Induced Fit Protocol; Glide version 5.7; Prime 
version 3.0, Schrodinger, LLC: New York, NY, 2011. 
 
 
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
Sp
ec
tr
a 
 
  
 
S
R
E
13
4 
1H
.e
sp
11
10
9
8
7
6
5
4
3
2
1
0
-1
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
3.
00
2.
53
3.
59
1.
51
0.
91
2.
41
1.
04
1.
97
2.
39
4.
51
TM
S
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
13
4 
13
C
.e
sp
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
C
H
LO
R
O
FO
R
M
-d
175.21
138.48
128.28
127.55
127.44
72.84
70.29
70.05
61.56
34.13
29.35
21.52
14.14
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
SR
E1
51
S 
1H
.e
sp
11
10
9
8
7
6
5
4
3
2
1
0
-1
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
3.
61
6.
54
4.
07
1.
45
0.
93
2.
34
1.
10
2.
00
2.
25
4.
65
C
H
LO
R
O
FO
R
M
-d
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E1
51
S 
13
C
.e
sp
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
C
H
LO
R
O
FO
R
M
-d
175.36
138.62
128.31
127.58
127.45
72.83
70.34
61.60
34.31
29.63
29.13
24.65
14.19
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
15
5 
1H
.e
sp
11
10
9
8
7
6
5
4
3
2
1
0
-1
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
2.
65
5.
31
1.
11
1.
21
0.
88
2.
00
0.
92
1.
68
C
H
LO
R
O
FO
R
M
-d
C
O
O
E
t
O
H
H
O
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
15
5 
13
C
.e
sp
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
175.14
70.30
62.33
61.57
33.85
32.09
20.98
14.13
C
O
O
E
t
O
H
H
O
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
15
3_
1H
.e
sp
11
10
9
8
7
6
5
4
3
2
1
0
-1
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
2.
93
6.
34
3.
96
1.
49
0.
92
2.
00
0.
95
1.
87
C
H
LO
R
O
FO
R
M
-d
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
15
3_
13
C
.e
sp
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
C
H
LO
R
O
FO
R
M
-d
175.34
77.25
77.00
70.36
62.85
61.59
34.24
32.57
25.52
24.65
14.17
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
16
1 
1H
.e
sp
11
10
9
8
7
6
5
4
3
2
1
0
-1
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
3.
34
2.
50
2.
51
2.
45
2.
48
2.
49
1.
21
8.
00
15
.0
1C
H
LO
R
O
FO
R
M
-d
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
S
R
E
16
1 
13
C
.e
sp
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
C
H
LO
R
O
FO
R
M
-d
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
g6
71
00
p2
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
-4
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
1.
00
0.
97
0.26
-0.57
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
16
1 
31
P
H
.e
sp
0.
6
0.
5
0.
4
0.
3
0.
2
0.
1
0
-0
.1
-0
.2
-0
.3
-0
.4
-0
.5
-0
.6
-0
.7
-0
.8
-0
.9
-1
.0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
1.
00
0.
97
M
02
(s
xt
)
M
01
(m
)
0.38
0.34
0.30
0.26
0.22
0.18
-0.47
-0.51
-0.55
-0.58
-0.62
-0.66
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
15
7_
g6
68
01
h.
es
p
11
10
9
8
7
6
5
4
3
2
1
0
-1
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
6.
78
2.
11
2.
24
2.
28
2.
10
2.
00
1.
11
5.
10
1.
94
13
.3
5C
H
LO
R
O
FO
R
M
-d
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
SR
E1
57
_g
66
81
3c
.e
sp
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
C
H
LO
R
O
FO
R
M
-d
170.00
135.84
128.48
127.84
127.74
77.26
77.00
76.74
69.14
67.77
61.42
32.79
32.74
29.94
29.89
28.45
25.04
24.31
14.04
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
S
R
E
15
7_
31
P
.e
sp
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
-4
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
1.
00
0.
97M
02
(s
)
M
01
(b
r. 
s.
)
0.31
-0.59
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
15
7_
31
P
H
.e
sp
0.
5
0
-0
.5
-1
.0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
-0
.100.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
1.
07
1.
00
M
01
(b
r. 
sp
t)
M
02
(s
xt
)
0.31
-0.53
-0.57
-0.61
-0.65
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
S
R
E
16
9 
1H
.e
sp
11
10
9
8
7
6
5
4
3
2
1
0
-1
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
2.
21
2.
07
2.
04
2.
00
1.
04
D
E
U
TE
R
IU
M
 O
XI
D
E
W
at
er 4.35
3.74
1.72
1.56
1.40
1.31
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
16
9 
13
C
.e
sp
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
180.24
75.94
65.19
33.39
30.09
20.67
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
16
9 
31
P
.e
sp
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
-4
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
1.
00
1.
02
M
02
(b
r. 
s.
)
M
01
(b
r. 
s.
)
2.96
1.67
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
16
9 
31
P
H
.e
sp
3.
5
3.
0
2.
5
2.
0
1.
5
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
1.
00
1.
00
M
02
(d
)
M
01
(b
r. 
t)
2.96
1.68
1.64
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
16
3 
1H
.e
sp
11
10
9
8
7
6
5
4
3
2
1
0
-1
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
0
0.
05
0.
10
0.
15
0.
20
0.
25
0.
30
Normalized Intensity
5.
95
2.
05
2.
06
2.
00
1.
01
D
E
U
TE
R
IU
M
 O
XI
D
E
W
at
er 4.36
3.79
3.78
3.76
3.75
1.70
1.56
1.30
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
16
3 
13
C
.e
sp
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
179.92
179.89
76.19
76.15
65.60
33.40
29.87
28.31
24.71
23.97
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
 
S
R
E
16
3 
31
P
.e
sp
22
0
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
-2
0
-4
0
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
1.
00
0.
95M
01
(s
)
M
02
(s
)
2.24
1.16
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
 
S
R
E
16
3 
31
P
H
.e
sp 2
.5
2.
0
1.
5
1.
0
0.
5
C
he
m
ic
al
 S
hi
ft 
(p
pm
)
00.
1
0.
2
0.
3
0.
4
0.
5
0.
6
0.
7
0.
8
0.
9
1.
0
Normalized Intensity
1.
00
0.
90
M
02
(d
)
M
01
(t)
2.27
2.24
2.21
1.18
1.14
Electronic Supplementary Material (ESI) for RSC Advances
This journal is © The Royal Society of Chemistry 2013
238 
 
7.3 Experimental for Chapter 3 
The research described in Chapter 3 has been accepted for publication before submission of this 
thesis. The supplementary material to this publication reporting experimental details is 
appended with permission of the copyright owners and can also be accessed at 
 
http://dx.doi.org/10.1016/j.jmb.2012.12.019 
The citation for this work is Blackmore, N. J.; Reichau, S.; Jiao, W.; Hutton, R. 
D.; Baker, E. N.; Jameson, G. B.; Parker, E. J., Three Sites and You Are Out: 
Ternary Synergistic Allostery Controls Aromatic Amino Acid Biosynthesis in 
Mycobacterium tuberculosis. J. Mol. Biol. 2013, 425 (9), 1582-1592. © 2012, 
Elsevier. 
 
The author of this thesis contributed the crystal structures of MtuDAH7PS in complex with Phe 
only in site 1 (PDB code 2YPO) and in complex with Tyr (PDB code 2YPP). Crystal soaking 
conditions were optimised in order to allow extended soaking times without degradation of 
diffraction quality and power of the crystals. The author of this thesis carried out extensive 
optimisation of ligand concentrations and soaking times to obtain the structures reported in the 
publication. The author of this thesis collected, processed and analysed diffraction data, refined 
the structures and deposited the final structures in the Protein Data Bank, wrote the section of 
the paper describing the results and discussion of the X-ray crystallographic analysis and 
contributed to the other sections. 
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THREE SITES AND YOU ARE OUT: TERNARY SYNERGISTIC ALLOSTERY 
CONTROLS AROMATIC AMINO ACID BIOSYNTHESIS IN MYCOBACTERIUM 
TUBERCULOSIS 
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Table S1: Summary of soaking conditions and occupancy of ligand sites 
Structure  
(PDB-code) 
Soaking 
conditions 
Occupancy of sites 
  Site 1 Site 2 Site 3 
Phe only (2YPO) 200 µM Phe 
1h 
No lig Phe No Lig 
Tyr (2YPP) 330 µM Tyr 
3 days* 
No lig Tyr Tyr 
Trp and Tyr 
(2YPQ) 
2 mM of each Trp Tyr Tyr 
* The final soak concentration of Tyr was achieved by adding two aliquots (0.5 µL) of 
a 1 mM Tyr solution to a 2 µL hanging drop containing enzyme crystals. 
 
  
Table S2. Collection and refinement parameters for the new liganded MtuDAH7PS 
structures 
 
 
Phe in site 2 Tyr in both site 3 and 
site 2 
Tyr+Trp 
A. Data collection    
Crystal system Trigonal Trigonal Trigonal 
space group P3221 P3221 P3221 
Unit cell parameters       
a (Å) 203.97 203.45 205.69 
b (Å) 203.97 203.45 205.69 
c (Å) 66.6 66.49 66.77 
Resolution range (Å) 44.161-2.00 Å (2.11-
2.00)  
47.05-2.30 Å (2.42-
2.30) 
39.72-2.80 Å 
(2.90-2.80)  
Measurements 568312 513469 161471 
Unique reflections 106936 67961 39770 
Redundancy 5.3 (5.4) 7.6 (3.9) 4.06 (4.00) 
Completeness (%) 99.9 (100) 97.0 (86.7) 99.2 (99.9) 
I/σ(I) 6.0 (1.6) 4.8 (3.1) 7.2 (2.4) 
Rmerge (%) 10.2 (47.0) 12.6 (23.7) 12.8 (44.9) 
Wilson B-value (Å2) 21.7 29.6 57.9 
B. Refinement    
Resolution (Å) 44.16 -2.00 A (2.11-
2.00) 
44.02-2.30 Å (2.42-
2.30) 
175.67-2.76 Å 
(2.83-2.76) 
Rcryst (%) 13.9 13.9 18.1 
Rfree (%) 15.9 16.4 24.9 
Amino acids (chain length 
464 residues) 
458+457 
7576 atom sites 
460+462  
7374 atom sites 
457+460  
7251 atom sites 
Water molecules 387 154 81 
Other 2 Phe ligands, 2 Mn2+, 
5 SO42-, 6,glycerol  
3 Tyr ligands, 2 Mn2+, 
5 SO42-, 3 Cl-, 4 
glycerol 
3 Tyr ligands, 2 
Trp ligands, 2 
Mn2+, 2 PO42-, 2 
SO42-, 2 Cl-, 5 
glycerol  
Mean B (Å2)    
 Protein 28.3 29.9 41.0 
 Water 29.7 24.2 43.2 
 Other 30.4 27.3 49.9 
r.m.s.d. from target valuesa    
 Bond lengths (Å) 0.023 0.021 0.023 
 Bond angles (°) 2.002 2.058 3.114 
 Dihedral angles (°) 6.287 6.500 10.675 
Ramachandran b    
 Most favored (%) 97.6 98.2 95.7 
 Allowed (%) 2.1 1.6 4.1 
 Disallowed (%) 0.3 0.2 0.2 
PDB-code 2YPO 2YPP 2YPQ 
 
 
 Figure S1: Omit map for Phe-only structure (PDB code 2YPO), showing electron density for 
phenylalanine and waters in site 2 of both subunits in the asymmetric unit (yellow: subunit A, blue: 
subunit B). 2Fo-Fc omit map contoured at 1.0σ is shown in blue, Fo-Fc omit map contoured at 3.0σ 
shown in green (positive) and red (negative, not observed in this part of the map). 
 
 Figure S2: Omit map for the Tyr-only structure showing electron density for tyrosine and waters in site 
2 of both subunits in the asymmetric unit (PDB code 2YPP, yellow: subunit A, blue: subunit B). 2Fo-Fc 
omit map contoured at 1.0σ is shown in blue, Fo-Fc omit map contoured at 3.0σ shown in green 
(positive) and red (negative, not observed in this part of the map). 
 
 Figure S3: Omit map for the Tyr-only structure showing electron density for tyrosine in site 3 in 
subunit B (blue carbons, PDB code 2YPP). 2Fo-Fc omit map contoured at 1.0σ is shown in blue, Fo-Fc 
omit map contoured at 3.0σ shown in green (positive) and red (negative, not observed in this part of the 
map). 
 
 
 Figure S4: Circular dichroism plots for MtuDAH7PS wild type (blue), R171A (Red) 
and R256A (green). 
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 Figure S5: Overlay of the binding mode of Phe (magenta, from PDB code 2YPO) and Tyr (green, from 
PDB code 2YPP) in site 2 of subunit B. yellow carbons: residues in subunit A. blue carbons: residues 
in subunit B, except Arg171, which is shown with red carbons. 
 
  
Kinetic characterization of wild type and mutants of MtuDAH7PS 
Table S3: Kinetic parameters for wild-type MtuDAH7PS, R171A MtuDAH7PS and 
R256A MtuDAH7PS. 
MtuDAH7PS E4P Km µM PEP Km µM kcat s-1 Specific Activity U mg-1 
Wild Type 28 ± 2 37 ± 4 4.7 ± 0.1 5.5 ± 0.1 
R171A 35 ± 3 60 ± 6 7.0 ± 0.3 8.3 ± 0.3 
R256A 33 ± 1 16 ± 2 5.5 ± 0.1 6.5 ± 0.1 
 
 
 
  
ITC data  
Table S4: Trp dissociation constants for wild-type MtuDAH7PS, and the R171A and 
R256A mutants. Trp binding for MtuDAH7PS was found to fit a two-site binding 
model to give two Kd values for MtuDAH7PS R171A.  
MtuDAH7PS Kd (µM) 
Wild-type 4.7 ± 0.1 
R171A 1 ± 8 and 1 ± 3 
R256A 3.4 ± 0.4 
 
Table S5: ITC experimental conditions.  
*Number of injections stated excludes the first 2 µL injection. 
 
MtuDAH7PS in 
cell Background 
ligand in cell 
Titrated 
ligand 
Number and volume 
of injections* 
Figure 
140 µM wild type  None 2.5 mM Tyr 56 x 5 µL S6A 
30 µM wild type 50 µM Phe 3 mM Tyr 28 x 10 µL S6B 
30 µM R171A None 2 mM Phe 28 x 10 µL S7A 
30 µM R171A 
None 3 mM Tyr 28 x 10 µL S7B 
30 µM R171A 50 µM Phe 3 mM Tyr 28 x 10 µL S7C 
70 µM R171A None 3 mM Trp 56 x 5 µL S7D 
30 µM R256A None 900 µM Phe 28 x 10 µL S8A 
60 µM R256A None 2 mM Tyr 28 x 10 µL S8B 
50 µM R256A 50 µM Phe 3 mM Tyr 28 x 10 µL S8C 
30 µM R256A None 300 µM Trp 28 x 10 µL S8D 
      
Figure S6: ITC of  inhibitor binding to wild-type MtuDAH7PS.  A. Tyr only, B. 50 
µM Phe background present in the cell whilst titrating in Tyr. 
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Figure S7: ITC of inhibitor binding  to R171A MtuDAH7PS, titrating in A. Phe only, 
B. Tyr only and D. Trp only. C. has a 50 µM Phe background in the cell, and titrating 
in Tyr. 
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Figure S8: ITC of inhibitor binding to R256A MtuDAH7PS. A. Phe only, B. Tyr 
only, C. 50 µM Phe background in the cell and titrating in Tyr and D. Trp only.  
 
 
A.	  
D.	  
B.	  
C.	  
Table S6: Primer table for site-directed mutagenesis. 
Oligonucleotide Sequence (5’–3’) 
R171A Fwd GTC GCG GCT GGT CGC GGC TTA CGC TAA C 
R171A Rev GTT AGC GTA AGC CGC GAC CAG CCG CGA C 
R256A Fwd GTG CTC GAC TAC GAG GCC GCC ATG TTG AGG TT 
R256A Rev AAC CTC AAC ATG GCG GCC TCG TAG TCG AGC AC 
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7.4 Experimental for Chapter 4 
7.4.1 D-Amino acids 
D-Phe and D-Tyr were from Sigma-Aldrich and ≥98% enantiomeric excess by g.l.c. according 
to the supplier. D-Trp was obtained from Accela and the enantiomeric excess was ≥99% by 
chiral HPLC according to the supplier. 
7.4.2 Isothermal titration calorimetry 
ITC experiments were carried out on a VP-ITC microcalorimeter (Microcal, GE Healthcare) at 
298 K. Before each experiment, the protein was buffer exchanged into the same SEC buffer 
(page 172) that was used for the preparation of the ligand solution. The pH of each ligand 
solution was adjusted to the pH of the original buffer solution after complete dissolution of the 
ligand. For all experiments, the cell contained a solution of MtuDAH7PS and the syringe 
contained the ligand solution. Experiments consisted of 29 injections, one 2 µL injection and 28 
subsequent injections of 10 µL each, using a reference power of 10 µCal s-1. The protein 
concentration was measured by UV absorption at 280 nm and all solutions were filtered and 
degassed in a vacuum immediately before use. Before the titration, the cell and the syringe were 
washed with buffer several times, and in addition, the syringe was washed with the ligand 
solution. For data analysis, the initial data point was deleted to allow for diffusion of the ligand 
across the needle tip during the initial equilibration period. In an independent experiment, heats 
of dilution were measured and subtracted from the titration data before curve fitting of the data 
using Origin (version 7.0, OriginLab®) using the models supplied by MicroCal. 
7.4.3 Crystal soaking 
Crystals were soaked in solutions containing D-amino acids using the established procedures 
(see page 177) and concentrations stated in Table 4.1, page 66. 
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7.5 Experimental for Chapter 5 
7.5.1 Virtual screening 
The library of 16,000 diverse fragments (composed and prepared by Dr Jack Flanagan, 
Auckland Cancer Society Research Centre) was docked using GOLD.130-131, 133 Native ligand-
biased libraries were prepared and docked using Glide and programs from the Schrödinger Suite 
2011.136-137, 177-180 Ligands for all libraries were obtained from the ZINC database.138 
Preparation of the binding site(s) 
General 
The structures of MtuDAH7PS without allosteric ligands present (PDB code 3NV8), in complex 
with Phe (3NUD), Trp (3NUE) and both Trp and Phe (3KGF) were obtained from the Protein 
Data Bank. The tetramers were generated from the dimers present in the asymmetric unit of the 
crystal structures and the tetramer structures overlaid using Pymol.176 The Molprobity143 server 
was used to add hydrogen atoms and suggest any Asn, Gln or His side chain flips. Side chain 
flips were applied if they resulted in more favourable hydrogen-bonding interactions or 
reduction of steric clashes. 
Site 1 (Phe site) 
Due to the conformational change associated with Phe binding at site 1 (see Chapter 1), two 
receptors were prepared for virtual screening of potential Phe site ligands: One resembles the 
conformation in the absence of ligand which shows Trp3 of subunit B in a solvent exposed 
position and will be referred to as “Trp3 out”. The “Trp3 out” receptor was generated from the 
crystal structure of MtuDAH7PS in complex with the first hit VS6. The second receptor is 
generated from the conformation observed in the Phe bound structures (PDB codes 3NUD and 
2YPO), in which Trp3 of subunit B occupies a position between the two Phe ligands and will be 
referred to as “Trp3 in”. For screening in GOLD, the centroid of the carbon atoms in the phenyl 
side chains of the Phe ligands in both subunits was determined in the Phe-bound structure (PDB 
code 3NUD) and those coordinates used as the centre of the docking site for both the “Trp3” in 
and “Trp3out” receptor. Ligands were docked into a 12 Å sphere around this point, using either 
the “Trp3 in” or “Trp3 out” receptor. “Trp3 in” and “Trp3 out” receptors were also used for 
screening using Glide: for the “Trp3 in” receptor, the centre of the docking site was defined as 
the Phe ligand in subunit A of the structure with PDB code 2YPO (Phe only in site 1). Screens 
were run using the “Dock similar size ligands” option in Glide and into a 10 Å3 box around the 
position of the native Phe ligand. For the “Trp3 out” receptor, the docking site was defined as a 
12 Å3 box around the VS6 ligand and the maximum length of the ligand limited to 15 Å. 
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Site 2 (Trp site) 
Site 2 of subunit A of the Trp bound structure (PDB code 3NUE) was chosen for docking due to 
lower B-factors in this subunit of the model when compared to the same region in subunit B. All 
non-protein ligands were removed from the receptor, except for two water molecules which 
were found to mediate contacts between Trp and the protein (numbered HOH2697 and 
HOH9043 in the structure with PDB code 3NUE). Ligands were docked into two versions of 
the receptor: the first version of the receptor included the two water molecules mentioned above 
and allowing them to move by up to 1 Å from the position observed in the crystal structure, and 
the second version which excluded the two water molecules. The docking site was defined as a 
10 Å sphere around the centroid of the imidazole ring of the Trp ligand in subunit A. A 15 Å 
sphere around the Trp was carefully checked for the correct protonation state of all histidine 
side chains before commencing docking experiments. 
Libraries  
Fragment-like library 
The fragment-like library used was a custom in-house library at the Auckland Cancer Society 
Research Centre (ACSRC) at the University of Auckland. It was generated from the screening 
collection of 16 trusted vendors. Compounds were protonated by the pipeline used for the ZINC 
online database, giving a single 3D conformational state with a protonation state predicted for 
pH 7. The library was further filtered to only include compounds with high predicted solubility, 
xlogP −5.0 to 2.5, polar surface area 0–150 Å2 and molecular weight 100–1250 g mol-1. Known 
and predicted aggregators and compounds which displayed structural features which commonly 
lead to toxicity or elimination from medicinal chemistry projects were also excluded. This 
resulted in a library of 16,505 fragment-like compounds which were processed using omega2 
(openeye) to generate a single low energy conformer and enumerate around a maximum of 10 
stereo-centres. 
Customised native-ligand biased library 
For compounds similar to Trp, the ZINC database was searched for compounds containing 3-
substituted indoles, the 2-substituent was forced to be a proton. This returned 3520 compounds. 
For compounds similar to Phe and Tyr, ZINC was searched for molecules with a Tanimoto 
similarity of greater than 50% to Phe and Tyr, respectively. This returned 3084 compounds for 
Phe and 3028 compounds for Tyr. The collections of ligands thus obtained were prepared for 
docking using LigPrep integrated in the virtual screening workflow in Schrödinger Suite 2011: 
one low energy conformer per compound was obtained by minimisation using the OPLS2005 
force-field, the possible protonation states at pH 7.0 ± 2.0 were assigned using Epik. A 
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maximum of 32 stereoisomers and one low energy ring conformation were generated per 
compound. 
Docking 
The docking parameters in GOLD were optimised by extraction of the native ligands from the 
respective crystal structures and redocking them into their binding sites while varying the 
docking parameters such as scoring function, number of dockings, inclusion of water molecules, 
rotatable polar hydrogens. The docking parameters which reproduced the observed binding 
modes of the native ligands most closely and reliably were used for the virtual screening of the 
fragment library. For docking into site 1 (Phe site), a minimum root mean square difference of 
1.5 Å between docking solutions was also enforced in order to force exploration of different 
docking positions in the compared to site 2 (Trp site) more extensive cavity of the “Trp3 out” 
receptor. Each compound in the fragment-like library was docked 10 times using the chemPLP 
scoring function in GOLD and the best three solutions retained. These poses were then rescored 
using the Goldscore scoring function. 
The native-ligand biased libraries were used in the virtual screening workflow implemented in 
the Schrödinger Suite. All docking was carried out using the OPLS2005 forcefield,scaling of the 
van der Waals radii at 0.8 and a post-docking minimisation step and Epik state penalties. The 
virtual screening workflow is a three-stage process: first, a fast high-throughput but lower 
accuracy docking step is used for initial screening of the compound library provided. The 
compounds scored in the top 20% after the high-throughput docking step were kept for the 
subsequent docking runs. The remaining compounds were used in the second docking run with 
SP precision, the top 50% of compounds by docking score. The third and final docking step was 
conducted using XP precision, one docked conformation of the best 300 compounds were kept 
for evaluation. 
7.5.2 Physical screening of compounds selected from virtual screening 
Compounds selected from virtual screening were obtained from Apollo Scientific, Vitas-M 
Laboratories, ChemBridge, Acros Organics and Sigma-Aldrich and were used without further 
purification. VS6 was synthesised as previously described.181 50–100 mM stock solutions in 
DMSO were prepared depending on solubility. Compounds which were obtained in quantities 
larger than 50 mg were also tested for aqueous solubility and aqueous solutions used for kinetic 
assays and crystal soaking if aqueous solubility was adequate. 
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Kinetic assays 
Virtual screening hit compounds were screened for inhibitory effect by the standard kinetic 
assay (see page 176). Due to the high absorbance at 232 nm of most of the selected compounds, 
assays were conducted in 1 mm path-length cuvettes. Enzymatic activity was not affected by the 
addition of DMSO up to the levels used in the assays with the virtual screening hits. All 
activities were normalised to the activity in the absence of any putative inhibitors. Virtual 
screening hits were tested at 1 mM concentration, alone and in the presence of 100 µM Trp or 
Phe respectively. In case of limited ligand solubility an assay solution saturated in ligand was 
prepared and precipitated ligand removed by centrifugation before transfer to the assay cuvette. 
Crystallography 
Crystal soaks were performed as described in the General Methods (see page 177). Typically, 
crystals were soaked in droplets containing 5–10 mM of virtual screening hit. If ligand 
solubility did not permit the use of theses concentrations, a saturated solution as indicated by 
formation of small amounts of precipitate in the droplet was used for crystal soaking. In case of 
higher ligand solubility, solutions of up to 40 mM concentration were used for crystal soaking. 
Data collection, structure solution and refinement was as described in the General Methods (see 
pages 178-179). 
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